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General introduction l1s 
Colorectal cancer (CRC) is the second most common malignancy, as well as the second most 
common cause of cancer-related death in the Western world1• CRC has a long pre-clinical phase 
involving adenomas that slowly progress over time into carcinoma. This long pre-clinical phase, 
combined with the fact that CRC is often symptomless in the early stages, make the disease very 
suitable for screening2•3• Many screening methods are currently available and can be broadly divided 
into invasive imaging strategies and non-invase strategies. The latter are in particular based on fecal 
occult blood testing (FOBT), but other fecal as well blood tests are available. Current European 
guidelines recommend fecal immunochemical testing (FIT)4 • This thesis will explore the current 
status of colorectal cancer screening with focus on FIT. Part one provides a discussion of the main 
topics of this thesis. The second part will explore different screening strategies and the effect of FIT 
over multiple rounds of screening. In the third part the use of FIT as a quantitative test will be further 
evaluated. In the fourth part quality issues concerning CRC screening will be investigated. In the last 
part, findings of this thesis will be discussed and future perspectives will be provided. 
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Introduction 
Colorectal cancer (CRC) is the second most common malignancy, as well as the second most 
common cause of cancer-related death in the European Union5• The number of new cases is 
approximately 430,000 per year. This number is rising rapidly, both as a result of expansion of the 
elderly population as well as an increase in risk factors, including a sedentary life style, smoking, 
alcohol intake and obesity. Around 45% of patients diagnosed with CRC will die as a result of the 
disease in spite of intensive treatmentli. 
Patients are diagnosed with CRC either through screening or when they present with symptoms. 
Colorectal cancer develops from adenomas that are seen as non-malignant precursors of CRC. A 
small proportion of adenomas slowly progress over time into carcinoma; the so-called adenoma-
carcinoma sequence3•7• This pre-clinical stage is often symptomless, which explains that CRC 
mostly remains undetected at an early stage. Symptoms related to CRC include a change in bowel 
habits, abdominal pain, weight loss, blood loss, anemia and fatigue. Less frequent symptoms as 
first presentation of CRC are symptoms of obstruction, or metastatic disease such as peritonitis or 
jaundice. At present, colonoscopy is considered the gold standard for CRC diagnosis in symptomatic 
patients. Colonoscopy allows visualization of the entire colon, as well as tissue sampling for 
histopathology, and instantaneous removal of (precancerous) polyps (Figure 1 ). 
Figure 1. Pedunculated advanced adenoma at co/onoscopy 
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Screening for colorectal cancer 
Screening is an appealing concept for colorectal cancer as the disease meets all the screening criteria 
as defined by Wilson and Jungner in 19688• These screening principles, later redefined by the WHO, 
state that screening is justified when a disease is common and associated with a high morbidity 
and mortality, with availability of adequate screening tests to detect the disease at an early stage 
with the possibility of treatment with improved outcome compared to later detection9• Colorectal 
cancer is indeed common, has a long pre-clinical phase, and often does not cause symptoms until 
at a late stage. In addition, when CRC is detected at an early stage, various treatment options are 
available and survival is considerably higher than at an advanced stage of disease10. All these factors 
combined make screening for CRC more suitable than any other malignancy2• 
Several screening methods are available varying widely in invasiveness and diagnostic accuracy. 
Screening modalities can broadly be divided into invasive imaging screening strategies and non-
invasive screening strategies. The latter are in particular based on fecal testing, but novel strategies 
are being developed based on breath and blood tests. No single screening test has been shown 
to be advantageous over others with respect to impact on CRC-related morbidity and mortality. 
Many screening strategies involve a two-step method, starting with one screening test followed 
by colonoscopy in those who test positive. This approach is generally associated with higher 
participation than primary colonoscopy screening, and has the advantage of requiring fewer 
endoscopic resources 11 • The choice of a screening test is most often based on the available 
colonoscopy resources, expected participation rates, and intended detection rates. It is important 
to realize that all screening strategies, except colonoscopy, require a follow-up colonoscopy in case 
of a positive exam or test. Furthermore, each strategy involves a different screening interval at which 
the procedure needs to be repeated in case of a negative previous result. 
Endoscopic screening strategies 
Colonoscopy is considered the gold standard for CRC diagnosis. Therefore, many consider primary 
colonoscopy screening as the preferred method for screening. The fact that colonoscopy allows 
complete visualization of the colon and simultaneous removal of polyps is an important advantage 
of colonoscopy-based screening. This enables reduction of both incidence and mortality of CRC3. 
Nevertheless, there are also disadvantages to colonoscopy screening such as the significant burden 
and cost s12• Consequently, participation rates in colonoscopy-based screening programs tend to be 
II 
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low, often resulting in a low number of detected neoplasia relative to the invited population(13). 
Moreover, because of the invasiveness of the procedure, there is a risk of serious complications such 
as haemorrhage and perforation 12• A colonoscopy is considered to be required every 10 years in 
case of no findings at screening colonoscopy (i.e. a negative colonoscopy). 
Flexible sigmoidoscopy (FS) examines the colon up to the splenic flexure. Screenees are usually 
referred for subsequent colonoscopy when polyps larger than 10 mm or more than three polyps 
are seen. Concerns have been raised about missing right-sided lesions, and the resulting limited 
efficacy in reducing proximal CRC mortality12. However, a decrease in CRC incidence and mortality 
has been shown up to 23% and 31%, respectivelyl4• Most often used screening interval for FS is 5 
years in case no (advanced) polyps are found at endoscopy. 
Computed tomography-colonography (CTC) allows radiological imaging of the entire colon in 
two-dimensional and three-dimensional images. In case large polyps are detected at CTC (usually 
defined as polyps with a diameter ~ 6mm or ~ 1 Omm) patients are referred for colonoscopy. CTC 
tends to generate higher participation rates than colonoscopyl 5• In a randomized trial comparing 
CTC with colonoscopy a similar yield for advanced neoplasia amongst invitees was found, yet this 
finding was mainly due to the relatively high participation rate of CTC13• Similar to FS, a CTC is to be 
repeated every 5 years in case no significant findings are found. 
Video capsule endoscopy (VCE) is the most recently emerging endoscopic screening strategy16• It 
involves the use of a wireless camera shaped in the form of a large capsule that is swallowed by 
the screenee. It allows visualization of the entire gastrointestinal tract. In the past years VCE has 
undergone considerable improvement regarding frame speed and angle of view resulting in a 
sensitivity up to 88% and a specificity of 82% for the detection of adenomas >5 mm in population-
based screening setting 17• 
Fecal occult blood test screening strategies 
While adenomas don't cause overt symptoms in most subjects, they can intermittently bleed 
which can lead to detection of occult blood in feces. Essentially, two types of fecal occult blood 
tests (FOBTs) are available: the guaiac FOBT and fecal immunochemical test (FIT). The gFOBT detects 
blood by using paper from Guaiacum trees and hydroperoxidase. This leads to a blue discoloration 
of the paper when haem is present. A positive result of the test is defined by this blue discoloration. 
A test usually consists of three set s of cards with two panels each. The test needs to be performed 
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three times by the screenee on separate stools. Several, large, randomized trials have demonstrated 
that screening with repeated gFOBT reduces CRC-related mortalityl 8•19• At present the use of gFOBT 
is largely replaced by FIT for several reasons. Firstly, FIT is easier to use than gFOBT and requires the 
screenee to take only one stool sample resulting in higher participation rates20• Secondly, FIT has a 
higher sensitivity compared to gFOBT in particular for the detection of precancerous adenomatous 
polyps. FIT is consequently associated with a higher detection rate of advanced neoplasia per 
screening round. This results in a lower rate of interval carcinomas21 • Lastly, FITs detect human 
globin using an antibody-based assay. This allows automated, quantitative measurements, whereas 
gFOBT is only available as a qualitative test that needs to be read manually. For all the above-
mentioned reasons, FIT is currently regarded as the preferred method of non-invasive screening 
and recommended by European as well AsiaPacific guidelines4•22• Quantitative FIT output allows 
for adjusting the threshold for the definition of a positive test, which is relevant in situations with 
limited colonoscopy capacity as the cut-off can be adjusted to yield maximal results within restricted 
resources. Many FIT brands are available worldwide, that all use varying sampling techniques (e.g. 
brushes or spatulas) and buffers (Figure 2). 
Figure 2. Different FIT brands. 
It is becoming more evident that different brands of FIT vary in measurement results leading to 
different positivity rates at the same cut-off expressed in IJg Hb/g feces (23, 24). So far, there is no 
evidence favouring one FIT over another12.25• Screenees undergoing gFOBT or FIT are recommended 
to repeat screening annually or biennially. 
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Novel developments in non-invasive screening strategies 
In the past years many novel screening modalities have emerged rapidly. These are all relatively 
new compared to established endoscopic and FOBT-based screening strategies. These screening 
modalities are most often non-invasive strategies involving DNA/RNA or protein biomarkers, the 
fecal microbiome and volatile markers. Biomarkers are based on the principle that malignant 
lesions shed cells or blood into the feces that can be detected in the form of aberrant DNA, RNA or 
proteins26• It is of importance to realize that the performance of such biomarkers might be different 
per CRC subtype as CRC can develop through various pathways. This implicates the need for the 
use of multiple tumor markers27.28• A recent study using a multi-target stool DNA and FIT showed 
a marked improvement in sensitivity when combined with FIT, mainly regarding the detection of 
advanced adenomas (42% using the combination versus 23% for FIT alone)29. It is notable that 
this increase in sensitivity was joined by a much higher positivity rate requiring more colonoscopy 
resources and a decrease in specificity. Regarding protein-based biomarkers, fecal tumor M2 
pyruvate kinase (M2-PK) has received much attention, with a reported sensitivity and specificity of 
79% and 80% for CRC30• However, to detect these biomarkers, often a full stool sample is needed, 
which comes with much impracticality and requires a considerable effort from the screenees. While 
such inconveniences could substantially influence adherence to a screening program, this has not 
yet been investigated and requires further research. 
Growing attention has been given to gut microbiota in colorectal cancer development, under the 
assumption that the presence of colorectal neoplasia may be associated with specific microbiota31 -34• 
One of the first bacteria associated with CRC was Streptococcus bovis35• At present, several bacteria 
have been recognized to be of importance in colorectal carcinogenesis, such as E. Coli, Bacteroides 
Fragilis and Fusobacterium nucleatum33·36• The exact role of these bacteria has yet to be elucidated, 
however, it is thought that multiple bacteria play different roles and that carcinogenesis is a dynamic 
process associated with diverse changes in the microbiome37• Combining microbiota with current 
non-invasive screening strategies could theoretically improve screening strategies as it could also 
detect non-bleeding lesions that are missed using FOBT-based strategies. 
Volatile organic biomarkers could present an interesting new possibility for the detection and 
screening of CRC. Volatile organic compounds can be found in various excreted biological materials, 
such as feces, urine, and breath38• It has been shown that these volatile markers can be used as 
a 'smell-print' for CRC and are detectable by the use of canine scent detection or electronic nose 
(39). However, analyzing volatile markers is at present costly and inconvenient, as it requires the 
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use of dogs or nanosensors. Following, research on the use of these markers both in diagnosis of 
CRC in symptomatic patients as well as in a screening setting is sparse and further research is much 
awaited. 
Quality of colonoscopy in colorectal cancer screening 
Given the low point-prevalence of CRC, measuring cancer detection rates is not feasible as a quality 
indicator for CRC screening programs, resulting in a need for surrogate indicators. Therefore, quality 
in colonoscopy is most often measured by adenoma detection rates (ADR) and cecal intubation 
rates (CIR), because they are considered to be a proxy for a thorough and complete examination of 
the colon40A1 • The ADR is defined as the proportion of (screening) colonoscopies where at least one 
adenoma is found. Much focus has been on ADR, as an endoscopists' ADR is inversely correlated with 
post-colonoscopy interval cancer rates4244• This supports the need to monitor endoscopists' ADRs. 
Most guidelines recommend an ADR equal to or above 25% (30% in men and 20% in women)44•45• In 
the past years, many improvements have been made with respect to visualization of the colo rectal 
mucosa, such as optimizing bowel preparation and development of higher resolution and wider 
view endoscopes46• Cleanliness of the colon is frequently scored by means of the validated Boston 
Bowel Preparation Score, to measure bowel preparation as a quality outcome among hospitals or 
within studies47 • Studies have shown a correlation between adequate bowel preparation and ADR46A8• 
There is much evidence favoring a "split"-dose preparation, with the second dose taken on the same 
day as the colonoscopy. Increasing the amount of time spent viewing during the withdrawal of 
the scope has also been shown to affect the number of polyps found and increase the potential to 
detect adenomas. An endoscope withdrawal time of six to nine minutes is associated with a higher 
ADR compared to a withdrawal time of less than six minutes49•50• Not surprisingly, ADR is influenced 
by the qua I ity of endoscopic imaging, which has greatly evolved over the past years. H ig h-d efi nition 
white light (HDWL) endoscopy has become the current standard and is recommended by the recent 
guideline51• There have been many studies focusing on novel image-enhancement techniques such 
as narrow-band imaging and auto-fluorescence endoscopy, and devices such as caps on the tip of 
the endoscope. No studies have convincingly shown superiority of use of any of these techniques 
over HDWL endoscopy in terms of ADR2•46• However, chromoendoscopy (i.e. adding through-the 
scope-infusions to improve mucosal visibility) has shown efficacy in the detection of small or flat 
mucosal lesions52• Notably, an improvement in detection of adenomas, may not necessarily result 
in a higher ADR and comes with substantial costs. Also, there are some limitations regarding 
practicality and more research is warranted to confirm if these utilities are of additional value in 
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adenoma detection and ultimately in decreasing CRC incidence. 
In addition to technical improvements in colonoscopy equipment, improvement in optical 
diagnosis of polyps has received much attention. This refers to reliable endoscopic assessment of a 
polyp during colonoscopy, which would in theory make the pathologist's assessment unnecessary. 
Accurate optical diagnosis of small and diminutive polyps would allow to resect and discard these 
polyps, without the need for histopathological assessment53• Furthermore, with the worldwide 
introduction of screening programs, the proportion of CRCs that are diagnosed at an early stage 
increases11 • The rise in the detection of these early stage lesions (i.e. Tl lesions) underlines the 
importance of adequate diagnosis and resection54• Several polyp classification systems have 
therefore been developed, to aid clinicians in recognizing worrisome features of polyps before 
resection55-59. Figure 3 shows a simplified overview of two frequently used classification systems, 
the Kudo pit pattern and NICE classification. The timely recognition and endoscopic removal of 
malignant polyps may reduce the need for surgery. Moreover, removal of precancerous adenomas 
and early stage cancers has a substantial effect on CRC mortality3. 
KUDO NICE 
Type I round pits 
color: same or lighter than 
~ background Type II asteroid or vessels: none papillary pits Type 1 surface pattern: dark or white spots of same size or regular absence of 
pattern 
Type Ills 
small tubular or 
roundish pits 
e color: browner than background large tubular or vessels: brown vessels roundish pits surface pattern: oval, tubular or branched Type2 0 white structures Type llll 
~ branch- or gyrus-like pits Type IV 
color: brown to darker than 
0 background non-structural vessels: areas of disrupted or missing pits or loss of pits vessels Type3 surface pattern: unstructured or absent TypeV 
pattern 
Figure 3. Simplified overview of KUDO and NICE classification. 
In case CRC is diagnosed, it is staged according to the Tumor Node Metastases (TNM) staging system 
of the American Joint Committee on Cancer/Union for International Cancer Control60• The clinical 
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staging (named cT, eN, eM) can be done through endoscopic, radiographic and intraoperative 
findings. Prior to surgical interventions the patient is most often referred for a CT-scan of the 
thorax and abdomen to assess local tumor size and invasions, lymphatic and distant metastases, 
and tumor-related complications. In addition, histological examination of the resection specimen 
is required to confirm the diagnosis of CRC, and for pathologic staging (named pT, pN, pM). TNM-
staging of CRC provides an outline for therapy and prognosis. Furthermore, when the diagnosis of 
CRC is confirmed by histology, it is important to assess family history of cancer. It is estimated that in 
a relatively large number of patients a definable inherited component might play an important role 
in the development of CRC, such as for example Lynch syndrome6 1• Recent guidelines recommend 
to test for Lynch syndrome, including assessing microsatellite instability, by all CRC patients up to 
the age of 70 years old62• 
Current status of screening in Europe and the Netherlands 
In 2003, the Council of the European Union recommended population screening for CRC. This 
led in 2010 to the publication of European Guidelines for Quality Assurance in Colorectal Cancer 
Screening and Diagnosis4 • These guidelines outline targets for key performance indicators for CRC 
screening including adherence, follow-up, and cancer detection rates. In Europe large variations 
between screening programs exist for several reasons. Firstly, many programs were already ongoing 
at the time of publication, and therefore did not follow guidelines for standardization across Europe. 
Secondly, the guidelines leave some room for choice of screening strategy such as age ranges and 
screening intervals. Lastly, there are considerable differences with respect to financial resources and 
colonoscopy capacity across European countries. 
In Europe, CRC screening primarily concerns organized population-based screening, which involves 
a systematic process of inviting the target population, including monitoring and often program 
quality assurance. This is in contrast with opportunistic screening, which happens when either an 
individual asks a treating physician for a screening test, or vice versa (screening is offered by a doctor 
or health professional). Unlike an organized screening program, opportunistic screening may not 
be monitored. In 1972 Germany was among one of the first countries to offer CRC screening by 
means of opportunistic gFOBT-based screening. In 2015, 24 European countries have established 
or are preparing a nationwide organized or opportunistic CRC screening program63• Of these 24 
countries, 12 have a population-based organized program, nine have opportunistic programs, and 
three are executing pilot studies. Most countries with a high incidence have some form of screening 
in place. However, Slovakia has the highest CRC rates in Europe (age-standardized incidence rate is 
II 
30 I Chapter 1 
42.7 per 100.000 and age-standardized mortality rate 18), without an organized screening program, 
but offers only opportunistic colonoscopy63.64. 
In the Netherlands, a screening program was started in January 2014, and is a biennial, FIT-based, 
organized population-based program. All inhabitants in the age 55 to 75 years are invited for 
screening with the FOB-Gold. There has been controversy about the type of FIT that was chosen, as 
previous research on CRC screening in the Netherlands was done using the OC-sensor65• 
Remarkable differences with regard to screening modality are seen between countries63 • Some 
countries still use gFOBT, Italy uses FIT except for some regions where FS is used, and Germany uses 
gFOBT accompanied by opportunistic colonoscopy. Poland offers colonoscopy every ten years, and 
while initially having an opportunistic character, it changed into an organized program several years 
ago. Most other countries screen by means of FIT. The programs vary in their test cut-off as well as 
age range, but all screen men and women alike. They also, almost without exception, use a single 
test per screening round, and predominantly use two-year intervals. Large differences in adherence 
and colonoscopy uptake after a positive FIT exist. The choice for a particular cut-off is primarily 
determined by colonoscopy capacity. All these differences lead to different effects of screening in 
terms of cumulative yield, and possibly mortality. It is key to realize these differences in use of FIT 
exist. Also, it is important for countries to report their screening methods and outcomes to evaluate 
how these different FIT-programs relate to each other, and to be able to make a fair comparison. 
Summary and conclusion 
Colorectal cancer is a major burden worldwide, however incidence and mortality rates fluctuate 
markedly per country. Patients are either diagnosed when presenting with symptoms or through 
screening programs. Efficacy of a screening program depends on the willingness to undergo the 
screening modality as well as on test accuracy and burden. Additionally, as various screening 
methods are available, costs and colonoscopy capacity are of influence when implementing a 
screening program. In the past decennia many countries have commenced on a CRC screening 
program, though the screening strategies vary per country, with FOBT-based screening and 
colonoscopy being the most frequently used modalities. There is a shift from opportunistic screening 
towards organized population screening programs that contain extensive monitoring. In addition, 
previous gFOBT-based programs are now switching to FIT. Little evidence is yet available on the 
comparison of FIT-based programs and colonoscopy-based programs. Improvements could still be 
made in reporting and standardizing outcomes of screening programs, including the reporting of 
fecal hemoglobin concentrations for FIT. Moreover, despite the quantitative nature of the FIT, it is 
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still used invariably in a qualitative manner using a pre-specified cut-off. Future research on the 
effect of FIT-screening over multiple rounds, the occurrence of interval cancers, and ultimately its 
effect on incidence and mortality reduction is much awaited. 
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Figure 4. Overview of age-standardized incidence and mortality rates, and screening programs in Europe (estimates by Globocan 64, 
original empty map retrieved from www.freevectormaps.com). 
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Aims 
In this thesis we aim to explore the current status of colorectal cancer screening, thereby comparing 
available screening methods, while focusing on the use of fecal immunochemical testing (FIT) in an 
organized population-based screening program. 
Outline of the thesis 
This thesis will start with describing the current status of colorectal cancer (CRC) screening both in 
the Netherlands as well as internationally (PART 1). 
In PART II, different screening modalities will be discussed with a focus on screening with FIT. At 
present many screening modalities are available and there is no evidence showing superiority 
of one screening strategy over another. At present, the most commonly used strategies can be 
broadly divided into non-invasive tests, such as fecal occult blood tests and invasive screening 
strategies, such as colonoscopy. In Chapter 2 we will compare fecal occult blood testing with FIT 
versus guaiac fecal occult blood testing (gFOBT) in a Cochrane systematic review and meta-analysis. 
Following in Chapter 3, FIT will be compared to endoscopic screening strategies (sigmoidoscopy 
and colonoscopy) in a randomized setting over four rounds of FIT-screening. In Chapter 4, we will 
further examine FIT-based CRC screening by comparing two different FIT-brands and propose a 
new approach to adequately compare differences between brands. Next, as FIT screening requires 
biennial screening rounds, we will concentrate on multiple rounds of FIT screening and the effect 
on diagnostic yield after three rounds (Chapter 5). In Chapter 6 we will further explore trends in 
adherence to screening over four consecutive rounds in. So far, FIT screening has a relatively low 
sensitivity for advanced adenomas. The combination of FIT with other non-invasive markers may in 
theory improve sensitivity without losing specificity. Hence, in Chapter 7 we will eva luate the use of 
the gut microbiome in FIT screening as an additional biomarker. 
In PART Ill, the value of using the quantative fecal hemoglobin ()ib) concentration in FIT will be 
further explored. Currently, FIT is used as a qualitative test even though the precise measurement 
of fHb in 11g Hb allows quantitative results. Therefore, we studied the effect of baseline tHb 
concentration in screenees with a FIT below the cut-off (i.e. a tHb concentration < 10 11g Hb/g feces) 
on the risk of advanced neoplasia during long-term follow-up in Chapter 8. Next, we evaluate the 
use of different cut-offs for men and women by calculating diagnostic test accuracy over a wide 
range of fHb concentrations (Chapter 9). Screenees with a positive FIT are at high risk of having 
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advanced neoplasia, often leading to extensive and burdensome colonoscopies. Also, many 
countries are struggling with colonoscopy capacity and no literature is available on the amount of 
second-look colonoscopies that come from those high-risk patients. Therefore in Chapter 10 we 
tried asses the number of second-look colonoscopies in FIT-based screening and to predict the risk 
of a second.-look colonoscopy by using fHb. Lastly in Chapter 11, we explore the pro's and con's of a 
hypothetical scenario in which FIT cut-off is lowered so that the screening interval can be extended. 
In PART IV, quality issues in a CRC screening setting will be discussed. Firstly by assessing the quality 
of web- based information for screenees, or those contemplating to take part in screening (Chapter 
12). Both FIT sensitivity and quality of colonoscopy determine the rate of interval carcinomas in CRC 
screening. In Chapter 13 the number of interval carcinomas over four rounds of FIT- screening will 
be evaluated. In addition, screen-detected carcinomas and interval carcinomas will be compared 
with regard to tumor characteristics, stage and location. To prevent the occurrence of interval 
carcinomas, as well as preventing unnecessary invasive surgical procedures, recognition of early 
stage lesions (i.e. T1 lesions) is of paramount importance. This is especially important in screening 
setting, as more early stage lesions will be detected over the course of multiple rounds. In Chapter 14 
we will investigate the number of early stage lesions detected and adequately diagnosed over four 
rounds of screening. Moreover, we will focus on the number of unnecessary surgical procedures for 
these lesions. Lastly, as CRC screening for a great part depends on the execution of the colonoscopy, 
many quality guidelines and parameters have been established over the past years, and in 
Chapter 15 we will compare these quality indicators between both secondary and tertiary hospitals. 
In PART V, the main findings and conclusions will be summarized and discussed. Finally, future 
perspectives will be provided. 
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Abstract 
Background Worldwide, many countries have adopted colorectal cancer (CRC) screening 
programmes, often based on fecal occult blood tests (FOBTs). These FOBTs fall into two categories 
based on technique and detected blood component: qualitative guaiac-based FOBTs (gFOBT) 
and the more recently developed fecal immunochemical tests (FIT) that can be both qualitative 
and quantitative. Screening by means of gFOBT has been proven to reduce CRC-related mortality. 
The effectiveness of FIT screening in decreasing CRC-related mortality has not yet been studied 
in large long-term prospective randomised controlled trials. The primary objective of this review 
was to compare diagnostic accuracy of gFOBT and FIT screening for detecting advanced colorectal 
neoplasia in average-risk individuals. 
Methods We searched MEDLINE, EMBASE, Cochrane Library, BIOSIS Citation Index, and Science 
Citation Index Expanded until January 31st 2015. Only studies that provided the number of true 
positives, false positives, false negatives, and true negatives for gFOBT and/or FIT with colonoscopy 
as the reference standard were included. Two types of studies were included; those in which all 
participants underwent both the index test and the reference standard (type I); and those in which 
only participants with a positive index test underwent the reference standard while the negatives 
were followed for at least one year for development of interval carcinomas (type II). The target 
population were asymptomatic, average-risk individuals undergoing colorectal cancer screening 
were included. Two authors independently selected studies for inclusion and collected the data 
from each study. In case of doubt a third author made the final decision. We used a bivariate and 
HSROC statistical model to obtain summary estimates of sensitivity and specificity and summary 
ROC curves. 
Main results A total of twenty-three type I studies involving 85,403 participants were included, 
reporting on a total of thirty-two fecal occult blood tests. Six studies evaluated gFOBT, thirteen 
studies evaluated FIT, and four studies included both gFOBT and FIT. Twenty-one studies reported 
advanced neoplasia as outcome, and nineteen studies reported on colorectal cancer. The cut-
off for positivity of FIT varied between 2.4 to 50 IJg Hb/g feces. The summary curve estimated by 
the HSROC model showed that FIT had a higher discriminative ability than gFOBT for advanced 
neoplasia (p=0.002), and colorectal cancer (p=0.025). 
We included nineteen type II studies reporting a total of twenty-three tests involving 1,495,344 
participants. Overall six gFOBT studies, ten FIT studies, and three studies combining both gFOBT 
and FIT were included. The cut-off for positivity of FIT varied between 2.4 to 1 0 11g Hb/g feces. The 
summary curve estimated by the HSROC model showed that FIT had a higher discriminative ability 
than gFOBT for colorectal cancer (p<0.001 ). 
Conclusion FIT is superior to gFOBT in detecting advanced neoplasia and colorectal cancer in 
average-risk individuals. The specificity of both tests is similar. These results strongly support current 
guidelines for implementing FIT-based CRC screening programs and the switch from gFOBT to FIT 
testing for existing programs. 
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Background 
Based on the Wilson & Jungner criteria published in 1968 and updated by the World Health 
Organization in 2008, screening is justified when (1) a disease is common and associated with 
significant morbidity or mortality; (2) screening tests are sufficiently accurate in detect ing early 
stage disease, are acceptable to invitees, and are feasible in general clinical practice; (3) treatment 
after early detection by screening improves prognosis relative to treatment after usual diagnosis; 
and (4) the potential benefits outweigh the potential harms and costs of screening. Colorectal 
cancer (CRC) screening fulfils all ofthese criteria1•2 • 
There are various methods for CRC screening. These vary in level of supporting evidence, 
effectiveness, test-related burden, costs and willingness of target subjects to undergo screening. The 
screening modalities for CRC broadly fall into two categories; (a) fecal tests (i.e., fecal occult blood 
tests and fecal DNA testing), and (b) partial or full structural exams (i.e., flexible sigmoidoscopy, 
colonoscopy and computed tomography-colonography (CTC)). Colonoscopy can be used as the 
reference standard for those with a positive screening test or as a primary CRC screening tool. 
Stool blood tests are conventionally known as fecal occult blood tests (FOBTs), which are used as 
a two-step testing approach in CRC screening (i.e., positive test result requires further examination 
with visualization of the colon, predominantly by means of colonoscopy). FOBT screening is based 
on the principle that a large proportion of colorectal neoplasia bleed microscopically before any 
clinical signs or symptoms become noticeable. Bleeding tends to be intermittent, and blood is 
distributed unevenly in the stool. The concept of detecting CRC by testing for blood in the stool 
is based on the observation that cancers bleed because of disruption of the normal mucosa. The 
amount of blood increases with the size of the polyp and/or the stage of the cancerH . In general, 
the amount of fecal hemeoglobin tends to be absent or low in those without neoplasia, higher for 
those with advanced adenomas, and highest for those with CRC. Fecal occult blood testing detects 
a higher proportion of CRCs and a lower proportion of advanced adenomas, since CRCs tend to 
have a more constant bleeding pattern and give rise to higher amounts of blood in stools than 
advanced adenomas, which are believed to bleed more intermittently. In this way FOBT screening 
identifies those individuals who are most likely to have advanced neoplasia. Therefore, it should be 
followed by visualization of the colon and rectum. Colonoscopy is considered the gold standard for 
detection of advanced neoplasia with high sensitivity and specificity (both above 90%) and has the 
advantage that (adenomatous) polyps and early CRCs can be removed during the same procedure. 
A meta-analysis of the accuracy of colonoscopy (performed for various indications), reported that 
gFOBT versus FIT - systematic review and meta-analysis 147 
the pooled miss rate for adenomas ~ 1 Omm was 2%, for ~5- 1 Omm 13%, and for 1-Smm 26%8• 
FOBTs fall into two categories based on the detected component of blood: guaiac-based FOBTs 
(gFOBT) and the more recently developed fecal immunochemical tests (FIT) for hemeoglobin. 
Guaiac-based fecal occult blood test 
Guaiac-based FOBTs enable detection of occult blood in stool through the pseudo-peroxidase 
activity of heme. However, peroxidase also reacts with non-human heme present in red meat. Also, 
several fresh fruits and vegetables contain peroxidase activity, which may lead to false-positive test 
results. Vitamin C may block the peroxidase reaction, resulting in false-negative test results. Guaiac 
FOBTs may detect bleeding from any site in the gastro-intestinal (GI) tract, including the stomach, 
as heme remains relatively stable during transport through the Gl-tract9• The usual gFOBT protocol 
consists of three test cards, each containing two panels. The screenee is instructed to collect two 
fecal samples from three consecutive bowel movements yielding a total of six stool panels. Applying 
a hydrogen peroxide reagent to the feces on the guaiac material in the panel leads to oxygenation 
of guaiac, which in turn leads to a blue colour change when heme is present. A panel is considered 
positive if such coloration appears 10. The number of positive panels for referral to colonoscopy varies 
between screening programs. In most programs, a single positive panel is sufficient for referral, 
however in others the number of positive panels is set at five out of six. In this case, less positive 
panels imply renewed gFOBT testing. Prior to fecal sampling, individuals are asked to restrict their 
diet and medication as this might affect the number offalse-positive and false-negative test results. 
The sensitivity and specificity of gFOBT screening varies widely due to the variation in type of test 
(brand), instructions for stool collection, number of stool samples per screening round, the use of 
non-hydrated or rehydrated stool samples, double reading of the test, the number of positive panels 
used to refer a screened person for colonoscopy, and the interval between successive screening 
rounds. In some trials, rehydrated gFOBT has been studied; rehydration reduces the false negative 
rate (improves sensitivity) while increasing the false positive rate (reduces specificity)11•12• 
Guaiac FOBTs are the only stool tests for which there is evidence of efficacy from four prospective, 
randomised controlled trials (RCTs). These trials from the USA, United Kingdom, Denmark and 
Sweden demonstrated that multiple rounds of annual or biennial gFOBT screening can reduce CRC-
related mortality by approximately 13-33%11 •13• 15• The American trial, which used rehydrated gFOBT, 
also demonstrated a reduction in the incidence of CRC11 • A subsequent meta-analysis reported a 
pooled 15% reduction in CRC -related mortality among the three biennial screening trials with gFOBT 
compared to controls16. The American trial recently reported an overall reduction in CRC mortality 
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of 27% after 30 years of follow-up17• The efficacy of gFOBT screening in reducing CRC-related 
mortality is limited due to a limited sensitivity for detecting CRC and low sensitivity for detection 
of advanced adenomas18• Furthermore, the process of analysing gFOBTs is time consuming and is 
faulted by the possibility of inaccurate processing and evaluation 19• 
Fecal immunochemical test 
FITs have several technological advantages compared to guaiac based screening. FIT specifically 
targets human globin, a protein that along with heme constitutes the hemeoglobin molecule. 
Therefore, FITs only detect human blood, in contrast to the gFOBT which can falsely detect other 
substances. For this reason, FITs are less subject to interference by dietary factors and medication. 
Studies have suggested that NSAID or aspirin use increased the sensitivity of FIT without a decrease 
in specificity20•21• In addition, FITs are more specific for lower Gl-tract bleeding since globin is 
degraded by digestive enzymes in the upper Gl-tract. This improves their specificity for neoplasia in 
the colon and rectum. The sample collection for most FIT variants is less demanding than for gFOBT-
sampling, both in terms of requiring a single sample and less direct handling of stools (smear cards 
for gFOBTs vs brush/spatula for FIT testing). Furthermore, FIT screening does not require dietary 
restrictions. Both qualitative and quantitative FITs have been developed and are described below. 
Qualitative FITs 
Qualitative tests require a manual interpretation of test results as positive or negative. There is a 
range of such tests on the market. They often use immunochromatographic technology, and 
allow for simple, office-based analysis. Since qualitative FITs provide dichotomous test results and 
thresholds for a positive test differ between brands, test performances differ22.23. However, like 
gFOBT, inter-observer variations in interpretation of test results may influence performance. 
Quantitative FITs 
Quantitative FITs on the contrary can be analysed automatically, quantifying the amount of 
hemeoglobin found in the stool sample. One advantage of quantitative FITs in CRC screening 
programs is that the cut-off level (i.e. the amount of hemeoglobin above which the test is considered 
positive and individuals are referred for follow-up examination) can be adjusted. This allows the 
number of FIT-positives to be matched with the available resources for further investigation, 
in particular colonoscopy capacity24.Quantitative FITs have further important advantages over 
qualitative FITs due to the use of automated analysis. This automation removes inter-observer 
variation in interpretation of test results, improves reproducibility, and allows for high-throughput 
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testing. Nevertheless, studies suggest variable performance of different brands of quantitative FITs, 
even when the standardized same cut-off is used22.To date, there are no long-term prospective 
randomized data that demonstrate that FIT is superior to gFOBT in terms of reducing CRC-related 
mortality. However, a recent ecological study compared regions in Italy with and without population 
FIT screening. CRC -specific mortality was 22% lower in areas with a FIT screening program compared 
with areas without a screening program25.With this review, we aim to compare the diagnostic test 
accuracy measures of gFOBT and FIT screening in order to answer the question "Can gFOBT be 
replaced by FIT for primary CRC screening?'~ In order to answer this question, an overview of the test 
performance characteristics for both types of FOBT will be provided. 
Target condition being diagnosed 
FOBT screening primarily aims at early detection of bleeding colorectal neoplasia, since only 
bleeding lesions can be detected by stool blood tests. CRC screening in general aims at lowering 
CRC mortality by early detection of CRC and lowering CRC incidence by removal his pre-malignant 
lesion i.e., adenomatous polyps. 
Index tests 
The tests under evaluation are two FOBTs: gFOBT and FIT. More detailed information about the tests 
and the methods of execution have been previously described. FIT can be both quantitative as well 
as qualitative, the latter does not report individual fecal Hb concentrations. 
Alternative tests 
There are several alternative tests that can be used for CRC screening purposes. These tests vary 
in the level of supporting evidence, attendance, effectiveness, and test-related burden, costs. 
Alternative screening modalities usually considered as effective CRC screening tools include flexible 
sigmoidoscopy, colonoscopy, computed tomography-colonography and, more recently, capsule 
endoscopy, fecal DNA testing and serum molecular markers.26,27 
Rationale 
In the Western world, many countries have adopted a CRC screening program, often based on 
FOBT.28 Screening by means of gFOBT has been proven to reduce CRC-related mortality. The results 
on effectiveness of FIT screening in decreasing CRC-related mortality are not yet available. The main 
explanation for this is that many countries have already implemented a CRC screening program. In 
addition, decisions on the optimal screening test have to be based on data about the sensitivity and 
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specificity, existing RCT results, and modelling29. 
Objectives 
The primary objective of this review is to compare the diagnostic test accuracy of gFOBT and FIT 
screening for detecting advanced colorectal neoplasia in average-risk individuals. 
Investigation of sources of heterogeneity 
We aimed to investigate the following sources of heterogeneity. 
A. Heterogeneity related to characteristics of the study population (i.e. sex, age limits, ethnicity, 
selection of invitees (identified from general practitioner records or population registers), cancer 
stage, distribution and cancer location. 
B. Heterogeneity related to the number of FOBTs performed per screening round 
C. Heterogeneity related to the cut-off value used for FIT or the number of positive panels used to 
refer a gFOBT-screened person for colonoscopy. 
Due to reasons described later in this review, analysis for heterogeneity could not be performed for 
all of these factors. 
Methods 
Criteria for considering studies for this review 
Types of studies: Two different types of studies were included and categorized in this review: 
Type I studies: All (randomised, comparative) accuracy studies in which all participants underwent 
both the index test and the reference standard. Diagnostic case-control studies were considered 
inappropriateforthis review because such studies are likelyto overestimate diagnostic performance30• 
Moreover, literature suggests that measures of accuracy may vary with the prevalence and stage-
distribution of the target condition 31 .For instance, the sensitivity of a test will often vary according 
to the severity of the detected disease (e.g. advanced CRCs are more easily detected with FOBTs 
than early stage tumours). For these reasons, we did not include case-control studies in this review. 
Type II studies: All (randomised, comparative) accuracy studies in which all participants with a 
positive index test were referred for the reference standard and all participants with a negative 
index test were followed for at least one year to identify development of interval carcinomas. Only 
data from the first screening round were included for analysis. 
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Participants 
Asymptomatic average-risk individuals aged 40 years and above were considered as representative 
for a CRC screening program. Study participants included subjects volunteering for a medical health 
check-up (including CRC screening), as well as individuals identified from population registers, and 
general practitioner or managed care organisation records. 
Index tests 
The index test was either gFOBT or FIT (both qualitative and quantitative) as described previously 
in the Background section. 
Comparator tests 
Studies were included regardless of whether they made comparisons with other CRC screening 
modalities. 
Target conditions 
The primary target condition was CRC, which was defined as the invasion of malignant cells beyond 
the lamina muscularis mucosa. Patients with an intra-mucosal carcinoma or carcinoma in situ were 
classified as having high-grade dysplasia32.The secondary target condition was advanced neoplasia, 
which included CRC and advanced adenomas. An advanced adenoma was defined as an adenoma 
with a greatest dimension of at least 10 mm, or an adenoma with ~ 25% villous component, and/ 
or high-grade dysplasia32• For each included study, we assessed whether these definitions were 
applied. If another definition was adopted in a study, we stated this in the characteristics of included 
studies. 
Reference standards 
Studies were included for this review if colonoscopy was used as the primary reference standard. 
Only in case of an incomplete colonoscopy, CTC or double contrast barium enema (DCBE) was 
accepted as reference. Furthermore, in type II studies participants with a negative index test result 
had to be followed for at least one year to assess the development of interval carcinomas. Interval 
carcinomas were defined as CRC diagnosed in an FOBT negative screenee in the period between 
two successive FOBT screening rounds33.1f a study did not use this definition, we stated this in the 
characteristics of included studies. 
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Exclusion criteria 
We excluded studies where more than 5% of the population consisted of high-risk individuals. 
High-risk individuals were defined as patients with a history of CRC; subjects with a personal 
history of adenoma(s); individuals scheduled for diagnostic colonoscopy because of hereditary CRC 
syndromes or a positive family history of CRC; symptomatic subjects with complaints suspicious for 
CRC such as rectal blood loss, changed bowel habits, or weight loss; and all patients with a history of 
inflammatory bowel disease. We also excluded studies in which a positive gFOBTtest result needed 
to be confirmed by a positive FIT test result or vice versa. We excluded studies in which less than 
75% of the participants with a positive FOBT underwent colonoscopy or in case of an incomplete 
colonoscopy, CTC or DCBE. 
Electronic searches 
To identify appropriate studies, the Trial Search Coordinator of the Cochrane Colorectal Cancer 
Group in collaboration with the Medical School Library of the Erasmus MC conducted a literature 
search by using the electronic databases Medline, Embase, the Cochrane Library, BIOSIS and SCI-
expanded. The Embase, Medline and Biosis searches were run in OVID. There were no restrictions 
on date or language of the articles being reviewed. Native speakers related to our departments and 
personal acquaintances translated articles written in languages other than English. The searches 
were developed using the Boolean term 'AND' between the topics colorectal cancer and fecal occult 
blood test. To cover the topic of colorectal cancer, the searches were developed by searching MeSH 
and/or EmTree terms colorectal neoplasms, colorectal cancer and large intestine tumour, and the 
text words: colorectal, rectal, rectum, colon*, cancer*, carcinoma*, adenocarcinom*, neoplas*, 
tumor*, tumour*, polyp* and adenom*. To cover the topic of fecal occult blood testing, the search 
was developed by searching MeSH and/or Em Tree terms occult blood, immunochemistry and feces 
analysis, and the text words; fecal, fecal, feces, feces, stool*, occult blood, occult blood test*, FOBT*, 
gFOBT*, FIT*, immunochem*, immunological*, guaiac*, fecal immunochem*, fecal immunochem* 
and test*. In exploratory searches, we identified articles that used gFOBT brand names without 
explicitly mentioning either gFOBT or FOBT in the title, abstract or MeSH terms. We have therefore 
incorporated most of the gFOBT brand names in our literature search. This brand name issue was 
not present when searching for articles related to the FIT. Differing from the previous published 
search strategy in our protocol, we did not include the brand name "colorectal" as this yielded too 
many irrelevant results. Initial searches were conducted in September 2013. A second search was 
conducted on January 31st, 2015. We performed a further search on March 21st, 2016. Those results 
have been added to 'Studies awaiting classification' and will be incorporated into the review at the 
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Searching other resources 
The references of all included relevant studies were hand-searched for additional trials. In addition, 
we searched for articles citing the relevant studies included in the review. We defined relevant 
included articles as any included article that was published within the 5 years preceding our search. 
Furthermore, we searched PubMed for Related Articles of the most relevant included articles. We 
examined the first 20 results from 'PubMed Related Articles' after sorting by publication date from 
newest to oldest. We also contacted principal investigators of the included articles to clarify aspects 
of methods and results, and ask for any unpublished data in the area of FOBT characteristics, where 
necessary. 
Selection of studies 
Two reviewers (EJG and EHS) independently assessed whether the titles and abstracts were eligible 
for further reading. After this initial retrieval, all selected articles were read entirely. Disagreements 
about including a study for this review were resolved through discussion with a third reviewer (AvR). 
All studies that did not meet the inclusion criteria, as ascertained in reading the full article, were 
listed in a separate table with reasons for exclusion. The reference management software EndNote 
X7 was used for the selection process. 
Data extraction and management 
Data were extracted from those trials that fulfilled the inclusion criteria. The data that were extracted 
for both advanced neoplasia and CRC were: 
- Positivity rate (PR), i.e. the proportion of participants having a positive index test result. 
- True positives (TP), i.e. participants having a positive index test result, followed by detection of 
advanced neoplasia by means of the reference standard. 
- False positives (FP), i.e. participants having a positive index test result, but no advanced neoplasia 
when assessed with the reference standard. 
-True negatives (TN), i.e. participants having a negative index test result, and no advanced neoplasia 
during colonoscopy for Type I studies and no interval CRC identified during follow up for Type II 
studies. 
- False negatives (FN), i.e. participants having a negative index test result, and advanced neoplasia 
during colonoscopy for Type I studies and interval CRC identified during follow up for Type II studies. 
The analyses only include the main outcome measures sensitivity and specificity (which were derived 
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from TP, FP, TN, FN). For CRC we included data from both type I and II studies, and for advanced 
neoplasia we included data from type I studies only. For both study types, the extracted data were 
merged into separate 2 x 2 tables (containing TP, FP, FN, TN). We excluded non-interpretable test 
results and FOBT-positives who refused to undergo the reference standard from the 2x2 table and 
in consequence from the meta-analysis. If data were lacking in a specific article we contacted the 
principal investigators to ask for the original data and/or tried to reconstruct the aforementioned 
cell frequencies from the information that was published. If this was not successful, we excluded the 
study. The data presented in the 2 x 2 table were used to conduct meta-analysis on sensitivity and 
specificity. For type II studies, only data regarding CRCs were generally available during follow-up. 
Therefore, for type I studies we were able to extract data for both advanced adenomas and CRC, but 
for type II studies we extracted data for CRC only. We extracted data for all possible cut-offs. Since the 
concentration used for cut-off [ng Hb/ml buffer in the device] is unique to the device or system and 
cannot be compared with other devices, cut-offs were transformed to the internationally accepted 
unit of IJg Hb/g feces34• All data were extracted independently by two reviewers (EJG and EHS). 
Assessment of methodological quality 
Two authors (EJG and EHS) independently assessed the quality of each individual study using 
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) too!35• We excluded some of 
the questions from the QUADAS-2 tool in case they were not applicable. Details of each study are 
described in the Characteristics of Included studies table. If data was not specified in the article, 
this was mentioned. When authors did not respond also manufacturers were contacted to retrieve 
additional details about the test used if needed. 
Descriptive analysis 
The descriptive analysis provides an overview of all available studies. Tables were split by gFOBT 
or FIT, and by type I or type II studies. For all study types, the following test characteristics were 
extracted into 2x2 tables: TP, FP, TN, and FN. The extracted data were entered into Review Manager 
5. Study-specific estimates and exact 95% confidence intervals (CI) of sensitivity and specificity were 
obtained and displayed in forest plots per test type. Different symbols were used per test type, in 
order to create a clear overview of between-test variability. 
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Inferential statistics 
In secondary analyses, we compared the performance of the gFOBTs and versus the FITs. We 
complied with the methods and techniques introduced and explained in chapter 10 of the Cochrane 
Handbook for Systematic Reviews of Diagnostic Test Accuracy36.We started with an exploration of 
the study-specific sensitivities and specificities that were extracted from the included studies using 
Rev Man software. Based on the available reported sensitivities and specificities, we used the bivariate 
model, and the Rutter and Gatson is Hierarchical summary receiver-operator curves (HSROC) model 
to explore differences between tests and identify potential sources of heterogeneity37• When at least 
three studies were found in which both gFOBT and FIT were compared with the reference standard 
we analysed these as a separate group from studies in which only one of the two tests was compared. 
When less of these studies were found, we allowed that these contributed an observation to both 
series of tests. These studies were then included twice in the data set. We also calculated initial 
summary estimates of sensitivity and specificity when it turned out that more than three studies 
using common cut-off points for test positivity were available. If enough studies appeared per test 
brand with the same outcome parameters, we performed meta-analyses. The HSROC model was 
used to analyse sensitivities and specificities for type I and type II studies separately, including all 
studies. For the quantitative FIT where 2x2 tables for multiple cut-offs were available, we used the 
cut-off as advised by the manufacturers for this analyses. 
We investigated the effect of cut-off by carrying out subgroup meta-analyses for cut-offs where 
sufficient data were available. As some studies reported 2 x 2 data for more than one cut-off, this 
analysis allowed us to include all of the available data. To analyse the sensitivities and specificities 
from the various studies and test types that used the same cut-off, we used the bivariate model as 
introduced by van Houwelingen et al., extended by Reitsma et. al., and explained in the Cochrane 
Manual Chapter 1 036•38•39• The bivariate model was fitted using proc nlmixed from SAS version 9.2 
conforming to the examples ofSAS syntax given in chapter 10 of the Manual. We primarily compared 
the accuracy of gFOBT and FIT tests, employing a model that had the same between study variance/ 
covariance matrix in these two test types. In order to include studies that had zero counts in any of 
the four cells we added 0.5 to cells containing no observations. Model output provided confidence 
and prediction region parameters and summary estimates of test accuracy measures per test type 
(gFOBT or FIT). 
Investigations of heterogeneity 
The 12 statistic40 was not calculated as it doesn't account for heterogeneity explained by phenomena 
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such as positivity threshold effects, it is therefore not routinely used in Cochrane DTA reviews. The 
magnitude of observed heterogeneity was depicted graphically by the prediction ellipse. We 
planned to address heterogeneity by adding covariates of interest to the HSROC model. The factors 
that we aimed to include in our heterogeneity analyses are described in our objectives. However, 
there are several caveats to keep in mind: 
A. Heterogeneity related to gender was assessed as percentage of male participants; investigation of 
heterogeneities within other population characteristics was not feasible due to lack of information 
provided in individual studies. Nevertheless, only (studies with) average-risk individuals, as defined 
in our protocol, were included. The well-defined criteria resulted in homogenous studies according 
to prediction ellipses. Investigation of heterogeneities within cancer stage, distribution and cancer 
location was not feasible due to lack of information provided in individual studies. 
B. Heterogeneity related to the number of tests and/or the number of stools per screening round 
was assessed. 
C. Summary estimates of sensitivity and specificity for the two most common cut-off levels to refer 
screenees for further evaluation by the reference standard (i.e. cut-off value for FIT in !Jg/ml or the 
number of positive panels for gFOBT) were performed. Heterogeneity related to the quantitative or 
qualitative nature of FIT was assessed. 
Sensitivity analyses 
Sensitivity analyses were performed in which the QUADAS-items were used to identify studies 
that scored differently on certain quality items to determine the effect of poor study quality on 
the overall results. The impact of each study was tested by removing each one from the analysis 
separately and recalculating the summary estimates. 
Assessment of reporting bias 
Investigation of publication bias in diagnostic test accuracy studies has proven to be problematic, 
because many studies are done without ethical approval or study registration4 143 . Therefore, 
identification of studies from registration until final publication of the results is not possible41 • 
Furthermore, funnel plot-based tests that are commonly used to detect publication bias in reviews 
of randomised controlled trials, have been shown to be misleading for diagnostic test accuracy 
reviews such as ours. Therefore we did not assess reporting bias. 
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Results 
Results of the search 
The search identified 5,355 titles, of which 2,797 remained after removal of duplicates. Of these, 
2,1 94 were excluded on the basis of title and abstract. Manual removal of duplicates for the 
remaining articles resulted in 38 additional duplicate articles. From 40 articles, the PDF could not 
be retrieved, even after trying to contact the authors. Full articles were retrieved for 369 titles. After 
hand-searching the references of all included articles and PubMed related articles of included 
studies, nine additional articles were identified and fully assessed. A total of 378 full-text articles 
were assessed for eligibility, of which 337 articles were excluded because they met one of the 
exclusion criteria or were otherwise assessed as ineligible for the following reasons: 
In 162 studies, only FOBT-positive subjects had undergone the reference standard without follow-
up of FOBT-negatives: 
Forty-seven studies did not focus on average-risk subjects; 
Thirty-six studies had not used colonoscopy as the first choice of reference standard; 
Fifteen studies only provided data on cumulative mortality over multiple screening rounds 
making it impossible to determine absolute numbers of advanced neoplasia detected per 
screening round; 
Thirteen studies the full-text was a letter or editorial, and thirteen were reviews; 
Fourteen articles encompassed the same cohort as an already included article; 
Six articles summarized the results of multiple screening rounds and separate data-extraction 
of the first round was not possible; 
Four articles focussed on digital FOBT where a stool sample was obtained by digital rectal 
examination; 
Twenty-seven articles were excluded for various other reasons (Figure 1 ). 
A total of 41 studies were included. One additional study (Faivre 2004) was included after contacting 
the author to obtain data on another article to be included44• We combined two articles (Brenner 
2013, Haug 201 1) for gFOBT and FIT results45•46.Both studies analysed the same population of 3,077 
patients. For the Haug's study the authors provided results for different FIT cut-offs to allow direct 
comparison with other studies using the same cut-off. The 15 excluded cases in the original article 
for the analysis about left/ right sided lesions were included in our analysis after contacting the 
principal investigators. 
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Table 1. Overview test characteristics per study for type /studies. VI 00 
-
Study Test brand 9FOBT FIT FIT method FIT 10 1!9 FIT 20 1!9 AN CRC Other cut-off Nrofstools (') 
::;;-
Alhquist 2008 47 Hemocult + + + 3 OJ 
"'0 
rl' 
Hemocult Sensa + + + 3 11> , 
Brenner G 2010 48 HemoCARE (gFOBT) + + + 3 N 
lmmoCARE-C (FIT) + Qualitative + + unknown 3 
Brenner H 2013 45 Hem occult + + + 
Chen 2014 49 OC-Iight + Qualitative + + + 
Cheng 2002 50 OC Hemodia + Qualitative + + + 
Chiu 2013 51 OC-Iight + Qualitative + + + 
Cruz-Corrrea 2007 52 Hemocult II + + + 3 
de Wijkerslooth 2012 53 OC-sensor + Quantit ative + + + + 
Graser 2009 54 brand not specified + + 3 
FOB-Gold + Quantitative + + 14 ng/ ml= 2.41Jg/ g 2 
Haug 2011 46 RIDASCREEN + Quantitative + + + + 
Hernandez 2014 55 OC-sensor + Quantitative + + + + 
Hoepffner 2006 56 Hemocult + + + 
Hb ELISA lmmunodiagnostik + Unknown + + + 10 IJg/g 
Imperiale 2004 57 Hemocult II + + 3 
Imperiale 2014 58 OC-sensor + Quantitative + + 
Khal id- de Bakker 201 1 59 OC-sensor + Quantitative + + + + 
Levy 2014 60 Inverness Clearview + Qualitative + + 50 IJg/g 
Alere Clearview + Qualitative + 6 IJQ/g 
Polymedco OC-Light + Qualitative + + + 
Quidel QuickVue + Qualitative + + 50 IJg/g 
Lieberman 2001 12 Hemocult II + + + 3 
+ + 
Nakama 2000 61 latro Hemcheck + Qualitative 
Omata 2011 62 OC-micro + Quantit ative + 
Park 2010 63 Hemocult II + 
OC-sensa + Quantitative + 
Sung 2003 64 Hemocult II + 
Wong 2014 65 Hemosure + Qualitative 
Wu 2014 66 ACON Laboratories + Qualitative 
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Table 2. Overview test characteristics per study for type //studies. 0\ 0 
-
Study Test brand 9FOBT FIT FIT method FIT 101-19 FIT 201-19 CRC Other cut-off Nr of stools (') 
:::;; 
Bouvier 1999 67 Hemocullt II + n.d. OJ 
"0 
rl' 
Castig lione 2007 68 OC-Hemodia + Quantitative + 1 11> , 
Chiang 2014 22 OC-sensor + Quantitative + N 
HM-Jack Quantitative + 
Crotta 2012 69 OC-sensor + Quantitative + 
Denters 2012 70 Hemoccult II + 3 
OC-Sensor + Quantitative + 
Faivre 2004 44 Hemocullt II + 3 
Giai 2014 71 Hemocullt II + 3 
ltoh 1996 72 OC-Hemodia + Qualitative + 
Kronberg 1987 73 Hemocullt II + 3 
Launoy 2005 74 Mag stream + Quantitative 20 ng/ ml= 67 IJg/g 2 
Levi 2011 75 Hemocullt Sensa + 3 
OC-micro + Quantitative 70 ng/ ml= 141J/ g 3 
McNamara 2014 77 OC-sensor + Quantitative + 2 
Paimela 2010 78 Hemocullt + 3 
Parra-Bianco 2010 79 Hemofec + 3 
OC-Iight + Qualitative + 
Parente 2013 80 HM-Jack + Quantitative 100 ng/ ml= 2SO IJg/g 
Steele 2009 81 Hema-screen + 3 
Sieg 2002 82 unknown + Quantitative 5 IJg/ g and 10 IJg/g 
Van Roon 2013 83 OC-Sensor + Quantitative + 
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A total of 23 type I studies were included: five were performed in the United States, five in Germany, 
four in Taiwan, two in the Netherlands, two in Japan, and the remaining studies were performed 
in France, Spain, South-Korea, China and Hong Kong. Seven studies compared more than one test 
and of those there were six studies in which participants had undergone more than one index test; 
resulting in 91,971 test evaluations with a total of 32 separate tests in 85,403 participants. Overall, 
six gFOBT studies, thirteen FIT studies, and four studies combining both gFOBT and FIT screening 
were included for this review. The earliest study was published in 2000 (Nakama 2000), with the 
majority being published between 2008 and 2013. For all but one study (Nakama 2000) advanced 
neoplasia was the main outcome. Twenty papers separately described the numbers of detected 
CRC and advanced adenoma. In two studies, no CRC was detected. For eleven studies, data for a 
cut-off of 10 1-1g Hb/g feces could be retrieved, and for eight studies a cut-off of 20 1-1g Hb/g feces was 
used. For all included gFOBT studies a positivity criterion of at least one positive panel was used. All 
but two studies used a single stool sample for FIT-testing and for all but two gFOBT-studies three 
consecutive stools were used (Table 1 ). 
A total of nineteen type II studies were included: four were performed in France, three in Italy, two in 
Japan, two in the Netherlands, and the remaining studies were performed in Taiwan, Denmark, lsrel, 
Ireland, Scotland, Finland, Spain (Tenerife), and Germany. Four studies compared more than one 
index test with each participant undergoing one FOBT. In total they reported on a total of 23 tests 
in 1,495,344 participants. Overall, six gFOBT, ten FIT, and three combination studies were included. 
Out of the studies combining gFOBT and FIT, two studies randomized participants and one study 
performed both tests in all participants. The earliest study was published in 1987 (Kronborg 1 987), 
with the majority being published in 2002 to 2014. All studies had at least one year of follow-up, 
with a maximum of four years of follow-up. Eleven of nineteen included studies had exact two years 
of follow-up. For four studies, data with a cut-off of 10 IJg Hb/g feces could be retrieved, and for four 
studies (five FITs) data with a cut-off of 20 IJg Hb/g feces. All but one study used a single stool sample 
for FIT-testing and for all gFOBT-tests, three consecutive stools were used (Table 2). 
An updated search in March 2016 identified 391 additional records. A total of 355 records were 
excluded based on title and/or abstract, 36 study reports from this updated search have been added 
to 'Studies awaiting classification: 
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Records identified through database 
searching January 2015 
(n=5355) 
Records screened after duplicates removed 
(n=2797) -
Full-text articles retrieved 
(n=369) -
Full-text articles assessed for eligibility 
(n=378) t--00 --w 
Studies included in qual itative synthesis 
type I (n=23) 
type II (n= 18) 
Additional includes 
identified through 
other sources 
(n=l) 
Studies included in quantitative synthesis 
(meta-analysis) 
type I (n=23) 
type II (n= 19) 
Figure 1. Flowchart of search and included studies. 
Records inlcuded 
(n=2428) 
2350 based on title and/ or abstract 
38 manually deduplicated 
40 no PDF 
Fu ll-text articles retrieved after screening 
162 
47 
36 
15 
13 
13 
14 
6 
4 
27 
of related articles 
(n=9) 
Excluded full-texts 
(n=337) 
type II w ithout follow up 
not average risk 
notcompared to colonoscopy 
cumulative mortality 
editorial or letter 
(systematic) review 
same cohort as included article 
cumulative screening rounds 
case control study 
other 
Additional records 
identified through 
database searching 
March 2016 
355 records excluded 
based on title o r 
abstract 
36 studies awaiting 
classifcation 
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Methodological quality of type I studies 
The overall quality of type I studies is summarized in Figures 2A and 2B using QUADAS-11. Nineteen 
(83%) studies clearly included a representative spectrum of average-risk participants, which reflects 
population-based screening. For three studies this spectrum was unclear because the studies it were 
either retrospective or did not describe exclusion criteria clearly. However, all these studies were 
performed in an average-risk CRC screening setting and therefore included for analysis. One study 
(Cruz-Correa 2007) had a high risk of bias regarding the spectrum as it included patients referred for 
colonoscopy outside of a screening setting. However, only asymptomatic patients over the age of 55 
years were included, for these reasons we choose to include this article for analysis. Eighteen (78%) 
of the studies had a low risk of bias concerning the index test; four were unclear because either 
the method of collection was not clearly described or the positivity threshold was not described. 
One study (4%) had a high risk of bias since the study conducted the index test differently than as 
advised by the manufacturer. Unanalysable tests were only reported in five studies (22%). Twenty-
two studies (96%) had low concerns regarding applicability of the index test; with one study rated 
as unclear because this study did not describe whether the threshold was pre-specified. All studies 
had a low risk concerning the reference standard with over 80% of the participants undergoing 
colonoscopy as the reference standard. However, many studies had missing values and FOBT-
positivity rates were often lacking. The majority (87%) of studies had clear definitions of advanced 
adenomas; mainly defined as adenomas ;::: 10 mm, adenomas with at least 25% villous component, 
and /or high grade dysplasia. 
Methodological quality of type II studies 
The overall quality of type II studies is summarized in Figures 3A and 3B. Fourteen studies (74 %) 
clearly included a representative spectrum of participants with an average-risk of developing 
advanced neoplasia. Two studies had a high risk of bias with regard to selection of patients; in one 
study (ltoh 1996) Japanese workers in a FIT-based screening programme could have experienced 
gFOBT screening during earlier years. In another study (Sieg 2002), the article stated that subjects 
below the age of 44 could also participate if they heard of the study, but when contacted the 
authors stated this was not the case. Risk of bias concerning the index test was potentially present if 
the paper did not specify how the authors had handled non-interpretable or borderline test results. 
Around 84% specified their reference standard as being colonoscopy. Three studies were marked as 
unclear because while they used colonoscopy as a reference standard, they did not describe how 
many people underwent CT-colonography or DBCE in case of a failed colonoscopy. With regard 
to flow and timing, 47% of the studies had a low risk of bias. This was due to multiple reasons. All 
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Risk of Bias 
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Applicability Concerns 
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Figure 2A. Type I studies. Risk of bias and applicability concerns graph: review authors' judgements about each Fdomain presented 
as percentages across included studies 
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Figure 3a. Typ e II studies. Risk of bias and applicability concerns graph: review authors' judgements about each domain presented 
as percentages across included studies 
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studies had at least 1 year of follow up, five studies had a follow-up of three years, and one study 
had a follow-up of four years. 
Twenty-one type I studies reported on advanced neoplasia (AN) as outcome; their median sample 
size was 1,046 (range 126 to 18,296). Figure 4 shows the Forrest plot of all included studies reporting 
on advanced neoplasia. 
gFOBT 
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95%CI) Sensitivity (95%CI) Specificity (95%CI) 
Ahlquist 2008 51 115 239 3359 0.18 [0.13, 0 .. 22] 0.97 {0.96, 0.97] • • 
Alhquist 2008 29 67 261 3407 0.10 [0.07, 0.1 4] 0.98 [0.98, 0.99] • • 
Brenner 2012 8 25 18 595 0.31 [0.14, 0.52] 0.96 [0.94, 0.97] 
-
• 
Brenner 2013 19 92 203 1921 0.09 [0.05, 0.13] 0.95 [0.94, 0.96] • • 
Cruz-Correa 2007 0 3 4 119 0.00 [0.00, 0.60] 0.98 [0.93, 0.99] .. 
Graser 2009 5 26 20 225 0.20 [0.07, 0.41] 0.90 [0.85, 0.93] 
---
• 
Hoepffner 2006 2 17 4 133 0.33 [0.04, 0.78] 0.89 [0.82, 0.93] ... 
Imperiale 2005 47 99 387 1972 0.11 [0.08, 0.14] 0.95 [0.94, 0.96] • • 
Lieberman 2001 73 166 233 2413 0.24 [0.19, 0.29] 0.94 [0.93, 0.94] • • 
Park 2010 12 49 60 639 0.17 [0.09, 0.27] 0.93 [0.91, 0.95] ..... • 
Sung 2003 9 92 54 350 0.14 [0.07, 0.25] 0.79 [0.75, 0.83] 1~1 I I II I I I ~ I 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 
FrT 
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensit ivity (95% Cl) Specificity (95% Cl) 
Brenner 2012 9 45 17 575 0.35 [0.17, 0.56] 0.93 [0.90, 0.95] --+-- • 
Chen 2014 56 173 198 5669 0.22 [0.17, 0.28] 0.97 [0.97, 0.97] ... • 
Cheng 2002 40 448 42 4537 0.49 [0.38, 0.60] 0.91 [0.90, 0.92] 
---
• 
Chiu 2013 199 1131 461 16505 0.30 [0.27, 0.34] 0.94 [0.93, 0.94] • • 
de Wijkerslooth 2012 45 76 74 1061 0.38 [0.29, 0.47] 0.93 [0.92, 0.95] ........ • 
Graser 2009 8 37 17 223 0.32 [0.15, 0.54] 0.96 [0.81 , 0.90] 
-
... 
Haug 2011 66 87 177 1995 0.27 [0.22, 0.33] 0.96 [0.95, 0.97] ... • 
Hernandez 201 4 34 33 62 650 0.35 [0.26, 0.46] 0.95 [0.93, 0.97] 
--
• 
Hoepffner 2006 4 5 2 145 0.67 [0.22, 0.96] 0.97 [0.92, 0.99] 4 
Imperiale 2014 228 964 594 8203 0.28 [0.25, 0.31 J 0.89 [0.89, 0.90] • • 
Khalid-de Bakker 2011 6 9 32 282 0.1 6 [0.06, 0.31 J 0.97 [0.94, 0.99] 
----
• 
Levy2014 1 2 18 196 0.05 [0.00, 0.26] 0.99[0.96, 1.00] - .. 
Levy 2014 2 40 13 253 0.13 [0.02, 0.40] 0.86 [0.82, 0.90] 
-------
.. 
Levy 2014 3 4 36 0.20 [0.01 , 0.72] 0.92 [0.79, 0.98] 
-Levy 2014 1 6 1 44 0.50 [O.Ql , 0.99] 0.88 [0.76, 0.95] 
--Omata 2011 27 131 50 877 0.35 [0.25, 0 .47] 0.87 [0.85, 0.89] 
---
• 
Park 2010 38 71 34 627 0.53 [0.41 , 0.65] 0.90 [0.87, 0.92] +- .. 
Wong 2014 30 120 137 3840 0.18 [0.12, 0.25] 0.97 [0.96, 0.97] ... • 
Wu 2014 10 83 19 895 0.34 [0.18, 0.54] 0.92 [0.90, 0.93] 1 ~11 I I I I I I • 1 
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 
Figure 4. Forrest plot of all gFOBTand FIT (Type I) for advanced neoplasia. Fora// FIT's a cut-offof 10 meg Hb/ g faeces was used, 
unless this cut-off was unavailable. 
Sensitivities for detecting AN ranged from 0% to 33% for gFOBT and from 5% to 67% for FIT screening. 
Specificities ranged from 79% to 98% and from 86% to 99%, respectively. The cut-off for positivity 
of FIT varied between 2.4 to 50 IJg Hb/g feces. The summary curve estimated by the HSROC model 
for all Type I studies for AN can be found in Figure 5. FIT showed a higher discriminative ability for 
AN than gFOBT (p=0.002). 
In addition, sensitivities and specificities were calculated solely for those studies reporting on FIT 
screening with a cut-off value of 10 IJg Hb/g feces and 20 IJg Hb/g. Analyses for cut-off 10 IJg Hb/ g 
feces contained both qualitative as quantitative FITs. The sensitivity of FIT screening for detection of 
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AN ranged between 5% and 67% with a cut-off of 10 tJg Hb/ g, and from 13 to 44% with a cut-off of 
20 f..ig Hb/ g. The sensitivity for AN was lower for gFOBT screening with a summary sensitivity of 16% 
(95% (112-21 %) compared to 31 % 995% Cl 25-39% for FIT with a cut-off of 10 tJg Hb/ g and 27% 
(95% Cl21 -34%) with a cut-off of 20 tJg Hb/g Specificities of FIT screening for detecting AN ranged 
from 87% to 97% for a cut-off of 10 tJg Hb/ g, and from 89% to 100% for a cut-off of 20 tJg Hb/ g. No 
significant differences in summary specificity for AN were found between gFOBT (94%; 95% Cl 92-
96%), FIT with a cut-off of 10 tJg Hb/ g (95%; 95% Cl 92-97%) and with a cut-off of 20 tJg Hb/ g (97%; 
95% Cl 94-98%). 
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Figure 5. Summary curve using the HSROC model for gFOBT and FIT (Type I) adjusting for multiple cut -offs for advanced neoplasia. 
Scale of individual study points is based on sample size. 
Type I studies - diagnostic test accuracy of gFOBT and FIT for colorectal cancer 
Nineteen type I studies reported on colorectal cancer (CRC) as separate outcome measure; their 
median sample size was 2,235 (range 285 to 18,269). Figure 6 shows the Forrest plot of all included 
studies reporting on colorectal cancer. Sensitivities ranged from 13% to 100% for gFOBT, and from 
0% to 100% for FIT. Specificities ranged from 80% to 98% for gFOBT and from 85% to 96% for FIT. The 
cut-off for positivity of FIT varied between 2.4 to 50 tJg Hb/ g feces. The summary curve estimated 
by t he HSROC model for CRC can be found in Figure 7. FIT showed a higher discriminative ability for 
FJ 
681 Chapter 2 
CRC than gFOBT (p=0.025). 
gFOBT 
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl) 
Ahlquist 2008 12 154 7 3591 0.63 [0.38, 0.84] 0.96 [0.95, 0.97] • • 
Ahlquist 2008 9 87 10 3658 0.47 [0.24, 0.71] 0.98 [0.97, 0.98] • • 
Brenner 2012 2 31 0 613 1 .00 [0. 1 6, 1 .00] 0.95 [0.93, 0.97] • 
Brenner 2013 5 106 10 2114 0.33 [0. 1 2, 0.62] 0.95 [0.94, 0.96] • • 
Graser 2009 30 0 245 1 .00 [0.03, 1 .00] 0.89 [0.85, 0.93] • 
Imperiale 2004 4 142 27 2332 0.13 [0.04, 0.30] 0.94 [0.93, 0.95] 
----
• 
Liebermann 2001 12 227 12 2634 0.50 [0.29, 0.71] 0.92 [0.91 ' 0.93] • • 
Park2010 4 57 9 690 0.31 [0.09, 0.61 l 0.92 [0.90, 0.94] • 
Sung 2003 1 100 3 401 0.25 [0.01 0.81] 0.80 [0.76, 0.83] • 
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 
FIT 
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl) 
Brenner 2012 2 52 0 592 1 .00 [0. 1 6, 1 .00] 0.92 [0.90, 0.94] • 
Chen 2014 9 220 4 5863 0.69 [0.39, 0.91] 0.96 [0.96, 0.97] • • 
Cheng 2002 14 474 2 4577 0.88 [0.62, 0.98] 0.91 [0.90, 0.91] 
-----
• 
Chiu 2013 22 1308 6 16960 0.79 [0.59, 0.92] 0.93 [0.92, 0.93] 
--------
• 
de Wijkerslooth 2012 7 114 1 1134 0.88 [0.47, 1 .00] 0.91 [0.89, 0.92] • • 
Graser 2009 1 44 0 240 1 .00 [0.03, 1 .00] 0.85 [0.80, 0.89] .. 
Haug 201 1 11 142 3 2169 0.79 [0.49, 0.95] 0.94 [0.93, 0.95] • • 
Hernandez 2014 5 62 0 712 1 .00 (0.48, 1 .00] 0.92 [0.90, 0.94] • • 
Imperiale 2014 48 1144 17 8780 0.74 [0.61, 0.84] 0.88 [0.88, 0.89] 
----
• 
Levy 2014 0 7 0 45 Not estimable 0.87 [0.74, 0.94] 
-Levy2014 0 3 1 213 0.00 [0.00, 0.97] 0.99 [0.96, 1 .00] • 
Levy2014 0 42 1 265 0.00 [0.00, 0.97] 0.86 [0.82, 0.90] • 
Levy2014 0 4 0 40 Not estimable 0.91 [0.78, 0.97] 
-Nakama 2000 79 753 17 16815 0.82 [0.73, 0.89] 0.96 [0.95, 0.96] ~ • 
Ornata 2011 6 151 2 926 0.75 [0.35, 0.97] 0.86 [0.84, 0.88] • 
Park 2010 12 97 1 660 0.92 [0.64, 1 .00] 0.87 [0.85, 0.89] 
-
• 
Wong 201 4 2 148 10 3967 0.17 [0.02, 0.48] 0.96 [0.96, 0.97] • • 
Wu2014 3 90 2 912 0.60 [0. 1 5, 0.95] 0.91 [0.89, 0.93] • 
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 
Figure 6. Forrest p lot of all gFOBT and FIT (Type I) for colorectal cancer. For all FIT's a cut-off of 7 0119 Hbl g faeces was used, unless 
this cut-off was unavailable. 
In addition, sensitivities and specificities were calculated solely for those studies reporting on a cut-
off of 10 11g Hb/g feces and 20 11g Hb/g for FIT. Sensitivities for CRC ranged from 13% to 1 OOo/o for 
gFOBT, from Oo/o to 1 OOo/o for a FIT cut-off of 10 11g Hb/ g, and from 50% to 1 OOo/o for a cut-off of 20 11g 
Hb/g. Sensitivity for CRC was lower for gFOBT with a summary sensitivity of 41 o/o (95% Cl 29-54%), 
compared to 81 o/o (95% Cl 71-89%) for a FIT cut-off of 10 11g Hb/ g, and 76% (95% Cl 61-86%) for a 
FIT cut-off of 20 11g Hb/g. Specificities for FIT ranged from 87% to 99% when using a cut-off of 10 
11g Hb/ g, and from 88% to 96% with a cut-off of 20 11g Hb/g. No significant differences in summary 
specificity for colo rectal cancer were found between gFOBT (94%; 95% Cl91 -95o/o), FIT with a cut-off 
of 10 11g Hb/ g (93%; 95% Cl 91-95%), and with a cut-off of 20 11g Hb/ g (93%; 95% Cl 90-95%). 
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Specificity 
Figure 7. Summary curve using the HSROC model for gFOBT and FIT (Type I) adjusting for multiple cut-offs for colorectal cancer. 
Scale of individual study points is based on sample size. 
Type I studies - linked ROC 
Four studies (Brenner 2010, Brenner 2013 & Haug 201 1 combined, Graser, 2009, Hoepffner 2006, 
Park 201 0) compared FIT and gFOBT in the same population. The cut-off for positivity of FIT varied 
between 2.4 to 10 11g Hb/ g feces. The summary curve estimated by the HSROC model for linked 
Type I studies for AN, can be found in Figure 8. FIT showed a higher discriminative ability for AN than 
gFOBT (p=0.073). 
Type I studies heterogeneity analyses 
There was a significant difference in sensitivity or specificity, or both, for males versus females for FIT, 
both for outcome AN as CRC (p<O.OOl ). For gFOBT, difference in accuracy for males versus females 
was significant for outcome AN but not for CRC (p=0.002 and p=0.638, respectively). There was no 
evidence (all p-values >0.01) to suggest a difference in sensitivity or specificity, or both, between 
studies using one, two or three stools per screening round. There was no significant difference in 
sensitivity or specificity, or both, between studies using a quantitative or a qualitative FIT at a cut-off 
of 10 11g Hb/ g for the outcome AN as well as CRC (p = 0.645 and p = 0.21 6, respectively). 
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Figure 8. Linked-HSROC curve of studies (Type I) with outcome advanced neoplasia (including: Brenner 2012, Graser 2009, Brenner 
2013 and Haug 2011 com bined, Park 2010, Hoepffner 2006). Scale of individual study points is based on sample size 
Type I studies sensitivity analyses 
For the analyses including all cut-offs, a sensitivity analysis was undertaken by excluding the studies 
that yielded an high risk of bias following the QUADAS assessment (Aihquist 2008, Brenner 2013, 
Cruz-Correa 2007, Hoepffner 2006, Ornata 2011, Sung 2013). Even when excluding these studies, FIT 
remained significantly superior to gFOBT in the HSROC model. 
Type II studies - diagnostic test accuracy of gFOBT and FIT for colorectal cancer 
There were nineteen type II studies that reported on CRC as separate outcome; their median sample 
size was 7,355 (range 1,1 79 to 747,076). Figure 9 shows the Forrest plot of all included studies 
reporting on CRC. 
Sensitivities for detection of CRC ranged from 57% to 67% for gFOBT, and from 63% to 100% for FIT. 
Specificities ranged from 98% to 99% for gFOBT and from 91 % to 97% for FIT. The cut-offfor positivity 
of FIT varied between 5 to 250 IJg Hb/g feces. The summary curve estimated by the HSROC model, 
including confidence ellipses for all Type I studies for AN, can be found in Figure 10. FIT showed a 
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higher discriminative ability for AN than gFOBT (p<0.001 ). In addition, sensitivities and specificities 
were calculated separately for those studies reporting on a FIT cut-off of 10 ~g Hb/ g feces, and those 
with a cut-off of 20 ~g Hb/g for CRC. Sensitivities for detection of CRC ranged from 75% to 100% 
when using a cut-off of 10 ~g Hb/g, and from 63% to 94% with a cut-off of 20 ~g Hb/ g. Sensitivity 
for CRC was lower for gFOBT with a summary sensitivity of 63% (95% Cl 58-67%), compared to 87% 
(95% Cl 80-92%) for a cut-off of 10 ~g Hb/g, and 88% (95% Cl 74-94%) for a cut-off of 20 11g Hb/ g. 
Specificities for FIT ranged between studies from 92% to 96% when using a cut-off of 10 11g Hb/ g, 
and from 92% to 97% for a cut-off of 20 ~g Hb/ g. Specificity for CRC was higher for gFOBT with a 
summary specificity for colorectal cancer of 98% (95% Cl98-99o/o) for gFOBT, compared to 92% (95% 
Cl 92-95%) for FIT with a cut-off of 10 ~g Hb/ g, and 95% (95% Cl93-97o/o) at a cut-off of 20 ~g Hb/ g. 
gFOBT 
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl) 
Bouvier 1 999 152 1451 100 69604 0.60 [0.54, 0.66] 0.98 [0.98, 0.98] .. • 
Denters 2012 8 45 4 2055 0,67 [0.35, 0.90] 0.98 [0.97, 0.98] • • 
Faivre 2004 42 387 21 23649 0.67 [0.54, 0.78] 0.98 [0.98, 0.99] 
--
• 
Giai 2014 180 1535 138 84897 0.57 [0.51, 0.62] 0.98 [0.98, 0.98] ... • 
Kronborg 1987 14 195 9 20448 0.61 [0.39, 0.80] 0.99 [0.99, 0.99] 
----
• 
Levi 201 1 8 55 5 2173 0.62 [0.32, 0.86] 0.98 [0.97, 0.98] • 
Paimela 2010 66 659 35 36673 0.65 [0.55, 0.75] 0.98 [0.98, 0.98] 
---
• 
Parra-Bianco 2010 8 35 6 1621 0.57 [0.29, 0.82] 0.98 [0.97, 0.99] • 
Steele 2009 367 2595 180 163771 0.67 [0.63, 0.71] 0.98 [0.98, 0.98] .. • I I I I I I 
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 
FIT 
Study TP FP FN TN Sensitivity (9S% Cl) Specificity (95% Cl) Sensitivity (9S% Cl) Specificity (95% Cl) 
Castiglione 2007 65 894 16 26390 0.80 [0.70, 0.88] 0.97 [0.97, 0.97] 
---
• 
Chiang 2014 1197 21539 381 723959 0.76 [0.74, 0.78] 0.97 [0.97, 0.97] • • 
Chiang 2014 284 6639 101 201905 0.74 [0.69, 0.78] 0.97 [0.97, 0.97] .. • 
Crotta 2012 5 62 3 1585 0.63 [0.24, 0.91 ] 0.96 [0.95, 0.97] • 
Denters 2012 12 174 4 2634 0.75 [0.48, 0.93] 0.94 [0.93, 0.95] 
-
• 
ltoh 1996 77 1130 12 26358 0.87 [0.78, 0.93] 0.96 [0.96, 0.96] ...... • 
Launoy 2005 22 344 4 6985 0.85 [0.65, 0.96] 0.95 [0.95, 0.96] 
-----
• 
Levi 2011 6 102 0 1071 1.00 [0.54, 1.00] 0.91 [0.90, 0.93] • • 
McNamara 2014 16 402 4549 0.94 [0.71' 1.00] 0.92 [0.91, 0.93] 
-
• 
Nakama 1996 10 147 4 3204 0.71 [0.42, 0.92] 0.96 [0.95, 0.96] • • 
Parente 2013 95 1957 8 36293 0.92 [0.85, 0.97] 0.95 [0.95, 0.95] ..... • 
Parra-Bianco 2010 14 129 0 1573 1.00 [0.77, 1.00] 0.92 [0.91, 0.94] 
-
• 
Sieg 2002 23 206 6 5053 0.79 [0.60, 0.92] 0.96 [0.96, 0.97] 
-----
• 
van Roon 2013 22 338 2 4141 0.92 [0.73, 0.99] 0.92 [0.92, 0.93] 
-----
• 
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 
Figure 9. Forrest plot of all gFOBT and FIT (Type II) for colorectal cancer. For all FIT's a cut-off of 7 0 meg Hb!g faeces was used, unless 
this cut-off was unavailable. 
Type II studies heterogeneity analyses 
There was a significant difference in sensitivity or specificity, or both, for males versus females for 
gFOBT, for the outcome CRC (p<0.001 ). There was no significant difference in sensitivity or specificity, 
or both, between studies using a quantitative or a qualitative FIT at a cut-off of 10 ~g Hb/ g for the 
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outcome CRC (p = 0.684). Heterogeneity related to the number of stools per screening round was 
not performed for gFOBT since all studies used three stools. For the following covariates analyses 
were not possible due to convergence difficulties; gender for FIT, number of stools for FIT. 
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Figure 10. Summary curve using the HSROC model for gFOBT and FIT (Type II) adjusting for multiple cut-offs for co/orectal cancer. 
Scale of individual study points is based on sample size. 
Type II studies sensitivity analyses 
For the analyses including all cut-offs, a sensitivity analysis was undertaken by excluding the studies 
that yielded an high risk of bias following the QUADAS assessment (Giai 2014, ltoh 1996 Nakama 
1996, Parra-Bianco 2010, Sieg 2002)l1•72•76•79•82.Even when excluding these studies, FIT remained 
significantly superior to gFOBT in the HSROC model. The effect of removing studies, in which 
the percentage of participants with a positive FOBT that underwent the reference standard was 
unknown, was herein evaluated (Nakama 1996, Giai 2014)11•76• 
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Table 3. Summary of findings. 
Diagnostic accuracy of gFOBT compared to FIT 
Patients/ population 
Prior testing 
Settings 
Index test 
Importance 
Reference standard 
Studies 
Quality concerns 
Test /subgroup* 
Type I 
advanced neoplasia 
co/orectal cancer 
Type II 
co/orectal cancer 
Conclusions 
Asymptomatic, average-risk individuals over the age of 40 years undergoing colorectal 
cancer screening 
Only the results of the first screening round were included in this analysis 
Population- based colorectal cancer screening 
Guaiac faecal occult blood test or faecal immunochemical test 
Many screening programmes worldwide are currently changing from gFOBT to FIT-based 
screening 
Colonoscopy is the gold standard for the diagnosis of colo rectal cancer w hich was used as 
the reference standard. Only in case a colonoscopy was not complete a CT-colonography (or 
double contrast barium enema) was used as a surrogate. 
Prospective and retrospective studies including average-risk individuals invited for 
colorectal cancer screening 
Type 1: all screenees underwent both the index test and colonoscopy (n=23). 
Type II : only screenees with a positive index test underwent colonoscopy and all screen 
negatives were followed for at least one year (n=19). 
Due to strict inclusion criteria most studies were of high quality. Few studies had unclear risk 
of bias due to poor reporting of a pre-specified cut-off value. Only three studies had a high 
risk of bias regarding the selection of study population. Regarding these studies, sensitiv ity 
analyses showed significant differences in outcome when excluding these studies from 
analyses. 
studies summary summary summary summary 
(participants) sensitivity specificity sensitivity specificity 
gFOBTIFIT gFOBT gFOBT FIT* FIT* 
(%, 95% Cl) (o/o, 95% Cl (o/o, 95% Cl) (o/o, 95% Cl) 
1 o (15.7 41 ) I 15 (12-19) 94 (91 -96) 31 (25-39) 95 (92-97) 
16 (55.881) 
8 (15.465) I 41 (29-54) 94 (91-96) 82 (71-89) 93 (90-95) 
15 (69.998) 
9 (413.191 )1 14 63 (58-67) 98 (98-99) 87 (80-92) 92 (92-95) 
(1.082.153) 
The results of this syst ematic review concludes that FIT is the preferred tool for FOBT-based 
population CRC screening due to the higher sensitivity and comparable simi lar specificity as 
compared to gFOBT. 
CAUTION: The results on this table should not be interpreted In Isolation from the results of the individual Included studies contributing to each summary test accuracy measure. 
These are reported in the main body of the text of the review. 
*results for FIT cut-off 10 ~9 Hb/ g faeces are shown. 
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Discussion 
The main results are presented in the summary of findings (Table 3). For this review we chose to 
include two types of studies and report the results separately as they differ in type of study and 
yield comparable but not similar results. We included twenty-three type I studies and nineteen 
type II studies. Four type I studies evaluated the diagnostic accuracy of gFOBT, thirteen studies 
evaluated FIT and four studies assessed both gFOBT and FIT tests. Twenty-one studies evaluated the 
diagnostic accuracy for advanced neoplasia and nineteen studies evaluated the diagnostic accuracy 
for colorectal cancer. FIT showed a higher discriminative ability than gFOBT as assessed by the 
HSROC curve for both advanced neoplasia (p=0.002) and CRC (p=0.025). As type I studies allowed 
the use of multiple FIT cut-offs within one study population, the two most commonly used cut-offs 
worldwide (1 0 and 20 11g Hb/g feces) were analysed separately and these results were in line with the 
overall analyses. Nineteen type II studies were included, with six studies evaluating the diagnostic 
accuracy of gFOBT, ten studies evaluating FIT, and three studies combining both. In type II studies 
FIT also showed a higher discriminative ability than gFOBT as assessed by the HSROC curve for CRC 
(p<O.OOl ). The results of this systematic review demonstrate that FIT is the preferred tool for FOBT-
based population screening due to the superior sensitivity and similar specificity compared as to 
gFOBT screening. Furthermore, beside some qualitative tests, many FITs are quantitative tests which 
allows use of different cut-offs to tailor for screening resources and colonoscopy capacity. Finally, 
various studies have consistently shown that FIT screening is associated with higher uptake than 
gFOBT screening which is an important finding to reach a high coverage of the target population 
(i.e. cumulative uptake). 
Strengths 
The results of this review are based on strict and thorough searching without any language or date 
restrictions. The use of diagnostic test accuracy, or randomised controlled trial filters may lead to 
the loss of some studies, for this reason we have not used any filters84• Two independent reviewers 
identified and extracted data from the studies, thus decreasing inaccuracies related to single-person 
data extraction85• All included studies reported the results for average-risk, asymptomatic individuals 
after the age of 40 years, making our results reflective of a screening population. Also, data for 
different cut-offs were retrieved, in cases where this had not already been reported in the original 
publication, contacting the author provided additional data for most studies allowing sub-analyses 
with the two most commonly used cut-offs. These cut-offs were converted to the internationally 
used measuring standard of 11g Hb/g feces34• To avoid potential bias caused by the use of an 
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inappropriate reference standard, e.g. barium-enema or sigmoidoscopy, we restricted the studies to 
those with colonoscopy as the reference standard. As mentioned above, two types of studies were 
included for this review and analysed separately. The inclusion of type I studies allowed evaluating 
both advanced neoplasia and colorectal cancer as outcome of FOBT-based screening. Advanced 
neoplasia is of special importance because by removing adenomas development of colorectal 
cancer and CRC deaths might be prevented29.86. In type II studies sensitivities and specificities were 
calculated with the use of interval carcinomas identified through adequate follow-up as a surrogate 
for the gold standard; colonoscopy. This different character of type I and type II studies may explain 
the observed differences in sensitivity and specificity. The use of interval carcinomas as endpoint in 
type II studies may underestimate the true proportion of false negatives, as by definition only those 
cancers were reported that had become clinically evident during the observation period. On the 
other hand, Type II studies are more reflective of a FOBT based screening programme in a general 
population. In these studies willingness to undergo FOBT as a primary screening tool was assessed 
whereas in type I studies participants had to be willing to undergo a full colonoscopy irrespective 
of the FOBT-result. For this reason type II studies are also often performed in larger populations. 
Combining both types of studies provides insight on both settings, and results in a broad evaluation 
of FOBT diagnostic test accuracy in colorectal cancer screening. Type I studies give insight in test 
sensitivity, whereas type II studies give insight in program sensitivity. The overall quality of included 
studies was high, supporting the validity of the results of our analyses. 
Weaknesses 
This systematic review was designed to evaluate the diagnostic test accuracy of two types of FOBTs 
commonly used for colorectal cancer screening. Even though diagnostic test accuracy is of major 
importance in screening, usability of the test and participation, e.g. willingness to undergo the 
screening test, is also very relevant. One major limitation of this review is that these latter points 
have not been taken into account for this review as they do not involve diagnostic test accuracy. 
Yet, these factors are also of importance when estimating screening efficacy on population level 
(programme sensitivity and specificity). The ultimate purpose of screening programmes is a 
decrease in colorectal cancer-related mortality. However, diagnostic test accuracy can only be 
used as a surrogate in estimating mortality decrease after screening. In past years, results of large 
prospective gFOBT-based screening trials have been published that unfortunately could not be 
included in this review as their main outcome was mortality. Mortality rates could not be converted 
into contingency tables to calculate sensitivity and specificity. We excluded non-interpretable test 
results and FOBT-positives who refused to undergo the reference standard from the 2x2 table and 
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in consequence from the meta-analysis. Missing FOBT results are likely to be completely random 
(incidental missing data) and will not lead to biased estimates of test accuracy. Because only the 
participants who received the reference standard were included in the type I studies analysis 
(complete case analysis) and positive participants who did not receive the reference standard in the 
type II studies were excluded from analysis, estimates of the accuracy of the diagnostic tests could 
be biased87. Because of the large size of the studies, we believe that excluding these participants 
for whom the reference standard result is missing is mostly at random and will not bias the results 
but will only decrease precision. We attempted to conduct a comprehensive search for studies, but 
the fact that the studies awaiting classification have not yet been incorporated may be a source of 
potential bias. Another limitation is the inability to explore the sources of heterogeneity concerning 
age, gender, ethnicity, adenoma type, tumour localization and stage distribution, because of limited 
information in the included studies. This problem was more prominent in type II studies, which 
often described large populations without prospective registration of study outcomes, but rather 
national databases of hospitals or cancer registries. The chosen random effect model accounts to 
a certain level for heterogeneity across studies by considering both within and between-study 
variation. This leads to a greater precision of the pooled estimates, but larger confidence88.For only 
for a limited amount of studies was a direct comparison possible, as most studies did not perform 
both tests in the same patients. This could be a limitation, as results from non-comparative studies 
may differ from comparative studies89.However, in this review results from the comparative studies 
are in line with the overall results. Many test brands are available, and sub analyses of these brands 
was not possible due to limited data and the use of different sub-types of the same brand. 
A previously published meta-analysis evaluated the test accuracy of FIT for colorectal cancer but not 
advanced neoplasia and did not compare these results to the performance of gFOB~0.To the best 
of our knowledge there is only one other systematic review comparing the diagnostic test accuracy 
of gFOBT and FIT74 .The highest summary sensitivity of this study for FIT (OC-sensor) was 87% and 
specificity was 93%, and for gFOBT (Hemoccult,) the summary sensitivity was 47% and summary 
specificity was 95%. They did not distinguish between type I, type II, and case-control studies, 
possibly leading to underestimation (type II studies) or overestimation (case-control) studies of 
test accuracy30• Even though this large variation in type of studies included, their search strategy 
was very limited yielding only 761 hits and 22 inclusions. Finally, only three brands of FOBTs were 
included in their meta-analysis. In general this is the first review to adequately and systematically 
present an evaluation of gFOBT and FIT screening in an average-risk population. 
Applicability of findings to the review question 
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All participants included in this review were asymptomatic, average-risk individuals over the age 
of 40 years old, and invited for colorectal cancer screening, making the findings of this review 
extremely relevant for colorectal cancer screening programmes. Two types of studies were included. 
Type I studies are more homogenous than type II studies, yet may be less representative of a FOBT-
based screening population. This is due to the fact that all screenees had to be willing to undergo 
colonoscopy. For type II studies false negatives were identified through interval carcinomas that 
were identified during follow-up. This might give an underestimation of test sensitivity, yet is 
appropriately representative of FOBT population-based screening programmes. 
Implications for practice 
Fecal immunochemical testing has a superior sensitivity compared to guaiac fecal occult blood 
testing and is the preferred method of occult blood screening in terms of diagnostic test accuracy. 
Test usability and participation were not evaluated for the purpose of this review. The summary 
of findings table should be interpreted with acknowledgement of this. However, FIT's quantitative 
nature allows the use of different cut-offs tailoring to screening resources and colonoscopy 
capacity24• Furthermore, it should be noted that several studies consistently reported higher rates 
of participation for FIT than for gFOBT screening91 •92• Both gFOBT and FIT have lower sensitivity for 
colorectal cancer than colonoscopy as gold standard. However, when combining test accuracy 
with participation FIT-based screening in many populations results in a higher diagnostic yield of 
advanced neoplasia compared to other CRC screening methods10•28• 
Implications for research 
Future studies should be conducted in a prospective manner mimicking population-based 
colorectal cancer screening and targeting average-risk populations. We encourage authors to 
systematically report data on participation, positivity rate and colonoscopy adherence. Also, future 
studies should report a clear definition of advanced neoplasia and interval carcinomas. In the 
included studies definitions of interval carcinomas were often vague or completely missing. The 
ultimate purpose of colorectal cancer screening is decreasing mortality, so future studies should be 
conducted to compare long-term follow up on mortality between gFOBT- and FIT-based colorectal 
cancer screening programmes. 
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Abstract 
Background Several modalities for colorectal cancer (CRC) screening are available; these in 
particular include colonoscopy, flexible sigmoidoscopy (FS) and fecal immunochemical testing 
(FIT). No literature is available on the comparison of endoscopic screening and multiple rounds of 
FIT screening. 
Methods We compared three CRC screening strategies involving 30,007 asymptomatic persons 
aged 50-74 years. Selected persons were either invited for four rounds of FIT (n=15,046), for once-
only FS (n=8,407), or for once-only colonoscopy (n=6,600). Primary outcome was diagnostic yield 
(DY) of advanced neoplasia (AN), evaluated in an intention-to-screen analysis (defined as number 
of screenees with AN detected relative to all invitees) and in an as-screened analysis (defined as 
number of screenees with AN detected relative to all participants). 
Results Participation rate was significantly higher for FIT screening (77%) than for FS (31 %; p<0.001) 
and colonoscopy (24%; p<0.001). Number of colonoscopies performed relative to eligible invitees 
was higher for colonoscopy (24%) compared to FIT (13%; p<0.001) and FS (3%; p<0.001). In the 
intention-to-screen analysis, the DY for AN was higher with FIT-screening (4.5%; 95% Cl 4.2-4.9), 
compared to colonoscopy (2.2%; 1.8-2.6) and FS (2.3%; 2.0-2.7).1n the as-screened analysis, detection 
of AN was higherfor endoscopic screening: 9.1 % (7.7-1 0.7) with colonoscopy and 7.4% (6.5-8.5) with 
FS, compared to 6.1 % with FIT (5.7-6.6). CRC detection among participants was similar for all three 
strategies. Number needed to screen to detect one AN was lower for FIT: 22 screenees, compared to 
43 for FS and 46 for colonoscopy. 
Conclusion Multiple-round FIT screening detects significantly more AN on a population level, 
compared to once-only FS and colonoscopy screening, and with significantly fewer colonoscopies 
needed. 
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Introduction 
Colorectal cancer (CRC) is the third most common malignancy in the world. Its incidence increases, 
both as a result of expansion of the elderly population as well as an increase in risk factors 1• The 
implementation of CRC screening programs has increased substantially over the past decades. A 
range of screening methods is available, varying in invasiveness and diagnostic accuracy. It is yet 
unclear which modality has the largest effect on CRC-related morbidity and mortality2• At present, 
screening programs differ markedly around the world, with colonoscopy, flexible sigmoidoscopy 
and faecal occult blood testing as the most commonly used screening strategies3. 
Colonoscopy as a first-line screening tool is more popular in the United States, whereas most 
countries in Europe and Asia prefer a two-step approach using less invasive screening methods, 
such as fecal occult blood testing or sigmoidoscopy as a first screen, followed by a colonoscopy in 
case of a positive test3. This two-step approach has the advantage of potentially higher participation 
rates and a lesser demand on colonoscopy capacity, but the disadvantage of lower sensitivity for 
detection of advanced neoplasia. 
Annual or biennial screening with guaiac fecal occult blood testing has been shown to reduce CRC 
mortality rates 1 1• 12• At, present, the use of the guaiac test is largely replaced by FIT, as quantitative test 
for hemoglobin, FIT has a higher diagnostic accuracy for AN and is easier to use13. 16 • Nevertheless, 
FIT still has a relatively low sensitivity for CRC, and especially advanced adenomas, with reported 
cancer miss rates of 25% in a single round of FIT-screening 17• Consequently, the effectiveness of a 
FIT-screening program is highly dependent on participation and adherence to repeat screening, e.g. 
longitudinal adherence18• 
As the majority of advanced neoplasia is located in the rectum and sigmoid colon, flexible 
sigmoidoscopy is considered a suitable method for CRC screening8• Several large randomized 
trials reported corresponding CRC-related mortality reductions rang ing between 31 % and 38% 
8
'
10
• However, concerns have been raised about missing proximal advanced neoplasia, and the 
subsequent limited efficacy in reducing proximal CRC. 
Colonoscopy is currently considered as the reference standard for diagnosing CRC and its precursor 
lesions, colorectal adenomas. It allows for simultaneous inspection of the colon and removal of 
lesions. Currently, no literature is available on the effect on mortality rates of primary colonoscopy 
screening in randomized trials. For that purpose, three randomized controlled colonoscopy screening 
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trials started a few years ago, of which the first results are expected after 20204-6. A systematic 
review and meta-analysis of observational colonoscopy studies suggested that colonoscopy led to 
a significant mortality reduction with a summary estimate of 68% 7• While colonoscopy is highly 
effective in detecting CRC and colorectal adenomas, it is also an invasive procedure associated with 
patient discomfort, complication rates and substantial costs. 
Several studies have compared endoscopic screening strategies to FIT and find higher uptakes for 
FIT screening yet lower detection rates for advanced neoplasia+6.However, these studies comprise 
only one round of screening, while true the impact of FIT-screening is attained over multiple rounds. 
For this reason we aimed to compare the diagnostic yield of once-only colonoscopy, once-only FS 
and four rounds of FIT in population-based CRC screening, including interval cancer rate. As it is of 
key importance for policy makers to know the impact of different screening programs over multiple 
rounds with long-term follow up. 
Methods 
Study population and design 
For the purpose of this study we combined the results of three population trials, each comprising 
randomly selected, screening-naive persons from the same source population. The design of these 
trials has been described previously 19•22• 
In short, 30,052 asymptomatic persons aged 50 to 75 years living in the west of the Netherlands were 
invited for CRC screening. These persons were randomly selected from municipal registers, sorted 
according to household and were randomized before invitation. Those allocated to FIT-screening 
were invited between November 2006 and December 2014 for four rounds of FIT-screening with 
two-year intervals. Those allocated to flexible sigmoidoscopy (FS) were invited between November 
2006 and November 2007, for once-only FS. Those allocated to colonoscopy were invited between 
June 2009 and August 2010 for once-only colonoscopy. 
Symptomatic persons with rectal blood loss or a recent change in bowel habits were asked not to 
participate but to consult their general practitioner. Persons with a history of CRC or inflammatory 
bowel disease were also asked not to participate. Participants reporting a colonoscopy or CT-
colonography in the past 3 years, those with an estimated life expectancy of less than 5 years, and 
those who were not able to give informed consent were excluded. In the FIT-screening cohort, 
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persons were notre-invited for following rounds in case of a positive FIT in a previous round, passing 
the upper age limit or, or moving out ofthe selected postal area. 
Intervention 
All invitees received an advance notification letter, followed by a kit two weeks later by postal mail. 
This kit contained an invitation letter, information brochure, and an informed consent form. For 
FIT-invitees the kit further contained a single FIT-test and testing instructions. For FS-invitees and 
colonoscopy-invitees the invitation letter contained a telephone number of the screening unit to 
schedule an appointment for an intake. A reminder was sent six weeks after the initial invitation to 
invitees who had not yet responded. 
Fecal immunochemical test 
Persons allocated to FIT received one FIT every two years. They were instructed to collect a single 
sample of one bowel movement. In the first 3 rounds invitees received the OC-Sensor (Eiken, Japan), 
and in the fourth round invitees were randomized to receive either the OC-Sensor or the FOB-
Gold (Sentinel, Italy). Invitees were asked to sample feces according to instructions and post the 
feces sample within 24 hours after collection, keeping the sample in the refrigerator until mailing. 
Participants signed an informed consent form with the date of sample collection. The test result 
was considered positive when the hemoglobin concentration in the FIT sample was ;;::: 10 11g Hb/ g 
faeces. Previous results have shown that the OC-Sensor and FOB-Gold perform equally well over the 
relevant concentration range 23. 
Flexible sigmoidoscopy 
Invitees allocated to an intake appointment who had scheduled for sigmoidoscopy received a 
phosphate enema by mail with instructions for self-administration. Administration of the enema 
by a nurse in the screening unit was offered as an alternative. All sigmoidoscopies were performed 
by experienced endoscopists in a dedicated centre. The FS was defined as complete when reaching 
the splenic flexure. Participants did not receive sedatives. Participants were referred for colonoscopy 
when one of the following criteria was met: presence of a polyp with a diameter ;::: 10 mm; an 
adenoma with serrated, villous histology (;:::25% villous) or high-grade dysplasia; ;:::3 adenomas; ;:::20 
hyperplastic polyps; or invasive CRC. 
Colonoscopy 
All FIT-positive, FS-positive or once-only colonoscopy participants were scheduled for colonoscopy, 
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unless contraindicated. Experienced endoscopists (> 1000 colonoscopies) performed all 
colonoscopies for this study. Participants received standard bowel preparation: low-fibre diet and 
oral intake of 2 litres of transparent fluid and a laxative solution (Moviprep; Norgine, Amsterdam, 
The Netherlands or Picoprep; Ferring, Hoofddorp, The Netherlands) at home. Colonoscopy was 
performed under conscious sedation with carbondioxide insufflation. All quality parameters 
were recorded on a standardized clinical record form (CRF). Polyps were removed during the 
same procedure if possible. If immediate endoscopic treatment was impossible, the screenee was 
either planned for a second look colonoscopy to remove the lesion or, biopsies were obtained and 
pathological assessment of these tissue samples provided a definitive diagnosis and participant 
was referred to our colorectal multidisciplinary team for further treatment. In case of incomplete 
colonoscopy, a computed tomographic colonography (CTC) was performed. All complications were 
registered. Surveillance after removal of adenomatous polyps, large (~ 10 mm) serrated lesions 
or cancer was recommended according to the Dutch surveillance guideline24• Screenees with a 
negative colonoscopy were discharged from screening for 10 years. 
Colorectal Lesions 
The following data on colorectal lesions were collected with the case report form: location, size, 
macroscopic aspect, and morphology. Additionally, details on polypectomy technique and 
endoscopic assessment of radicality were recorded for all lesions detected during colonoscopy. 
All removed lesions were collected and evaluated by an experienced gastrointestinal pathologist 
according to the Vienna criteria25. The lesions were classified as adenoma (tubular, tubulovillous, 
villous), serrated polyp (hyperplastic, sessile serrated adenoma, traditional serrated adenoma), 
adenocarcinoma or miscellaneous. Dysplasia was defined as either low-grade or high-grade. 
Advanced adenomas were defined as adenomas ~ 10 mm, adenomas with high-grade dysplasia 
or adenomas with a villous component of at least 25%. Cancers were staged according to the 
American Joint Committee on Cancer classification26• AN was defined as advanced adenoma and/ 
or colorectal cancer. 
Screen detected and Interval colorectal cancers 
Screen detected CRCs were defined as CRCs detected by screening. An interval colorectal cancer was 
defined as a CRC diagnosed in the interval between a negative screen and the next recommended 
exam27• Data from all invitees were linked to our Dutch Comprehensive Cancer Centre to identify 
interval cancers, which was up to date until March 2015. 
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Statistical analysis 
The main outcome of this study was the diagnostic yield of AN. This was analysed both in an 
intention-to-screen analysis, where it was defined as the number of screenees with AN relative to 
all invitees, and as an as-screened analysis, in which it was defined as the number of screenees 
with AN relative to all participants. Additionally, we evaluated participation rate, positivity rate and 
colonoscopy rate for each screening strategy. For FIT-screening cumulative rates over four rounds 
were used in these analyses. Moreover, results per FIT-screening round were separately calculated 
and presented. Participation rate was calculated as the number of invitees returning a FIT relative 
to the number of all eligible invitees. Positivity rate was defined as the proportion of participants 
having a positive test result relative to the number of tests returned. Differences in means were 
analysed using Student's t-test. Differences in proportions were analysed using Chi-square testing. 
Participation rate, positivity rate and diagnostic yield are reported as proportions with 95% 
confidence intervals. All tests were conducted using SPSS version 21.0 (SPSS Inc, Chicago, Ill). 
Ethical approval 
The Dutch National Health Council approved the study (decisions 2006/02 WBO, 2009/03WBO, 
2013/20 WBO, The Hague, Netherlands). All screenees gave written informed consent. 
Results 
Screening population 
A total of 30,052 average-risk persons were randomly selected to be invited for colorectal cancer 
screening. Five percent of these (n=1 ,485) did not meet the inclusion criteria, resulting in 14,651 
invitees for FIT-screening, 7,882 invitees for FS-screening, and 5,982 invitees for colonoscopy 
screening. The median age was similar for all three screening groups: 59 years for FIT (IQR 55-65 
years), 59 years for FS (IQR 54-65) and 60 years for colonoscopy (IQR 54-65). There were no gender 
differences, with 50% (n=14,328) of the invitees being male (FIT n=7,264 (50%); FS n=3,941 (50%); 
colonoscopy n= 2,982 (50%)). 
Participation and colonoscopy rates 
An overview of the study design, participation rates and adherence to diagnostic follow-up is 
provided in Figure 1. In the FIT-group, participation rates were significantly higher with 73% of 
invitees participating at least once and 60% participating to the first invitation, compared to 30.9% 
of invitees in the FS group and 23.8% of invitees in the colonoscopy group (p<0.001 ). Among FIT-
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screenees, 18.9% had a positive FIT in one of the four rounds, whereas 9% of FS-screenees had a 
positive test. As a result of these participation and positivity rates, a total of 12.8% of those invited 
for FIT-screening underwent a colonoscopy, for the FS group this figure was 2.7% and for the 
colonoscopy group this was the highest with 23.8% (p<0.001 ). 
Selection from general population north and south regions of the Netherlands 
n = 30,052 
I 
I I I 
Frr Sigmoidosropy Colonoscopy 
n =15,046 n = 8,406 n = 6,600 
Eligible invitees Eligible invitees Eligible invitees 
n=14,651 n=7,882 n=5,982 
I I 
Partid pati on rate t Participation rate Partid pati on rate 
73% 31% 24% 
(n=10.743) (n=2,435) (n=1,426) 
I I 
Posti vity rate H Positivity rate * 
19% 9.0% 
(n=2,054) (n=219) 
I I 
Colonoscopies § Colonoscopies § Colonoscopies § 
13% 3% 24% 
(n= 1,879) (n= 216 ) (n= 1,426) 
... . . . t culllulati.ve, '*'among p articipants , § am.ong el i!:Jible invitees 
Figure 1. Study flow: three screening trials. 
Diagnostic yield 
In the intention-to-screen analysis including all invitees, FIT detected significantly more AN compared 
to FS and colonoscopy; 4.5% (95% Cl4.2-4.9) versus 2.3% (95% Cl 2.0-2.7) and 2.2% (95% Cl 1 .8-2.6; 
Table 1 ), respectively. Moreover, FIT detected three times more CRC per invitee than endoscopic 
screening: 0.6% (95% Cl 0.5-0.7) versus 0.2% (95% Cl 0.1 -0.3; Table 1) for both colonoscopy and FS. 
Higher rates of non-advanced adenomas and small serrated polyps were found for colonoscopy 
and FS compared to FIT. Among screenees with serrated polyps, similar rates of sessile serrated 
adenomas or large hyperplastic polyps (i.e. > 1 Omm) were found for all strategies, with 0.2% (95% Cl 
0.1 -0.3) for FIT, 0.1 % (95% Cl 0.1 -0.2) for FS and 0.3% (95% Cl 0.3-0.5) for colonoscopy. Figure 2 shows 
the cumulative increase in diagnostic yield for AN and CRC (supplementary Table 1 provides the 
cumulative participation rate, positivity rate, colonoscopy rate and diagnostic yield among invitees 
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of FIT-screening over four rounds). 
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Figure 2. Cumulative diagnostic yield (DY) over four rounds of FIT-screening for advanced neoplasia (AN) and colorectal cancer (CRC) 
in the intention-to-screen analysis (A) and as-screened analysis (8). 
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Table 7. Diagnostic yield of three screening strategies. 
Intention-to-screen 
Advanced neoplasia 
Colorectal cancer 
Advanced adenomas 
Non-advanced adenomas 
Serrated polyps 
As-screened 
Advanced neoplasia 
Colorectal cancer 
Advanced adenomas 
Non-advanced adenomas 
Serrated polyps 
Non-screen detected * 
Interval cancer 
• maximum follow-up: colonoscopy= 5.8 years, FS= 5 years, FIT = 8.3 years 
" 0.13% FIT-interval cancer 0.05% post-colonoscopy interva l cancer 
- 0.09% FS-interval cancer 0.03% post -colonoscopy interval cancer 
Interval cancers 
FIT 
o/o (95o/o Cl) 
(n= 14,651) 
4.5 (4.2-4.9) 
0.6 (0.5-0 .7) 
3.9 (3.6-4.3) 
3.2 (2.9-3.5) 
1.1 (0.9-1.3) 
(n= 10,743) 
6.1 (5.7-6.6) 
0.8 (0.6-0.9) 
5.4 (5.0-5.8) 
4.3 (3.9-4.7) 
1.5 (1.3-1.7) 
(n= 14,651) 
0.2 (0.1 -0.3)** 
Sigmoidoscopy Colonoscopy 
o/o (95o/o Cl) o/o (9So/o Cl) 
(n= 7,882) (n=5,982) 
2.3 (2.0-2.7) 2.2 (1.8-2.6) 
0.2 (0.1 -0.3) 0 .2 (0.1 -0.3) 
2.1 (1.8-2.4) 2.0 (1.7-2.4) 
3.7 (3.3-4.1) 5.6 (5.0-6.2) 
5.9 (5 .4-6.4) 3.9 (3.5-4.5) 
(n=2,435) (n= 1,426) 
7.4 (6.5-8.5) 9.1 (7.7-10.7) 
0.5 (0.3-0.9) 0.6 (0.3-1 .2) 
6.7 (5.8-7.8) 8.5 (7.1-10.0) 
12.0 (1 0 .7-13.3) 23.4 (21.3-25.7) 
19.1 (17.5-20.7) 16.5 (14.6-18.5) 
(n= 7,882) (n= 5,982) 
0 .1 (0-0.2)*** 0.01 (0-0.1 ) 
Linkage to the Dutch Comprehensive Cancer Centre provided data on interval cancers (Table 1 ). 
Among invitees, 19 (0. 13%) FIT-negative screenees developed a cancer within the screening interval, 
6 (0.09%) FS-negative screenees, and 1 (0.01 %) colonoscopy screenee developed CRC, despite the 
absence of advanced neoplasia at colonoscopy. Furthermore, 7 post-colonoscopy CRC (0.05%) 
were diagnosed in those with a positive FIT, and 1 (0.03%) in a participant with a positive-FS. Taking 
into account these program-related interval cancers, endoscopic screening had a significantly 
lower interval cancer rate compared to FIT-screening (Table 1 ). However, it should be noted that 
colonoscopy had a much shorter follow-up time than FIT-screening, 5.8 years compared to 8.3 years 
respectively. 
In the as-screened analysis, including only those who participated in screening, colonoscopy 
detected more AN (9.1 %; 95% Cl 7.7-1 0.7) than FS (7.4%; 95% Cl 6.5-8.5) and FIT (6.1 %; 95% Cl 5.7-
6.6). However, CRC detection rates were similar for FS (0.5%; 95% Cl 0.3-0.9), colonoscopy (0.6%; 95% 
Cl 0.3-1.2) and FIT (0.8; 95% Cl 0.6-0.9). Colonoscopy detected more non-AN, with almost a quarter 
of the participants having non-AN as most advanced finding (23.4; 95% Cl 21.3-25.7). 
Regarding serrated polyps, FIT-screening yielded the lowest rate of 1.5% (95% Cl 1.3-1.7) compared 
to colonoscopy (16.5%; 95% Cl 14.6-18.5) and FS (19.1 %; 95% Cl 17.5-20.7). No differences were 
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found regarding stage and location of CRCs among the three screening strategies (Table 2). 
The number needed to invite (NNI) to detect one participant with AN was 22 for FIT, 43 for FS and 
46 for colonoscopy. The NNI to detect one CRC was 178, 606 and 664, respectively. [NNS toevoegen] 
Next, the number needed to scope by colonoscopy (NNSc) to detect one AN was 2 for FIT, 3 for FS 
and 11 for colonoscopy. The NNSc to detect one CRC was 23, 17 and 159, respectively. 
Table 2. Location and stages of screen-detected cancer and interval cancers. 
FIT FS Colonoscopy 
Screen- Interval cancer Screen- Interval cancer Screen- Interval cancer 
detected cancer detected cancer detected cancer 
% (n=83*) % (n= 1 9*) % (n= 1 3) % (n= 1 0*) % (n=9) % (n= 1) 
Stage 
54(45) 26 (S) 77 (10) 20 (2) 78 (7) 
II 13 (1 1) 16 (3) 0(0) 20 (2) 1 1 (1) 100 (1) 
Ill 32 (26) 37 (7) 23 (3) 40 (4) 1 1 (1) 
IV 1 (1 ) 21 (4) 0(0) 20 (2) 0 (0) 
Location 
Distal 68 (56) 58 (11 ) 85 (1 1) 3 (30) 44(4) 
Proximal 32 (27) 42 (8) 15 (2) 7 (70) 56 (S) 100 (1) 
*post-colonoscopy CRC not included 
Stages and location of screen-detected and interval cancers 
Location and stages of screen-detected cancers and interval cancers are described in Table 2. No 
significant differences were seen between the three screening strategies when comparing stages of 
screen-detected cancers (p=0.54), nor between location of lesions (i.e. distal vs. proximal; p=0.19). 
However, it should be noted that few proximal cancers were detected in the FS-screening group. 
Regarding the interval cancers after a negative FIT or FS, participants had a comparable distribution 
of cancer stage, both with around 20% stage IV cancers. Notably, most interval cancers in the FS 
group were located in the proximal colon. Only one interval cancer was detected in the colonoscopy-
arm, which was a stage II tumor and located in the proximal colon. 
Discussion 
This analysis of three large CRC screening trials is the first to report outcomes of endoscopic-
screening versus multiple rounds of FIT-screening in an average-risk population. Our results indicate 
a higher diagnostic yield of AN among invitees in FIT-screening, compared to FS-screening and 
colonoscopy-screening. No differences were found regarding the detection of CRC among all three 
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strategies. This yield was reached with significantly fewer colonoscopies for FIT- and FS-screening 
compared to colonoscopy-screening. Among participants, colonoscopy had the highest diagnostic 
yield for AN, while also detecting the largest number of clinically non-relevant neoplasia. 
Our study has several strengths; firstly, invitees were all randomly selected from the same population, 
using equal criteria for selection. All data were prospectively collected and screenees were I inked to 
the Netherlands Cancer Registry by the Dutch Comprehensive Cancer Centre to account for interval 
cancers. Since 1989, the Netherlands Cancer Registry registers all patients diagnosed with cancer 
in the Netherlands and provides a unique and fully covered database. Furthermore, for all three 
screenings strategies, all endoscopies were performed in the same endoscopy centres with similar 
quality indicators and performance. As there was no national screening program at the start of the 
screening studies, this could not have influenced awareness and subsequently participation rates. 
To fully appreciate our results, some limitations also need to be addressed. The colonoscopy-
screening trial started three years later than the FIT-screening and FS-screening trials, leading to 
different follow-up times. This makes comparing interval cancer rate between the three modalities 
arduous. Additionally, ideally one more round of FIT and subsequent two-year follow-up should be 
completed to encompass the same time frame (i.e. 1 0 years) for each screening modality and thus 
to be able to fully compare the results to colonoscopy screening. 
Participation rates are of crucial importance in a screening program, as they directly affect diagnostic 
yield. While a small difference in uptake might seem irrelevant, in population-based screening such 
small percentages can lead to large numbers of additional screenees28• In our study, participation 
rates were highest for FIT and lowest for colonoscopy screening. Though participation rates vary 
widely geographically, endoscopic screening consistently shows lower participation rates compared 
to FOBT-based screening3• 4• 10• 29.31 • A previously published randomized controlled study in Italy 
showed participation rates after one round of screening of 14.8% for colonoscopy and 50.4% for 
FIT-screening29• A Spanish randomized controlled study comparing colonoscopy and FIT-screening, 
showed participation rates after one round of screening of24.6% and 34.2%, respectively. Notably, in 
both studies FIT participation rates were substantially lower than in our study and study recruitment 
strategies differed from our study. Other studies have reported participation rates varying from 46% 
to 63% over multiple rounds of FIT-screening, with up to 78% of FIT screenees attending screening 
at least once over four rounds of screening32• 33• These latter findings are in line with our results, 
with around 73% of FIT-screenees participating at least once. Our findings also confirm the stable 
attendance rates over multiple rounds of FIT, as described in other large screening cohorts32•33• 
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In the intention-to-screen analysis, which comprises the total eligible study group, diagnostic yield 
was highest for FIT-screening. FIT-screening in particular identified three-times more participants 
with CRC than endoscopic screening. Though colonoscopy yielded significantly more screenees 
with AN in the as-screened analysis, CRC detection rates for participants were similar for all three 
strategies. After four rounds of FIT-screening, the diagnostic yield of CRC was even slightly higher 
with FIT than after once-only colonoscopy. A fifth FIT-screening round would likely increase the 
difference and thus potentially reach the level of statistical significance. However, comparing CRC 
detection rates of FIT and endoscopic screening is complex and results should be interpreted with 
caution, as CRCs detected in FIT-screening could in theory have been prevented in a once-only 
colonoscopy by the removal of advanced adenomas. 
Comparing results between screening programs in different countries is also challenging and should 
be done cautiously, because of differences in organizational structures, populations, and quality 
parameters.(34) The previously mentioned Spanish study found that FIT and colonoscopy yielded 
similar CRC detection rates even after only one round of screening.(4) Future screening rounds of 
that study will determine whether this effect will increase by time and what the influence is on the 
interval cancer rate. In some settings FS is repeated every 5 years, for these settings diagnostic yield 
of once-only FS over 5 years might best be compared to three rounds of FIT-screening. Our results 
showed a higher diagnostic yield for FIT both for AN and CRC over three rounds, with similar interval 
cancer rates. 
CRC screening puts a large demand on colonoscopy capacity, and consequently many countries 
struggle with a gap between available and required resources. In some other countries, like the 
United States, capacity is less of a problem, but high use of an expensive modality strains budgets. 
Moreover, as it is an invasive procedure it comes with considerable risks and burden for patients. 
FIT and FS identify participants at higher-than-average risk for AN to selectively refer those for 
colonoscopy. As a result, the number needed to scope to detect AN in one screenee was 2 for 
FIT-screening, 3 for FS, compared to 11 for once-only colonoscopy. FIT and FS screening require 
substantially fewer colonoscopies to yield a similar diagnostic yield. 
The low detection rate of non-AN and serrated polyps with FIT could be seen as an advantage, as it 
would reduce the number of screenees that would have to undergo an unnecessary colonoscopy, 
(i.e., a negative colonoscopy) which in turn would have a beneficial influence on colonoscopy-
related resources and costs. On the other hand, the lower use of colonoscopy also implies that 
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lesions remain undetected and may progress to cancer. This in particular pertains to sessile serrated 
adenomas (SSA). Our data show that for all three screening strategies similar rates of SSA as a most 
advanced finding are detected and that these were found in only a small number of participants. 
A recent study has shown that sessile serrated adenomas are associated with the existence of 
synchronous AN. This would suggest that FIT would possibly also detect these SSA's through the 
detection of occult blood from the also present AN 35• 
In conclusion, different screening strategies are associated with marked differences in uptake and 
diagnostic yield. Over four rounds, FIT was the most effective strategy in population-based CRC 
screening, leading to detection of high rates of CRC and AN, while requiring the lowest colonoscopy 
demand. Since many countries are considering to implement screening programs, the findings 
of this study aid in deciding on choice of screening strategy worldwide, based on expected 
participation rates and available colonoscopy resources. 
Comparison of colonoscopy, sigmoidoscopy and multiple rounds of FIT 199 
References 
1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer 
incidence and mortality. Gut. 2016:[E-pub ahead of print] doi:1 0.1136/gutjnl-2015-31 0912. 
2. 
3. 
Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev 
Clin On col. 2013;1 0(3):130-42. 
Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP. et al. Colorectal cancer screening: a global overview of 
existing programmes. Gut. 2015;64(1 0):1637-49. 
4. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, et al. Colonoscopy versus fecal immunochemical testing in 
colorectal-cancer screening. N Eng I J Med. 2012;366(8):697-706. 
5. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, et al. The Nord ICC Study: rationale and 
design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012;44(7):695-702. 
6. Colonoscopy Versus Fecal lmmunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) (CONFIRM): 
ClinicaiTrials.gov; 2010 [updated 2016; cited 2016]. Available from: https://clinicaltrials.gov/ct2/show/ NCT01239082. 
7. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer 
incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. 
BMJ. 2014;348:g2467. 
8. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening 
in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 201 0;375(9726):1624-33. 
9. Hoff G, Grotmol T, Skovlund E, Bretthauer M, Norwegian Colorectal Cancer Prevention Study G. Risk of colorectal cancer 
seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ. 2009;338:b1846. 
10. Segnan N, Sen ore C, Andreoni B, Azzon i A, Bisanti L, Cardelli A, et al. Comparing attendance and detection rate of 
colonoscopy with sigmoidoscopy and FIT for colo rectal cancer screening. Gastroenterology. 2007;132(7):2304-12. 
11. Shaukat A, Mangin SJ, Geisser MS, Led erie FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colo rectal 
cancer. N Eng I J Med. 2013;369(12):11 06-14. 
12. Kronborg 0, Fenger C, Olsen J, Jorgensen OD, Sondergaard 0. Randomised study of screening for colorectal cancer with 
faecal-occult-blood test. Lancet. 1996;348(9040):1467-71. 
13. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head 
comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 
2013. 
14. Faivre J, Dancourt V, Denis B, Dorval E, Piette C, Perrin P, et al. Comparison between a guaiac and three immunochemical 
faecal occult blood tests in screening for colo rectal cancer. European Journal of Cancer. 2012;48(16):2969-76. 
15. European Colorecta l Cancer Screening Guidel ines Working G, von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, et al. 
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the 
full supplement publication. Endoscopy. 2013;45(1 ):51-9. 
16. Sung JJ, Ng SC, Chan FK, Chiu HM, Kim HS, Matsuda T, et al. An updated Asia Pacific Consensus Recommendations on 
colorectal cancer screening. Gut. 2015;64(1 ):121-32. 
17. de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, et al. lmmunochemical fecal occult 
blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 201 2;1 07(1 0):1570-8. 
18. Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Ostbye T, et al. Longitudinal adherence to feca l occult blood 
100 I Chapter 3 
testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011 ;1 06(6):1125-34. 
19. Kapidzic A, Grobbee EJ, Hoi L, van Roon AH, van Vuuren AJ, 5pijker W, et al. Attendance and yield over three rounds of 
population-based fecal immunochemical test screening. Am J Gastroenterol. 2014;1 09(8}:1257-64. 
20. de Wijkerslooth TR, de Haan MC, Stoop EM, Deutekom M, Fockens P, Bossuyt PM, et al. Study protocol: population screening 
for colo recta l cancer by colonoscopy or CT colonography: a randomized controlled trial. BMC Gastroenterol. 201 0;1 0:47. 
21. Stegeman I, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers E, Elferink MA, et al. Participation, yield, and interval 
carcinomas in three rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol. 2015;39(3}:388-93. 
22. Hoi L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, ReijerinkJC, et al. Screening for colorectal cancer: 
randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. 
Gut. 201 0;59(1 ):62-8. 
23. Grobbee EJ, van derVIugt M, van Vuuren A, Stroobants AK, Didden P. Mundt MW, et al. Comparison ofOC-Sensor and FOB-
Gold in Population-Based Colorectal Cancer Screening Based on FIT. Gastroenterology. 2016;148(4):S-160. 
24. Dekker E, van Leerdam ME, Hazewinkel Y, Sanduleanu S, Vasen HF, Lansdorp-Vogelaar I, et al. Nederlandse Richtijn 
Coloscopie Surveillance: Nederlandse Vereniging voor Maag-, Darm- en Leverziekten; 2013. Available from: http://www. 
md l.nl/u ploads/240/1308/Richtlijn_ Coloscopie_Su rvei II a nce_defi nitief_20 13.pdf. 
25. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classification of gastrointestinal 
epithelial neoplasia. Gut. 2000;47(2):251-5. 
26. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and 
the future ofTNM. Ann Surg Oncol. 201 0;17(6):1471 -4. 
27. Sanduleanu S, le Clercq CM, Dekker E, Meijer GA, Rabeneck L, Rutter MD, et al. Definition and taxonomy of interval 
colorectal cancers: a proposal for standardising nomenclature. Gut. 2015;64(8):1257-67. 
28. Kuipers EJ, Spaander MC. Colorecta l Cancer Screening by Colonoscopy, CT-Colonography, or Fecallmmunochemical Test. 
J Natl Cancer In st. 2016;1 08(2). 
29. Sali L, Mascalchi M, Falchini M, Ventura L, Carozzi F, Castiglione G, et al. Reduced and Full-Preparation CT Colonography, 
Fecallmmunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial. J Natl 
Cancer In st. 2016;1 08(2). 
30. Gupta S, Halm EA, Rockey DC, Hammons M, Koch M, Carter E, et al. Comparative effectiveness of fecal immunochemical 
test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a 
randomized clinical trial. JAMA Intern Med. 2013;173(18):1725-32. 
31. lnadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, et al. Adherence to colorectal cancer screening: a randomized 
clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-82. 
32. Crotta S, Segnan N, Pagan in S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of 
colo rectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol. 2012;1 0(6):633-8. 
33. Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Fecallmmunochemical Test Program Performance 
Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016;164(7):456-63. 
34. Klabunde C, Blom J, Bulliard JL, Garcia M, Hagoel L, Mai V, et al. Participation rates for organized colorectal cancer screening 
programmes: an international comparison. J Med Screen. 2015;22(3):119-26. 
35. IJspeert JE, de Wit K, van der Vlugt M, Bastiaansen BA, Fockens P, Dekker E. Prevalence, distribution and risk of sessile 
serrated adenomas/polyps at a center with a high adenoma detection rate and experienced pathologists. Endoscopy. 
2016. 
Comparison of colonoscopy, sigmoidoscopy and multiple rounds of FIT l1 01 
Supplementary file 
Supplemantary table 1. Cumulative participation rate, positivity rate, colonoscopy rate and diagnostic yield among invitees of 
FIT-screening over four rounds (n= 7 4,65 7) 
2 rounds 3 rounds 4rounds 
o/o (95o/o Cl) o/o (95o/o Cl) o/o (95o/o Cl) II Participation rate 67 (66-68) 71 (70-72) 73 (73-74) 
Positivity rate* 12 (12-13) 16 (15-16) 19 (18-20) 
Colonoscopy rate 8 (7-8) 10 (10-11) 13 12-13) 
Advanced neoplasia 3.1 (2.8-3.4) 3.7 (3.4-4.0) 4.5 (4.2-4.9) 
Colorectal cancer 0.4 (0.3-0.5) 0.5 (0.4-0.6) 0.6 (0.5-0.7) 
Non-advanced adenomas 1.7 (1.5-1.9) 2.4 (2.2-2.7) 3.2 (2.9-3.5) 
Serrated polyps 0.6 (O.S-0.7) 0.8 (0.7-1.0) 1.1 (0.9-1.3) 
•among participants 
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Abstract 
Objective Colorectal cancer (CRC) screening programs are implemented worldwide; many are 
based on fecal immunochemical testing (FIT). The aim of this study was to evaluate two frequently 
used FITs on participation, usability, positivity rate and diagnostic yield in population-based FIT-
screening. 
Design Comparison of two FITs was performed in a fourth round population-based FIT-screening 
cohort. Randomly selected individuals aged 50-74 were invited for FIT-screening and were randomly 
allocated to receive an OC-sensor (Eiken, Japan) or FOB-Gold (Sentinel, Italy) test (March-December 
2014). A cut-off of 10 1-1g Hb/ g feces (i.e. 50 ng Hb/ml buffer for OC-sensor and 59 ng Hb for FOB-
Gold) was used for both FITs. 
Results In total 19,291 eligible invitees were included (median age 61, IQR 57-67; 48% males): 
9,669 invitees received OC-Sensor and 9,622 FOB-Gold; both tests were returned by 63% of invitees 
(p=0.96). Tests were non-analysable in 0.7% of participants using OC-Sensor vs. 2.0% using FOB-
Gold (p<0.001 ). Positivity rate was 7.9% for OC-Sensor, and 6.5% for FOB-Gold (p=0.002). There was 
no significant difference in diagnostic yield of advanced neoplasia (1.4% for OC-Sensor vs. 1.2% for 
FOB-Gold; p=0.15) or positive predictive value (PPV; 31 o/o versus 32%; p=0.80). When comparing 
both tests at the same positivity rate instead of cut-off, they yielded similar PPV and detection rates. 
Conclusion The OC-Sensor and FOB-Gold were equally acceptable to a screening population. 
However, FOB-Gold was prone to more non-analysable tests. Comparison between FIT brands is 
usually done at the same Hb stool concentration. Our findings imply that for a fair comparison on 
diagnostic yield between FITs positivity rate rather than Hb-concentration should be used. 
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Introduction 
Colorectal cancer (CRC) is one of the major causes of death in the Western World1•2•3• Population 
based colorectal cancer screening aims to detect CRC and its precursors in an earlier phase, 
thereby reducing CRC morbidity and mortality4. Of the currently available screening tests, fecal 
occult blood tests (FOBT) and sigmoidoscopy are the only strategies that have been proven in 
prospective randomized controlled trials to reduce CRC-related mortality5• The evidence favouring 
fecal immunochemical testing (FIT) over guaiac fecal occult blood testing (gFOBT) is substantial6• 7• 
8
• 
9
• 
10
• 
11
• FIT is more likely to detect hemoglobin from the lower Gl-tract than most gFOBTs. FIT is also 
easier to use resulting in higher participation rates. In addition, FIT enables quantitative measuring 
fecal hemoglobin (Hb), allowing the use of different cut-off concentrations, and can be analyzed by 
automation. 
Many countries have implemented FIT-based CRC screening programs or are about to do so12. When 
implementing a national screening program, choosing the appropriate test is of key importance. FIT 
tests can be based on dry sampling, using cards, or wet sampling, using tubes with buffers8• The most 
frequently used FITs involve wet sampling (i.e. storage and transport of feces in a wet preservative), 
and different FIT-brands in this category are available. These various FIT-brands often have different 
sampling tubes and buffer volumes, resulting in different expressions of Hb-concentration that are 
not interchangeable13• Such differences complicate direct comparison of FITs. It has been proposed 
to standardize quantitative FIT results in ~g Hb per gram feces, allowing diagnostic test accuracy to 
be compared more easily between FITs using the same standardized cut-off14• At present, there is no 
evidence favouring a specific FIT brand15• 
As small differences in test characteristics can have major effects on a population-level, it is 
important to further assess brand-related differences. In the Netherlands, several pilot-studies have 
been performed using the OC-Sensor (Eiken, Japan)16• 17• 18• However, the recently started nationwide 
program has selected the FOB-Gold t est (Sentinel, Italy) through a European bid. Few comparative 
data are available for these two tests. To the best of our knowledge, no study has investigated the 
OC-Sensor and FOB-Gold head-to-head in a screening setting. Such a comparison is relevant since 
both t ests are among the most widely used FIT t ests. We therefore aimed to compare the OC-Sensor 
and FOB-Gold with regard to participation rate, usability, positivity rate and diagnostic yield, using 
a standardized cut-off of fecal Hb concentration. 
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Methods 
Study population/ study design 
Details about the design of the on-going population-based CRC screening pilot-program have been 
described previously?· 16• 17• 19• 20. This trial was registered at www.trialregister.nl (identifier NTR5385). 
In short, from June 2006 the demographic data of all individuals between 50 and 74 years living in a 
selected region in the southwest and northwest of the Netherlands were obtained from municipal 
population registers. As there was no CRC screening program at the time of the trial the target 
population was screening-naive when first approached. 
This study was part of a dynamic (i.e., including all subjects included in any of the first three rounds 
as well as individuals who moved into the target areas and those who had reached the target age) 
cohort study,. Individuals who had moved out of the selected area or passed the upper-age limit 
were not re-invited. Invitations for this 4th screening round were done similar to previous rounds. 
This implied that for the Southern region, random samples were taken from the target population 
by a computer-generated algorithm (Tenalea, Amsterdam, The Netherlands). In the Northern 
region random samples of selected postal code areas were taken. For this fourth round of screening 
both cohorts were combined. Invitations were sent out between March 2014 and December 
2014. Individuals with a history of inflammatory bowel disease or CRC, as well as those who had 
undergone a colonoscopy in the past 2 years, had an estimated life expectancy of <5 years, or were 
unable to give informed consent were excluded from the study. 
Intervention and randomization; two types of FIT-screening 
All invitees were randomly allocated to receive either the OC-sensor (Eiken, Japan) or the FOB-Gold 
(Sentinel, Italy) sorted according to household without stratification. Randomization was performed 
before invitation in a 1:1 ratio. People in the same household were allocated to the same test, to 
avoid confusion in handling the FIT. The FIT was sent by mail with the instructions to collect a single 
sample of one bowel movement using a collection device probe. The test result was considered 
positive when the hemoglobin concentration in the FIT sample was ~ 10 1-1g Hb/g feces. This cut-off 
corresponds to 50 ng Hb/ml for the OC-sensor and 59 ng Hb/ ml for the FOB-Gold. In case of an non-
analysable test a new FIT was sent to the participant. 
FIT analysis 
The OC-sensor device collected 10 mg feces with a serrated shaped probe attached to the cap in 
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2.0 ml preservative buffer. The FOB-gold pierceable tube collected 1 0 mg feces with a serrated 
shaped probe attached to the cap in 1.7 ml preservative buffer. Participants were asked to dip 
the probe four times in the feces and to reinsert the probe into the respective device. Participants 
were asked to post the feces samples within 24 hours after collection and keep the sample in the 
refrigerator. Together with the FIT test participants signed an informed consent form with the date 
of sample collection. Participants returned FIT test and permission form at ambient temperature by 
freepost to two laboratories (Laboratory Clinic Chemistry, Academic Medical Centre, Amsterdam or 
Gastroenterology & Hepatology laboratory, Erasmus Medical Centre, Rotterdam, the Netherlands). 
At arrival in the laboratory, the FIT test was screened for collection date and presence of permission 
form and administrated in !COLON IT database. !COLON database was developed and owned by 
the regional organization for Population Screening South-West Netherlands, Rotterdam, the 
Netherlands. After arrival at the laboratory OC-sensor FIT test was stored at -20°C, FOB-gold FIT test 
was stored at 4 oc (median 3 days, range 1-6 days) untill analysis. Both FITs were stored according to 
the manufacturers recommendations. FIT test, which were inappropriately used or non-analysable, 
were marked in !COLON, and participants received a new FIT test. All other specimens received in 
the laboratory were analysed. If a specimen was received in the laboratory > 7 days from date of 
sample collection and the test result was < 1 0 1-1g Hb/g feces, the participant received a new FIT 
test and the test result was discarded. If a specimen received in the laboratory > 7 days from date 
of sample collection and test result was~ 10 1-1g Hb/g feces, the participant received a positive test 
result and a reference for colonoscopy. The number of and reasons for non-analysable FITs were 
recorded by the laboratory analysists. 
The OC sensor FIT tests were analysed on two OC-sensor 1-1 systems (Eiken, Japan), the FOB-gold FIT 
tests were analysed on a Sentinel Sentifit 270 system (Sentinel, Italy). All FIT tests were allowed to 
warm to room temperature before analysis and analysed once. The analytical working range was 
1-200 1-1g Hb/g feces for the OC sensor 1-1, and 1-170 1-1g Hb/g feces for the Sentifit 270. Samples 
with Hb level above the upper analytical working limits were not diluted or re-analysed. Before 
the start of the study the OC sensor 1-1 system and the Sentifit 270 system were compared. Fifty-
five fecal samples were spiked with different concentrations of Hb, from each spiked sample two 
OC sensor Fit tests and two FOB-gold Fit tests were taken and analysis on OC sensor 1-1 or Sentifit 
270 respectively. Using paired Student T-test no significant difference was found by levels ::;; 65 1-1g 
Hb/g feces (p=0.412). The OC senor 1-1 was calibrated with 6 calibrators. In the Erasmus MC this was 
done every week and in advance of every analytical run two quality controls (low and high) were 
measured. In the AMC the calibration took place when necessarily, indicated by the results of the 
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controls, and was monitored by two controls at the start and at the end of each run calibrators and 
controls were from Eiken, Japan. The Sentifit 270 was calibrated with 6 calibrators every month or 
earlier when another latex lot was used for analysis. Three quality controls (low, middle and high) 
were run every analytical run before and after analysis of the samples. Calibrators and controls were 
from Sentinel, Italy. Analyses were carried out in a fourteen-month period by seven technicians and 
two staff members, with over 8 years expertise in FIT analysis. Samples that appeared to be over 
range were not diluted and re-analysed. 
Follow-up evaluation 
Participants with a positive FIT result were scheduled for colonoscopy within 4 weeks. In case of 
an incomplete colonoscopy, a computed tomographic colonography was performed. Experienced 
endoscopists,all board-certified gastroenterologists who had performed at least 1 ,OOOcolonoscopies, 
performed all colonoscopies for the current trial. The maximum reach of the endoscope, quality 
of bowel preparation, data on location, size, macroscopic aspect, morphology, and endoscopic 
assessment of completeness of resection was recorded for all lesions detected during colonoscopy. 
All lesions were collected and evaluated by experienced gastrointestinal pathologists according 
to the Vienna criteria and World Health Organization classification21 •22. Advanced adenomas (AA) 
were defined as an adenoma with a diameter ~ 10 mm, and/or with a ~25% villous component, 
and/or high-grade dysplasia. Advanced neoplasia (AN) included AA and CRC. Cancers were staged 
according to the 7th edition of the American Joint Committee on Cancer classification,[23]. Advice 
regarding surveillance colonoscopy after removal of adenomatous polyps, large(~ 10 mm) serrated 
lesions or cancer was given to the clients according to the Dutch guideline. Participants with a 
negative colonoscopy were referred back to the screening program, but were considered not to 
require FIT-screening for 10 years. 
Statistical analysis 
The analysis was based on the intention-to-screen principle. The primary outcome measure was the 
diagnostic yield for advanced neoplasia, defined as the proportion of participants being diagnosed 
with AN relative to the total number of invitees. When more than one lesion was present, the 
screenee was classified according to the most advanced lesion. 
Additional outcome measures were the participation rate, usability, the positivity rate, the 
positive predictive value for CRC and AN, the diagnostic yield of CRC defined as the proportion 
of participants with CRC relative to the number of invitees, and detection rate for AN and CRC, 
defined as the proportion of subjects with AN/CRC relative to all participants. The participation rate 
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was calculated as the number of participants relative to all eligible invitees. The PR was defined as 
the proportion of participants with a positive test result. Usability was defined as the number of 
non-analysable tests. The PPV refers to the participants in whom AN is detected relative to those 
undergoing colonoscopy after a positive FIT or, in case the colonoscopy was incomplete, computed 
tomographic colonography. As this is a dynamic cohort, outcomes were also separately analysed 
for first-time and repeat-round invitees. Adenoma detection rate was defined as the proportion of 
colonoscopies in which one or more adenomas were found. 
Differences in proportions between groups were analysed for statistical significance using the 
x2-test statistic. Differences in means between groups were tested using the Student's t statistic. 
Participation rate, PR, DR, and PPV were calculated and described as proportions with 95% 
confidence intervals (95% Cl). All p values were two-sided and considered significant if <0.05. 
Analyses were conducted using SPSS for Windows version 21.0. 
Sample size calculation 
Sample size was guided by the size of the dynamic cohort, invited for the three previous screening 
rounds. This cohort consists of approximately 20,000 people. We anticipated that differences in 
participation would be crucial in driving any differences in diagnostic yield. Diagnostic yield would 
also be affected by failures, positivity, and positive predictive values. Inviting 20,000 people would 
then have a power of at least 80% to detect an absolute difference in diagnostic yield of 5 per 1,000 
invitees or more, assuming 60% participation with FIT-based screening, a 6% positivity rate, and a 
30% positive predictive value, using two-sided testing at a 5% significance level. 
Ethical approval 
The study was approved by the Dutch National Health Council (Population Screening Act; 
publication no. 2013/20). 
Results 
We invited 19,618 persons, of whom 327 had to be excluded because they met one of the exclusion 
criteria (n=306), had moved (n = 19}, or died (n=2), leaving 19,291 eligible invitees (Figure 1 ). Of 
the 9,669 invitees who received the OC-Sensor, 4,706 (49%) were male. Of the 9,622 invitees who 
received the FOB-Gold, 4,584 (48%) were male. The median age in both study arms was 61 years 
(IQR 57-67). The proportion of first -time invitees was 14.2% in the OC-sensor group and 14.8% in the 
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FOB-Gold group (p=0.23). 
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Figure 1. Study design. 
In the OC-Sensor group, 6,040 returned the FIT (63%), versus 6,014 in the FOB-Gold group (63%) 
(p=0.96). Participation was lower among first-time invitees, yet over all rounds participation was 
similar for both FIT-brands (57% for OC-sensor and 56% for FOB-Gold; p=0.73). Non-analysable tests 
were reported in 41 (0.7%) participants in the OC -Sensor arm versus 118 ( 2.0%) in the FOB-Gold arm 
(p<0.001 ). The main reason for an unalyzable test was a too large sample of feces collected in the 
tube by the participant (Table 1 ). 
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Table 1. Reasons for failure to analyse FIT. 
Reasons OC-sensor (%) FOB-Gold(%) 
(n=41) (n=118) 
too large sample 40(98) 97 (82) 
too little sample 1 (2) 5 (4) 
loss of buffer 0 7 (6) 
analytical technical failure 0 9 (8) 
More participants tested positive at the pre-specified cut-off of 10 1-1g Hb/ g feces with the OC -Sensor: 
479 (7.9%) versus 390 (6.5%) for FOB-Gold (p=0.002). The difference in positivity rate disappeared at 
higher cut-offs (Figure 2). 
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Figure 2. Positivity rates (PR) for the OC-sensor and FOB-Gold at different cut-offs. 
Positivity rates among first time invitees were higher and similar for both FITs, respectively 9.5% 
for OC-sensor and 9.1% for FOB-Gold (p=0.86). Fecal hemoglobin concentrations were distributed 
differently across both t est s, with the OC-Sensor measuring higher values of Hb concentrations, 
ranging up t o 1333 1-1g Hb/ g feces, versus 179 1-1g Hb/g feces for FOB-Gold (p <0.0001, Figure 3). 
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Figure 3. Fecal hemoglobin concentrations of OC-sensor and FOB-Gold . 
Adherence to colonoscopy among FIT-positive screenees was 90% for both tests_ Overall adenoma 
detection rate was 58%. Advanced neoplasia was detected in 137 participants in the OC-Sensor 
group (1.4%) and in 114 in the FOB-Gold group (1.2%; p=0.15). Specific colonoscopy findings are 
described in Table 2. 1n 537 FIT-positives (68%), no adenomas or only non-advanced adenomas were 
detected. Advanced adenomas were detected in 224 (28.4%) participants, and CRC was diagnosed 
in 27 (3.4%) participants, with most CRCs detected at an early stage (56% stage 1). For the two FITs, no 
significant differences were observed in colonoscopy findings, including non-advanced adenomas, 
advanced adenomas and CRC, neither between st ages of CRC 
Table 2 . Colorectal cancer stage fo r the OC-sensor and FOB-Gold among FIT-positive screenees. 
OC-sensor (%) FOB-Gold (%) p-value 
(n=l3) (n= 14) 
stage I 8 (61.5) 7(50.0) 
stage II 1 (7.7) 1 (7.1 ) 0.63* 
stage Ill 3 (23.1) 4(28.7) 
stage IV 1 (7.7) 2 (14.3) 
* overall p -va lue 
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The diagnostic yield for CRC was 0.1% in both groups (p=0.84). The detection rate of AN among 
participants was 2.3% for OC -Sensor and 1 .9% for FOB-Gold (p=O. 1 5; Table 3). 
Table 3. Test characteristics for the OC-sensor and FOB-Gold for all invitees (n= 19,291) and for first time invitees (n=2,796). 
All invitees First-time invitees 
OC-sensor FOB-Gold p-value OC-sensor FOB-Gold p-value 
(n=9,669) (n=9,622) (n=1,371) (n=1,424) 
Positive predictive value(%) 
Adv. neoplasia 31.3 32.0 0.86 51.5 44.6 0.49 
Colorectal cancer 3.0 4.0 0.45 6.1 6.2 1.0 
Diagnostic yield (invitees,%) 
Adv. neoplasia 1.4 1.2 0.15 2.5 2.0 0.45 
Colorectal cancer 0.1 0.1 0.84 0.3 0.3 1.0 
Detection rate (participants,%) 
Adv. neoplasia 2.3 1.9 0.15 4.4 3.6 0.52 
Colorectal cancer 
The detection rate for CRC was 0.2% for both tests (p=0.84). The PPV for AN was 31% for OC -Sensor 
and 32% for FOB-Gold at the pre-specified cut-off (p=0.80). For CRC the PPV was 3.0% for OC -Sensor 
versus 4.0% for FOB-Gold (p=0.45). In addition, as this study concerns a fourth round of screening 
we have stratified the results per number of participations to (previous) screening rounds for all 
participants of this fourth round (Table 4). 
Both the PPV as well as the detection rate for AN was highest in those who participated for the first 
time. Because equal cut-offs did not result in equal PRs, we next calculated the PPV for different PRs 
using multiple cut-offs, this is illustrated in Figure 4. This yielded a similar PPV for both tests when 
comparing tests at the same PR's, and resulted in similar partial area's under the curve (p=0.48). 
This figure illustrates that both tests performed equally in terms of diagnostic yield for AN when 
comparing them at the same positivity rate and thus also at an equal number of colonoscopies 
required. 
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Figure 4. Positive predictive value and positivity rate 
Discussion 
In CRC screening programs, willingness to undergo a screening modality, easy use of the test and 
diagnostic accuracy are vital. In this cohort of biennial population-based FIT-screening, we observed 
similar performance of the OC-Sensor and FOB-Gold. Both tests had the same participation rate 
of 63%. A higher positivity rate was found for OC-Sensor, resulting in more colonoscopies and a 
slightly higher detection rate of AN. A significantly higher proportion of non-analysable tests was 
found with FOB-Gold. Both tests performed similar in terms of positive predictive value. However, 
screening with the OC-Sensor test led to a higher diagnostic yield, mainly due to the previously 
mentioned higher positivity rate. When comparing both tests at the same positivity rates by raising 
the cut-off of the OC-sensor, they showed similar positive predictive values. 
Our study has several strenghts. All invitees were randomly selected from the general population and 
were at average risk of developing CRC. Invitees from the same household received the same test-
brand, so that confusion about use or shape of the test was avoided. In addition, risk of exchanging 
the two FITs between participants living in the same household was thereby prevented. Adherence 
to colonoscopy after a positive FIT was high with 90% of screenees undergoing colonoscopy. A 
possible limitation for the results of our study is that it was performed in a 4th round of FIT-screening, 
with the consequence that the majority of the population was not screening-na"ive. However, as 
Table 4. Positive predictive value and detection rate in participants according to number of par ticipations over all rounds (n= 12,054). 
1st time participants 2nd time participants 3rd time participants 
(n=2,582) (n=2,459) (n=1 ,720) 
OC-sensor FOB-Gold OC-sensor FOB-Gold OC-sensor FOB-Gold 
Positive predictive value(%} 
Advanced neoplasia 45.1 43.0 30.7 27.3 27.3 22.6 
Colorectal cancer 5.7 4.7 0 7.6 
Detection rate (participants, %) 
Advanced neoplasia 4.3 3.5 1.9 1.5 1.7 1.4 
Colorectal cancer 0.5 0.4 0 0.4 
II 
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the cohort included previous participants as well as newly invited individuals, it represents a true 
population-based screening population. Secondly, it is possible that participants were more familiar 
with the OC-sensor, which had been used in the first three rounds, and this may have influenced 
the usability of the FOB-Gold. However, a higher rate of non-analysable tests was also found among 
first time participants (1.0% for the OC-sensor vs. 2.9% for the FOB-Gold, p-value <0.001). Lastly, 
a more precise comparison of the diagnostic test accuracy of the two FITs could have been made 
by applying both tests on the same fecal samples, with all participants undergoing subsequent 
colonsocopy. This would have allowed to evaluate prime indicators of diagnostic performance, 
including sensitivity, specificity and the area under the receiver-operating curve. However, such 
a design might influence the willingsness to participate and would not have allowed for a fair 
comparison of participation rates and usability. 
In our study, the main reason for non-analysable tests was a too large sample of feces collected 
by in the tube by the participant. These findings are in line with previously published results24• 25• 
A possible explanation for this sampling error could be the round shape of the opening of the 
FOB-Gold, making it possible to sample larger volumes of feces, whereas OC-Sensor has a small 
oval opening (Figure 5). It should be noted that the FOB-Gold test-tube that was used in our study 
has been adjusted before the start of the study by the manufacturer to prevent participants from 
unscrewing the wrong side of the test causing loss of buffer26• 
Figure 5. The FOB-Gold (left) and OC-sensor (right). 
Concerns have been raised about the so-called prozone effect in FIT-screening27• 28• This effect could 
lead to an underestimation of high Hb concentrations because the relative large amount of antigen 
(in this case Hb) is greater than the quantit y of antibody present in the test. This could lead to 
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underestimation of true Hb concentration at very high fecal Hb concentrations. Our results indicate 
that OC-Sensor is less subject to this effect than the FOB-Gold, with a large difference in distribution 
of the highest concentrations of Hb between both tests. The ability to measure high values is often 
driven by properties of the analytical equipment. However, it is important to realize that such high 
concentrations are usually much higher than most cut-offs, and are therefore not likely to influence 
positivity rates. 
In our cohort OC-Sensor had a higher positivity rate than FOB-Gold at a cut-off of 10 11g Hb/ g feces. 
This is in contrast with results from a Spanish study, in which the FOB-Gold had a higher positivity 
rate than the OC-Sensor24• This difference can be explained by multiple factors. First, in the Spanish 
study a higher positivity cut-off (1 00 ng Hb/ml) was used; we found that for higher cut-offs the 
difference in positivity rate between the tests was less pronounced. Second, the Spanish study used 
the same cut-off (expressed in ng Hb/ml buffer) for both tests. However after standardizing this to 
11g Hb/g feces, this cut-off relates for the OC-Sensor to a higher cut-off than for the FOB- Gold, 20 
11g Hb/g and 1711g Hb/ g feces respectivelyl 4•29• Last, the Spanish study was conducted in 2009, after 
which date both manufacturers have improved their buffer to increase the conservation of Hb in 
the sample. 
Besides participation, test accuracy is crucial for screening effectiveness. In our study, the positive 
predictive value was comparable for both tests. In literature, the above mentioned Spanish study is 
the only other study that compared the same two brands of FIT in a screening population, allowing 
comparison of participation rates in addition to test accuracy. This study was performed in a first 
round of screening and demonstrated superiority of the OC-Sensor in participation rates, with 
similar positive predictive values for both tests24 • Other studies that have evaluated the OC-sensor 
and/or FOB-Gold test relied on different designs to evaluate test performance. Such study designs 
however do not allow comparison of participation rates. One of those studies compared the two 
FITs to gFOBT, and concluded that apart from the superiority of FIT over gFOBT, no differences 
in performance were found between FITs9• These findings are in accordance with our results, 
confirming that similar test performance of both FITs can also be expected in a population-based 
screening setting. Another study sent both FITs to screenees, and in case of one or two positive 
test results participants were referred for colonoscopy. In this setting a relative sensitivity could 
be calculated, showing a lower sensitivity for the FOB-Gold, and comparable specificity,[30]. As all 
participants in our study only received one out of two tests, sensitivity could not be calculated. 
However, as both groups were randomized, prevalence of AN should be similar between groups and 
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as a result the detection rate is a direct reflection of the relative sensitivity. Also, future follow-up will 
allow determining the incidence of interval carcinomas to determine program sensitivity per test. 
As it has become clear that different FITs use a variety of sampling techniques and report Hb 
concentration in different units, more attention has been given to standardizing fecal hemoglobin 
concentrations14• Due to these differences a comparison between FITs could prove to be arduous. 
It has been proposed to standardize the measuring units to 11g Hb/g feces, taking into account the 
amount of buffer and sampling volume14• However, a Taiwanese study concluded that even after 
standardization, different brands of quantitative FITs perform differently13• Our findings are in line 
with these results, showing different positivity rates and PPVs per test at the same cut-off. This is 
likely explained by the fact that standardizing FITs to 11g Hb/ g feces is hampered by several factors. 
Firstly, wet sample FITs do not directly determine hemoglobin concentration in feces, but determine 
hemoglobin concentration in the kit's storage buffer. This depends on both the fecal hemoglobin 
concentration and the amount offecal material put into the buffer. Although manufacturers assume 
that the volume of fecal material sampled is stable per device, sampling volumes can in practice 
vary substantially. This affects the reported fecal hemoglobin concentrations. Secondly, different 
FIT brands make use of antibodies against different epitopes. This could potentially influence test 
performance and positivity rate. As a result, the same cut-off in 11g Hb/ g feces can lead to different 
positivity rates depending on the FIT brand. Therefore we chose to compare the positivity rate 
between both FITs, this resulted in comparable PPVs. Another advantage of this approach is that the 
positivity rate directly reflects the required colonoscopy capacity. Evidently, a higher positivity rate 
leads to more colonoscopies and consequently results into a higher detection rate of AN in case of 
similar PPV's. As colonoscopy capacity is for most countries the main determinant in a CRC screening 
program, information on required capacity using test positivity rate is crucial when implementing a 
population-based screening program or when contemplating on changing to a different FIT brand 
within an already existing program 12• This necessitates a comparative analysis of test performances 
not solely based on similar cut-offs but firstly based on similar PRs. Moreover, if programs intent 
to use different cut-off concentrations for different populations (e.g., based on age, gender or 
screening history) PRs for the different cut-offs per subgroup should be addressed. Our comparison 
shows that both tests perform equally regarding detection rate and PPV at cut-offs that result in 
equal PRs requiring the same number of colonoscopies. Notably, miss rates of early stage cancers 
between tests is another important outcome, the fact that both tests led to very similar numbers of 
cancers detected strongly suggests that they will also perform similar in terms of interval cancers. 
This trial shows that the OC-Sensor and FOB-Gold can be expected to perform similar in population-
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based screening, with no major differences in diagnostic yield. Despite standardization on Hb 
concentration, differences in positivity rate and diagnostic yield can be expected, but adjusting for 
PR will result in an equal number of colonoscopies, and a similar diagnostic yield. When comparing 
different FIT-brands, our results indicate a need for standardizing on positivity rate, rather than on 
fecal hemoglobin concentration. 
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Abstract 
Introduction Fecal immunochemical test (FIT) screening for colorectal cancer (CRC) requires timely 
successive rounds for an optimal preventive effect. However, data on attendance and trend in yield 
over multiple rounds of FIT screening are limited. We therefore conducted a consecutive third round 
of FIT screening in a population-based CRC screening trial. 
Methods Average-risk subjects aged 50-74 years were approached for three rounds of 1-sample FIT 
(OC -sensor, Eiken Chemical, Japan) screening. Subjects with a hemoglobin level ;:::: 50 ng/ ml (;:::: 10 11g 
hemoglobin/g feces) were referred for colonoscopy. Subjects with a positive FIT in previous rounds 
were notre-invited for FIT screening. 
Results In the first round 7,501 subjects were invited. Participation rate was 62.6% in the first, 63.2% 
in the second and 68.3% in the third round (p<0.001). In total, 73% (5,241 /7,229) of all eligible 
subjects participated in at least one of three rounds. The positivity rate was significantly higher 
in the first (8.4%) compared to the second (6.0%) and third (5.7%) screening round (p<0.001 ). The 
detection rate of advanced neoplasia declined from the first to subsequent rounds (round 1: 3.3%; 
round 2: 1.9%; round 3: 1.3%, p<0.001). The positive predictive value for advanced neoplasia was 
40.7% in the first, 33.2% in the second and 24.0% in the third screening round (p<0.001). 
Conclusion Repeated biennial FIT screening is acceptable with increased participation in successive 
screening rounds, and more than 70% of all eligible subjects participating at least once over 
three rounds. The decline in screen-detected advanced neoplasia over three screening rounds 
is compatible with a decreased prevalence of advanced neoplasia as a result of repeated FIT 
screening. These findings provide strong evidence for the effectiveness of FIT screening and stress 
the importance of on-going research over multiple screening rounds. 
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Introduction 
Colorectal cancer (CRC) is a major health concern worldwide. Screening using fecal occult blood 
testing (FOBT) results in detection and treatment of CRC at an earlier stage, which is associated with 
improved surviva l. A meta-analysis based on four large randomized controlled trials demonstrated 
that guaiac fecal occult blood (gFOBT) testing reduces CRC-related mortality1• A recently p'ublished 
study showed that the effect of gFOBT screening on CRC mortality persists for many years2• Economic 
analyses found gFOBT screening to be cost-effective3• More recently, fecal immunochemical testing 
(FIT) gained ground based on randomized trials showing higher attendance as well as a higher 
sensitivity for detection of advanced neoplasia with a similar specificity4·5• Moreover, quantitative 
measurement of fecal human globin concentrations offers the opportunity to provide tailored 
screening for specific regions or countries based on available colonoscopy capacity and cost-
effectiveness analyses3.6. FIT screening has therefore become the first-choice fecal occult blood test 
for CRC screening7. Various CRC screening programmes worldwide currently rely on FIT or are about 
to start with or switch to FIT-based screening. 
The sensitivity of a single round of FIT screening for the detection of advanced neoplasia is however 
limited. Recent stud ies showed that FIT at a low cut-off detects approximately 85% of CRCs and up 
to 35% of large adenomas8•9• Successive screening rounds are required to optimize the impact of FIT 
screening on a population level. Participation and detection rates in successive rounds attribute to 
the effectiveness of FIT-based programmes. Longitudinal adherence of the same subjects represents 
a critical factor, but information concerning sustained attendance and diagnostic performance over 
repeated rounds of FIT screening is very limited. 
We and others demonstrated a stable attendance rate over two rounds of FIT screening, with 
detection of substantial numbers of advanced lesions in both rounds10•11 • Data on further rounds in FIT 
screening with longer follow-up periods are scarce. One relatively small Italian study on four rounds 
of a biennial FIT screening programme reported stable attendance rates and test performances. 
However, the attendance rate of 56% during the first round was relatively low 12• Further data on 
repeated FIT screening are warranted, as these provide more insight in the programme sensitivity 
of FIT screening. Such information is also required to address the important question whether FIT 
screening with higher sensitivity for advanced neoplasia can be applied with longer screening 
intervals than biennial gFOBT screening7• 
We therefore evaluated attendance and detection rates of three rounds of FIT screening in a Dutch 
population-based CRC screening programme. 
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Methods 
Study population and study design 
Details about the design of this on-going population-based CRC screening programme have been 
described previously 4,1 0. In short, demographic data of all individuals between 50-74 years living 
in the southwest of the Netherlands were obtained from municipal population registers. Random 
samples were taken from the target population by a computer-generated algorithm (Tenalea, 
Amsterdam, The Netherlands). Since there was no CRC screening programme at the time of the trial 
in the Netherlands, the target population was screening-na"lve when first approached. Individuals 
with a history of inflammatory bowel disease or CRC, as well as those who had undergone a 
colonoscopy, sigmoidoscopy or barium contrast enema in the last 3 years, those with an estimated 
life expectancy of less than 5 years, and subjects who were unable to give informed consent were 
excluded from the study. Subjects were not invited for the third screening round in case of a positive 
FIT in the first or second screening round, when they had become older than 74 years, when they 
had moved out of the region, or when they had died. Recruitment took place between November 
2006 and December 2012. 
Intervention; FIT screening 
With each screening round, one FIT (OC-sensor, Eiken Chemical, Japan) was sent by mail to collect a 
single sample of one bowel movement. The test result was considered positive when the hemoglobin 
concentration in the FIT sample was ;?: 50 ng/ml, which corresponds to ;?: 10 11g hemoglobin/ g feces. 
Study subjects were initially divided over three groups to undergo repeated FIT testing at different 
screening intervals in the second round (ie, one, two and three years, respectively). No differences in 
attendance and det ection rate were found between the different intervals 10. The positive predictive 
value did also not differ between the three screening intervals (one-year interval: 36.2%; two-year 
interval: 32.9%; three-year interval: 30.6%; p=0.773) (derived from 1 0). We therefore included 
subjects with a one-, two-, and three-year interval between the first and second round. Based on 
these results, a two-year interval was applied to all groups in the third screening round. In total, 
5,482 subjects were invited for third round screening (1 ,838 subjects in the group with a previous 
one-year interval between the first and second round; 1,835 subjects with a two-year interval; and 
1,809 subjects with a three-year interval). 
Follow-up evaluation; colonoscopy 
Subjects with a positive FIT were scheduled for colonoscopy within 4 weeks. In case the colonoscopy 
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was incomplete a CT-colonoscopy was performed. Experienced endoscopists, all board-certified 
gastroenterologists who had performed at least over 1,000 colonoscopies, performed all 
colonoscopies for the current trial. The maximum reach of the endoscope, adequacy of bowel 
preparation as well as the characteristics and location of any polyps were recorded. Gastrointestinal 
pathologists evaluated all removed polyps. Patients with a positive colonoscopy entered a 
surveillance programme according to guidelines of the Dutch Society of Gastroenterology, while 
subjects with a negative colonoscopy were referred back to the screening programme, but were 
considered not to require FIT screening for ten years. 
Screen-detected and interval carcinomas 
Except for individuals who had moved out of the Netherlands, all recruited participants were 
followed for the development of CRC. Screen-detected cancers were defined as cancers identified 
at colonoscopy performed after a positive test result. Interval cancers were defined as colorectal 
cancers diagnosed within the time period between attendances to screening. Interval cancers were 
identified through linkage with the Dutch Comprehensive Cancer Centre (www.iknl.nl). 
Statistical analysis 
For each screening round, we calculated the attendance rate (AR), the positivity rate (PR), the 
detection rate (DR) of CRC and advanced adenomas, and the positive predictive value (PPV) for CRC 
and advanced adenomas. 
The AR was calculated by dividing the number of participants by all eligible subjects (defined as 
all invitees minus the excluded subjects). The PR was defined as the proportion of participants 
having a positive test result. The DR was defined as the proportion of participants being diagnosed 
with advanced neoplasia. This was calculated as the number of screened individuals diagnosed 
with advanced neoplasia divided by all screened individuals with an analyzable FIT test. Advanced 
neoplasia included CRC and advanced adenomas. An advanced adenoma (AA) was defined as an 
adenoma with a diameter ;;::: 10 mm, and/or with a ;;::: 25% villous component, and/or high grade 
dysplasia. When more than one lesion was present, the screenee was classified according to the 
most advanced lesion. The PPV refers to the subjects diagnosed with advanced neoplasia (AN) 
proportionally to screenees with a positive FIT undergoing subsequent colonoscopy, or in case 
the colonoscopy was incomplete a CT-colonoscopy (n=3). For the overall adenoma detection rate 
(ADR), we used both advanced and non-advanced adenoma. 
Differences in proportions between groups were analyzed by Chi-square testing. Differences in 
means between groups were tested using the Student t-test. AR, PR, DR, and PPV were calculated 
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and described as proportions with 95% confidence intervals (95% Cl). We fitted a logistic regression 
model to the data to determine differences in participation and FIT characteristics between the 
different groups that attended the third screening round (ie, subjects that had participated one, two 
or three times over the three rounds). To determine the number of true positives per 1,000 invitees 
(subjects with a positive FIT identified with AN during follow-up colonoscopy) per screening round, 
the participation rate was multiplied by the positivity rate and the positive predictive value. The 
percentage of stable attenders was defined as the number of subjects attending all rounds while 
they were eligible, divided by the total amount of subjects that were eligible over the three rounds. 
The cumulative attendance was defined as the number of eligible invitees attending at least once. To 
assess differences in attendance rate between the three rounds, a generalized estimating equation 
was used to account for clustering at the level of the invitee. The test characteristics in the first two 
rounds of 1-sample FIT screening were compared to those in the third screening round by using a 
logistic regression model 10. The diagnostic yield was compared to that of different CRC screening 
methods. All p-values were two-sided and considered significant if < 0.05. All tests were conducted 
using SPSS version 20.0. 
Ethical approval 
The Dutch National Health Council and the Institutional Review Board of the Erasmus MC University 
Medical Centre approved the study. All screenees gave written informed consent. 
Results 
Attendance 
Baseline characteristics and the results of the first and second 1-sample FIT screening rounds have 
previously been described 4,1 0. Briefly, during the first round, a total of 7,501 average-risk subjects 
were invited to participate in screening. Participation rates in the first, second and third round were 
62.6% (4,523/7,229, 95% 061.4-63.7), 63.2% (3,864/6,111, 95% 062.0-64.4), and 68.3% (3,704/5,423, 
95% Cl67.1-69.5), respectively (p<0.001) (Table 1 ). Figure 1 shows the trial profile for each screening 
round for the three groups (group 1: one-year interval between the first and second round; group 
II: two-year interval between the first and second round; group Ill: three-year interval between the 
first and second round; group I-III: two-year intervals between the second and third round). Seventy-
three percent (5,482/7,501) of the initial cohort was eligible to be invited for the third screening 
round. In total, 1,247 subjects were not eligible for successive screening rounds because they had 
become 75 years or older (round 2: n= 342; round 3: 295), or had had a positive 
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FIT in previous rounds (round 1: n=380; round 2: n= 230).1n addition, subjects were excluded during 
the first or second round because they had moved away (n=233), had died (n=170), or met one of 
the exclusion criteria (n=369). 
In total, 5,482 subjects were invited to attend the third screening round (Table 1 ). A total of 59 
subjects (1.1 %) were excluded (47 subjects met one of the exclusion criteria, eleven had moved 
away and one had died) (Figure 1). Out of 5,423 eligible invitees, 3,704/5,423 (68.3%; 95%067.1-
69.5) returned a FIT. The test was analyzable in 3,700 (99.9%) subjects. Of the participants in the third 
round, 78.5% (2,907 /3,704) attended all three rounds, 13.9% (516/3,704) attended two rounds, and 
7.6% (281 /3,704) had attended no previous round (Table 3). With respect to the non-participants in 
first-round screening, 18.8% (437/2330, 95% (117.2-20.4) attended the second round, while 23.2% 
(471/2,031, 95% Cl 21.4-25.1) of second round non-participants attended the third round. 
Table 1. Overview of participation and FIT performance characteristics per screening round 
Round 1 Round 2 Round3 p-value 
o/o (95o/o Cl) o/o (95o/o Cl) o/o (95o/o Cl) 
(n=7229) (n=6111) (n=5423) 
Participation rate 62.6 (61.4-63.7) 63.2 (62.0-64.4) 68.3 (67.1-69.5) <0.001 
Positivity rate 8.4 (7 .6-9 .2) 6.0 (5.2-6.7) 5.7 (5.0-6.5) <0.001 
Colonoscopies (n) 364 (95 .8%) 223 (97.0%) 200 (94.8%) 
Detection rate 
Non-advanced neoplasia 1.7 (1.3-2.1) 1.2 (0.9-1.6) 1.6 (1.2-2.1) 0.259 
Advanced neoplasia 3.3 (2.8-3 .8) 1.9 (1.5-2.4) 1.3 (1.0-1.7) <0.001 
Advanced adenoma 2.8 (2.3-3.3) 1.7 (1.4-2.2) 1.2 (0.9-1.6) <0.001 
Colorectalcancer 0.5 (0.3-0.7) 0.2 (0.1 -0.4) 0.1 (0.1-0.3) 0.007 
Positive predictive value 
Advanced neoplasia 40.7 (35.7-45.8) 33.2 (27.3-39.6) 24.0 (18.6-30.4) <0.001 
Advanced adenoma 34.6 (29.9-39.7) 30.0 (24.4-36.4) 21.5 (16.4-27.7) 0.005 
Colorectal cancer 6.0 (4.0-9.0) 3.1 (1.5-6.4) 2.5 (1.0-5.9) 0.094 
The number oftimes invitees participated during three screening rounds displayed for the number 
of times invitees were eligible is summarized in Table 2. In total 7,229 of 7,501 invitees were at least 
once eligible for screening. The proportion of stable attenders (ie, invitees attending all rounds while 
they were eligible) was 56.3% (4,073/7,229) (Table 2). The cumulative attendance rate (ie, eligible 
invitees attending at least one screening round) was 72.5% (5,241 /7,229). 
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Table 2. Number of times invitees participated displayed for the number of times they were eligible 
Times eligible Times participated Total 
0 2 3 
0 272 (100) 272 
374 (33.6) 740 (66.4) 1114 
2 181 (26.2) 85 (12.3) 426 (61.6) 692 
3 1433 (26.4) 473 (8.7} 610 (11 .2) 2907 (53.6) 5423 
Total 2260 1298 1036 2907 7501 
Proportion of positive tests 
In total, 380/ 4,523 (8.4%, 95% Cl 7.6-9.2%) tested positive in the first round, 230/3,864 (6.0%, 55% 
Cl 5.2-6.7) in the second round, and 211 / 3,704 (5.7%, 95% 5.0-6.5) in the third round (Table 1). The 
positivity rate (PR) was significantly higher in the first compared to the second and third round (both 
p<0.001 ), whereas the PR was similar in round two and three (p=0.67). 1ndividuals that participated 
for the first time in the th ird round had a significantly higher PR compared to individuals who 
underwent repeated screening (p<0.001 ) (Table 3). 
Table 3. Participation and FIT performance characteristics for subjects who have been invited in all three screening rounds 
(n=5482), by number of consecutive tests performed (ie, one, two or three out of three rounds) 
Times participated* p -value 
1 out of 3 rounds 2 out of 3 rounds 3 out of 3 rounds 
(n=281) (n=516) (n=2907) 
Positive tests in the third round (n) 33 45 133 
% (95% CI) 11.7 (8.5-16.1) 8.7 (6.6-11.5} 4.6 (3.9-5.4) <0.001 
Colonoscopies performed n (% ) 31 (94.0) 43 (95.6) 126 (94.7) 
Detection rate 
Advanced neoplasia (n) 13 7 28 
% (95% CI) 4.6 (2.7-7.8) 1.4 (0.6-2.8) 1.0 (0.7-1.4) <0.001 
Advanced adenoma (n) 12 6 25 
% (95% CI) 4.3 (2.4-7.4) 1.2 (0.5-2.6) 0.9 (0.6-1.3) <0.001 
Colorectal cancer (n) 3 
% (95% CI) 0.4 (0.1 -2.5} 0.2 (0.0-1.4) 0.1 (0.0-0.3) 0.32 
Positive predictive value 
Advanced neoplasia % (95% Cl) 41.9 (26.1-59.6} 16.3 (8.0-30.4) 22.2 (15.8-30.3) 0.01 
Advanced adenoma % (95% Cl) 38.7 (23.5-56.5) 14.0 (6.4-27.8) 19.8 (13.8-27.7) 0.01 
Colorectal cancer % (95% Cl) 3.2 (0.5-19.6) 2.3 (0.3-14.7) 2.4 (0.8-7.1) 
*only participants eligible for three rounds 
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Follow-up and test performance characteristics 
The detection rate (DR) and positive predictive value (PPV) for advanced neoplasia for the three 
rounds are described in Table 1.1n the third round, 200 (94.8%) of211 screenees that tested positive 
underwent a complete colonoscopy. The remaining 11 subjects either refused colonoscopy (n=1 0), 
or turned out to have too severe co-morbidity to benefit from an endoscopic procedure (n=1 ). The 
DR of advanced neoplasia (AN) was 3.3% (95% Cl 2.8-3.8) in the first, 1.9% (95% Cl 1.5-2.4) in the 
second, and 1.3% (95% Cl 1.0-1.7) in the third round (p<0.001 ). The PPV for AN was 40.7% (95% Cl 
35.7-45.8) in the first, 33.2% (95% Cl 27.3-39.6) in the second, and 24.0% (95% Cl 18.6-30.4) in the 
third round (p<0.001) (Table 1). The DR declined significantly over the three screening rounds. In 
addition, the PPVonly differed significantly between the second and third screening round (p=0.02), 
but not between first and second round screening (p=0.07). The overall adenoma detection rate 
(ie, of both advanced and non-advanced adenoma) in this study over three screening rounds was 
57.4% (95% Cl53.9-60.8). 
Both the DR and PPV were significantly higher in individuals that participated for the first time (Table 
3, subgroup 1 out of 3 rounds) compared to individuals that underwent repeated screening (Table 3: 
subgroup 2 out of 3 rounds and subgroup 3 out of 3 rounds; DR: p<0.001; PPV: p=0.01 ). 
The number of true positives (subjects with a positive FIT identified with AN during follow-up 
colonoscopy) per 1,000 subjects invited was 21 in the first round and 34 after two consecutive 
screening rounds 7. After three consecutive rounds of FIT screening, this number was 43 per 1,000 
invitees. 
Interval carcinomas 
After record linkage with the Dutch Comprehensive Cancer Centre, 43 CRCs were found in the total 
study population. Thirty-four CRCs (79.1 %) were screen-detected tumors, of which 22 (65%) were 
detected in the first, seven (21 %) were detected in the second and five (15%) were detected in the 
third screening round. The remaining nine (20.9%) were interval carcinomas of which three were 
detected between the first and second round and six between the second and third round. Two 
of the interval cancers between the first and second round were detected in participants with a 
negative FIT: one Stage Ill tumor (FIT result at baseline, 24 ng/ml) was detected nine months after 
baseline screening, and one stage II tumor (FIT result at baseline, 7 ng/ml) was diagnosed two years 
and five months after FIT screening. The third CRC was diagnosed at stage I in a subject with a 
positive FIT but negative colonoscopy 10. One year and four months after the index colonoscopy, a 
subsequent colonoscopy was performed because of symptoms and revealed a tumor located at 50 
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em of the anal verge. Two of the interval cancers between the second and third round were detected 
in participants with a negative 2nd round FIT: one stage IV tumor was detected 12 months after 2nd 
round screening (FIT result at 2nd round, 48 ng/ml), and one stage Ill tumor was detected 5 months 
after 2nd round FIT screening (FIT result at 2nd round, 0 ng/ml). Two of the interval cancers were 
diagnosed in subjects with a positive 2nd round FIT but negative subsequent colonoscopy. In one 
subject a second colonoscopy because of symptoms revealed a stage Ill CRC in the sigmoid twenty-
four months after the index colonoscopy. A stage I CRC was diagnosed in the splenic flexure thirty-
six months after the index colonoscopy. The fifth and sixth CRC were diagnosed in subjects who had 
a negative FIT result in the first round (24 respectively 0 ng/ml), were ineligible for the second round 
due to age, and developed a CRC two years and ten months (stage II) respectively three years and 
two months (stage Ill) after first round screening. 
Discussion 
This is a population-based study on the performance of repeated FIT screening with three 
rounds. Given the scarcity of information on impact of repeated FIT screening, such data are of 
major importance for countries considering or planning the implementation of population-based 
FIT screening. We observed a high and increasing attendance and a decline in detection rate of 
advanced adenoma over three consecutive rounds. 
A very important early indicator for an effective population-based screening programme is uptake. 
We observed a high attendance per screening round that increased over successive screening 
rounds. Uptake in previous FOBT studies varied, but data of our group and others showed through 
randomized studies that FIT screening results in a higher uptake compared to gFOBT screening4•5•13-18• 
Furthermore, we found a relatively high percentage of stable attenders of 56% (4073/7229) (ie, 
subjects attending all rounds while they were eligible). Obviously, participation depends on the 
willingness of participants to repeat screening. We previously observed that a positive attitude 
towards CRC screening, and sufficient knowledge on CRC screening are strong predictors for 
participation in successive rounds19• This suggests that increased awareness on CRC screening 
and sufficient information on CRC and FIT screening may have enhanced the uptake in successive 
rounds, as the target population was screening-na·ive when first approached. In our study, previous 
non-attenders were re-invited. Scottish investigators reported that such practice improves uptake 16• 
This is in line with our findings, where response in non-responders of previous rounds was 18.8% 
in round two (when inviting non-responders of the first round), and 23.2% in round three (when 
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inviting non-responders of the second round), thus contributing to overall participation. 
The considerable decrease in DR of advanced neoplasia from 3.3% to 1.3% over the three rounds 
supports the notion that consecutive FIT screening has a beneficial effect by decreasing the 
prevalence of AN. In contrast, an Italian study on repeated FIT screening revealed a stable DR of 
advanced neoplasia over successive rounds (1.5-1.3%)12• That study however applied a higher cut-
off value (1 00 ng Hb/ ml). The initial decrease in DR in our study is likely to be explained by the 
enhanced sensitivity of a FIT at a low cut-off (50 ng/ ml), compared to FIT screening with a higher 
cut-off value. In the Italian study, where average-risk subjects in the same age group as in our study 
were invited, the detection rate of AN was 1.5% in the first round. Even when adopting the higher 
cut-off of 100 ng Hb/ml as used in this study, our detection rate of AN remained higher in the first 
round (2.5%)2°. This difference may be explained by the lower attendance rate during the first round 
than seen in our cohort (56% vs. 62%)4•12• Based on the above we postulate that FIT screening at a 
low cut-off results in a high DR and thus high sensitivity, subsequently causing a decline in DR in 
following rounds. In line with the decrease in DR, also a decline in PPV for advanced neoplasia was 
observed over repeated screening rounds. The false-positive rate (FPR), defined as subjects that 
had a positive FIT, but no advanced neoplasia on follow-up colonoscopy (ie, only non-advanced 
neoplasia, hyperplastic polyps and/or no findings at all), did not rise over the three screening rounds 
(FPR round 1: 5.1 %; round 2: 4.1 %; round 3: 4.4%, p=0.050). This indicates that the decrease in PPV 
was mainly due to the decrease in DR. Such a decrease in PPV in following screening rounds is 
what one would expect and prefer, since it is a confirmation of the effectiveness of the screening 
programme. The question raised based on our data, is whether the PPV has decreased too much, 
whether eg, the screening interval of two years that was based on the less sensitive gFOBTs used 
in the past, is too short. Possible ways to increase the PPV are indeed lengthening the interval, but 
also by using higher cut-off levels in consecutive rounds. This would of course, as a price for the 
higher PPV, decrease programme sensitivity and consequently the effectiveness. Evidently, there 
is an optimum for the PPV, where it is neither too low, nor too high. Whether a PPV for advanced 
neoplasia of 23% is below that optimum depends on local resources. This also needs considering 
the long term incidence and mortality reduction, while comparing different intensities of screening. 
Naturally, the models used for these analyses must be validated for whether they reproduce the low 
PPV in successive screening rounds as presented in this study. 
Strong indicators to assess the effectiveness of a CRC screening programme are the number of 
screen-detected and interval CRCs over consecutive rounds. A decline in the total number of CRCs 
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was seen in this study, from 25 (88% screen-detected carcinomas) to 13 (54% screen-detected 
carcinomas). Subjects with a negative colonoscopy were referred back to the screening programme, 
and were considered not to require FIT screening for ten years. The reason we chose to do so and 
not to offer them another FIT in subsequent rounds, is because we now from previous studies that 
the chance of finding advanced lesions in these subjects is very low. Brenner et al. showed in a 
population-based case-control study that people with a previous negative colonoscopy had a 
strongly reduced risk of CRC compared to people who had never undergone colonoscopy2 1• Lower 
risks even beyond ten years after negative colonoscopy were observed for both left- and right-
sided colorectal cancer, and therefore it was concluded that screening intervals for CRC screening 
by colonoscopy could be longer than the commonly recommended ten years in most cases22• A 
retrospective analysis found similar results, ie, that the risk of developing CRC remains decreased for 
more than ten years after a negative colonoscopy23 . Findings of a more recent study also support 
the ten-year examination interval recommended by existing guidelines for persons at average 
risk who had a negative colonoscopy. Even a single negative colonoscopy was associated with a 
very low long-term risk of colorectal cancer24• However, more data are necessary to determine the 
optimal interval between negative colonoscopy after positive FIT and referal back to the screening 
programme. Another strong indicator to determine the impact of a screening programme and 
especially to compare it to other screening tests, is by the overall diagnostic yield of advanced 
neoplasia over time. For three consecutive rounds of 1-sample FIT screening, the diagnostic yield 
per 1,000 invitees was 43 in this study. Three rounds of FIT-based screening using a cut-off of 50 ng/ 
ml reached a higher yield than sigmoidoscopy or colonoscopy screening, when accounting for the 
low uptake of these more invasive screening methods (the diagnostic yields of advanced neoplasia 
per 1,000 invitees of primary sigmoidoscopy and colonoscopy screening are 33 respectively 19)1. 
This study has several limitations. Recruitment took place in a population that at baseline had limited 
knowledge on CRC and CRC screening. Such awareness likely increased over time, particularly 
because of the onset of a national CRC screening programme in 2014. This may have positively 
affected the participation rate in the second and third screening round. Different screening intervals 
were applied in the second round. However, these intervals are unlikely to influence the results, 
since detection rates of advanced neoplasia as well as the PPV (one-year interval: 36.2%; two-year 
interval: 32.9%; three-year interval: 30.6%; p=0.773) were similar after a one-, two- or three-year 
interval, respectivelyl 0 • 
In this population-based CRC screening study on three rounds of 1-sample FIT screening, an increase 
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in uptake over successive screening rounds was seen. This implies that repeated FIT screening 
is acceptable on a population level. Furthermore, a decline in DR and PPV was seen over three 
consecutive rounds, suggesting that consecutive FIT screening has a beneficial effect on decreasing 
the prevalence of advanced neoplasia. A decrease was seen in the number of screen-detected and 
interval CRCs over consecutive screening rounds, providing further and even stronger evidence for 
the effectiveness. These results stress the importance of on-going research over multiple screening 
rounds. To optimize the effectiveness of screening programmes, more emphasis should be put on 
improving the uptake, especially that of previous non-responders. 
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Abstract 
Background The effectiveness of fecal immunochemical test (FIT)-based screening programs is 
highly dependent on consistent participation over multiple rounds. We evaluated adherence to FIT-
screening over four rounds and aimed to identify determinants of participation behavior. 
Methods A total of 23,339 randomly selected asymptomatic persons aged 50-74 years were invited 
for biennial FIT-based CRC screening between 2006 and 2014. All were invited for every consecutive 
round, except for those who had moved out of the area, passed the upper age limit, or had tested 
positive in a previous screening round. A reminder letter was sent to non-responders. We calculated 
participation rates per round, response rates to a reminder letter, and differences in participation 
between subgroups defined by age, sex and socioeconomic status (SES). 
Results Over the four rounds, participation rates increased significantly, from 60% (95% Cl 60-61 ), 
60% (95% Cl 59-60), 62% (95%CI 61 -63) to 63% (95% Cl62-64) (p for trend < 0.001) with significantly 
higher participation rates in women in all rounds (p<0.001). Of the 17,312 invitees eligible for at 
least two rounds of FIT-screening, 12,455 (72%) participated at least once, while 4,857 (28%) never 
participated; 8,271 (48%) attended all rounds when eligible. Consistent participation was associated 
with older age, female sex, and higher SES. Offering a reminder letter after the initial invite in the 
first round increased uptake with 1 2%; in subsequent screening rounds this resulted in an additional 
uptake of up to 10%. 
Conclusion In four rounds of a pilot biennial FIT-screening program, we observed a consistently 
high and increasing participation rate, while sending reminders remains effective. The substantial 
proportion of inconsistent participants suggests the existence of incidental barriers to participation, 
which, if possible, should be identified and removed. 
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Introduction 
eolorectal cancer (eRe) is a major cause of cancer-related death and its prognosis is largely 
dependent on stage at diagnosis1• Population-based eRe screening aims to detect eRe in an early 
stage and to detect and remove precursor lesions, thereby reducing eRe morbidity and mortality2• 
Fecal occult blood test (FOBT)-based screening using guaiac FOBT (gFOBT) has been shown to 
result in a reduction in eRe-related mortality in a number of randomized controlled trials with a 
15% reduction in eRe-related mortality in a meta-analysis3-6. 
In the last decade, several studies have shown that the performance of the fecal immunochemical 
test (FIT) is superior to that of gFOBF-9• Although FIT-based randomized controlled trials with long-
term follow-up are lacking, a recent observational study demonstrated a 22% reduction in eRe-
mortality in areas where FIT-screening programs were implemented compared to areas without 
screening10 • However, FIT has a relatively low sensitivity for eRe and its precursors, and one round 
of FIT-screening results in a cancer miss rate of 12-25% depending on the cut-off used 11 • Screening 
invitations are therefore usually repeated every two years, and the effectiveness of a FIT-screening 
program is highly dependent on participation in multiple rounds. Ideally, eligible invitees accept the 
invitation to be screened in every screening round (consistent participation) 12•13• 
A high rate of consistent participation increases the program-sensitivity of FIT-screening14-17• On the 
other hand, the succes of a biennial FIT-based screening program might be overestimated if the 
willingness to participate in multiple rounds is low. Knowing possible determinants of inconsistent 
participation could help in targeting the information to specific groups. Previous studies showed, for 
example, that especially socioeconomically deprived persons are less likely to accept eRe screening 
invitations 18-23• 
Several studies on FOBT-screening are available, usually reporting on participation rates in a single 
round. We aimed to examine patterns in participation in an invitational program of biennial FIT-
based screening over four screening rounds and to identify possible predictors for consistent and 
inconsistent screening behavior. 
Methods 
Study population/ study design 
This study was performed in our ongoing pilot program of population-based eRe screening. Details 
about the design of our program have been described previously9•24-26 • In short, demographic data 
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of persons between 50 and 74 years living in the southwest and northwest of the Netherlands were 
obtained from municipal population registers. For the southwest region, random samples were 
taken from the target population by a computer-generated algorithm (Tenalea, Amsterdam, The 
Netherlands). In the northwest region random samples of selected postal code areas were taken. 
The study was conducted in a dynamic cohort. Persons in the target age range that had moved into 
the targeted postal code area at any time during the recruitment period were included, as well as 
those that reached the lower age limit of 50 years. 
No national screening program had been implemented at the start of this pilot-program, and thus 
the target population was screening-naive when first contacted. In the Netherlands, a national 
FIT-based CRC screening program was gradually initiated from January 2014 onwards. Invitees for 
our cohort were not invited for the national program. The selected persons were invited for each 
consecutive round, except for those who had moved out of the area, those that had passed the 
upper age limit, institutionalized people, invitees unable to give informed consent and those who 
had tested positive in a previous screening round. In our information leaflet and in our informed 
consent form, persons with a history of inflammatory bowel disease, proctocolectomy or CRC were 
asked not to participate CRC screening but report this reason for non-participation back to our 
screening organization via the informed consent form. Participants reporting a colonoscopy in the 
past 2 years during intake after a positive FIT were excluded from further participation, as well as 
those with an estimated life expectancy of less than 5 years. Recruitment took place between June 
2006 and December 2014 (first round June 2006 to February 2007; second round August 2008 to 
June 2009; third round February 2011 to February 2012, fourth round March 2014 to December 
2014). During the first round, invitees from the northwest region were randomly allocated to receive 
either a gFOBT or a FIT as screening test. Invitees who received a gFOBT in this first round were 
excluded from our analyses. Date of birth, sex and postal codes of all invitees were collected using 
the municipal population register. Socioeconomic status (SES) was based on social status scores 
provided by the Netherlands Institute of Social Research (www.scp.nl). The social status score of a 
postal code area is based on the unemployment rate, education level, average income and position 
on the labor market. Social status scores are available for almost all postal codes in the Netherlands. 
The standard deviation in the Netherlands in 2006 (start of pilot) was 0.96. Based on the social status 
score we assigned invitees to one of three socioeconomic status categories: high, average or low. 
The first available postal code of the invitee was used to categorize invitees. 
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FIT-screening 
Every two years, all invitees received a pre-announcement letter about the screening program by 
mail, followed two weeks later by an invitation kit containing an invitation letter, information leaflet 
and a FIT with testing instructions. In the first, second and third round, all invitees received an OC-
Sensor (Eiken Chemical Co, Tokyo, Japan) as FIT. In the fourth round, invitees were randomized to 
receive either an OC-Sensor (Eiken Chemical Co, Tokyo, Japan) or an FOB Gold (Sentinel Diagnostics 
SpA, Milan, Italy). As no differences in participation behavior were seen between the two tests, we 
included both arms in our analysis27• The FITs were returned to one of our two selected specialized 
laboratories and dates of return were registered. A test positivity threshold of ~ 10 11g Hb/g feces was 
used. People with a positive FIT were referred for colonoscopy. 
All non-responders received a reminder letter by mail after 2 to 6 weeks. Date of dispatch was 
registered. A positive response after the reminder letter was defined as a FIT arriving at the 
laboratory 3 or more days after sending out the reminder letter. This interval of 3 days was based 
on the mail system delivery times, which maximally take 3 days between sending and delivering. 
Date of dispatch of the reminder and date of return of the FIT at the laboratories were recorded for 
calculating return time. 
Statistical analysis 
The participation rate was calculated as the number of participants relative to all eligible invitees. 
For each screening round, we calculated participation rates per sex. For our analyses of adherence to 
FIT-screening, we only included invitees who were eligible in at least two rounds in order to be able 
to observe the three different screening patterns (see below). 
Differences in screening behavior were used to assign participants to one of three groups: consistent 
participation (i.e. attending all rounds when eligible), inconsistent participation (i.e. attending 
at least once but less than the total times eligible) and non-participants (not participating in any 
round of FIT-screening). The percentage of consistent participants was defined as the number of 
invitees attending all rounds for which they were eligible relative to the total number of invitees. 
The percentage of inconsistent participation was defined as the number of invitees attending 
inconsistently relative to the total number of invitees. Similarly, the percentage of non-participants 
was defined as the number of invitees who never responded to any of the screening invitations. 
Differences in proportions between groups were evaluated for statistical significance using the 
x2-test statistic. We evaluated participation over rounds with the chi-square test statistic for trend. 
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Differences in medians between groups were tested using the Kruskai-Wallis test statistic. P-values 
<0.05 were considered to correspond to statistically significant differences. Data analysis was 
performed using SPSS22 for Windows (SPSS Inc., Chicago, Ill, USA). 
Ethics approval 
The Dutch National Health Council approved the study. All included screenees gave written 
informed consent to participate in the study. 
Results 
Population 
Our dynamic cohort consisted of 23,339 invitees, of whom 323 had to be excluded because they 
never met the inclusion criteria; 49 invitees had moved out, 12 invitees had died and 262 invitees 
met one or more of the exclusion criteria (e.g having IBD, history of CRC, proctocolectomy, reporting 
a colonoscopy in the past 2 years during intake after a positive FIT or having an estimated life 
expectancy of less than 5 years) leaving 23,016 eligible invitees. Baseline characteristics of the eligible 
invitees are summarized in Table 1. Median age of the invitees was comparable between rounds, 
except for invitees in the fourth round, who had a median age of 61 (IQR 56-67). The distribution of 
men and women over all rounds was comparable, with 50%, 49%, 49% and 48% men, respectively 
(p=O. 1 27). The majority of invitees had an average SES. The percentage of invitees with a low SES 
increased over the years, from 9% during the first round to 14% during the fourth screening round. 
Table 1. Baseline characteristics 
Round 1 Round 2 Round 3 Round4 p-value 
Invitees* (n) 14,65 1 14,059 16,042 16,495 p <0.001 
Age (median; IQR) 59 (54-65) 60 (55-65) 59 (54-65) 61 (56-67) p <0.001 
Sex (male; n, %) 7,264 (SO) 6,880 (49) 7,841 (49) 7,955 (48) p=0.127 
SES (n; %) p<0.001 
Low 1,328 (9) 1,412(10) 1,637 (10) 2,281 (14) 
Average 10,602 (72) 10,004 (71) 11,296 (70) 11,117(67) 
High 2,72 1 (19) 2,643 (19) 3,094 (19) 3,088 (19) 
Missing 0 0 15 (0.1) 9 (0.1) 
*el igible invit ees 
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Participation 
Over the four rounds, participation rates increased significantly, from 60% (95% Cl60-61 ), 60% (95% 
Cl 59-60), 62% (95%061-63) to 63% (95% Cl 62-64) respectively (Figure 1; p for trend <0.001 ). 
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Figure 1. Overall participation per screening round with percentage distribution of type of response to participation (initia l response 
versus response after reminder letter). 
Differences between men and women over 4 rounds of FIT-screening are shown in Figure 2, with 
significantly higher participation rates for women in all4 rounds (p<0.001 ). 
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Figure 2. Participation rates per round of FIT-based screening subdivided by sex. 
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Adherence to screening and determinants of adherence 
A total of 17,312 invitees were eligible for two or more rounds of FIT-screening (Table 2).1n this group, 
8,271 invitees (48%) were consistent participants and 4,184 (24%) were inconsistent participants. 
Table 2. Adherence to FIT based CRC screening over multiple rounds. 
Times participated 
Times eligible 0 2 3 4 total 
2 1,766 (34%) 90S (17%) 2,S61 (49%) 5,232 
3 1,011 (31 %) 427 (13%) 482 (1S%) 1,36S (42%) 3,285 
4 2,080(24%) 6S6 (8%) 686 (8%) 1,028 (12%) 4,34S (49%) 8,795 
total 4,857 1,988 3,729 2,393 4,345 17,312 
Analysis restricted to invitees w ho were eligible at least two screening rounds. Highlighted light grey blocks represent consistent participation 
Overall, 12,455 (72%) invitees participated at least once, while 4,857 (28%) never participated in 
the FIT-screening program. Of the 8,795 invitees that were eligible for all four rounds, 4,345 (49%) 
participated in four rounds, 2,370 (27%) in one or more rounds and 2,080 (24%) participated in 
none. Table 3 lists the differences between consistent, inconsistent and non-participants. Consistent 
participants were significantly older, more often female, and more likely to have a high SES. 
Table 3. Determinants of FIT-screening participation behavior. 
Consistent Inconsistent 
(n=8271, 48%) (n=4184, 24%) 
Median age * (IQR) 57 (52-63) 55 (51-61 ) 
Males 45% 50% 
SES*(%) 
Low 7% 11% 
Average 71 % 72% 
High 22% 17% 
•age when first eligible 
Reminder letter 
Never 
(n=4857, 28%) 
55 (51-62) 
54% 
14% 
70.% 
16% 
p-value 
p<0.001 
p<0.001 
p<0.001 
In the first screening round, 49% (95%(148-49) of the invitees responded within the first 2-6 weeks 
after receiving the initial invitation kit, and in the first round 12% (95%CI 11-12) participated after 
having been sent a reminder letter (see Figure 1 ). The percentage of participants responding to the 
initial invitation increased after the first round, with participation rates of 50%, 56% and 54% for the 
2nd,3rd and 4th round, respectively. An additional uptake of up to 10% was observed after sending 
a reminder letter (Figure 1) within every single episode. On average, FITs were returned within 15 
days after sending a reminder letter (first round after 12 days (IQR 7-21 ); second round after 13 days 
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(IQR 7-32); third round after 15 days (IQR 8-27); fourth round after 14 days (IQR 7-28)). 
Discussion 
In four rounds of a pilot biennial FIT-screening program, we observed consistently high and 
increasing participation rates of 60% to 63% in each round. Sending a reminder letter after an initial 
non-response resulted in an increased participation rate, adding 10% to 12% in each screening 
round. Almost half of the invitees that were eligible for two or more screening rounds were consistent 
participants, while almost a quarter never participated. Consistent participants were typically older, 
more often female, and more likely to have a high socioeconomic status. 
Strengths of our study include that our large cohort consists of an average risk population, 
comprising all the age ranges that are usually invited for CRC screening programs worldwide. This 
population was screen-na"lve when first approached, without the presence of any other colorectal 
cancer screening initiatives in the population. More over, it covers four FIT-based screening rounds, 
while the majority of long term studies so far was based on gFOBT-based screening. However, some 
study limitations have to be acknowledged. Socioeconomic status could only be assigned by postal 
code, as a proxy for individual-level SES. Regrettably, no data were available on the ethnicity of 
all invitees, nor their marital status, both factors that could also be associated with participation28• 
Our pilot-program started in 2006, at a time that general awareness of CRC and CRC screening in 
the Netherlands was limited. That awareness has likely increased over time, especially after 2014, 
when a national Dutch CRC screening program was launched. This might have positively affected 
participation rates in the third and fourth screening round in our pilot program. 
Similar participation rates, ranging between 56% and 63%, have been reported for a pilot study 
over four rounds of biennial FIT-screening in ltaly29• Our percentage of consistent participants are in 
line with these data. Studies reporting on adherence to FIT-screening over a longer time interval are 
scarse25•29•30 • Most reports are based on studies using gFOBT, reporting consistent adherence rates 
over multiple rounds, ranging from 39% to 44%13•22•31 • 
As in several studies, women were more likely to participate in our FIT-screening program than men. 
A study from the United Kingdom also described sex differences in participation within a gFOBT-
screening pilot consisting of three rounds20• Denis et al. reported an overall6% higher participation 
rate for women in a first screening round within a gFOBT-screening program that consisted of four 
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rounds, with a gradually decreasing difference over time32 . In contrast to these studies, the sex 
difference in our study remained comparable and significant different, though this difference was 
small. A possible explanation could be that women are generally more familiar with the concept 
of screening. In the Netherlands, women are invited for cervical cancer screening every five years, 
since 1996 (invitations between the age of 30-60 years), and for breast cancer screening every two 
years, sinds 1990 (invitations between the age of 50-75 years). So far, no other national screening 
programs have targeted men. Yet the fact that the difference between participation in men and 
women did not decrease over four rounds, in contrast to what Denis et al reported, suggests that 
there may be other factors involved. Possibly, men are less likely to respond the mailed invitations as 
compared to women and would, for instance, endorsement of the test by their general practitioner 
encourage them to participate. 
A higher SES and older age were also significantly associated with consistent participation. These 
determinants for adherence to FIT-screening are comparable with those in the previously reported 
one-time FOBT-screening studies and gFOBT-based CRC screening studies2o-23•31•33 • Pornet et al 
compared occasional participants with compliant participants in a gFOBT-screening program and 
also reported that occasional adherence was positively assiocated with living in socioeconomically 
deprived areas. 
Response times for participation varied over screening rounds, with prompter participation in later 
screening rounds. A potential explanation could be that most invitees grew familiar with the program 
and the FIT as a screening test over successive rounds, thereby lowering the barrier to participate 
and to perform the test. An alternative, additional factor could be the increased awareness of CRC 
and CRC screening over time. 
Response rates further increased after sending reminder letters to non-participants, and this effect 
was seen in each of the four rounds. Previous one-time screening studies with varying intervals for 
sending reminder letters also showed a positive effect on uptake from sending a reminder letter34• 
Santare et al reported a very high proportion of 29% received FITs (OC-Sensor) after sending a 
reminder letter after 21 days, but this was studied in Latvia, which has an opportunistic screening 
program with very low uptake (7.6%)35• Tinmouth et al reported a 9.7% increase in participation 
after sending a reminder letter in a gFOBT-based CRC screening after 6 months. Participation 
rates doubled after sending a new gFOBT kit36• Our results indicate that sending a reminder letter 
to all non-responders after 6 weeks, in every screening round, consistently results in a positive 
Adherence over four rounds of FIT-screening l1s1 
contribution to overall participation and that reminders remain effective over multiple rounds. 
About one in four invitees eligible for more than one round participated once or more often, but not 
in all screening rounds for which they had been invited. This indicates that the decision to participate 
in screening is not always the outcome of a one-time assessment. It is possible that eligible citizens 
change their behaviour in time, and one must acknowledge that also practical issues, such as work-
related responsibilities, could prevent consistent participation. 
While screening uptake was high and increased over rounds, and about half of the FIT invitees were 
consistent participants, almost a quarter of the invitees never participated in any of the rounds of 
FIT-screening. It would be relevant to investigate whether these invitees made an informed decision 
not to participate, or whether participation was hampered by barriers, such as limited health literacy, 
distrust of government initiated health initiatives, cost considerations, or other issues. Health 
literacy is an individual's capacity to obtain, process, and understand basic health information and 
services needed to make appropriate health decisions. Limited health literacy has been shown 
to be associated with a restricted use of preventive health services, such as cancer screening37• A 
questionnaire study performed in the second round of our pilot-program of FIT-screening showed 
that one of the more frequently reported reasons for non-participation in FOBT-screening was lack 
of abdominal complaints, which suggests limitations in CRC knowledge in this group38• Adequate 
CRC knowledge was found to be a strong predictor for participation in successive rounds39• It is 
conceivable that we need to diversify our invitation and information strategy, taking into account 
differences between groups, to achieve equity, enabling men and women, in all age groups and 
socioeconomic layers, in making well-informed decisions about participation in CRC screening. 
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Abstract 
Objectives Many countries use fecal immunochemical testing (FIT) to screen for colorectal cancer 
(CRC). However, FIT has a lower sensitivity for precancerous adenomas and serrated lesions. There 
is increasing evidence that fecal microbiota play a crucial role in CRC carcinogenesis. Therefore, we 
assessed the possibility of measuring the fecal microbiome in FIT as additional biomarker in CRC 
screening. 
Methods Positive FIT samples (n=200) of an average-risk screening cohort were analyzed for 
universal 165, and bacteria previously associated with CRC, i.e. Escherichia coli, Fusobacterium 
nucleatum, Bacteroides and Fecalibacterium prausnitzii by qPCR. The results were compared to 
colonoscopy findings. 
Results Of the FIT-positive samples, 20 had to be discarded for various reasons resulting in 180 
samples. Fecal microbiome was stably measured with no significant decrease in fecal microbiota up 
to 6 days for E. coli (p=0.53), F. nucleatum (p= 0.30), Bacteroides (p=O.OS) and F. prausnitzii (p=0.62). 
Total bacterial load (i.e. 165) was significant higher in patients with CRC and high-grade dysplasia 
(p=0.006). For individual bacteria, relative to 165, no association was found with colonic lesions. No 
significant differences in fecal microbiome in FIT were found between screenees with and without 
advanced neoplasia. 
Conclusions To the best of our knowledge we are the first to describe the use of measuring 
microbial content in FIT samples for population-based CRC screening. Our results show that the 
fecal microbiome can be measured in FIT samples and remains stable for 6 days. Total bacterial 
load was higher in CRC and high-grade dysplasia. These results pave the way for further research to 
determine the role of microbiota in FIT, to increase FIT sensitivity. 
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Introduction 
Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality 1. Its burden 
is likely to increase by 60%, to over a million cancer deaths by 2030 2. The etiology of CRC is 
complex and not yet completely understood. It is believed that, in addition to hereditary factors, 
environmental risk factors such as a Western diet, smoking, lack of physical activity, and obesity 
play an important role in the development of CRC 3. Furthermore, there is increasing attention for 
the gut microbiome and its role in colorectal carcinogenesis4-6• It is estimated that at least 20%, and 
perhaps more, of the cancer burden worldwide can be attributed to microbial agents7• 
An association between CRC and specific fecal bacteria was already reported a long time ago8• 
In a small Dutch study of 12 patients with Streptococcus bovis bacteremia, we diagnosed CRC in 
eight and gastric cancer in one patient9. In contrast to gastric cancer, in which a single pathogen 
plays a predominant carcinogenic role, CRC appears to have a more complex etiology with 
potential etiological contribution of multiple bacterial species playing different roles6•10-12• Most 
gut bacteria cannot easily be cultivated, yet sequencing of bacterial DNA using quantitative 
polymerase chain reaction (qPCR) nowadays allows identification of the composition of the fecal 
microbiota6. Evidence to date suggests that inflammatory processes triggered by enterotoxigenic 
bacteria (i.e. alpha-bugs) can contribute to CRC development by facilitating DNA damage in 
intestinal epithelial cells (IEC)8 . Bacteria such as Bacteroides and Enterobacteriaceae have been 
shown to induce pro-inflammatory factors and reactive oxygen production in IEC11•13• The ensuing 
accumulation of genetic lesions can contribute to oncogenesis along the adenoma-carcinoma 
sequence. Several studies have shown that the bacterial composition of malignant lesions differs 
from that of surrounding normal tissue14-16• This resulted in the postulation of the so-called 'driver-
passenger model'11 • This theory dictates that pro-oncogenic driver bacteria, (the alpha-and helper 
bugs) help trigger the development of colorectal neoplasia, while disease progression causes an 
altered microenvironment that favors other (commensal) bacteria. Such 'passenger' bacteria, which 
may or may not promote tumor growth, can eventually out-compete the 'driver' bacteria 11 •17• This 
theory suggests that fecal microbiota is dynamic during the course of disease progression, and that 
different (pre)malignant lesions may be associated with different modulations of the microbiome. 
While most previous research has focused on the role of the gut microbiome in the pathogenesis 
of CRC, it is of significant interest to see whether altered bacterial presence may be valuable in 
improving screening strategies for CRC15•18• 
In the past decennia an increasing number of countries have embarked on CRC screening. Many 
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of those use fecal immunochemical tests (FIT) as their screening method19• FIT tests rely on the 
measurement of trace amounts of blood from neoplastic lesions. However, not all lesions bleed 
(in particular serrated adenomas are less prone to blood loss), and conversely, occult blood can be 
detected in fecal samples of healthy individuals20• In spite of high participation rates and a relatively 
high sensitivity for CRC of 75-85% depending on the cut-off used, the sensitivity of FIT for detection 
of advanced adenomas is much lower and generally ranges below 50%21-23• For this reason there is 
an urgent need for additional markers to increase FIT sensitivity without losing its specificity, as the 
latter is of crucial importance in a screening setting. Investigation of the fecal bacterial composition 
could present one such possible additional marker. Hence, it would be of great interest to detect 
bacterial species in the rest materials of FIT-screenees, which would preclude additional material 
collection from screenees. To the best of our knowledge no study has yet described the detection 
of microbiota in FIT. Therefore, the aim of our study was to evaluate the possibility of measuring 
fecal microbiota in FIT, and to assess the potential use of bacterial species detection as an additional 
diagnostic biomarker in CRC screening. Based on their previously described association with CRC, 
we selected bacteria from 4 different genera: suspected driver bacteria of the Enterobacteriaceae 
(Escherichia coli) and Bacteroides species, the most often associated CRC bacterium, Fusobacterium 
nucleatum, and the anti-inflammatory Clostridiaceae Fecalibacterium prausnitzii (F. prausnitzii) 
which was described to be less prevalent in CRC patients18•24• 
Methods 
Patients, FIT-screening, and data collection 
Details about the design of this ongoing population-based CRC screening program have been 
described previously25·26.ln short, demographic data of all individuals between 50 and 74 years living 
in the southwest of the Netherlands were obtained from municipal population registers. Random 
samples were taken from the target population by a computer-generated algorithm (Tenalea, 
Amsterdam, The Netherlands). As there was no CRC screening program at the time of the trial in 
the Netherlands, the target population was screening-naive when first approached. At present, 
four rounds of FIT-screening have taken place. Individuals with a history of inflammatory bowel 
disease or CRC, as well as those who had undergone a colonoscopy, sigmoidoscopy, or barium 
contrast enema in the past 3 years, those with an estimated life expectancy of <5 years, and subjects 
who were unable to give informed consent were excluded from the study. For this study only FIT 
samples of the end of the third and beginning of the fourth screening round were used, aiming 
for a total of 200 FITs to be included. Recruitment of this third and fourth screening round took 
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place between February 2013 and August 2014. In the third screening round all invitees received 
the OC-sensor (Eiken, Japan). In the fourth screening round invitees were randomized between 
the OC-sensor and FOB-Gold (Sentinel, Italy). Participants were instructed to send the FIT within 
one day after collection and to keep the FIT in the refrigerator until sending it to the laboratory. A 
cut-off of ~ 101Jg Hb/g feces was used to refer the screenee for a colonoscopy within 4 weeks. All 
colonoscopies were performed by gastroenterologists with an experience based on at least 1,000 
colonoscopies. All colonoscopy findings were prospectively registered using pre-defined clinical 
registration forms. All lesions were evaluated by trained gastrointestinal pathologists according 
to the Vienna criteria27. Advanced adenomas (AA) were defined as an adenoma with a diameter 
~ 10 mm, and/ or with a ~25o/o villous component, and/or high-grade dysplasia. Advanced neoplasia 
(AN) included AA and CRC, w ith the most advanced lesion used for analysis. Serrated polyps were 
defined as serrated adenomas (with our without dysplasia) and hyperplastic polyps. For this study 
only FIT-positive screenees were included. 
Bacterial quantitative analysis 
After occult blood measurement, FIT samples were stored at -20°C until analysis. DNA was isolated 
from FIT liquid by Wizard Genomic DNA Purification kit (Promega, Leiden, the Netherlands) with 
modifications. Bead-beating was performed 3 times for 30 seconds to lyse bacteria. Protein was 
precipitated from the supernatant by Protein Precipitation Buffer, followed by isopropanol 
precipitation of DNA. DNA was washed with 70% ethanol and resuspended in Tris-EDTA (TE) buffer. 
DNA concentration was measured by Nanodrop (ThermoFisher Scientific), and adjusted to 1 Ong/ 
!Jl. Bacterial DNA (E. coli, F. nucleatum, Bacteroides, F. prausnitzii and universal bacterial 16S) was 
detected by PCR or qPCR. Specificity of primers (Table 1) was determined by primer blast search 
against all bacteria (http:/ /www.ncbi.nlm.nih.gov/ tools/primer-blast/ ) 28-37. In addition, DNA was 
amplified by PCR using GoTaq polymerase (Promega) and 35 cycles (95° for 15'; 56° for 30'; 72° for 
30") on a 2720 Thermal Cycler (Applied Biosystems, ThermoFisher) and PCR products were verified 
by 2o/o agarose gel-electroforesis (for examples see Figure 1 ). Analysis of bacterial abundance was 
performed by SybrGreen based quantitative PCR (qPCR). qPCR reactions were performed in a 201JL 
volume, containing 1 OiJL SYBR 411 Select Master Mix for CFX (ThermoFisher Scientific), 21JL Forward+ 
Reverse primer (end concentration 11JM), 71JL H20 and liJL template. Cycle conditions were 95° for 
10 min (initial denaturation), followed by 40 cycles of (95° for 15'; 56° for 30'; 72° for 30") and melt 
curve analysis on StepOnePius real time PCR System (Applied Biosystems, Thermofisher). 
For each bacterium, DNA for standard curves was prepared by PCR using DNA isolated from FIT tests 
as template. PCR products were purified using lnvisorb 411 Fragment CleanUp kit (Stratec molecular, 
160 I Chapter 7 
Berlin, Germany), DNA concentration was measured, and DNA dilutions ranging from 0.0001-10 ng/ 
!JI were prepared. The amount of DNA in test samples was inferred from their Ct value through 
calculation of standard curves run on each separate plate, and corrected for total amount of DNA 
present in the FIT liquids. Copy number per gram PCR product was inferred from the weight of 
one PCR product as calculated by the accumulated weight of the basepairs in the product, and 
results were presented as absolute bacterial content (copy number/g FIT fluid) or as ratio of the 
total amount of 16S copies/gr FIT fluid. Samples where bacterial DNA was undetectable were given 
a value <than the lowest detectable value for that PCR product, in order to prevent loss of these 
samples from group comparisons. 
Table 1. Primer sequences used in this study 
Bacterium Sequence (5'-3') Product size References 
Universai16S Bact-1369-F cggtgaatacgttcccgg 14S 28,38 
Bact-1492-R tacggctaccttgttacgactt 
F. nucleatum Forward cttaggaatgagacagagatg 140 29,30 
Reverse tgatggtaacatacgaaagg 
E. coli Forward catgccgcgtgtatgaagaa 96 31 ,32 
Reverse cgggtaacgtcaatgagcaaa 
Bacte roides Forward cggacgtaagggccgtgc 140 33,34 
Reverse ggtgtcggcttaagtgccat 
F. prausnitzii Fprau223F gatggcctcgcgtccgattag 198 35,36 
Fprau420R ccgaagaccttcttcctcc 
Microbiota stability in FIT 
For analysis of the stability of the microbial content of FIT over time, seven FIT tests were taken from 
one stool sample of a healthy volunteer, and tests were stored at -20°( immediately, or after 24, 
48, 72, 96, 120 and 144 h in order to mimic FIT transit time. The experiment was performed three 
times, with the same fecal donor. DNA was isolated from all samples simultaneously upon thawing, 
and presence of E. coli, F. nucleatum, Bacteroides, F. prausnitzii and universal bacterial 16S were 
detected by PCR and qPCR as described above. F. nucleatum and E. coli were below detection level 
in this donor. Therefore, stability of bacterial DNA was also tested by spiking tests with a known 
concentration (0.012 ng/ IJI) of E. coli PCR product, which has the added benefit of circumventing 
measurement of bacterial growth/death. Spiked FIT without stool was used as control. 
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Figure 7. Stability of bacterial composition in FIT in spiked E. coli PCR (A), 165 (B), F. prausnitzii (C), Bacteroides (0). Bacterial 
composition remained stable up to at least 144 hours. 
Statistical analysis 
Descriptive data were reported as proportions or means with the standard deviation. For non-
normally distributed data the median and interquartile range (IQR) were given. Chi-Square tests 
were used to analyze categorical data; continuous data were analyzed using Student's t-tests or 
one-way ANOVA. Linear regression analysis was used to assess bacterial load and transit time. 
Correction for multiple testing was done according to Bonferroni resulting in a two-sided p-value 
of <0.01 that was considered to be statistically significant. Statistical analysis was performed using 
IBM SPSS version 21.0. 
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Ethical approval 
The study was approved by the Medical Ethical Committee of the Erasmus MC, Rotterdam (reference 
number: MEC-2014-212). 
Results 
FIT screenees 
A total of 200 samples from FIT positive screenees were collected. Of these, 20 samples had to be 
discarded for various reasons (e.g. because multiple samples from the same screenee were included, 
because a sample was misclassified, or because pathology outcome was missing), resulting in 180 
samples available for analysis of microbial content. Of those, 56% were male with a median age 
of 64 years (IQR 58-69 years). Median fecal Hb concentration was 21 11g Hb/g feces (IQR 13-55 11g 
Hb/g feces) . All screenees included in this study underwent colonoscopy and in 31% (n=SS) patients 
advanced neoplasia was detected, of whom 5 were diagnosed with CRC. All colonoscopy findings 
are described in Table 2. 
Table 2. Most advanced lesion at colonoscopy of FIT positive screenees 
Finding at colonoscopy 
Normal 
Serrated polyps 
Tubular adenoma < 10 mm 
Tubular adenoma >=1 0 mm 
(Tubulo)vi llous adenoma 
High-grade dysplasia 
Colorectal carcinoma 
Total 
*numbers do not add up exactly to 100% due to rounding 
Stability microbiota in FIT over time 
n(%) 
41 (22.4) 
25 (1 3.7) 
59 (32.2) 
33 (18.0) 
14 (7.7) 
3 (1.6) 
5 (3.3) 
180 (1 00*) 
Transit time of the FIT from screenee to the laboratory could potentially affect the microbial 
composition detected. Although growth of anaerobic bacteria is not expected, and FIT buffer 
contains bacteriostatic sodiumazide, degradation of bacterial DNA might occur. Therefore, we first 
analyzed the stability of the bacterial composition in FIT. An artificially spiked E. coli PCR product 
cou ld be reliably measured in stool samples that were left at ambient temperature for up to 48h 
(Figure 1 A). 
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Endogenous universa l bacterial 165, F. prausnitzii and Bacteroides DNA was consistently detected 
by (q)PCR for even longer periods, with no loss in detection levels for up to 
1 44h (Figure 1 B-0). 
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Figure 2. Transit time (interval between fecal sampl ing and arrival of the FIT specimen at the laboratory) and absolute copy 
number/ gram FIT test per 165 for E. coli (A), F. nucleatum (B), Bacteroides (C), F. prausnitzii (D). 
The average time between fecal sampling by the screenee and analysis at the laboratory (i.e. 
transit t ime) was 1 day (IQR 1-2 days), with 91% of FITs arriving at the laboratory within 2 days after 
sampling. For all screenees the correlation between absolute copy number of the four bacteria and 
transit time were evaluated (Figure 2). No significant decrease in fecal microbiota was seen up to 
6 days for E. coli (p=0.53), F. nucleatum (p=0.30), Bacteroides (p=O.OS) and F. prausnitzii (p=0.62, 
Figure 2). 
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Figure 3. Copy number per gram FIT liquid for 7 65 (A) and E. coli (8) according to co/onoscopy outcomes. 
Microbiome in FIT and findings at colonoscopy 
For all samples, copy number per gram (copy nr./g) FIT liquid was calculated for the total number 
of bacteria (i.e. 165) and the four predefined bacteria. A significant difference was seen for 165 , 
with increasing abundance of total bacterial content in screenees with high-grade dysplasia and 
CRC (p=0.006; Figure 3A). For E. coli, the copy nr./g was lower in patients with tubular and villous 
adenomas compared to patients with a normal colonoscopy, serrated polyps, high-grade dysplasia 
and CRC (p=O.OOS; Figure 38). For F. nucleatum, F. prausnitzii, and Bacteroides, no association was 
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observed between the presence of the bacteria and any particular lesion (Supplementary Figure 1 ). 
No significant association between amounts of bacteria and presence of advanced neoplasia was 
observed (Supplementary Figure 2). 
To correct for potential differences in amount of fecal matter in the FIT, the bacteria were also 
calculated relative to the total bacterial presence as determined by universal165 (copy nr./g of 16S). 
No significant differences were found when evaluating FIT microbiota according to all colonoscopy 
findings, including CRC, for E. coli (p=0.97), F. nucleatum (p=0.98), Bacteroides (p=0.15) and F. 
prausnitzii (p=0.91 ; Figure 4). 
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Figure 4. Absolute copy number per 165 and most advanced co/onoscopy finding* for E. coli (A), F. nuc/eatum (8), Bacteroides (C) and 
F. p rausnitzii (D). 
In addition, no significant differences in microbiota were found between screenees with and without 
advanced neoplasia (E. coli p=0.30; F. nucleatum p=O.SS; Bacteroides p=0.12; F. prausnitzii p=0.93; 
Figure 5). When evaluating FIT microbiota according to location of the most advanced lesion (i.e. 
B 
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distal vs. proximal), again no significant differences were seen for all four bacteria (Supplementary 
Figure 3). 
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Figure 5. Microbiome in absolute copy number per 7 65 for screenees with no advanced neoplasia (no AN) and advanced neoplasia 
(AN) for E. coli (A), F. nuc/eatum (8), Bacteroides (C), F. prausnitzii (D). 
Discussion 
To t he best of our knowledge we are the first to describe assessment of the microbiome in FIT 
samples. Our results show that fecal microbial DNA can be isolated from FIT samples and that it 
remains stable up to 6 days. Screenees w ith high-grade dysplasia and CRC had a higher load of 
t otal universa i1 6S. With respect to specific microbial composition, no relation w as found between 
numbers of specific bacteria and colonoscopy findings relat ive to total 165, except that numbers 
of E. coli were reduced in patients w ith tubular and villous adenoma. With regard to location of 
the lesion no differences were found between a lesion in the distal or proximal colon and number 
of feca l bacteria found. For this st udy four bacteria l species were chosen, together represent ing a 
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wide spectrum of genera thought to be of importance in CRC carcinogenesis. E. coli and Bacteroides 
species are considered to promote inflammation driving the colorectal epithelium to a carcinogenic 
state6•18•39• This state of inflammation and dysbiosis gives room for opportunistic bacteria, such 
as F. nucleatum, to further induce carcinogenesis, whereas anti-inflammatory bacteria such as 
F. prausnitzii may be 'crowded out' 24.Consequently various bacteria take part in the process of 
carcinogenesis, with many of these bacteria being variably present during carcinogenesis11 • This 
could explain why lower concentrations of E. coli were found in tubular and villous adenomas, 
although screenees with normal colonoscopy and those with CRC had similar concentrations. While 
E. coli and Bacteroides have been identified in a number of studies as carcinogenic factors in CRC, 
our findings did not support a role for these bacteria as additional biomarker in FIT samples to 
identify FIT-positive screenees at risk of carrying advanced adenomas. 
A previous study has suggested a role for F. nucleatum in the detection of sessile serrated lesions, 
with the mucus cap on these lesions suggested as a cause for the high levels of F. nucleatum14• 
Additional detection of sessile serrated lesions would be especially valuable in FIT screening, as 
FIT is known to have a poor sensitivity for these lesions40• However, our results did not show any 
association between F. nucleatum and hyperplastic polyps or serrated lesions compared to other 
neoplasia or a normal colon (p= 0.82; data not shown). This could be because F. nucleatum is not 
sensitive enough by itself as a biomarker in a screening setting due tooverabundance in healthy 
subjects13• Further studies have to assess the prevalence of F. nucleatum in FIT-negative screenees 
who also undergo colonoscopy. 
Most studies regarding the role of the microbiome in colorectal carcinogenesis have looked 
specifically at the microbiome at and around the tumor-site and it is conceivable that a fecal sample 
obtained by FIT is not representative of onsite mucosal dysbiosis41 • However, microbiota on mucosa 
retrieved during colonoscopy or surgery could be influenced by the bowel preparation that all 
patients undergo prior to the intervention. Furthermore, most of these studies had a case-control 
design and were thus prone to overestimate diagnostic performance42• To date, there are two other 
studies that looked at the fecal microbiome in FIT screenees, showing a difference in overall fecal 
microbiome between normal patients and patients with colorectal adenomas15.43. In both studies 
the microbiome was analyzed in full stool samples and not in the FIT samples themselves, making 
comparison with our data complex. However, a full stool sample may ask for a considerable effort 
from the screenee, making the design undesirable in a screening setting as it might hamper 
participation rates. Furthermore, the microbiota-based model described in one of these studies 
was based on sequencing a selection of stool samples43• Such a data-driven strategy has several 
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limitations and can lead to overly optimistic estimates of diagnostic test accuracy44. 
The strengths of our study include the fact that all FIT samples were retrieved from a population-
based CRC screening cohort, consisting of average risk screenees, resulting in a high external validity. 
Also, as gut microbiota were measured in FIT samples, no additional stool samples were required 
from the participants. It is the first study showing fecal microbiota related to colonoscopy outcomes 
ranging from no findings to CRC. This allows comparison of microbiota between previously untreated 
patients across the adenoma-to-carcinoma range. Furthermore, we included only FIT samples that 
tested positive for occult blood, precluding the possibility of a bias introduced by potential microbe-
blood interactions45• However, in order to appreciate our results, some limitations also need to be 
addressed. Firstly, we did not compare our findings to histological material to confirm the presence of 
bacteria on the mucosal surface. Furthermore, as only FIT-positive subjects underwent colonoscopy, 
it was not possible to evaluate prime indicators of diagnostic performance, including sensitivity, 
specificity and the area under the receiver-operating curve. However, we considered analysis of only 
FITs justified, as this is representative of population-based FIT screening where screenees do not 
undergo colonoscopy as primary screening method. Moreover, this is in line with our aim to study 
the presence of microbiota in FIT samples since this would enable implementation of microbiota 
assessment in FIT samples as an important additional tool. Secondly, we used the most advanced 
lesion detected during colonoscopy, while screenees sometimes have more than one lesion. The 
presence of multiple lesions could theoretically lead to our findings being an underestimation of 
the relation between fecal microbiome and colonic neoplasia. Yet, for screening purposes subjects 
at highest risk (i.e. with advanced neoplasia) are of most interest and therefore we believe that our 
findings adequately represent screening outcomes. Also, distribution of lesions is in accordance 
with previous literature on diagnostic yield of repeated rounds of FIT screening 25•46• 
In conclusion, our results illustrate that the gut microbiome can be measured in FIT-samples in CRC 
screening, with a higher total bacterial load for CRC and high-grade dysplasia. The need to increase 
FIT sensitivity, especially for advanced adenomas, remains of evident importance and further 
studies should be conducted to determine the role of microbiota in FIT. 
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Abstract 
Background and aims Colorectal cancer (CRC) screening using quantitative fecal immunochemical 
tests (FITs) is rapidly gaining ground worldwide. FITs are invariably used in a dichotomous manner 
using pre-specified cut-offs. To optimize FIT-based screening programs, we explored if fecal 
hemoglobin concentrations (tHb) of participants with a FIT below the cut-off (FIT be) could be used 
to predict future colorectal advanced neoplasia (AN) risk. 
Methods Average-risk subjects aged 50-74 years, were offered four rounds of population-based FIT 
screening (cut-off 10 11g Hb/ g feces). All subjects with a FITbco at first participation (baseline) were 
included. Hazard ratios (HRs) for AN were determined using Cox proportional hazard regression 
analyses. Logistic regression techniques were used to calculate risks of AN after consecutive FITbco 
results. 
Results Out of 13,566 invitees, 9,561 (70%) participated at least once and 7,663 (92%) had FITbco 
at baseline. Median follow up was 4.7 years (IQR 2.0-6.1 ). After eight years of follow-up, a higher 
cumulative incidence of AN was found in screenees with baseline tHb between 8 to 10 11g Hb/ g 
compared to those with tHb of 0 11g Hb/ g (5 vs. 33%; p<0.001 ). The multivariate HRs increased from 
1.2 to 8.2 for tHb concentrations between >0 and 211g Hb/ g and ~8 to 10 11g Hb/ g (p<0.001). A 14-
fold increased risk was found after two consecutive FITsbco with twice tHb of 811g Hb/ g versus twice 
0 11g Hb/g (p<0.001 ). 
Conclusion Among screenees with a FITbco' baseline and consecutive tHb are independent predictors 
for incident AN. These findings provide tools for personalized strategies in population-based CRC 
screening. This may decrease unnecessary screenee burden and could optimize use of resources. 
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Introduction 
Colorectal cancer (CRC) is among the most common causes of cancer-related mortalityl. 
Population-based CRC screening can significantly reduce disease burden. Fecal occult blood tests 
are widely accepted for this purpose2•3.A higher fecal hemoglobin (fHb) concentration is associated 
with a higher risk of advanced neoplasia (AN)4-7.Many screening programs worldwide use fecal 
immunochemical tests (FIT), that can be either qualitative (i.e. providing a positive or negative test 
result) or quantitative (i.e. quantifying fHb concentrations in feces)l-8. Although quantitative FITs 
provide exact fHb concentrations in 1-1g Hb/g feces, current screening programs routinely use fHb 
in a dichotomized fashion. As such, they are invariably used as qualitative tests. A test is considered 
positive above a fixed threshold that is the same for all screenees in all rounds of screening. Those 
with a positive test are recommended to undergo colonoscopy. Individuals with a negative test are 
offered a renewed FIT after a predefined screening interval without taking into account previous 
fHb concentrations. Most FIT screening programs rely on annual or biennial screening, requiring 
participants to repeat the test multiple times over the course of years. 
To increase screening efficiency and impact of FIT screening programmes, it is relevant to explore 
if screenees with a negative FIT, that is a fHb concentration below the pre-defined cut-off level (FIT 
below cut-off; FITbc)' can be categorized according to their actual fHb concentration into different 
risk groups for later development of AN. Such tailored screening would allow for targeted variation 
of screening intervals, and decrease screening and colonoscopy demand or optimize its use. 
Currently, many countries with CRC screening programs struggle to match colonoscopy demands 
with limited resources9- 11 • Over the course of multiple screening rounds, fHb concentration could 
then be of guidance in identifying those at low and high risk of AN, and thus form the basis of 
individualized screening strategies. Such information is of key importance for national population-
based CRC screening policies. Previous studies have mainly focused on fHb concentrations of FIT-
positive screenees, or have only assessed first round fHb concentrations5•12•13• At present, no I iterature 
is available on trends in individual fHb concentrations of FIT bco screenees over consecutive screening 
rounds. Furthermore, it is not known whether these previous fHb concentration(s) can be used as 
a predictor for the future detection of AN. Therefore, we aimed to investigate trends in fHb of FITbco 
results at first participation, and in subsequent rounds as a predictor for future incidence of AN. 
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Methods 
Study design and participants 
Details about this study cohort and the design have been described before14• In short, individuals 
living in the southwest of the Netherlands were approached for four rounds of FIT-screening. 
Demographic data of all individuals between 50 and 74 years living in this region were obtained 
from municipal population registers. Random samples were taken based on different postal codes. 
Exclusion criteria included a history of inflammatory bowel disease or CRC, a full colonic examination 
in the past two years, an estimated life expectancy of <5 years, and inability to give informed consent. 
In case of a positive FIT result, subjects were sent for colonoscopy and notre-invited for subsequent 
FIT rounds. Subjects were not invited when they had become older than 74 years, or when they had 
moved out of the region. The cohort was supplemented with new screening-na·lve subjects in round 
3 and 4 to best mimic a continuous, population-based screening cohort. Recruitment took place 
between November 2006 and December 2014. For this analysis all subjects participating in at least 
one screening round and with a negative FIT result, defined as a FIT result below the cut-off of 10 11g 
Hb/ g feces (FIT be) at their first participation (i.e. baseline), were included. 
FIT screening and colonoscopy 
Each screening round, eligible invitees received one FIT per mail. Invitees were instructed to collect 
one sample of one bowel movement. In the first 3 rounds subjects received the OC-sensor (Eiken, 
Japan), and in the last round subjects were randomized to receive either the OC-sensor or the FOB-
Gold (Sentinel, Italy). The OC-Sensor and FOB-Gold perform equally over the relevant concentration 
range15. Participants were asked to sample feces according to instructions and post the sample 
together with the consent form within 24 hours while storing it in the refrigerator until mailing. 
The OC sensor FITs were analysed on the OC-sensor 11 system (Eiken, Japan), the FOB-gold FITs 
were analysed on a Sentifit 270 system (Sentinel, Italy). All FIT tests were analysed once at room 
temperature. The analytical working ranges for the OC sensor 11 and Sentifit 270 were respectively 
1-200 feces and 1-170 11g Hb/g feces. Samples with fHb concentrations above the upper analytical 
working limits were not diluted or re-analysed. The test result of ~ 10 11g Hb/ g feces was considered 
positive. Subjects with a positive FIT were scheduled for colonoscopy within 4 weeks. In case 
colonoscopy was incomplete, a computed tomographic colonography was performed. 
Experienced board-certified gastroenterologists performed all endoscopies. The maximum reach 
of the endoscope, adequacy of bowel preparation, and characteristics and location of any polyps 
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were recorded. All polyps were removed and evaluated by dedicated gastrointestinal pathologists. 
Patients with a positive colonoscopy entered a surveillance program according to guidelines of the 
Dutch Society of Gastroenterology, whereas subjects with a negative colonoscopy were considered 
not to require FIT screening for 10 years. AN was defined as an adenoma of~ 10 mm, an adenoma 
with at least 25% villous histology and/or high-grade dysplasia, or CRC. 
Follow-up and interval carcinomas 
Except for individuals who had moved out of the Netherlands, all recruited participants were 
followed for the development of CRC. Colorectal cancers diagnosed outside of the screening 
program (including CRCs in participants who did not return to screening, FIT interval cancers, post-
colonoscopy CRCs, and CRCs detected at surveillance colonoscopy) were identified through linkage 
with the Dutch Comprehensive Cancer Centre (www.iknl.nl), which was up to date until March 2015. 
Statistical analysis 
Descriptive data were reported as proportions or means with standard deviation (±SD). For non-
normally distributed data, the median and interquartile range (IQR) were given. To investigate 
the role of a negative baseline FIT value, ~b concentrations were divided into six categories; 0, 
>0-2, ~2-4, ~4-6, ~6-8 and ~8- 1 0. Per category the cumulative incidence of AN over four rounds 
was calculated using life tables and curves. Patients were censored at the end of follow up if the 
event (i.e. AN) had not occurred. A Cox proportional hazard regression analysis was performed 
to calculate hazard ratios (HRs), including 95% confidence intervals, to identify factors associated 
with the development of AN. These factors included age, gender, socioeconomic status (SES), and 
baseline tHb. The date of the baseline FITbco was defined as time 0. Only tHb concentrations below 
10 j.lg Hb/g feces were used in these analyses. Factors with a p-value of < 0.10 in univariate analysis, 
were included in a multivariate model. Interaction terms were also evaluated in the multivariate 
model. A two-sided P value of < 0.05 was considered to be statistically significant. Analyses were 
performed using SPSS 21.0 statistics software (IBM Corp., Armonk, New York, USA). 
The prediction of an event (i.e. AN or CRC) given the outcome of tHb concentration of a FITbco at 
any round (i.e. visit) was analysed applying a logistic regression technique allowing for multiple 
repeated measurements per subject using SAS PROC GENMOD with the REPEATED statement 
with an independent variance assumption16• Each visit was hereby associated with the event. The 
analysis included adjustment for age at first round (or age at time of FIT screening), sex, and time 
of round in relation to event or last follow-up. Interactions between gender and age as well as non-
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linearity of age and ~b concentration were tested using both pre-specified groups and polynomial 
regression. Factors with a p-value < 0.10 in univariate analysis, were included in the multivariate 
model. A two-sided p-value < 0.05 was considered to be statistically significant. In addition, all 
analyses were adjusted for multiple testing. Using the results of logistic regression analyses heat 
plots were generated to depict the risk of AN after two FITbco· Analyses were performed using SAS 
9.4 (SAS Institute Inc., Cary, North Carolina, USA). 
13.566 subjects invited 
for FIT-based CRC 
screening 
278 (2%)subjects did 
not meet inclusion 
criteria 
9.557 (72%)ofeligible 
subjects participated at 
least one time 
I 
8. 744 (91 %) of 
participants had a 
negative RT at baseline 
(<10J.lg Htig feces) 
I I I 
5.488 (62%) subjects 585 (7%) subjects 1.596 (18o/o) subjects 1.075 (13%) subjects 
participated for the participated for the partic ipated for the participated for the 
first time in round 1 first time in round2 first time in round3 first time in round4 
I I I 
7.663 (87%) FIT 
negative subjects 
included for 
follow-up 
I 
Screen-detected Screen-detected Follow-up detected 
advanced adenomas col or ectal cancer colorectal cancer 
n=175 (2.3%) n=23 (0.3%) n=21 (0.3%) 
Figure 1. Flowchart of study design and carcinomas. 
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Results 
Baseline characteristics 
Over four rounds of biennial FIT screening, a total13,566 subjects were invited of whom 278 (2.0%) 
did not meet the inclusion criteria. Out of the 13,288 remaining subjects 9,557 (71.9%) participated 
at least once (Figure 1 ). Out of these participants, 8,744 (91.4%) had a FITbco at first participation and 
were included for analysis. Median age was 58 years (IQR 52-64 years) at baseline, with 47·1% of the 
screenees being male. Overall, 3,172 (36.3%) FITbco subjects participated in all four rounds, 1,235 
(14.3%) in three rounds, 2,254 (25.8%) in two rounds, and 2·059 (23.6%) in one round. Median time 
between screening rounds was 23 months (IQR 22- 24 months). 
Role of baseline fib in predicting risk of advanced neoplasia and colorectal caner 
The majority of subjects (62.7%) participated for the first time in round one, the remaining subjects 
participated in round two (6.6%), round three (18.3%), and round four (12.3%). Because follow-up 
ended after the fourth round, only baseline 1Hb of subjects participating in one of the first three 
rounds (n=7,663) were included for survival analyses. Median follow up was 4.7 years (IQR 2.0-6.1 
years). Over the following rounds, 821 (1 0.7%) participants with a baseline FITbco had a positive FIT, of 
whom 91.8% underwent colonoscopy (n=754). During follow-up 221 (3.0%) cases were diagnosed 
with AN; 175 with advanced adenomas, 24 with screen-detected CRC, and 22 with CRC detected 
during follow-up, of which 8 were FIT interval cancers (Figure 1 ). 
Cumulative incidences of AN per category of 1Hb are shown in Figure 2. After 5 years of follow-
up, screenees with a baseline 1Hb concentration between 8 and 10 11g Hb/ g had an 8-fold higher 
cumulative incidence of AN than screenees with a baseline 1Hb concentration of 0 11g H b/g (p < 
0·001 ). After 8 years of follow-up the cumulative incidence increased with 28% compared to 
screenees with a baseline 1Hb concentration of 0 11g Hb/g feces (p<0.001 ). 
Cox proportional hazard regression analysis showed baseline 1Hb concentration was associated 
with the hazard of developing AN in multivariate analysis (Table 1 ). Compared to screenees with 
a baseline 1Hb concentration of 0 11g Hb/ g feces, HRs increased from 1.2 (95% Cl 0.9-1.7) for fHb 
concentrations between >0 and 2 11g Hb/g, to 8.2 (95% Cl 4.5-15.0) for 1Hb concentrations of ;::8 to 
10 11g Hb/g (p<0.001 ). 
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Figure 2. Life table and curve for advanced neoplasia by fib level per 2J19 Hb!g. This figure shows that the effect on cumulative 
incidence of AN of baseline FIT is most prominent for fHb between 4 and 10 J19 Hb!g. 
Role of fib concentrations of consecutive FITs in predicting risk of advanced neoplasia 
To further explore the use of [1b of consecutive FITs, tHb concentrations of all screenees that had 
at least two consecutive FITsbco were analysed. In multivariate logistic regression, including time 
between FITs and total follow-up time, several FITbco combinations were evaluated to determine 
relative risk of developing AN, these are shown in Table 2. ORs remained similar regard less of the 
sequence of tHb results. 
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Table 1. Cox-regression analysis of baseline fib concentration for hazard of the detection of advanced neoplasia during follow-up. 
Advanced neoplasia 
Univariate analysis Multivariate analysis 
Gender (male) 
Age (years) 
Baseline 1Hb concentration 
0 ~g Hb/g 
>0-2 ~g Hb/g 
~2-4 ~g Hb/ g 
~4-6 ~g Hb/ g 
~6-8 ~g Hb/ g 
~8-1 0 ~g Hb/g 
Socioeconomic status 
High 
Average 
Low 
• p<O·OOl 
HR 
1·7* 
1·1* 
Ref.* 
1·3 
2·9 
6·5 
4·5 
8·9 
Ref. 
1·0 
0·6 
95o/o Cl 
1.3-2·3 
1·0-1·1 
0·9-1·8 
1·8-4·6 
4·2-10·2 
2·1-9·3 
4·9-16·4 
0·7-1·3 
0·4-1·0 
,Hb; fecal hemoglobin concentration, HR; hazard ratiof Cl; confidence interval, cone; concentration, ref ; reference category. 
HR 
1·6* 
1·1 * 
Ref.* 
1·2 
2·8 
5·7 
4·2 
8·2 
95o/oCI 
1·2-2·1 
1·0-1·1 
0·9-1·7 
1·7-4·4 
3·7-8·9 
2·1 -8·7 
4·5-1 5·0 
Table 2. Multivariate logistic regression analysis evaluating various hypothetical combinations of fHb concentration of 
two previously negative FITs and odds ratio (OR) of developing advanced neoplasia during follow-up. 
Advanced neoplasia 
Multivariate analysis 
OR 95o/o Cl p-value 
Gender (female) 2·1 1·3-3·2 0·001 
Age (years) 1·0 1·0-1·1 0·04 
Combination of first and second fHb concentration 
0 ~g Hb/g and 0 ~g Hb/g Ref. <0·001 
1 ~g Hb/g and 1 ~g Hb/g 1·7 1·5-1·9 
1 ~g Hb/g and 5 ~g Hb/g 4·4 3·1-6·3 
5 ~g Hb/g and 1 ~g Hb/g 4·5 3·1 -6·6 
5 ~g Hb/g and 5 ~g Hb/g 7·8 4·6-13-3 
1 ~g Hb/g and 8 ~g Hb/g 9·0 5·2-15·6 
8 ~g Hb/g and 8 ~g Hb/g 14·3 4·8-42·3 
fH b; feca l hemoglobin concentration, HR; hazard ratio, Cl; confidence interval, cone; concentration, ref; reference category 
Based on the logistic regression model risks were predicted for all possible combinations of rHb 
concentrations per 0.5 !Jg Hb/g feces. Using these risks, heat plots were generated for males and 
females starting screening from the age of 55 years (Figure 3). These heat plots visualize the risk of 
AN after two consecutive FIT bco at any round according to the combination of rHb concentrations. 
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These heat plots highlight the increased risk of screenees with 1Hb concentrations up to 10 j..lg Hb/g 
and illustrate two-fold increased risk of AN for men compared to women. 
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Figure 3. Heat plot of risk of advanced neoplasia (AN) during further follow up in screenees with two consecutive negative FITs 
for men (A) and women (B) starting screening at age 55 years. This plot illustrates the increased risk of AN according to fHb 
concentration. Notable is the two-fold increase for men compared to women. 
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Discussion 
This study shows that, in a repeated-round FIT-based CRC screening program, fecal hemoglobin 
concentration below the cut-off is an independent predictor of incident AN. We demonstrated over 
8 years of follow-up that screenees with a tHb concentration >0 11g Hb/g to 10 11g Hb/g have a 
significantly higher cumulative incidence of AN compared to those with a tHb concentration of 0 
11g Hb/ g. The risk of AN was 8-fold higher for screenees with a tHb concentration of more than 8 
11g Hb/ g compared to screenees with a tHb concentration of 0 11g Hb/ g. We further show that this 
predictive capacity becomes even stronger with consecutive FIT bco results obtained over repeated 
rounds. 
One other research group has studied the role of FIT concentrations below the cut-off12• This 
Taiwanese study used a cut-off of 20 11g Hb/ g feces (OC-Sensor 100 ng Hb/ ml buffer), and showed 
that HRs for AN during follow-up increased with tHb concentration up to 3.4 for subjects with an 
~b level of 16-20 11g Hb/g feces. This HR is substantially lower than the HRs found in our study. This 
can be explained by the fact that the investigators used tHb concentrations between 1-4 11g Hb/ g 
feces as a reference and screenees with a tHb concentration of 0 were not included in multivariate 
survival analysis. The results of this study were however hampered by the high rate of positive FIT 
screenees who did not undergo colonoscopy (42%) yet were included in the analyses. While there is 
no other literature on the use of quantitative FITbco results, a few studies did look at prior FITbco results 
of qualitative tests. An Australian study investigated the use of FIT in a colonoscopy surveillance 
program and found that subjects with a FITbco had the lowest risk of AN17.A Chinese study compared 
the number of FITb and found no differences in outcome between subJ·ects with one FITb versus 
ro ro 
subjects with three subsequent FIT bco18• However, as the fHb concentrations were not reported, 
results could not be stratified according to ~b concentration, and comparison of these results to 
our findings is not possible. 
To the best of our knowledge, we are the first to explore the use of tHb concentrations of FITbco over 
consecutive rounds as a predictive variable for AN in population-based CRC screening. Exploring 
tHb concentrations over the course of years makes sense, as it has been hypothesized that during 
the development from adenoma to carcinoma, in the adenoma-carcinoma sequence, adenomas 
will increasingly bleed. This natural history of adenomas is supported by our findings. Our results 
are further strengthened by the finding that in screenees who participated in all four rounds tHb 
increased among those that were diagnosed with AN in the fourth round (supplementary file 1 ). A 
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similar trend was also described by the Taiwanese study, demonstrating that median ~b increases 
over rounds among screenees that are diagnosed with AN in a later round12• 
Strengths of this study include the analysis over multiple rounds, stratifying for FITbco levels unto 
nil 11g Hb/ g feces. Also, only average risk individuals were included, and the program consisted of 
true population-based screening, with a consistent screening protocol. This makes these results 
applicable to all fecal occult blood screening programs worldwide8.0ur study also has its limitations, 
such as the limited number of subjects diagnosed with CRC after having participated in three or 
four rounds. One further issue of this study is that it is susceptible to verification bias, due to the 
fact that only FIT positive screenees are referred for colonoscopy. As such, the yield of AN could 
be equally high in screenees with low FIT-values, but these simply do not receive verification by 
colonoscopy. To partially assess the possibility of verification bias, we performed two additional 
analysis in which we compared yield of AN only in screenees with a positive FIT during follow-up or 
screenees with consistent FITb (i.e. interval cancer rate; supplementary file 2). Although numbers co 
are small, both analyses consistently showed that the yield of AN was higher in those with higher 
levels of tHb, similar as our base case analysis. Next, data from our primary colonoscopy screening 
trail in the same region and time period also showed that FITbco predicts AN in a single round of 
FIT (supplementary file 3) 19• These findings suggest that the impact of verification bias is small and 
corroborate our finding that FITbco is predictive for future AN. Despite the verification bias, the lack of 
colonoscopy in FIT negative screenees, is also a strength of our study. If all screenees would undergo 
colonoscopy, the opportunity to follow FITbco screenees for the development of AN would be lost. 
As more screening programs are being implemented worldwide and FIT is gaining popularity, the 
use of quantitative FIT should be further explored. Expressing FIT-results not solely as a positive 
or negative result, but incorporating fHb concentrations in risk prediction models to estimate risk 
of AN can improve screening efficiency. Our results justify evaluation of screening strategies in 
which fHb concentrations are used to establish screening intervals. In current practice, a screenee 
with a FITbco is re-invited in the next screening round to perform a 'new' FIT. This FIT result is 
used as a referral criterion for colonoscopy regardless of the fHb concentration measured in the 
previous round. By neglecting the previous FIT result, an opportunity is lost to use the quantitative 
information of two FITs for risk stratification. We demonstrate, as depicted by the heat plots, that 
previous FITs enable identification of those at low risk (e.g. screenees who twice had a result of 0 
11g Hb/g) and those at considerable risk. Such heat plots can be of use to visualize risks of AN for 
screenees and health care professionals. Identifying those at high risk of AN would possibly decrease 
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interval carcinoma rate. Next, combining fHb with known risk factors could facilitate establishing 
individual screening intervals. Such individualized screening intervals may increase adherence to 
screening, as the majority of participants (i.e. those with consecutive fHb concentrations of 0 11g 
Hb/ g feces and a low risk of AN) will then have to be screened less frequently. This in turn could 
increase screening efficiency. As a consequence, screening and subsequently colonoscopy demand 
would decrease. The latter is especially important, as many countries are struggling with limited 
colonoscopy capacity8•9• 23• 
The results of this prospective FIT-based CRC screening cohort show that fHb concentration of a FIT bco 
in a first round of screening is an independent predictor for the risk of incident AN. Furthermore, 
consecutive FITbco could be used in determining personalized screening strategies. These findings 
pave the way for the use of fHb concentration in both public health programs as well as clinical 
decision-making. These results aid in informing patients about the risk of AN after multiple FITbco' 
and to alter screening intervals accordingly. 
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Supplementary Figure 1. Median fecal Hb of subjects with FIT bco of>OIJg Hb!g that participated in a/14 rounds. Results are presented 
by occurrence of advanced neoplasia (AN) detected in the 4th round. This figure shows an increase in median fib concentration over 
consecutive rounds in subjects who had AN detected in the four th round, indicating that those screenees that bleed for other reasons 
than AN, show less of an increase in fib over rounds. 
196~. Chapter 8 
0,8 
~ 
"' ·~ 0,6 
a. 
0 
Q) 
c: 
"0 
~ 
c: 
~ 
"0 0.4 
"' 0 
~ 
c: 
Q) 
"0 
·c; 
.~ E o,2 
B. 
:::J 
u 
~ ~ 
.... 
Ql 
u 
c 
rtl 
u 
Iii 
-u Ql 
.... 
0 
0 
u 
'+-0 
Ql 
u 
c 
Ql 
"C 
·o 
c 
E 
::J 
u 
0 
1.25 
1.0 
0.75 
0.50 
0.25 
0 
0 
0 
- 5 <10 ~g Hb/g faeces 
- 0 <5 ~g Hb/g faeces 
0 ~g Hb/g faeces 
20 40 60 80 100 
follow-up (months) 
- 5 < 1 0 ~g Hb/g faeces 
- 0 <5 ~g Hb/g faeces 
0 ~g Hb/g faeces 
20 40 60 80 100 
follow-up (months) 
Supplementary Figure 2 . Life table ofFITb<o per 5119 Hb/g in those who had a positive FIT during follow-up (p <O.OOI;A) and those 
who never had a positive FIT in one of the four rounds (p=0.034;8). 
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Supplementary Figure 3. Predicted probability of advanced neoplasia (AN) of all subjects with fHb < 10119 Hb/g from previously 
published data••. 
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Abstract 
Background Despite differences between men and women in incidence of colorectal cancer (CRC) 
and its precursors, screening programs consistently use the same strategy for both genders. 
Objective To illustrate the effects of gender tailored screening, including the effects on miss rates 
of advanced neoplasia (AN). 
Methods Participants (50-75 years) in a colonoscopy screening program were asked to complete a 
fecal immunochemical test (FIT) before colonoscopy. Positivity rates, sensitivity and specificity for 
detection of AN at multiple cut-offs were determined. Absolute numbers of detected and missed 
AN per 1000 screenees were calculated. 
Results In total 1,256 underwent FIT and colonoscopy, 51 % male (median age 61 years; IQR 56-66) 
and 49% female (median age 60 years; IQR 55-65). At all cut-offs men had higher positivity rates than 
women, ranging from 3.8-10.8% versus 3.2-4.8%. Sensitivity for AN was higher in men than women; 
40-25% and 35-22%, respectively. More AN were found and missed in absolute numbers in men at 
all cut-offs. 
Conclusion More AN w ere both detected and missed in men compared to women at all cut-offs. 
Gender tailored cut-offs could either level sensitivity in men and women (i.e. lower cut-off in women) 
or level the amount of missed lesions (i.e. lower cut-off in men). 
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Introduction 
Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the Western world.1,2 
Detection of occult blood in feces by guaiac fecal occult blood testing (gFOBT) has been proven to 
reduce CRC-related mortality.3 In recent years, fecal immunochemical testing (FIT) has become the 
preferred method of detecting fecal occult blood for CRC screening. FIT is more sensitive for the 
detection of CRC and its precursors.4,5 Besides, FIT is easier to handle than gFOBT.6 Consequently, 
screening participation rates increase.4,7,8 Also, FIT-analysis can be automated and quantitated. 
Quantitative FITs enable adjustment of cut-off to vary test-characteristics and match demand with 
available resources, in particular colonoscopy capacity.9 
Men and women differ with respect to the prevalence of advanced colorectal neoplasia, with men 
having substantial higher prevalence of advanced adenomas and CRC than women.1 0,11 Repeated 
biennial gFOBT screening leads to a higher overall mortality reduction in men than in women.3 In 
fact, a recent gFOBT-based study showed that the prevalence of colorectal neoplasms was higher 
in men with a negative test than in women with a positive t est.12 Moreover, male gender seems to 
be a stronger predictor of CRC than a positive gFOBT.13 Results from the national gFOBT screening 
program in Scotland showed a lower proportion of interval cancers for men compared to women.14 
One study, using FIT, showed that men had higher positivity rates, as well as a higher detection 
rate.15 However, this study was limited as only FIT-positive (i.e. a fecal hemoglobin concentration 
> 10 1-1g Hb/ g feces) screenees underwent colonoscopy. 
As more screening programs are being implemented worldwide, these gender differences become 
more apparent. Despite these differences, screening programs consistently use same strategies for 
both genders with regards to cut-off and screening intervals.1 0,16 Even though the use of different 
cut-offs in men and women would allow tailored screening strategies for each gender and improve 
CRC screening efficacy. Most studies on gender differences in CRC screening used gFOBT or FIT 
with one cut-off for both genders. Results were often based on assessing equal sensitivity of the test 
for men and women, thereby not taking into account gender differences regarding detection rate 
and miss rate of lesions in absolute numbers. Therefore, we aimed to illustrate the effect of gender 
tailored FIT screening including the detection and miss rates of advanced neoplasia. 
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Methods 
The protocol of this population-based screening pilot (trialregister.nl; identifier NTR3549) has been 
described previously in detail.17,18 All authors had access to the study data and reviewed and 
approved the final manuscript. 
Study population 
Between June 2009 and July 2010, 6,600 asymptomatic individuals aged 50-75 years, living in the 
Amsterdam and Rotterdam regions were randomly selected from regional municipal administration 
registrations. They were invited for colonoscopy screening as primary screening modality or invited 
for computed tomography colonography. For the purpose of this manuscript only data of the 
population undergoing colonoscopy were used. 
Individuals with a history of inflammatory bowel disease or CRC, as well as those who had undergone 
a full colonic examination in the past 5 years, those with an estimated life expectancy of <5 years, 
and subjects who were unable to give informed consent were excluded from the study. As there 
was no CRC screening program at the time of the trial in the Netherlands, the target population was 
screening-naive when first approached. 
Fecal occult blood screening and colonoscopy 
Eligible subjects who gave informed consent for colonoscopy screening were asked to complete one 
sample FIT (OC-sensor, Eiken, Japan) before colonoscopy. Participants were instructed to perform 
FIT at home, within 48 hours before the colonoscopy, but before starting the bowel preparation. No 
dietary restrictions were given. All patients underwent subsequent colonoscopy by experienced 
endoscopists. Research staff attended all colonoscopies and prospectively documented colonoscopy 
quality indicators and data on CRC and polyp detection. 
Histology 
Experienced pathologists classified all removed lesions as non-neoplastic, serrated polyp, adenoma 
(tubular, tubulovillous or villous) or carcinoma. Dysplasia was defined as low-grade or high-grade. 
Advanced adenomas were defined as an adenoma larger than 10 mm, an adenoma with villous 
histology (>25%) and/or an adenoma with high-grade dysplasia. Advanced neoplasia (AN) included 
both AA and CRC. 
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Statistical analysis 
All screening participants who completed a FIT and subsequently underwent colonoscopy were 
included in the analysis. Baseline characteristics were described using descriptive statistics. The Chi-
square test was used for comparing proportions of advanced neoplasia between men and women. 
The Mann-Whitney U test was used for non-parametric distributions. The sensitivity, specificity, 
positive and negative predictive value (PPV I NPV), and detection rate (DR) of advanced neoplasia 
were calculated for the most commonly used cut-offs; 10 (FIT1 0), 20 (FIT20), 30 (FIT30) and 40 
(FIT40) 11g Hb/g feces. These values correspond to 50, 100, 150 and 200 ng Hb/ml buffer. Following, 
sensitivity and specificity for fecal Hb-concentrations for all cutoffs between 0 and 100 11g Hb/g 
feces were calculated. Absolute numbers of detected and missed AN per 1000 subjects screened 
were calculated for men and women. 
Results 
Baseline characteristics and colonoscopy outcome 
In total1,256 invitees underwent FIT and colonoscopy, 638 men and 618 women. Men (61 years, 
IQR 56-66) were slightly older than women (60 years, IQR 55-65). Gender-specific findings at 
colonoscopy are described in Table 1. AN detection rate was slightly higher in men than in women, 
10.6% (68/638) versus 8.3% (51 /618) (p=0.146). CRC was detected in 5 (0.8%) men and in 3 (0.5%) 
women. No differences between men and women were seen in location of AN or number of AN per 
participant. In subjects with CRC, the median fecal hemoglobin concentration was 61 11g Hb/g feces 
(range 0-251 11g Hb/g) in men and 7711g Hb/g feces (range 13-44811g Hb/ g) in women (p=0.76). In 
subjects with AN, men had a median fecal Hb concentration of 3.2 11g Hb/g feces (range 0-485 11g 
Hb/ g) and women 2.6 11g Hb/g feces (IQR 0-670 11g Hb/g) (p=0.94). 
Test characteristics 
Performance characteristics of FIT for AN are provided in Table 2. Differences in test characteristics 
were not significant. At each of the pre-specified cut-offs, men had slightly higher positivity rates 
than women. The positivity rates ranged from 3.2% to 10.8% for the highest and lowest cut-off. 
The sensitivity for AN ranged from 40% (95% Cl 29-52%) at FIT1 0 to 25% (95% Cl 16-37%) at FIT40 
in men, and from 35% (95% Cl 24-49%) at FIT10 to 22% (95% Cl12-35%) at FIT40 in women. The 
specificity of FIT for AN tended to be lower in men when compared to women up to cut-offs of 20 
11g Hb/g. The detection rate of AN was higher in men than women at all cut-offs. False positivity 
rates ranged from 1.1 % (95% Cl 0.5-2.3%) to 6.6% (95% (14.9-8.8%) for men and from 1.5% (95% Cl 
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0.8-2.8%) to 5.5% (95% Cl 4.0-7.6%) for women. True positivity rates ranged from 2.7% (95% Cl 1.7-
4.2%) to 4.2% (95% Cl 2.9-6.1 o/o) for men and from 1 .8% (95% Cl 1 .0-3.2%) to 2.9% (95% Cl1.8-4.6o/o) 
for women. Sensitivity and specificity were calculated for the study population at multiple cut-offs 
ranging from 0 to 100 11g Hb/ g feces (Figure 1 ). At an increasing cut-off, in both genders there is a 
relatively more rapid decline in sensitivity than an increase in specificity. Overall men had slightly 
higher sensitivities than women. For example, at a commonly used cut-off of 10 11g Hb/ g 
feces women should have a lower cut-off to reach the same sensitivity and specificity as men. 
Table 1. Findings at co/onoscopy in men and women. 
Men Women p-value 
n =638 (%) n =618 (%) 
Most advanced finding at colonoscopy 
no histology 17 (2.7) 3 (O.S) 
no abnormalities 303 (47.5) 357 (57.8) 
55A < 10mm 19 (3.0) 17 (2.8) 
HP 82 (12.8) 77 (12.4) 
TA < 10mm 149 (23.4) 113 (18.3) 
TA ~ 10mm 21 (3.3) 16 (2.6) 
55A ~ 10mm 1 (0.2) 1 (0.2) 
TVA 32 (5.0) 25 (4.1) 
VA 2(0.3) 0 
HGD 7 (1.1) 6(0.9) 
CRC 5 (0.8) 3 (O.S) 
Total advanced neoplasia 68 (10.6) 51 (8.3) 0.15 
Location of most advanced neoplasia** 
distal I proximal 51 (75) I 17 (25) 38 (75) I 13 (25) 0.95 
Number of advanced neoplasia per participant** 
1 I > 1 53 (77.9) I 15 (22.1) 42 (82.4) I 9 (1 7.6) 0.55 
* no histology: removed polyp not retrieved for histology; 55A: sessile serrated adenoma; HP: hyperplastic polyp; TA: tubular 
adenoma; TVA: tubular villous adenoma; VA villous adenoma; HGD: high-grade dysplasia; CRC: colo rectal cancer. 
**only subjects with advanced neoplasia included (men n = 68 and women n =51) 
Detected lesions in absolute numbers 
At all cut-offs, more lesions were detected as well as missed in men than in women (Figure 2 A, B). 
For all cut-offs the number needed to screen to identify one screenee with AN was higher in women 
than in men. It ranged from 38 to 56 subjects in women and from 24 to 38 subjects in men. Stepwise 
lowering cut-offs for men from FIT40 to respectively FIT30, FIT20 and FIT10 successively resulted in 
additional detection of 3, 0, and 7 AN. This required 8, 8, and 29 additional colonoscopies. Stepwise 
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lowering the cut-offs for women from FIT 40 to FIT1 0 successively resulted in additional detection of 
2, 4 and 1 AN. This required 2, 4 and 21 additional colonoscopies. 
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Figure 1. Sensitivi ty and specificity for men and women for all cut-offs ranging from 0 to 100 11g Hb! g feces. 
Discussion 
100 
In this colonoscopy-based screening program, we evaluated gender differences with respect to the 
efficacy of FIT screening in average risk individuals. Furthermore, we illustrated the effect of using 
different cut-offs on a broad spectrum of screening outcomes. Our study demonstrated that FIT had 
a higher sensitivity and lower specificity for AN in men than in women. By increasing the cut-off a 
relative more rapid decline in sensitivity was found than an increase in specificity for both genders. 
Furthermore, FIT had an overall higher PPV in men. When looking at diagnostic yield in absolute 
numbers, men had higher detection rates and miss rates of AN than women at all cut-offs. This 
last finding is of particular interest as in current literature little attention has been given to gender 
specific miss rates of lesions. 
A strength of this study is that this cohort was set in a population-based screening setting, making 
these results representative for average-risk screening populations. Also, as all participants 
underwent both colonoscopy and FIT, it is a very suitable population to demonstrate actual 
differences and to estimate the number of missed lesions. However, to appreciate our findings 
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Table 2 . Positivity rate, sensitivity, specificity, posit ive predictive value, negative predictive value, detection rate for men and 
women at different cut-offs. 
Men Women 
% (95%CI) % (95%CI) 
FIT 10 
PR 10.8 (8.6-13.5) 8.4 (6.5-10.9) 
sensitivity 39.7 (28.8-51.7) 35.3 (23.5-49.2) 
specificity 92.6 (90.2-94.5) 94.0 (91.7-95.7) 
PPV 39.1 (28.4-5 1.0) 34.6 (23.0-48.8) 
NPV 92.7 (90.4-94.7) 94.2 (91.9-95.8) 
DR 4.2 (2.9-6.1) 2.9 (1.8-4.6) 
FIT20 
PR 6.3 (4.6-8.4) 5.0 (3.5-7.D) 
sensitivity 29.4 (19.8-41 .2) 33.3 (21.8-47.2) 
specificity 96.4 (94.6-97.7) 97.5 (95.9-98.5) 
PPV 50.0 (35.0-65.0) 54.8 (37.4-71.1) 
NPV 92.0 (89.5-93.9) 94.2 (92.0-95.8) 
DR 3.1 (2.0-4.8) 2.8 (1.7-4.4) 
FIT30 
PR 5.0 (3.6-7.0) 3.6 (2.4-5.3) 
sensitivity 29.4 (19.8-41.2) 25.5 (1 5.4-39.1) 
specificity 98.0 (96.3-98.8) 98.4 (97.0-99.2) 
PPV 62.5 (44.9-77.3) 59.0 (38.2 -77.2) 
NPV 92.1 (89.6-94.0) 93.6 (91.4-95.3) 
DR 3.1 (2.9-4.8) 2.1 (1.2-3.6) 
FIT40 
PR 3.8 (2.5-5.6) 3.2 (2.1-5.0) 
sensitivity 25.0 (16.1-36.6) 21.6 (12.4-34.9) 
specificity 98.8 (97.4-99.4) 98.4 (97.0-99.2) 
PPV 70.8 (50.2-85.4) 55.0 (33.6-74.7) 
NPV 91.7 (89.2-93.6) 93.3 (91.0-95.1) 
DR 2.7 (1.7-4.2) 1.8 (1.0-3.2) 
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some limitations need to be discussed. Firstly, this cohort consists of relatively small numbers and 
was not powered to detect differences in men and women. Another limitation is that only persons 
willing to undergo colonoscopy as primary screening method participated, which could have led to 
a selection bias resulting in a population that is not representative of FIT-participants. Only 22% of 
all invitees decided to participate in colonoscopy screening, while FIT-screening generally has much 
higher participation rates around 60% 1 9,20. Nevertheless, the population includes only screening-
naive average risk subjects, and therefore we think that the risk of selection-bias is limited. 
The introduction of fecal immunochemical testing was an important step forward in population-
based colorectal cancer screening. FIT enables simple, low burden primary screening at relatively low 
costs and has a high uptake. For this reason, an increasing number of countries have implemented 
FIT-based screening programs or are in the process of doing so.21 This is mostly associated with 
a marked increase in colonoscopy demand. This asks for a strong focus on optimal use of limited 
resources. 
Differences between men and women in terms of number of advanced lesions, location of lesions 
and fecal hemoglobin concentrations are becoming more evident. Dissimilarities in prevalence 
of AN between men and women have been well described with men having a substantial higher 
prevalence of AN than women. 10,1 1 Consequently, research on tailored screening strategies 
become of significant importance. We are the first to describe the detection and miss rate of lesions 
in absolute numbers, showing that in men more lesions were both detected and missed for all cut-
offs. This was especially the case at higher cut-offs. A previous Polish study showed that the number 
needed to screen in colonoscopy-based CRC screening to identify one screenee with advanced 
neoplasia was considerably higher in women than in men 10 Our data shows that these numbers 
also apply to colorectal cancer screening programs based on FIT. At each FIT cut-off, 14 to 18 more 
women needed to be screened to find one case of AN compared to men. 
Differences in FIT screening between men and women can be explained by a combination of 
factors. It has been suggested that because men have a higher hemoglobin concentration in 
general, blood from bleeding polyps will contain more globin.22 As FIT specifically detects globin 
in feces, blood from these polyps could be detected more frequently in men. This is supported by 
the fact that differences in fecal Hb concentration have been found in men and women. 15,23 A 
second explanation could be that women have more right-sided lesions, as it is known that fecal 
occult blood testing may not be as sensitive for proximal lesions as it is for distal lesions. 14,22,24 
Yet, our data did not show differences in location of AN between men and women. Another reason 
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for gender differences in FIT test-characteristics, could be the differences in colonic transit time 
between men and women, with women having slower transit times.25 A slower transit time could 
lead to more degradation of Hb and could decrease the likelihood of blood being detected by FIT. 
An important question to be answered is how these results can be applied in colorectal cancer 
screening programs. Essentially, for gender-adjusted cut-offs in FIT-based CRC screening programs 
three scenarios are possible. These are the use of the same cut-off in both genders or, using a higher 
cut-off in men than women, or vice-versa. An increase of the cut-off for men compared to women 
can lead to a similar proportional sensitivity for detection of AN in both groups. As a consequence 
the difference in PPV between men and women would increase, with men having a substantial 
higher PPV. Also, a higher cut-off in men would lead to a further increase in miss rates of AN in men 
in absolute numbers and thus to a further increase in difference of miss rates in terms of absolute 
numbers of advanced lesions compared to women. Furthermore, using a lower cut-off for women 
would result in a higher rate of false-positive tests in women. The opposite strategy, i.e. increasing 
the cut-off for women compared to men, can lead to a similar miss rate in terms of absolute numbers, 
and to a similar PPV in both genders. It would however result in decreased sensitivity and detection 
rates for women. In this scenario a larger proportion of the colonoscopy capacity would be used 
for men. However, such a strategy could make sense given that men are at higher risk of AN and 
subsequently the development CRC. 
Other gender-based CRC screening strategies besides adjusting the cut-off, include the use of 
different age ranges for screening, changing screening modality, or the use of different screening 
intervals. A German study showed that women reached equivalent levels of CRC-related mortality 
as men at a 4 to 8 years higher age 26. Gender differences in other screening modalities, such as 
colonoscopy, sigmoidoscopy, fecal biomarkers and fecal DNA, have not yet been extensively 
investigated. However, using different methods or combinations of tests for men and women could 
optimize screening efficacy and should be further investigated. With regard to gender differences 
in patient-education there is still much to gain. Information on miss rates of advanced lesions is 
an important issue in client information. At present, men and women are informed in the same 
manner about FIT-based CRC screening. These results helps to accurately inform the client about the 
gender-dependent risk of miss rates and detection of advanced lesions in a FIT based CRC screening 
program. 
To conclude, colorectal cancer screening using FIT with the same cut-off for both genders results in 
a higher sensitivity and lower specificity for advanced neoplasia in men than in women. In absolute 
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numbers more advanced neoplasia are detected and missed in men for all cut-offs. Following, 
tailored cut-off based on gender could either level sensitivity in men and women by using a lower 
cut-off in women, or level the amount of missed lesions when using a lower cut-off in men. Adjusting 
cut-offs based on gender can contribute to the efficacy of FIT-based CRC screening programs and 
optimize the use of available endoscopy resources. In addition, individuals invited to attend a FIT 
based CRC screening should be informed accordingly about these gender differences. 
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Abstract 
Objectives Fecal immunochemical testing (FIT) and colonoscopy are tandem procedures in 
colorectal cancer screening (CRC). A positive FIT predicts advanced neoplasia (AN), which requires 
endoscopic detection and removal. En bloc or piecemeal resection of AN is associated with a 
significant rate of residual or recurrent neoplasia. Second look colonoscopies are indicated to 
assess completeness of removal of AN. These colonoscopies can make a substantial demand on 
colonoscopy capacity and health care system. This study is the first to evaluate the demand and risk 
factors for second look colonoscopy in FIT CRC screening. 
Methods All colonoscopies after a positive FIT, in subjects aged 50-74 years approached for 3 
rounds of FIT screening, were prospectively registered. Second look colonoscopies were defined as 
any colonoscopy within one year following a colonoscopy after positive FIT. 
Results Out of 1215 FIT-positive screenees undergoing colonoscopy, 1 OS (8.6%) patients underwent 
a second look colonoscopy of whom 30 (2.5%) underwent more than one (range 2-9) leading to a 
total of 149 (12.3%) additional colonoscopies. Main reasons for second look colonoscopies were 
assessment of complete AN removal (41.9%), and need for additional polypectomy (34.3%). Risk 
factors were advanced adenomas and poor bowel preparation (p<0.001 ). High fecal hemoglobin 
concentration was the only predictor of a second look colonoscopy before the index-colonoscopy 
(p<0.001 ). 
Conclusions Second look colonoscopies have substantial impact on colonoscopy resources, 
increasing the demand with 12%. The main reasons for these second-look colonoscopies were 
previous incomplete polypectomy and control of completeness of removal of neoplastic lesions. 
A high fecal hemoglobin concentration as measured by FIT can help to identify patients at risk of a 
second look colonoscopy. 
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Introduction 
Colorectal cancer (CRC) is a major cause of mortality and morbidity worldwide 1. Endoscopic 
detection and removal of adenomatous polyps reduces CRC-related mortality2•3• Colonoscopy is 
widely appreciated as optimal test for detection and removal of adenomas4•5• At present more and 
more CRC-screening programs are implemented worldwide. Recent EU guidelines recommend fecal 
immunochemical occult blood testing (FIT) as a tool for primary screening followed by colonoscopy 
in case of positive FIP·7• However colonoscopic examination has a low but not negligible miss rate 
for cancers and adenomatous polyps8. In one recent study, persistent adenomatous tissue was 
observed in 10.1 o/o of cases after colonoscopic polypectomy9• Missed and incompletely resected 
lesions are recognized as important contributors to interval colorectal cancers10•11• A so-called 
second look colonoscopy is recommended in case of doubt about missed neoplastic lesions, 
completeness of removal of lesions, or after an incomplete colon examination12•13• The positive 
predictive value of FIT for advanced neoplasia varies around 35-450fo1 4•16• En bloc, and especially 
piecemeal resection of advanced adenomas is associated with a relatively high rate of local residual 
or recurrent neoplasia12•13•17•18• One may therefore hypothesize that FIT screening may be associated 
with a significant rate of second look colonoscopies1+16• Although these colonoscopies can have 
a substantial impact on the required colonoscopy capacity and health care system, little is known 
about the demand for second look colonoscopy in a FIT screening program. This is to our knowledge 
the first study to assess the number and indications of second look colonoscopy in in a FIT-based 
CRC screening program and to identify patients at risk for a second look colonoscopy. 
Methods 
Patients 
Details about the design of this on-going population-based CRC screening program have been 
described previously14•15• In short, demographic data of all individuals between 50-74 years living 
in the southwest of the Netherlands were obtained from municipal population registers. In this 
screening program the OC-sensor FIT (Eiken, Japan) was used over multiple rounds with a maximum 
of three rounds. Intervals between rounds varied from one to three years. Individuals with a history 
of inflammatory bowel disease or CRC, symptomatic patients, as well as those who had undergone 
a colonoscopy, sigmoidoscopy or barium contrast enema in the last 3 years, those with an estimated 
life expectancy of less than 5 years, and subjects who were unable to give informed consent, were 
excluded from the study. All patients with a positive FIT, defined by a hemoglobin (Hb) concentration 
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of~ 50 ng/ ml which corresponds to~ 10 ~g Hb/g feces, were referred for colonoscopy. Colonoscopies 
were performed in 18 non-academic centers and in 1 academic center. 
Data collection 
Our primary endpoint was to assess the number and indications of second look colonoscopies after 
the first screening colonoscopy following a positive FIT. Second-look colonoscopy was defined as 
any secondary endoscopic procedure of the colon indicated within one year after the first screening 
colonoscopy, regardless of the endpoint reached, as often a second look colonoscopy was limited 
to the area where previous neoplastic lesions were removed 19.1n addition we looked for predictive 
factors to identify patients at risk. Predictive factors included age, sex, socio-economic status (low, 
average, high), bowel preparation, use of sedation, use of buscopan, type of endoscopist, type of 
hospital, fecal hemoglobin concentration, and presence of advanced neoplasia. 
Colonoscopy data were prospectively registered using a standardized endoscopy report completed 
after the procedure by the endoscopist. The following variables were systematically assessed: 
sedation (midazolam, fentanyl, propofol, none), level of bowel preparation (poor: < 90% of mucosa 
visible, medium: 90-99% of mucosa visible, good: 100% of mucosa visible), cecal intubation, 
detection of polyps or other lesions, and removal of polyps. Endoscopists were categorized as 
gastroenterologists, gastroenterology fellows, internists or nurse-endoscopists. Advanced neoplasia 
was defined as an adenoma of 1 Omm or larger, an adenoma with 25% or more villous histology or 
with high-grade dysplasia, and CRC. 
The overall quality of colonoscopy was evaluated based on indicators as defined by Rex et al 20. 
The cecal intubation rate (CIR) was defined as the proportion of colonoscopies in which the cecum 
was visualized. The adenoma detection rate (ADR) was defined as the number of colonoscopies that 
revealed at least one adenoma divided by the total number of colonoscopies. 
Statistical analysis 
Descriptive data were reported as proportions or means with the standard deviation. For non-
normally distributed data the median and interquartile range (IQR) were given. Chi-Square tests 
were used to analyze categorical data; continuous data were analyzed using Student's t-tests and 
Mann-Whitney U in case of a non-parametric distribution. Univariate logistic regression models 
were used to calculate odds ratios (OR) and 95% confidence intervals (CI) to assess the risk of a 
second look colonoscopy. ln case of a p-value < 0.20 variables were included in multivariate stepwise 
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backward regression analysis and described as the full model. All variables that remained significant 
using the stepwise backward method were shown in a final model. In multivariate analysis a full 
case analysis was performed. A two-sided p-value of < 0.05 was considered statistically significant. 
Statistical analysis was performed using IBM SPSS version 21.0. 
Results 
Patient characteristics 
A total of 1215 patients, 698 men and 517 women, with a median age of 63 years (IQR 57-68 years), 
underwent a colonoscopy following a positive FIT. Patients' characteristics are summarized in Table 
1. The median fecal hemoglobin concentration was 291Jg Hb/g feces (IQR 15- 861Jg Hb/g). 
Table 1. Baseline demographics and colonoscopy characteristics (n= 1215) 
Age, mean (years, IQR) 63 (57-68) 
Male gender (n,o/o) 698 (57.4) 
Sedation (n, o/o) 
Midazolam 348 (28.6) 
Fentanyl 22 (1 .8) 
Midazolam and fen tanyl 632 (52.0) 
Propofol 2 (0.2) 
No sedation 172 (14.2) 
Not reported 39 (3.2) 
Use of buscopan (n, o/o) 484 (39.8) 
Endoscopist (n, o/o) 
Gastroenterologist 911 (75.0) 
Internist 66 (5.4) 
Gastroenterology fellow 27 (2.2) 
Nurse-endoscopist 156 (12.8) 
Not reported 55 (4.5) 
Bowel preparation (n, o/o) 
Good 885 (72.8) 
Medium 241 (19.8) 
Poor 29 (2.4) 
Not reported 60 (4.9) 
Hospital (n, o/o) 
Academical 255 (21 .0) 
Non-academical 960 (79.0) 
Faecal Hb concentration (llg Hb/g feces, IQR) 29 (15-86) 
1m 
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Colonoscopy characteristics 
Of the 1 21 5 colonoscopies, more than half (52.0%) were performed under conscious sedation 
using both midazolam and fentanyl. Buscopan was used in 484 (39.8%) of the cases. Colonoscopies 
were performed by gastroenterologists (75.0%), nurse-endoscopists (1 2.8%), internists (5.4%), and 
fellows (2.2%). The bowel was adequately cleansed in 1 126 (97%) of 1 155 patients. The cecum was 
reached in 97.3% of the index colonoscopies. The overall adenoma detection rate was 55%. Adverse 
events within 30 days occurred in 36 colonoscopies (3%t consisting mainly of mild bleedings (1 .8%) 
managed during the index colonoscopy. Other adverse events were a decrease in saturation (0.4%) 
and blood pressure (0.2%) during colonoscopy. One iatrogenic perforation (0.09%) occurred, this 
was noted after colonoscopy in the sigmoid and required surgical removal of the perforated tissue. 
Table 2 . /ndications for second look colonoscopy (n= 1 05). 
Indication 
Control of completeness of removal of neoplastic lesion 
piecemeal resection 
resected polyps with positive histological margins 
high grade dysplasia or CRC in pathology 
doubt about endoscopic resection 
Additional polypectomy 
polyp size too large 
suspected high grade dysplasia or CRC** 
lack of time 
complex location 
procedure too painful 
Poor bowel preparation 
Marking adenoma I CRC 
Anticoagulant drugs 
Incomplete colonoscopy *** 
Obstructing CRC 
*does not add up to 100% due to rounding 
*"' biopsies were taken at initial colonoscopy 
·- includes: looping, diverticulosis, diverticulitis 
Second look colonoscopies 
n (%)* 
46 (43.8) 
19 (18.1) 
14 (13.3) 
9 (8.5) 
4 (3.8) 
34 (32.4) 
20 (19.0) 
5 (6.7) 
6 (5.7) 
2 (1.9) 
(0.8) 
14 (13.3) 
4 (3.8) 
2 (1.9) 
4 (3.8) 
(1.0) 
A total of 1 OS (8.6%) patients underwent a second look colonoscopy within one year, with a 
median time between the index colonoscopy of 63 days (IQR 35-101 days). The most frequently 
reported indications for second look colonoscopy were assessment of completeness of removal 
of a neoplastic lesion (43.8%) and additional polypectomy for various reasons (32.4%) (Table 2). 
Remaining indications were poor bowel preparation (13.3%), pre-surgical submucosa l marking of 
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an adenoma or malignancy (3.8%), and anticoagulant use (1.9%). One patient with a obstructing 
CRC underwent a second look colonoscopy to examine the complete colon after surgical removal 
of the CRC. 
Characteristics of the most advanced polyps removed in patients that underwent second-look 
colonoscopy are described in Table 3. The majority of these polyps were located in the recto-sigmoid 
(61 %) and were relatively large (median 15 mm, IQR 10-25 mm). 
Table 3 . Characteristics of most advanced polyps in patients that underwent second look colonoscopy (n = 80*) 
Size (in mm, median, IQR) 15 (10-25) 
Location (n, %) 
cecum 8 (10.0) 
ascendens 8 (10.0) 
hepatic flexure 2 (2.5) 
transversum 6 (7.5) 
splenic flexure 0 (0) 
descendens 4 (5.0) 
sigmoid 41 (50.0) 
rectum 9 (11.2) 
multiple locations** 2 (3.8) 
Histology (n, %) 
tubulair adenoma 21 (26.2) 
(tubulo)villous adenoma 26 (32.5) 
high grade dysplasia 23 (28.8) 
adenocarcinoma 70 (1 2.5) 
• includes all second look colonoscopies after additional polypectomy or for control of completeness of removal of lesions 
•• 2 patients had multiple polyps as a reason for second look colonoscopy (26 and 38 polyps respectively); most advanced lesion is used for histology 
Thirty patients (28.8%) underwent more than one follow-up colonoscopy (range 2-9 colonoscopies) 
leading to a total of 149 (12.3%) additional colonoscopies after the screening colonoscopy. The 
main indications for these subsequent colonoscopies were control for completeness of removal 
of a neoplasic lesion and additional polypectomy. In 61% of the colonoscopies with failed cecal 
intubation the decision was made not to repeat the colonoscopy and to refer the patient for CT-
colonography. 
Factors associated with second look colonoscopy 
Predictors for a second look colonoscopy in the univariate analysis are shown in Table 4. Bowel 
preparation and advanced neoplasia were the only significant predictors for a second look 
1m 
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colonoscopy after multivariate analysis. The only predictive factor before the initial colonscopy was 
FIT Hb-concentration (Figure 1 ). 
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Figure 7. Predicted probability of the risk of a second-look co/onoscopy for fecal hemoglobin (Hb) level. 
Discussion 
In this population FIT- based screening program we assessed the number and indications of second-
look colonoscopies. The results of our study indicate that 8.6% of our study population required a 
second look colonoscopy within one year after the initial screening colonoscopy. In 2.5% of the 
patients more than one colonoscopy was performed after the initial procedure. Together, this led 
to a 1 2.3% increase in colonoscopy demand compared to the volume of primary colonoscopies 
after positive FIT. In 76% of the patients a second look colonoscopy was performed for assessment 
of completeness of removal of neoplastic lesions or for further polypectomy of large or multiple 
lesions. Significant predictors for a second look colonoscopy were presence of advanced neoplasia 
and poor bowel preparation. The only significant predictor prior to the index colonoscopy was a 
high fecal hemoglobin concentration. 
While second look colonoscopies can have a substantial impact on colonoscopy demand, current 
knowledge on the volume of second look colonoscopies is limited. As more screening programs are 
implemented worldwide, it becomes important to estimate the number of colonoscopies needed 
for CRC screening. To our knowledge this is the first study to evaluate the need for second look 
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colonoscopies, as previous literature has mainly focused on failed cecal intubation as a cause for 
a second colonoscopyl 9•21 •22• In our cohort cecal intubation failed in 3% of the colonoscopies. Next, 
many studies have suggested that a poor bowel preparation is a frequent reason for colonoscopy 
failure23•24• We found that, although a poor bowel preparation almost always leads to a repeat 
procedure, it is an infrequent cause of second look colonoscopy. 
Previous FIT-based screening cohort studies have shown that FIT-positive screenees have a 35-45% 
incidence of advanced adenomas15-17. The removal of these adenomas is complex, time consuming 
and often followed by a second look colonoscopy to assess residual neoplastic tissue25•26• We 
found that in over two-thirds of our patients a second look colonoscopy was performed because 
of an incomplete polypectomy or to examine the polypectomy scar for residual neoplastic tissue. 
According to literature data, a second look colonoscopy for the control after polypectomy occurs 
in around 1% or 2% of the procedures with endoscopic treatment and is usually limited to the 
previously treated area 19. Our results indicate a much higher rate of second look colonoscopies. 
These findings are supported by the fact that significantly more advanced neoplasia were found in 
the patients undergoing a second look colonoscopy. A second look colonoscopy is recommended 
to be performed within 2 to 6 months or at least within 1 year after piecemeal resection 17.18. Our 
findings are in line with these guidelines as half of the second look colonoscopies were performed 
within 3 months following the index colonoscopy.lt should be noted that in only 20% of the patients 
residual tissue was found at second look colonoscopy. 
Advanced colorectal neoplasia is associated with a higher FIT hemoglobin concentration, and 
accordingly a higher Hb concentration leads to a higher positive predictive value for AN 27-30• These 
results are consistent with our findings and this readily explains the relation between a high fecal 
hemoglobin concentration and the need for a second look colonoscopy. Our findings can be of 
clinical importance and guidance for endoscopists and patients. Currently the physician is only 
informed about the qualitative result of the test, i.e. a negative or positive result and not about 
the quantative result. However, the exact value of the fecal hemoglobin concentration could be 
used for estimating the chance of finding advanced pathology at colonoscopy. Since a high fecal 
hemoglobin concentration is indicative of more advanced pathology, it may help the endoscopists 
to be prepared for a more difficult procedure and inform the patient accordingly. For example, 
patients with very high concentrations can be scheduled at the program of endoscopists with 
experience for removal of advanced lesions. 
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Our study has several limitations. Although the data were prospectively collected, the number 
of second look colonoscopies were retrospectively analyzed which could lead to possible 
underreporting of the actual number of colonoscopies. Secondly, we lacked information regarding 
the colonoscopy experience of each endoscopist. However, both CIR and ADR were above standards 
as required for CRC screening31•32• Thirdly, many colonscopies were performed without buscopan, 
as the use of buscopan is not common practice in the Netherlands and its use is mainly based on 
the preference of the endoscopists. Finally, in the fecal samples with very high concentrations of 
Hb, a prozone effect could have occurred. This could lead to measured values that are lower than 
the actual concentration in the sample in case of very high concentrations33• Such a prozone effect 
could lead to an underestimation of the true height of the fecal Hb level for values above 200 IJg 
Hb/g feces. 
In conclusion, we found that 8.6% of patients that underwent colonoscopy after a positive FIT 
undergo a second look colonoscopy, with the total number of procedures ranging from 2 to 9 
colonoscopies per patient. This leads to an extra 12% demand for screening colonoscopy. In over 
two-thirds of the patients a second look colonoscopy was performed for control of completeness 
of removal of neoplastic lesions or for additional polypectomy. FIT Hb-concentration was the only 
significant predictor prior to the screening colonoscopy and could be of clinical importance and 
guidance for endoscopists and patients. Our results show that second look colonoscopies have a 
substantial influence on colonoscopy burden in a FIT-based screening setting and should be taken 
into account when estimating colonoscopy capacity. 
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for colorectal cancer: can the screening interval be 
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Abstract 
Objective Colorectal cancer (CRC) screening programs based on fecal immunochemical testing for 
hemoglobin (FIT) typically use a screening interval of 2 years. We aimed to estimate how alternative 
FIT st rategies that use a lower than usual positivity threshold followed by a longer screening interval 
compare to conventional strategies. 
Methods We analysed longitudinal data of 4523 Dutch individuals (50-74 years at baseline) 
participating in round I of a one-sample FIT screening program, of which 3427 individuals also 
participated in round II after 1-3 years. The cohort was followed until2 years after round II . In both 
rounds, a cut-off level of ~SOng hemoglobin (Hb)/ ml (corresponding to 1 01Jg Hb/g feces) was 
used, representing the standard scenario. We determined the cumulative positivity rate (PR) and 
the numbers of subjects diagnosed with advanced adenomas (N_AdvAd) and early stage CRC 
(N_earlyCRC) in the cohort over two rounds of screening (standard scenario) and compared it to 
hypothetical single round screening with use of a lower cut-off and omission of the second round 
(alternative scenario). 
Results In the standard scenario, the cumulative (i.e. round I and II combined) PR, N_AdvAd, and 
N_earlyCRC were 13%, 180, and 26, respectively. In alternative scenarios using a cutoff level of 
respectively ~ 11 ng/ ml and ~22ng/ml (corresponding to 2 and 41Jg Hb/ g feces), the PRs were 18% 
and 13%, the N_AdvAd were 180 and 162, and the N_earlyCRC ranged between 22-27 and 22-26. 
Conclusion The diagnostic yield of FIT screening using a lowered positivity threshold in combination 
with an extended screening interval (up to 5 years) may be similar to conventional FIT strategies. 
This justifies and motivates further research steps in this direction. 
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Introduction 
Colorectal cancer (CRC) is the third most common cancer and cause of cancer-related deaths 
worldwide, with more than 1.2 million new cases and more than 600,000 deaths per year1• 
Randomized controlled trials have demonstrated that biennial screening with guaiac-based fecal 
occult blood testing (gFOBT) reduces CRC mortality by 15%2• 
Since the conduct of these trials, a substantial body of evidence has shown that the diagnostic 
performance of fecal immunochemical testing for hemoglobin (FIT) is superior to gFOBT 
screening3-6. Furthermore, FIT screening is associated with higher participation rates than gFOBT 
and has analytical advantages such as no cross-reactivity with dietary constituents and the option 
of measuring fecal hemoglobin levels quantitatively5•6 • Accordingly, the European guidelines for 
quality assurance in CRC screening recommend screening with FIT in preference to gFOB"fl. Current 
CRC screening programs based on FIT are typically designed analogously to gFOBT strategies8. That 
means that they use a screening interval of two years and a positivity threshold yielding a specificity 
well above 90%. 
However, studies reporting on repeated rounds of FIT screening consistently showed that the 
diagnostic yield of the first re-screening round is lower as compared to the initial screening round'}-11 • 
We further showed that the diagnostic yield in a second round of FIT screening is the same when 
using a 1-, 2-, or 3-year interval9 . When combining these observations with the fact that FIT - given 
its quantitative nature - offers flexibility to select the positivity threshold, it leads to the idea of 
considering alternative strategies for FIT screening. The positivity threshold at the initial round 
could be lowered, thereby increasing sensitivity at the cost of decreasing specificity. Subsequently, 
the interval to the second round could be significantly increased. 
Although strategies with a lower positivity threshold in combination with a longer interval may 
have advantages, for instance regarding the organizational effort, it needs to be considered carefully 
whether there are disadvantages, e.g. regarding the diagnostic yield and the colonoscopy load. 
We aimed to explore and estimate how such alternative FIT strategies compare to conventional 
FIT screening in terms of positivity rate and thus colonoscopy demand, detection of advanced 
adenomas and CRC detection. 
m 
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Methods 
Study overview 
To address the research question, we analysed longitudinal data of an ongoing population-
based CRC screening study that started in 2006 and aimed to investigate the diagnostic yield and 
adherence patterns over multiple rounds of FIT screening. As illustrated in Figure 1, we focused on 
the first and the second round of this study and considered the positivity rate and the diagnostic 
yield of these two rounds cumulatively. We then compared this standard scenario to various 
alternative scenarios that assumed use of a lower cutoff level at the first round and omission of the 
second round, resulting in an extended screening interval. 
Standard scenario AnernatiYescenarios 
First FITSO round 1 1 -~-
r------'------, ~ 1) Positivity rale 
I I. ~ 2) No. advanced Second FITSO round ···:•·- ac1enamas ~ 3) No. CRCs 
~ ., ICI'MII-delected 
~ b) a.ty stage 
Third screening round (end of follow-up) 
Figure 1. Illustration of the concept of the data analysis and outcomes of interest. 
Study design and study population 
Details about the design of the study have been described elsewhere [6,9]. Briefly, demographic data 
of all individuals aged 50-74 years living in the southwest of The Netherlands were obtained from 
municipal population registers to identify the target population. This population was screening-
na'lve since there was no CRC screening program at the time of recruitment for this study. Random 
samples were taken from the target population by a computer-generated algorithm (Tenalea, 
Amsteram, The Netherlands) to be invited for successive FIT screening rounds. A screening interval 
of 1, 2 or 3 years was assigned to equally sized groups between the first and the second round, while 
the screening interval was 2 years for all subjects between the second and the third round. Exclusion 
criteria were a history of CRC; inflammatory bowel disease; an estimated life-expectancy of less 
than 5 years; a colonoscopy, sigmoidoscopy or double-contrast barium enema within the previous 
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3 years; and inability to give informed consent. Subjects were no longer invited to subsequent 
rounds if they tested positive at a prior screening round, if they had become ~75 years of age if 
they had moved out of the region or had died. The occurrence of CRCs in the study population was 
determined by record linkage with the Dutch Comprehensive Cancer Centre (http://www.iknl.n l). 
Results of the first, second and third round of the study have been reported previously6•9•12. 
Screening intervention 
With each screening round, one FIT (OC-Sensor Micro, Eiken Chemical Co, Tokyo, Japan) was sent 
by mail to collect a single stool sample of one bowel movement. The test was considered positive 
when the hemoglobin (Hb) concentration in the FIT sample was ~50 ng/ml, which corresponds to 
10 11g Hb/g feces. Applying FIT at this cutoff level is called FIT50 in the following, and analogous 
terms are used for other cutoff levels. Subjects with a positive FIT 50 were scheduled for colonoscopy 
within 4 weeks. Experienced endoscopists performed all colonoscopies. The maximum reach of the 
endoscope, adequacy of bowel preparation as well as the characteristics and location of any lesions 
were recorded. Experienced gastrointestinal pathologists evaluated all removed lesions. Patients 
with relevant findings entered a surveillance program according to the guidelines of the Dutch 
Society of Gastroenterology, while patients with a negative colonoscopy were considered not to 
require FIT screening for 10 years13• 
Data analysis 
For the present analyses, we only included subjects who participated in the first screening round 
because we required baseline fecal hemoglobin for our approach. The cohort was followed from 
the first round (baseline), over the second round up to the time point of the third screening round, 
yielding a follow-up period of 3, 4, or 5 years depending on the interval assigned between the 
first and the second round9• In a first step, we considered the standard scenario with two FIT50 
rounds and determined the cumulative positivity rate (defined as the proportion of participants 
with a positive test result), the cumulative number of subjects diagnosed with advanced adenomas, 
as well as the total number of CRCs (detected either as a result of screening or during follow-up 
as interval CRC). We determined the number of screen-detected CRCs and non-screen-detected 
CRCs (i.e. interval CRCs). We also determined the number of CRCs that were diagnosed at an early 
stage (UICC I or II), regardless of whether they were screen-detected or not. In a second step, we 
estimated these outcomes for various alternative scenarios which assumed that a cutoff level equal 
or lower than 50 ng/ml had been used for FIT at the first round (baseline) and the second round 
had been skipped. The various alternative scenarios only differed with respect to the cutoff level 
m 
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used to classify baseline hemoglobin levels as positive or negative. Positivity rates of the various 
alternative scenarios could be assessed directly by determining the proportion of the cohort whose 
baseline hemoglobin levels were equal or above the respective cutoff level. The number of subjects 
diagnosed with advanced adenomas at the alternative scenarios could not be assessed directly 
given that only those with hemoglobin levels ~50 ng/ ml underwent colonoscopy at baseline. 
Therefore, we used an indirect approach to estimate this number as described in Table 1. 
Table 1. Approach to estimate the number of subjects diagnosed with advanced adenomas at the various alternative scenarios. 
A) Input parameters: Sensitivities for advanced adenomas at various cutoff levels according to the results of a diagnostic study 
that determined test performance characteristics of OC-Sensor Micro (Eiken Chemical Co, Tokyo, Japan)14• 
Cutoff level [ng hemoglobin I ml]* 
~11 
~14 
~36 
~so 
Sensitivity for advanced adenomas 
50% 
47% 
45% 
38% 
36% 
35% 
B) Based on these sensitivities, the number of subjects diagnosed with advanced adenomas at the various alternative 
scenarios was estimated in a two-step approach. 
Step 1: 
Step 2: 
Estimating the total number of subjects with advanced adenomas in the cohort at baseline: 
Given a sensitivity of 35% for advanced adenomas at a cutoff level of ~SO ng/ml, those subjects diagnosed 
with advanced adenomas in the first FIT SO round (N=126) were considered to make up for 35% of all subjects 
with advanced adenomas in the cohort at baseline. Dividing N=126 by 35%, it can thus be estimated that 
360 subjects in the cohort had advanced adenomas at baseline 
Estimating the number of subjects diagnosed with advanced adenomas at the hypothetical first round: 
This number (N=360) was multiplied with the sensitivity for advanced adenomas at the cutoff level of each 
respective scenario. For example, when using a cutoff level of 22 ng/ ml at the first round, it was estimated 
that 162 subjects would have been diagnosed with advanced adenomas (N=360 multiplied with 45%). 
The approach made use of the results of a diagnostic study that was conducted in a similar study 
population in the same Dutch region and determined test performance characteristics of OC -Sensor 
Micro (Eiken Chemical Co, Tokyo, Japan) at various cutoff levels14. 1n this study, all included subjects 
underwent both FIT and colonoscopy. To determine the number of screen-detected CRCs for the 
alternative scenarios, we considered persons who were diagnosed with CRC until the end of the 
follow-up period (screen-detected or interval CRC) and assessed whether their baseline hemoglobin 
level was equal or above the cutoff level of the respective scenario. We also determined the number 
of early stage CRCs (UICC I or II) for the alternative scenarios, taking into account uncertainty 
regarding stage progression as far as relevant. Accordingly, we distinguished between CRCs that 
were definitely or possibly detected at an early stage. The assumptions and criteria we used for 
classifying CRCs as screen-detected and early stage in the alternative scenarios are described in 
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detail in the Supplement. We also determined the number of FITs and follow-up colonoscopies for 
the standard scenario and the various alternative scenarios. 
Results 
Overall, 4,523 subjects (48% male) participated in the first FIT50 round. The mean age (standard 
deviation) was 60.5 (6.6) years. At the second round, 742 subjects (1 6%) were no longer eligible, 
and 354 subjects (8%) were eligible but did not participate. This left 3427 (76%) participants in the 
second FITSO round (91 o/o of those being eligible). A flow chart of the cohort from baseline to the 
end of the follow-up period is provided in the Supplement. A total of 36 CRCs were diagnosed in 
the cohort; 22 with first-round FIT50, 6 with second-round FIT50, and 8 during intervals. Figure 2 
provides information on these CRCs, including whether they were screen-detected with FITSO or 
interval CRCs, the respective baseline FIT level, the stage at diagnosis and the time between baseline 
and diagnosis. 
Screen-detected CRCs Interval CRCs 
(FIT50, n=28) (FIT50, n=8) 
Time Time 
Hbat UICC between Hbat UICC between baseline 
stage baseline baseline stage baseline [ng/m~ and [ng/m~ and 
diagnosis diagnosis 
2:50 I 1: n- 14 I Om : ~ 1 First FIT50 round 2:50 I II: n=3 I Om 
2:50 I Ill: n-5 I Om I 5" 
Iii 
~ 
-~ ~ I 24 I Ill I 9m p..) I 960. I I I 16m g 7 II 29m 
"' '< CD 
.. 
25 I 12m iii 
0 I 24 m 
0 I 24 m ~ I Second FIT50 round 14 Ill 24 m 
0 II 36m 
0 I 36m 
5" [ 36 Ill 17m 
n• 5 24 II 34 m 
p..) ~ 0 I 36m i 1 IV 36m 
iii 0 Ill 38m 
I End-of-follow-up I 
Figure 2. Information on colorectal cancers (n=36) occurring in the cohort during the follow-up period, including the respective 
baseline FIT level, the stage at diagnosis and the time between baseline and diagnosis. * This person tested positive at the first FITSO 
round but follow-up colonoscopy was negative. 
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Table 2 shows the outcomes of interest for the standard scenario and the various alternative 
scenarios. In the standard scenario (i.e. the two FITSO rounds), the cumulative positivity rate was 13%. 
Advanced adenomas were detected in 180 subjects, the majority of which (70%) were diagnosed 
in the first FITSO round [9]. Overall, 26 CRCs (72% of all CRCs) were diagnosed at an early stage, of 
which 22 were screen-detected. 
Regarding the alternative scenarios, Table 2 shows the results for selected cutoff levels ranging from 
11 to 50 ng/ml. Using FIT11 for the alternative single initial screening round yielded a similar number 
of subjects with advanced adenomas as the standard scenario, while the positivity rate was So/o 
higher (i.e. 18 vs. 13%; p<0.0001 ). The number of CRCs diagnosed at an early stage was estimated 
to range between 22 and 27. The lower estimate (i.e. 22) only included CRCs that would definitely 
have been diagnosed at an early stage, while the upper estimate (i.e. 27) also included those that 
would possibly have been diagnosed at an early stage (see Methods section and Supplement). A 
single-round FIT22 scenario yielded a similar positivity rate as the two-round standard scenario, 
while the number of subjects diagnosed with advanced adenomas was estimated to be 1 Oo/o lower. 
The number of early stage CRCs was estimated to range between 22 and 26. For FIT36, the positivity 
rate decreased to 1 Oo/o and the number of subjects diagnosed with advanced adenomas was 25% 
lower as compared to the standard scenario. The number of early stage CRCs was estimated to 
range between 21 and 25. There was a trade-off between a higher number of FITs in the standard 
vs. a higher number of colonoscopies in the alternative scenarios when the latter used cutoff levels 
below 22 ng/ml. For alternative scenarios with cutoff levels:?: 22 mg/ml both the number of FITs and 
colonoscopies were lower than in the standard scenario (Table 2). 
Discussion 
The quantitative nature of FIT as opposed to gFOBT offers new options for CRC screening that 
are yet to be fully explored. In this study, we explored FIT strategies that use a lower than usual 
positivity threshold in combination with an extended screening interva l (up to 5 years), based on 
the analysis of data from repeated FIT screening. While such strategies would save screening rounds, 
our results suggest that they likely do not markedly differ from conventional strategies with respect 
to diagnostic yield and cumulative positivity rate, with some trade-off depending on the respective 
cutoff level. There were scenarios with similar lesion detection and a higher number of follow-up 
colonoscopies, and scenarios with slightly lower lesion detection and a similar number of follow-
up colonoscopies. The number of FITs was, as a matter of course, halved compared to the standard 
Table 2. Positivity rate, number of subjects diagnosed with advanced adenomas, number of screen-detected co/orecta/ cancers, number of early stage co/orecta/ cancers and number of FITs and 
co/onoscopies for the standard scenario and the respective estimates for various alternative scenarios. 
Positivity rate Subjects with 
advanced 
CRCs (overall: n=36) 
adenomas* (n) 
Standard scenario 
Screen-detected 
CRCs** (n) 
I 
Early stage CRCs (UICC I or II; n) 
Possibly, category Possibly, category 
Definit e 
A3*** B3*** 
13% (580/4523) l 180 ~ 28 26 NA NA J 
Alternative scenario 
<!: 11 18% (826/4523) 180 27 22 3 2 
<!:14 16% (745/4523) 169 27 22 3 2 
<!:2 2 13% (578/4523) 162 26 22 2 2 
<!:36 1 0% (460/4523) 137 23 21 1 3 
2:45 9%(410/4523) 128 22 21 0 3 
<!:50 8% (380/4523) 126 22 21 0 3 
• For the hypothetical scenarios, the numbers of subjects with advanced adenomas were estimated as described In Table 1. 
••The number of interval CRCs Is calculated by subtracting the number of screen-detected CRCs from the overall number ofCRCs (n=36). 
FITs and colonoscopies (n) 
FITs 
7950 
4523 
4523 
4523 
4523 
4523 
4523 
Colonoscopies 
580 
826 
745 
578 
460 
410 
380 
- As described in more detail In the Supplement, these categories take into account that there is uncertainty regarding stage progression fo r some CRCs in the alternative scenarios. Category A: CRCs diagnosed at an advanced stage during the fo llow-up period 
that might have been at an early (or precancerous) stage if detected at baseline. Category B:This category refers to CRCs that were detected at an early stage at the second FIT SO round (i.e .. the round that was skipped at the alternative scenarios) and had a 
hemoglobin level at the first round below the cutoff level of the respective alternative screening scenario. As justified In the Supplement, we considered half of these CRCs to be possibly still at an early stage if diagnosed later. 
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scenario due to the longer interval. 
The next question is what motivates to further pursue this research, i.e. what may be advantages 
of such screening strategies. An obvious advantage is the reduction in the number of screening 
rounds, which saves efforts and costs related to the organization of each screening round and may 
also reduce the burden to the screenees. For example, offering screening from age 50 to 70 years 
requires 11 rounds when a 2-year interval is used, but only 5 rounds when a 5-year interval is used. 
Furthermore, the increased likelihood of detecting lesions at one single round going along with 
the higher per-test sensitivity (resulting from the lower positivity threshold) would be particularly 
advantageous for subjects who participate in screening on an irregular basis. For example, a person 
with advanced adenomas who participates in screening only once has a 50% chance of being 
detected by screening when FIT11 is used, but only a 35% chance when FITSO is used. In this study, 
this potential advantage was not apparent because the proportion of subjects who participated 
in both FITSO rounds was very high. However, it is expected to be relevant in settings with less 
favorable patterns of longitudinal adherence. This may occur when there is no or a suboptimal 
invitation system, as it is often the case in countries with a decentralized health system. For example, 
a retrospective cohort analysis from the United States evaluating adherence to repeated yearly 
FOBT showed that among 395.000 subjects who received exclusively FOBT and no other screening 
tool, about 40% were tested only once during a 5-year study period15. If strategies with a longer 
screening interval are used, the design needs to make sure that non-participants are re-invited after 
a reasonable time frame and not only several years later when invitation to the next screening round 
is due. 
Colonoscopy capacity needs to be taken into account when discussing the implications of 
alternative FIT strategies that use a lower positivity threshold. Our results suggest that the total 
demand for work-up colonoscopy could be rather similar to conventional strategies, with some 
variation depending on the respective cutoff level. From a program perspective, the higher number 
of positive tests per invited birth cohort is more or less compensated for by the lower number of 
birth cohorts that is invited per round due to the longer interval. It is important to note that this 
compensation is achieved during the steady state of an established screening program. When a 
program based on such alternative FIT strategies is started, the time taken for complete roll-out may 
need to be adapted in settings with limited colonoscopy capacity. 
To our knowledge, there are no other studies with a similar approach. We previously used 
microsimulation modeling to assess cost-effectiveness of various FIT screening strategies over a 
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period of 30 years, varying the cutoff level (SO- 200 ng/ml), the screening interval (1-3 years) and 
the age range to which screening is offered 16• Screening at a cutoff level of 50 ng/ml was found to be 
more cost-effective than at higher cutoff levels, which held true for the range of explored intervals. 
This indirectly supports our finding that screening at a lower cutoff level in combination with a 
longer interval may not be disadvantageous. The current study adds to these findings by lowering 
the cutoff level together with extending the screening interval in ranges not previously explored. 
Empirical evidence on FIT screening with intervals of three or more years is limited. The European 
guidelines for quality assurance in CRC screening and diagnosis recommend that the screening 
interval for FIT should not exceed three years, referring to three case-control studies from Japan7•17•19• 
These studies determined the risk of developing CRC and of dying from CRC according to FIT 
screening history However, the subgroup analyses that focused on the optimal screening interval 
had methodological issues regarding sample size and confounder adjustment as detailed in the 
Supplement. Apart from that, the positivity rate was 2.4% in these studies indicating that a high 
cutoff level was used. This is in contrast to our approach that compensated for the longer interval 
by lowering the cutoff level. 
Experimental evidence for varying the screening interval between 1, 2, and 3 years without varying 
the cutoff level has recently been reported from the study that the present analysis was based on [9]. 
The detection rate of advanced neoplasia at the second round did not vary between groups assigned 
to the different intervals. Although the comparison was not powered to detect small differences in 
detection rate between groups, these findings question the intuitive thinking that less frequent 
FIT screening (at a constant cutoff level) inevitably decreases the cumulative diagnostic yield. With 
respect to our analysis, it suggests that the screening interval could be extended to 5 years when 
the skipped round is compensated by use of a lower cutoff level at the former round. Our approach 
used lower than usual positivity thresholds for FIT. Generally, this is a way to bridge the difference 
between fecal occult blood test screening and primary colonoscopy screening where all screenees 
are offered colonoscopy irrespective of any blood in stool. As shown in our analysis, the overall 
demand for colonoscopy of such strategies may be kept at the same level as for conventional FIT 
screening if the screening interval is extended. Diagnostic studies suggest that when lowering the 
positivity threshold to the hemoglobin levels that we used in our analysis, the increase in sensitivity 
relative to the decrease in specificity is similar to higher cutoff levels14• Accordingly, we expect 
similar conclusions if our approach is applied to data from programs that used higher cutoff levels. 
In other words, lowering the positivity threshold (although not to the levels we used in our analysis) 
and extending the interval could also be an option for settings with a lower colonoscopy capacity. 
m 
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For some FIT products, analytical imprecision (that is, variability between measurements repeated 
under similar conditions) has been shown to vary according to the cutoff level20• Thus, if low cutoff 
levels are used for routine screening, the precision profiles need to be optimized accordingly. The 
recent optimization of buffers of several FITs has already contributed to this issue and allows use of 
lower cut-off levels. 
There are strengths and limitations to this study that should be noted. We developed an approach 
that was directly linked to empirical longitudinal data of FIT screening. This avoided the need for 
assumptions regarding conditional independence of sequential FIT testing, which plays a key role 
in the context of exploring longer screening intervals. There were uncertainties regarding stage 
progression for some CRCs, which we tried to address in a systematic and transparent way. The 
same applies to the number of adenomas detected in the alternative scenarios, which we estimated 
by combining the findings of the first FITSO round with the results of a study comparing FIT and 
colonoscopy in all subjects screened 14• The latter was conducted in a similar setting and showed 
a similar detection rate for FIT SO regarding advanced adenomas (3.1% vs. 2.8% in the first FIT SO 
round). The sample size of the diagnostic study was moderate, but the course of the ROC curve at 
lower cutoff levels was confirmed by other diagnostic studies on quantitative FIP1• 
There is uncertainty whether the clinical benefit of detecting advanced adenomas that bleed less 
vs. detecting those that bleed more is similar. It may be that the latter are more likely to progress 
to lesions that would be symptom-detected at an early stage anyway (and would thus not require 
screen-detection), but it may also be that the level of bleeding is positively associated with the 
progressive potential. As possible limitations, it should also be noted that not all CRCs testing 
positive with FIT at baseline may actually have been detected at work-up colonoscopy and that de 
novo CRCs could have occurred that were not detectable at baseline. 
Although imperfect, our approach can be considered as a step that helps deciding whether or not 
trials that directly compare conventional and alternative FIT strategies with an extended screening 
interval are justified. Further preliminary evidence from other databases on repeated FIT screening 
that are analysed in the same way would be of value: First, for the purpose of validation given the 
inherently low number of CRCs detected after the initial screening round in our study. Secondly, 
studies that used a higher cutoff level at the initial round would provide insights regarding 
generalizability to other settings. With respect to the time frame, our analysis was focused on 
skipping the FIT round that follows the initial screening. It will be interesting to conduct similar 
analyses for subsequent screening rounds to explore alternative FIT strategies from a longer-term 
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perspective. Finally, as the diagnostic yield of FIT differs by age and sex increased sample sizes 
would allow for subgroup analyses according to these factors. 
In conclusion, our findings suggest that the diagnostic yield of alternative FIT strategies using a 
lower than usual positivity threshold in combination with an extended screening interval (up to 5 
years) may be similar to conventional strategies. This justifies and motivates further research steps 
in this direction given that such alternative strategies could present interesting options for CRC 
screening, either generally or in particular settings. 
m 
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Supplementary files 
Supplement 1 
Assumptions and criteria for classifying CRCs as screen-detected CRCs and early stage CRCs in the 
alternative scenarios. 
Screen-detected CRC: 
A CRC in a person whose baseline FIT level was equal or beyond the cutoff level of the respective 
scenario was classified as screen-detected. This assumes that this CRC developed from a lesion 
that was detectable at baseline colonoscopy. The lesion may have been precancerous (i.e. not yet 
malignant) at baseline, but as this is not known we cautiously considered it as screen-detected 
rather than prevented CRC. 
Early stage CRCs: 
CRC definitely detected at an early stage: This category includes CRCs that were diagnosed at 
an early stage at baseline or during the follow-up period and would have tested positive at the 
hypothetical single initial round (i.e. the baseline haemoglobin level was equal or above the 
cutoff level of the respective scenario). This category also includes interval CRCs diagnosed at 
an early stage. 
CRC possibly detected at an early stage, category A: This category includes CRCs that were 
diagnosed at an advanced stage during the follow-up period and would have tested positive 
at the hypothetical single initial round (i.e. the baseline haemoglobin level was equal or above 
the cutoff level of the respective scenario). If detected at baseline, they might have been at an 
early (or precancerous) stage. 
CRC possibly detected at an early stage, category B: This category refers to CRCs that were 
screen-detected at an early stage at the second FITSO round of the standard scenario (i.e. the 
round that was skipped at the hypothetical scenarios), but would have tested negative at the 
hypothetical single initial round (i.e. the baseline haemoglobin level was below the cutoff 
level of the respective scenario). It is not plausible to assume that all of these CRCs would have 
been detected at an advanced stage at the alternative scenarios. They may: i) have remained 
at an early stage until being screen-detected at a following round or ii) have been symptom-
detected at an early stage. The latter is expected for 40% of CRCs given the stage distributions 
observed in the pre-screening era and among interval CRCs. 
To take into account the possibilities described under i) and ii), we classified half of these CRCs as 
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being possibly detected at an early stage. For example, in the alternative scenario using a cutoff 
level of 14 ng/ ml, 4 CRCs were in category B overall. We considered half of these CRCs (n=2) to 
possibly be still at an early stage if diagnosed later. 
Supplement 2 
Flow chart of the cohort from baseline to the end of the follow-up period. 
It describes screening eligibility and participation at the second FITSO round (corresponding to the 
round that would have been skipped at the alternative scenarios). 
First screening round (baseline) 
Individuals participating in the first round, 
n=4523 
_I Individuals who tested positive at the 
I first screening round, n-380 
J Individuals who moved out of the 
I region or with too short screening interval. n=96 
Individuals who died, n=26 
_I Individuals who were no longer 
I eligible because of age, n=204 
J Individuals fulfilling other exclusion 
-I criteria. n=36 
Second screening round y 
Individuals Individuals eligible but Individuals 
participating in the not participating in the not eligible for the 
second round, second round second round 
n=3427 (76%) n=354(8%) n=742 (16%) 
Third screening round (end of follow-up) 
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Abstract 
Background & Aims The efficacy of colorectal cancer (CRC) screening is dependent on participation 
and subsequent adherence to surveillance. The internet is increasingly used for health information 
and important to support decision-making. We evaluated the accuracy, quality, and readability of 
online information on CRC screening and surveillance. 
Methods A Website Accuracy Score and Polyp Score were developed, which award points for 
various aspects of CRC screening and surveillance. Websites were also evaluated using validated 
internet quality instruments (Global Quality Score, LIDA and DISCERN), and reading scores. Two 
raters independently assessed the top-30 websites appearing in Google.comTM. Portals, duplicates 
and news articles were excluded. 
Results Twenty websites were included. The mean Website Accuracy Score was 26 out of 44 (range 
9-41). Websites with the highest scores were www.cancer.org, www.bowelcanceraustralia .org and 
www.uptodate.com. Median Polyp Score was three out of ten. The median Global Quality Score was 
three out of five (range 2-5). The median LID A overall score was 74% and median DISCERN score was 
45, both indicating moderate quality. The mean Flesch-Kincaid Grade Level was 11th grade rating 
the websites as difficult to read, 30% had a reading level acceptable for the general public (Flesch 
Reading Ease>60). There was no correlation between the Google rank and Website Accuracy Score 
(rs=-0.31; p=0.18). 
Conclusions There is marked variation in quality and readability of websites on CRC screening. 
Most websites do not address polyp surveillance. The poor correlation between quality and Google 
ranking suggests that screenees will miss out on high-quality websites using standard search 
strategies. 
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Introduction 
Screening is effective in reducing the burden of colorectal cancer (CRC) and many countries have 
implemented CRC screening programs1•2• The success of CRC prevention is highly dependent 
on participation in the screening program. Initial participation and subsequent adherence to 
surveillance can be influenced by enhanced knowledge about CRC screening and colonoscopy 
outcome3A. As more screening programs are implemented worldwide, providing adequate patient 
oriented information is increasingly important. Most organized screening programs approach 
individuals for screening on a voluntary basis without personal contact with a health professionaF·5• 
Accordingly these individuals may search for additional information on screening themselves. 
The internet is widely regarded as an important channel of health information6•7.1n Western countries, 
more than half of the population uses a smartphone allowing instant and rapid access to the 
worldwide web8 . However, few regulations control the information that individuals or organizations 
list on their web sites. A systematic review reported that 70% of studies identified quality issues 
with health- and disease-focused internet websites9• Since the efficacy of a CRC screening program 
is dependent on informed participation, assessing the availability and quality of online information 
aimed at screenees is of crucial importance. Therefore, the aim of this study was to rate quality, 
accuracy and readability of web-based information on CRC screening from a screenee perspective. 
Methods 
Internet Search Strategy 
Web sites were identified by searching the World Wide Web with Google.comTM , the most frequently 
used Internet search engine10• The search was performed with English settings, with location tracking 
and search activity history switched off so search results were not influenced by location or past 
searches. Searches were carried out in 2014, 2015 and 2016. The following search terms were used: 
"colorectal cancer screening" OR "bowel cancer screening" OR "colon cancer screening" (quotations 
included). The search terms used reflect the most searched terms listed in the statistics provided via 
Google Trends. It is known that internet searchers do not typically view more than a few search hits 
and usually choose one of the first results displayed by the search engine11 • We therefore decided to 
examine the first 30 hits, corresponding with the first three pages of Google searches. 
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Table 1. Colorectal cancer screening specific Website Accuracy Score components and percentage of websites that were awarded 
points for these items. 
Website information components (maximum 44 points) 
CRC general information 
Description of the colon/bowel/large intestine 
Image of the anatomy of the intestines 
Explanation of polyp as precursor of colo rectal cancer 
Development of a polyp into malignancy is a slow process (takes years) 
Colorectal cancer can be prevented by removing precancerous polyps/adenomas 
Risk factors 
Unknown 
Age (>50 years) 
Gender 
History of previous polyps 
Familiy history of colo rectal cancer 
Hereditary I Familial adenomatous polyposis I Lynch syndrome 
Lifestlyle (2 points*): 
unhealthy life style (general) 
unhealthy diet (low fiber, high fat, red meat) 
smoking 
alcohol 
obesity 
* Mentions 1-2 life style factors: 1 point 
Mentions 3 or more life style factors: 2 points 
Symptoms of colonic polyps I CRC 
Most polyps are asymptomatic 
Mentions symptom(s) such as: 
blood in stool/ rectal bleeding 
change in bowel habit 
unexplained weight loss 
tenesmus (false urge) 
Recommendation to contact medical doctor in case of symptoms 
Screening for CRC 
Mentions that there are different methods of screening 
The detection and removal of polyps is main purpose of the screening program for colorecta l 
cancer 
Mentions that there are different methods of screening 
The detection and removal of polyps is main purpose of the screening program for colorecta l 
cancer 
Mentions that not all tests have same accuracy 
Websites 
N(%) 
15 (75) 
15 (75) 
17 (85) 
8 (40} 
15 (75) 
3 (15} 
13 (65) 
0 (0) 
15 (75) 
17 (85) 
14 (70) 
1 (5) 
13 (65) 
11 (55) 
13 (65) 
11 (55) 
16 (80 ) 
15 (75) 
16 (80) 
15 (75) 
7 (35} 
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Mentions that not all tests have same patient burden 
Colonoscopy is gold standard I most accurate for diagnosing polyps 
Colonoscopy 
+explanation of procedure 
+explanation risks (bleeding and perforation are mentioned) 
+ explanation polypectomy 
+explanation bowel preparation 
Mentions flexible sigmoidoscopy 
+explanation procedure 
+explanation risks 
Mentions FOBT (immunochemical or guaiac) 
+explanation procedure 
+has to be repeated every 1-2 years 
+stresses importance of repeated screening 
+ explains possibility of false positive/negative results 
Mentions barium enema 
+poor detection of (pre)cancer 
Mentions CT colonography 
+explanation procedure 
+explanation risks 
Mentions that all test s, when positive, need to be followed by colonoscopy 
Mentions surveillance after colonoscopy in case of adenomas 
Mentions that frequency of screening is different per test 
Describes possibility of interva l carcinomas (CRC after negative test) 
Describes limitations of screening such as overdiagnosis and overtreatment 
Inclusion and exclusion criteria 
7 (35) 
7 (35) 
20 (100) 
17 (85) 
14 (70) 
13 (65) 
13 (65) 
15 (75) 
13 (65) 
8 (40) 
20 (100) 
16 (80) 
13 (65) 
7 (35) 
11 (55) 
9 (45} 
3 (15) 
11 (55) 
10 (SO) 
8 (40) 
9 (45) 
3 (15) 
7 (35} 
4 (20) 
5 (25) 
English websites were included only if the main part of the site dealt with educational information 
about CRC-screening. Websites that merely contained portal links to other sites were excluded, as 
were duplicate websites, news articles and sites containing irrelevant information (e.g. advertising, 
retail sites, or patient fora). 
Accuracy assessment 
The variability and accuracy of the information provided by each website on key facts about CRC 
screening and surveillance was investigated. For this purpose a Website Accuracy Score specific for 
CRC screening was developed (Table 1). In addition a separate Polyp Score for colorectal polyps 
was developed to assess information on important aspects of polyps, colonoscopy outcome and 
surveillance guidelines (Table 2). The Website Accuracy Score and Polyp Score consist of a list of key 
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items deemed relevant for CRC screening and surveillance. They were generated through evaluation 
of the literature and discussions with key stakeholders. The Website Accuracy Score and Polyp Score 
went through five iterations and were pretested twice prior to its final use using a random selection 
of websites. The range of scores was 0 to 44 for the Website Accuracy Score and 0 to 10 for the Polyp 
Score. If a website did not discuss or name an item of the Website Accuracy Score or Polyp Score, 
zero points were awarded for that item. Items had to be clearly presented on the website; the search 
function of the website was not used to locate this information. 
Table 2. Polyp Score items and percentage of websites that were awarded points for these items. 
Website information components 
Polyp Score (maximum 10) 
Description of what a polyp is; growth/mushroom/ lump in the lining of the large bowel 
Image of a polyp 
Prevalence of people with polyps in population 
Explains that there are different types of polyps 
Explains that not all polyps have an equal risk of turning in to colon cancer 
Explains differences between adenoma and hyperplastic polyp 
Mentions that some polyp characteristics have a higher risk of malignant degeneration; i.e. 
histologica l findings (villous aspect ) 
Polyp size as risk factor 
Influence of degree of clean liness of bowel on polyp detection 
Explains surveillances intervals after polypectomy 
Quality assessment 
Websites 
N(%) 
15 (75) 
9 (45) 
6 (30) 
9 (45) 
10 (SO) 
4 (20) 
3 (15) 
3 (15) 
2 (10) 
2 (10) 
In addition to Website Accuracy Score and the Polyp Score, a selection of validated scores was used 
to assess the website quality and reliability. The overall quality of each website was rated using the 
Global Quality Score. This is a previously validated five-point Likert scale to rate the overall quality 
of a website (Table 3).12,13 It incorporates the accessibility of the information within the website, 
the quality of this information, the overall flow of information, and how useful the website reviewer 
thinks the particular website would be to a screenee. The Global Quality Score was assigned by the 
reviewer after evaluating the entire website. 
The LIDA instrument is a validated question based instrument, assessing the overall score (0-96), 
accessibility (0-54), usability (0-12) and reliability (0-30) of healthcare websites. The scores are 
reported as percentages of the maximum score, overall scores >90% represent good results and 
<50% represent poor results. The online LIDA instrument was used for this study14 • 
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The DISCERN tool is a validated 16-item questionnaire to rate the quality of written information on 
treatment choices for a health problem.15,16_ENREF _18 The first 8 questions address reliability, 
dependability and trustworthiness of a website, the next 7 questions focus on quality of information 
on treatment choices and the last question addresses the overall quality of the site. Each question 
is rated on a 5-point scale with a maximum score of 80. Questions were answered as if participation 
to CRC screening was the treatment choice. The total quality of each website was classified as high 
(~65 points), moderate (33-64 points), or low (16-32 points). 
Table 3. Global Quality Score criteria used to score web sites on colorectal cancer screening. 
Score Global Quality Score Description 
2 
3 
4 
5 
Poor quality, poor flow of the site, most information missing, not at all useful for patients. 
Generally poor quality and poor flow, some information listed but many important topics missing, of very 
limited use to patients. 
Moderate quality, suboptimal flow, some important information is adequately discussed but other 
information poorly discussed, somewhat useful for patients. 
Good quality and generally good flow, most of the relevant information is listed, but some topics nog 
covered, useful for patients. 
Excellent quality and excellent flow, very useful for patients. 
The amount of advertisements on each website was scored as none, little, average, or many and 
agreed through discussion by the two reviewers. 
Readability assessment 
Readability, referring to the reading difficulty based on word and sentence length, was assessed 
by the use of two readability scores. The Flesch Reading Ease Score (FRE) assigns a value between 
0 and 100 whereby a higher value represents a greater ease of reading. A section with a score of 
90- 100 is considered to be very easily understood, >60 is an acceptable level of difficulty for the 
general public and below 30 is considered very difficult to read17. The Flesch-Kincaid Grade Level 
(FKG) uses the same input variables as the FRE score and outputs a US school grade indicating the 
average school grade able to read the text17• The American Medical Association Foundation states 
that health-related materials for patients should be written at a level appropriate for those in the 
6th grade or below18• The FRE score and FKG score were calculated using the Microsoft Word 2007 
program. A random 100 word sample of text was extracted from each website and pasted into the 
program by both reviewers independently. 
Statistical analyses 
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The website assessment was performed by two independent raters (EHS, EJG). For Website Accuracy 
Score assessment, any difference in score between reviewers was resolved through discussion and 
by re-review of the website by both reviewers together to generate a single score for each website. 
Consensus in case of disagreement was achieved through discussion with a third reviewer (SvZ). For 
other quality parameters, the mean score of both website raters was used. Correlations between 
different quality parameters were analyzed using the Spearman rank-correlation coefficient 
because of non-normality of the data. Statistical tests were performed with the use of IBM SPSS 
software, version 21.0 and Graphpad Prism 5. A two-sided p-value <0.05 was considered significant. 
All authors had access to the study data and reviewed and approved the final manuscript. 
Results 
The search 
The Google search was carried out on April 9th, 2014 and resulted in over 2,000,000 hits. The 
first 30 results were evaluated of which 20 websites were included. Two portal websites leading 
to another site, one duplicate site, one website with information on insurance reimbursement, 
three news articles, and three guidelines and medical articles clearly aimed at health professionals 
were excluded. All websites were accessed between April 2014 and June 2014. Additional Google 
searches were carried out on August 7th, 2015 and February 22nd, 2016 to evaluate possible 
changes in Google rank position. Most websites were published by a professional medical society 
(35%) or a governmental organization (30%) (Figure 1 ). Almost half of the websites were from the 
United States (45%), others from the United Kingdom (25%), Canada (20%) and Australia (1 0%). 
Accuracy and quality of website information 
The mean Website Accuracy Score was 26 (range 9-41 ). Mostwebsites contained general information 
on CRC screening, but description and risk of different screening modalities and limitations of 
screening were not always captured (Table 2). 
35o/o 
WAS: 22of44 
GQS: 3of5 
FRE: 46 
FKG: 1111 
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20°/o 
WAS: 29 of44 
GQS: 3 of 5 
FRE: 52 
FKG: 10th 
Website type 
• Governmental organization 0 HospitaVhealth care organization 
Proffesional medical society 
Figure 1. Mean Website Accuracy Score, Global Quality Score and reading scores per website type. 
The median Global Quality Score was 3 (range 2-5). This score indicates that the quality of information 
of most websites was moderate. In many sites, some information was adequately discussed, while 
other parts of information were missing and the overall flow of information was suboptimal. There 
was a strong positive correlation between the Website Accuracy Score and the Global Quality Score 
with a Spearman's rho (rs) of 0.81 (p<O.OOl; Figure 2). 
r5 = 0.81 
• Q)40 P < 0.001 
... • • 0 
• u (/) • >. 30 I u 
Ill 
• ... • :I u 20 ~ 
• Q) 
• :t: 1/) • i 10 • ~ 
0 
0 1 2 3 4 5 
Global Quality Score 
Figure 2. Relationship of the Global Quality Score and the Website Accuracy Score used to evaluate colorectal cancer screening 
web sites. 
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The median Polyp Score was three (range 0-10, Table 2). The Polyp Score correlated positively with 
the Global Quality Score (rs=0.81; p<0.001 ). The median LID A overall score was 74% (lnterquartile 
range, IQR 11 ). The median LIDA score for accessibility was 88% (IQR 8), for usability 63% (IQR 22), and 
for reliability 52% (IQR 26). The median DISCERN score was 45 (IQR 20) indicating moderate quality. 
Ten percent of websites (2/20) were classified by DISCERN as high quality, 80% (16/20) as moderate 
and 10% (2/20) as low quality. Both the validated LIDA and DISCERN had a moderate correlation 
with the Website Accuracy Score; rs=0.45 (p<O.OS) and rs=0.66 (p<0.01) respectively. There was no 
correlation between the Google ranks and the Website Accuracy Score (rs=-0.31; p=0.18, rs=-0.47; 
p=0.08 and rs=-0.31; p=0.25 for the 2014, 2015 and 2016 search respectively). 
Table 4lists the top five websites as rated by CRC screening specific Website Accuracy Score and other 
evaluations of website quality. The complete scores per website are published in a supplementary 
table. Eight websites had initial inter-rater Website Accuracy Score differences of ~8. Differences 
in scoring of Website Accuracy Score or Polyp Score between reviewers were due to oversight or 
differences in interpretation. 
Table 4. Top 5 websites as ranked by the Website Accuracy Score with the corresponding Polyp Score, quality scores, reading 
scores and Google rank positions. 
Website Accuracy Quality Readability Googlerank 
WAS PS GQS DISCERN LID A FRE FKG 2014 2015 2016 
www.cancer.org 41 5 5 65 67% 62 9th 6 3 2 
www.bowelcanceraustralia.org 38 2 3 35 58% 58 lOth 5 X 29 
www.uptodate.com 37 6 5 69 85% 28 14th 27 13 16 
www.macmillan.org.uk 35 5 4 49 69% 48 11th 19 X X 
www.nlm.nih.gov/medllneplus 34 6 4 57 81% 59 8th 4 4 4 
FRE; Flesch Reading Ease score, FKG; Flesch-Kincaid Grade Level, GQS; Global Quality Score, PS; Polyp Score, WAS; Website Accuracy Score, X; Not in the first 30 Google results. 
Readability of web sites 
The mean Flesch Reading Ease Score was 48 (range 27-76), 30% of the websites had a reading level 
acceptable for the general public defined by a Flesch Reading Ease Score of >60. The mean Flesch-
Kincaid Gradel Level was 11 (SD ±2.2, range 5-16), indicating that the text would be understandable 
to an average 11th grade US student. The reading level of healthcare and governmental websites 
was the easiest, whereas the reading level of open access information sites was the most difficult 
(Figure 2). 
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Advertisements 
When assessing the amount of advertisement, 16 (80%) websites contained none, two (1 0%) 
contained a moderate amount of advertisement, and two (1 0%) websites contained many 
advertisements. The latter two were open access websites. Websites published by governmental 
organizations contained no advertisements. 
Discussion 
This study shows that there is marked variation in accuracy, quality and readability of information 
on CRC screening websites and that most websites do not address polyp surveillance. The best five 
websites as ranked by the Website Accuracy Score are www.cancer.org; www.bowelcanceraustralia. 
org; www.uptodate.com; www.macmillan.org.uk; and www.nlm.nih.gov/medlineplus. Their 
corresponding Google rank positions varied over time and some of these websites will be missed 
by standard Google searches (Table 4). 
The poor correlation between website accuracy and Google ranking is especially concerning given 
the fact that Google is a prominent search engine.1 0 Internet users often do not go beyond the first 
page of a search, which can result in missing websites that provide high quality information. This 
problem has been identified before12•13•19• 
Even though surveillance after colonoscopy, especially if adenomatous polyps were found, is 
important for CRC screening to reach its maximal efficacy, it was only mentioned in 15% of the 
websites. Surveillance intervals are based on findings during colonoscopy20• However, clear and 
easy to understand information on how findings during a screening colonoscopy, i.e. adenomatous 
polyps, determine the follow-up surveillance recommendations was lacking in most sites. This is 
reflected in the low overall median Polyp Score (3 out of 1 0) and the fact that only two websites 
(1 0%) described the actual surveillance intervals. This is an important information gap since 
adherence to surveillance is influenced by enhanced knowledge4 • Previous studies have shown that 
patients may not be sufficiently aware of important endoscopic findings and the consequences this 
has for subsequent surveillance recommendations3•21 .Understanding the need of surveillance likely 
will motivate participants to adhere to surveillance recommendations. 
The reading difficulty of most websites was far above the required standard. Only 5% of the websites 
met the recommended level by the American Medical Association Foundation of 6th grade or 
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below18• This suggests that most websites are too difficult for the average reader and this may result 
in misunderstanding of information. Other studies evaluating patient information websites also 
documented that the required reading levels were high and above the recommended 6th grade 
levei22.24• Our study showed that commercially funded websites were more difficult to read than 
governmental websites. This is in accordance with previous literature22• 
When evaluating the Website Accuracy Scores, it became apparent that most websites only 
focused on the predominant screening test used in the country where the website originated, 
and did not provide information on other options for CRC screening. It is debatable whether it 
is necessary to inform screenees about all possible screening tests that are available25• However, 
providing information that several different options exist may help individuals, who are interested 
in screening, to make an informed decision25•26• Colonoscopy and guaiac or immunochemical Fecal 
Occult Blood Test (FOBT) were described in all websites in detail. However, not all websites stressed 
the importance of the need for repeated screening when FOBT is used. This in spite of strong 
evidence that repeating stool testing at regular intervals is of paramount importance for FOBT-based 
screening to be effective in the long term1• Only 20% of the websites mentioned the possibility of 
the occurrence of interval carcinomas. This may in part be explained by the fact that this aspect of 
CRC screening has only gained a lot of attention during the last few years. However, not mentioning 
potential limitations of screening may stand in the way of informed decision-making27• 
A strength of this study is that the Website Accuracy Score and Polyp Score are CRC screening specific 
evaluation tools. These content specific outcome measures showed moderate to strong correlation 
with the validated generic outcome measures of Global Quality Score, LIDA and DISCERN. This 
provides further evidence that the use of these CRC screening specific outcome measures provide 
meaningful and relevant information. The advantage of the Global Quality Score over LIDA and 
DISCERN is that it is short and easy to perform. We believe that the Global Quality Score is a good 
score for overall flow and ease of use of any website providing health information. 
This is to our knowledge the first review that systematically assessed the quality, accuracy and 
readability of patient-oriented websites on CRC screening as well as polyp surveillance. Previous 
studies have reported on the quality of web-based information regarding CRC surgery or treatment 
but none were systematic reviews of existing websites23•28•29• Two other publications evaluated CRC 
screening websites but these did not include detailed information on polyps and surveillance30•31 • An 
American study focused on the readability and suitability of 12 CRC screening websites31 • However, 
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these sites were self-chosen by the author. Another brief review examined five chosen websites and 
evaluated their content and usability3°. In both of these publications no apparent selection criteria 
for quality were used. Most of the listed websites did not appear in our original 2014 search results, 
nor in the first three Google pages assessed in 2015 and 2016. 
Our study has some limitations. Both the Website Accuracy Score and Polyp Score were not 
validated separately prior to use on the selected websites. However, the good correlation with other 
previously validated quality instruments suggests adequate content validity. We only searched 
using English search terms thus only English websites were retrieved. Another possible limitation 
is the fact that quotation based search terms were used which require words to appear together in 
retrieved websites. Omission of quotation marks when searches are done could lead to different 
results. 
The internet is increasingly used by consumers to find relevant health information. There is evidence 
that experience and knowledge of Internet use has a significant impact on the uptake of CRC 
screening32• Furthermore, the credibility of cancer-related information on the internet is associated 
with population compliance with CRC screening, indicating the relevance of this study4·32• We 
believe health care providers interested in developing websites on CRC screening, for example for 
their own institutions, can use our approach to evaluate the quality and readability of provided 
information to develop the content of the site they are creating. Alternatively they can provide 
health care consumers to several of the high quality websites, listed in table 4 that we identified. 
Physicians should be aware of the limitation of Google searching for CRC screening. Our study may 
be helpful in that regard as it provides a list of those websites which provide the highest quality 
information on CRC screening. However, it is important to remember that the internet is "a live" and 
that quality of websites may change over time or that new high quality websites may be developed. 
In conclusion, our study showed that there is marked variation in overall quality of web-based 
patient information on CRC screening. Most websites lack important information regarding polyps 
and their importance for future follow up surveillance colonoscopies. Several high quality websites 
do exist but poor correlation with Google ranking suggests that these websites may be missed. High 
quality and readable websites are essential to provide patients with reliable information to make 
informed decisions on CRC screening and surveillance participation and to optimize efficacy. 
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Abstract 
Objective Fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening aims to detect 
CRC in an early stage, thereby reducing morbidity and mortality from this disease. Little information 
is available on the comparison of screen-detected CRC (SD-CRC) and non-screen-detected CRC 
(non-SD-CRC). 
Design Between 2006 and 2014, asymptomatic persons aged 50 to 74 were invited to four biennial 
FIT-screening rounds. CRCs were identified through linkage with the Netherlands Cancer Registry 
and were classified into four groups: SD-CRC, FIT interval cancers, colonoscopy interval cancers and 
CRC in non-participants. The latter three categories represent non-SD-CRC. We compared patient 
characteristics, tumor site, stage and outcome between the four groups. 
Results A total of 27,304 eligible individuals were invited for FIT-screening, of whom 18,716 (69%) 
participated at least once. Of these, 3,005 (16%) had a positive FIT in one of the 4 screening rounds. 
In total, 261 patients developed CRC within the four groups: 116 SD-CRC, 27 FIT interval CRC, 9 
colonoscopy interval CRC, and 1 09 CRC were detected in non-participants. Patient characteristics 
did not differ significantly between groups. SD-CRC, FIT interval cancers and CRC in non-participants 
were mostly located in the distal colon (71 %, 63%, 62%, respectively); while colonoscopy interval 
cancer were more often in the proximal colon (67%; p=0.01). Stage distribution differed between 
the four groups, with more favorable stages in patients with SD-CRC (p<0.001 ), and comparable 
distributions for FIT interval cancer and CRC in non-participants (p=0.39). Patients with SD-CRC and 
FIT interval cancers had a significantly higher survival rate than those with colonoscopy interval 
cancer and non-participants with CRC. 
Conclusion In this FIT-screening program, participants with SD-CRC had more favorable stages and 
a better survival compared to those with interval CRC and to non-participants with CRC. Our results 
support the effectiveness of FIT-screening programs. 
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Introduction 
eolorectal cancer (eRe) is one of the leading causes of cancer-related deaths in the Western World1.2. 
Approximately half of all diagnosed persons will die from the disease3. Survival is strongly related 
to tumour stage at time of diagnosis, with a 5-year survival of 94% for stage I eRe to 8% for stage 
IV eRe3• Population-based screening for eRe aims to detect cancer in an early stage to reduce eRe-
related mortality. 
High participation rates, together with the performance characteristics of a screening test, are crucial 
for screening effectiveness. While colonoscopy is considered the reference standard for detecting 
eRe and advanced adenomas, participation in primary colonoscopy screening is generally low 4•5• 
For this reason, screening with fecal occult blood test (FOBT) as a first-line test is typically preferred, 
as participation rates in FOBT screening are considerably higher1•5•7• Essentially, two types of FOBT 
screening exist; guaiac FOBT (gFOBT) screening and fecal immunochemical test (FIT) screening. The 
latter is gaining popularity, as it has several advantages, such as ease of use and better diagnostic 
accuracyB. 
In contrast with screen-detected eRe (SO-eRe), a proportion of screening invitees are diagnosed 
with eRe outside a screening program: so-called non screen-detected eRe (non-SD-eRe)9 • A part of 
these non-SO-eRe are interval cancers (le), which are defined as cancers detected after a negative 
screening exam and before the date of the next recommended screening9• These cancers can be 
missed by either the primary first- line screening test (e.g. FIT le) or they develop after a negative 
colonoscopy, following a positive FIT test (colonoscopy interval cancer within a FIT screening 
program)9 . The remaining part of non-SO-eRe are among those who did not participate in screening. 
Monitoring the incidence of non-SO-eRe, especially le, is a crucial part of the evaluation of any 
eRe screening program, and is an indicator of program sensitivity. Previous studies involving gFOBT 
screening have shown better survival rates of participants with screen-detected eRe, compared 
to those with interval cancers10• Only very limited data exist on cancers in FIT-based screening 
programs, following participants and non-participants over a longer follow up period. 
The aim of our study was to compare patient demographics, tumor site, stage and survival between 
patients with SO-eRe and non-SO-eRe in a population-based FIT screening program. 
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Methods 
Population and design 
Since 2006, two pilot programs of biennial FIT-based CRC screening have been conducted in the 
southwest and northwest regions of the Netherlands. Those two cohorts were combined for a 
fourth round of screening in 2014. Details about the design of these CRC screening programs have 
been reported previously11•12• In short, demographic data of all invitees between 50 and 74 years 
living in the target areas were obtained from municipal population registers. For the southwest 
region, random samples were taken from the target population by a computer-generated algorithm 
(Tenalea, Amsterdam, The Netherlands). In the northwest region random samples of selected postal 
code areas were taken. No national screening program had been implemented at the start of this 
pilot-program, and thus the target population was screening-naive when first contacted. In the 
Netherlands, a national FIT-based CRC screening program was gradually initiated from January 2014 
onwards. Invitees for our cohort were not invited for the national program. Selected persons were 
invited for each consecutive round, except for those who had moved out of the area, those that had 
passed the upper age limit, institutionalized people, invitees unable to give informed consent, and 
those who had tested positive in a previous screening round. In our information leaflet, persons 
with a history of inflammatory bowel disease or CRC were asked not to participate CRC screening. 
Participants reporting a colonoscopy in the past 2 years during intake after a positive FIT were 
excluded from further participation and those with an estimated life expectancy of less than 5 years. 
Characteristics 
Date of birth, sex, and postal codes of all invitees were collected from the municipal population 
register. Socioeconomic status was based on the "social status scores" that are available through 
the Netherlands Institute of Social Research (www.scp.nl). The social status score of a postal code 
area was derived from the unemployment rate, educational level, average income and position on 
the labor market. The standard deviation (SD) in the Netherlands in 2006 (start of pilot) was 0.96. 
Socioeconomic status was divided into three categories based on this SD into high, average and low 
SES. The first available postal code of the invitee was used to categorize invitees. 
Invitations and stool tests 
Since 2006, a FIT and an invitation letter were sent to invitees by postal mail biennially. Due to 
organizational and logistic issues the time interval has fluctuated between rounds (median time 
between invitations was 2.37 years; IQR 2.01 to 2.76). Invitations were sent between June 2006 and 
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December 2014 (first round June 2006-February 2007; second round August 2008-June 2009; third 
round February 2011 -February 2012, fourth round March 2014-December 2014). The FIT could be 
returned by (free) postal mail. Two different brands of stool tests were used in our dynamic cohort. 
In the first, second, and third round all invitees received an OC-sensor (Eiken Chemical Co, Tokyo, 
Japan). In the fourth round (executed between March 2014 and February 201 5), all invitees were 
randomly allocated to receive either an OC-Sensor or an FOB Gold (Sentinel Diagnostics SpA, Milan, 
Italy). 
Fecallmmunochemica/ Test 
A single FIT was sent to the screenee. Returned FITs were handled by one of two specialized 
laboratories. A hemoglobin value of 10 11g Hb/g feces was used as the positivity threshold; this 
corresponds to 50 ng/ml buffer for OC-Sensor and 58 ng/ml buffer for FOB-Gold. Actual FIT levels 
were recorded for all participants, in each round. 
Test results 
Screenees were informed about their test result by postal mail within 2 weeks. 
Screenees with a negative test result received a letter explaining that no blood had been detected 
in the stool sample and no follow-up was needed at that time. It was emphasized that the FIT is not 
100% sensitive and that vigilance for symptoms of CRC remained important. They were instructed 
to contact their general practitioner in case of symptoms, despite of the negative test result. 
Screenees with a positive test result were invited for a consultation at the outpatient clinic to discuss 
the test result and follow-up. In the absence of contra-indications and after informed consent, a 
colonoscopy was scheduled, within 2 weeks of the consultation. A colonoscopy was not advised if 
the colon had been imaged two years ago or less (colonoscopy or CT-colonography), in case of a life 
expectancy of less than 5 years, or severe co-morbidity. 
Follow-up colonoscopy and colorectallesions 
The colonoscopy was performed according to the international quality guidelines and all quality 
parameters were collected in a database [1 3]. Advice regarding surveillance colonoscopy after 
removal of adenomatous polyps, large (;;:: 10 mm) serrated lesions or cancer was given to the client 
according to the Dutch CBO consensus14 • Screenees with a negative colonoscopy were notre-invited 
from the population screening program until 10 years later. Data on the location, size, macroscopic 
aspects, morphology, as well as details on the technique for polypectomy and endoscopic 
assessment of radicality were recorded for all colorectal lesions detected during colonoscopy. 
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Collected lesions were evaluated by an experienced gastrointestinal pathologist, using the Vienna 
criteria 15• Cancers were staged according to the 7th edition of the American Joint Committee on 
Cancer classification 16. 
Screen detected cancers, non-screen detected cancers and reference population 
Afterfinishingthefourth round in December2014, the cohort was linked to the Dutch Comprehensive 
Cancer Centre for data between May 2006 and March 2015. Data on tumor stage, location and 
survival were collected for all CRC cases. All persons identified with CRC were categorized into 
groups as defined by Sanduleanu et al9 (Table 1 ). The proportion of FIT interval cancer was calculated 
by dividing the number of FIT interval cancers by the sum of SD-CRC and FIT interval cancers. 
Persons with CRC detected at a scheduled surveillance colonoscopy and CRC occurring in patients 
with a positive FIT who did not undergo a subsequent colonoscopy ( due to refusal), are reported 
separately. The median time between invitations (2.37 years; IQR 2.01-2.76) was used as a cut-off 
to categorize patients w ithin the FIT interval cancer category. If a patient developed a CRC within 
this interval, after a negative FIT, but was not (yet) invited for a consecutive round (having passed 
the upper age limit, or moved out of the area), the patient was categorized as having a FIT interval 
cancer. As a reference group we used all individuals diagnosed with CRC in the Netherlands during 
the same time period, and in the same age range (50-76 years), in that part of the population which 
had not been offered CRC screening. The upper range of 76 years was chosen based on the median 
time between invitations and the upper age limit for eligibility (74 + 2.37 years). The data on our 
reference group and on non-participants (since there was no informed consent) were anonymously 
analyzed and delivered by the Dutch Comprehensive Cancer Centre. Data on follow-up time, in days 
after diagnosis, and SES were not available for these groups. 
Data-analysis 
Tumor location was categorized as either distal to the splenic flexure or proximal (splenic flexure 
and proximal). Median follow up time was calculated from date of diagnosis to death or considered 
censored at the end of follow-up (31 March 2015). Separately, survival curves were estimated for 
patients with SD-CRC, FIT interval cancers, and post-colonoscopy cancers. Differences in proportions 
between groups were evaluated for statistical significance using the x2-test statistic. The log-rank 
test statistic was used comparing survival curves. P-values <0.05 were considered statistically 
significant differences. Data analysis was performed using SPSS 23 for Windows (Chicago, Ill). 
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Ethics approval 
Ethical approval for the study was provided by the Dutch National Health Council (WBO 2642467, 
2832758, 3049078 and 161536-112008, The Hague, The Netherlands). 
Table 1. Definitions of cancers. 
Terminology 
SD-CRC 
non-SD-CRC 
Reference 
Results 
Definition 
Screen-detected colorectal cancer defined as CRCs detected at colonoscopy following a positive 
FIT result 
Non screen-detected colorectal cancer defined as all CRCs that were not diagnosed at a 
colonoscopy following a positive FIT result an divided into three groups: 
1. FIT interval cancer defined as cancers diagnosed between screening rounds after negative 
FIT before the next FIT was due 
2. Colonoscopy interval cancer defined as cancers diagnosed after negative colonoscopy after 
a positive FIT w ithin the surveillance interval 
3. Colo rectal cancer in non-participants defined as cancers diagnosed in those who never took 
part in CRC screening 
The reference group was defined as all patients diagnosed with CRC in the Netherlands 
population during the same time period and in the same age range (50-76 years), that were 
not offered CRC screening. 
Patient demographics and colorectal cancers 
A total of 27,304 people were eligible for FIT-screening, of whom 18,716 (69%) participated at least 
once; 8,588 (31 %) never participated (Figure 1 ). Among participants, 3,005 (16%) had a positive FIT 
in one of the 4 screening rounds. Colonoscopy was performed in 2,762 of these (92% adherence). 
Over four rounds of population-based FIT screening, CRC was diagnosed in 160 (0,9%) participants, 
with 73% being SD-CRC, 24% being FIT interval cancer or colonoscopy interval cancer, 3% being 
CRCs in FIT positive persons not adhering to colonoscopy and 2% being survei llance detected CRCs. 
Among non-participants, 109 (1.3%) CRCs were diagnosed. 
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Invitees for FIT 
screening 
N=27,304 
II 
Participants Non-participants 
n=18,716 (68.5%) n=8,588 (31.5%) 
I FIT positive no 
- colonoscopy n= 5 
FIT negative FIT positive 
Surveillance n=15,711 n=3,005 -
detected carcinoma 
I I n=3 
FIT interval Screen -detected Colonoscopy CRC in non 
carcinoma cancer interval carcinoma participants 
n=27 n=116 n=9 n=109 
Figure 1. Flowchart of the 4 rounds of FIT-based CRC screening including screen-detected and non-screen-detected co/orectal 
cancers among participants (participating at least once) and non-participants (never participated). 
In our cohort, 269 patients were diagnosed with CRC, of which 116 (43%) were SD-CRC and 145 
were non-50-CRC. The latter group was made up by 27 (1 0%) FIT interval CRC, 9 (3.3%) colonoscopy 
interval CRC, and 109 (41 %) CRC detected in non-participants. Three CRCs were detected at 
scheduled surveillance (1.1 %) and five (1.9%) in patients not undergoing a colonoscopy after a 
positive FIT. These eight tumors were excluded from our further analyses. The FIT interval proportion 
was 19% (FIT interval cancers divided by the sum of FIT interval cancer and SD-CRC). 
Table 2 .Characteristics of patients with screen-detected CRC, non-screen-detected CRC and the reference group. 
Screen- Non-screen-detected CRC Reference 
detected group 
CRC 
SD-CRC FIT interval Colonoscopy CRC in non- p-value 
cancer interval cancer participant 
(n= 116) (n=27) (n=9) (n= 109*) n=72612 
Age at diagnosis(%) 0.831 
50-59 28 (24) 6 (22) 1 (11) 21 (19) 14651 (20) 
60-69 so (43) 11 (41) 6 (67) 49 (45) 31868 (44) 
>70 38 (33) 10 (37) 2 (22) 39 (36) 26093 (36) 
Sex(%) 0.709 
Male 73 (63) 16 (59) 4(44) 69 (63) 42486 (59) 
Female 43 (37) 11 (41) 5 (56) 40 (37) 30126 (42) 
SES score (%) 0.763 
Low 13 (1 1) 2 (7) 2 (22) N.A. 
Average 82 (71) 21 (78) 6 (67) N.A 
High 21 (18) 4 (15) 1 (11) 
*4 casus with 2 incidents, age at diagnosis first incident selected 
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Table 2 summarizes the characteristics of SD-CRC and non-SD-CRC separately. No significant 
differences were found regarding age at diagnosis between screening participants with SD-CRC 
and persons diagnosed with non-SD-CRC (p=0.83); most patients were diagnosed within the age 
group of 60-69 years. No gender differences were seen between the groups (p=0.71) with higher 
CRC rates in men in all groups: 63% males in the SD-CRC group, 59% in the group with FIT interval 
cancers, and 63% in the non-participants with CRC. Though more women than men were diagnosed 
with a post-colonoscopy interval cancer (44% versus 56%), this difference was not significant. There 
were also no significant differences in SES among the groups (p=0.76). The age and sex distribution 
was comparable with that of the reference population (no tested for statistical significance). 
Tumor location and stage distribution 
Tumor location and CRC stage distribution are described in Table 3. Screen-detected CRC, FIT 
interval cancers and CRC in non-participants were mostly located in the distal colon (71 %, 63%, 
62%, respectively), whereas colonoscopy interval cancers were more often located in the proximal 
colon (67%; p=0.063). 
Table 3. Tumor location and stage distribution of CRC in patients with screen-detected CRC, non-screen-detected CRC and the 
reference group. 
Screen- Non-screen-detected CRC Reference 
detected group 
CRC 
SD-CRC FIT interval Colonoscopy CRC in non- p-value 
cancer interval cancer participant 
(n= 116) (n=27) (n=9) (n= 109*) n=72612 
Tumor location* 
Proximal 34 (29) 10 (37) 7 (78) 38 (35) 23976 (33) 
Distal 82 (71) 17 (63) 2 (22) 67 (62) 0.063 47290 (65) 
Unknown 0 (0) 0 (0) 0(0) 4 (4) 1346 (2) 
Stage 
I 60 (52) 8 (30) 2 (22) 17 (16) 14002 (19) 
II 16 (14) 6 (22) 0 (0) 31 (29) <0.001 18384 (25) 
Ill 37 (32) 9 (33) 1 (11 ) 36 (33) 21819 (30) 
IV 3 (3) 4 (15) 6 (67) 23 (21) 16909 (23) 
Unknown (O) (O) 0 (O) 0(0) 2 (2) (1498 (2) 
• proximal (=splenic flexure and proximal) 
The stage distribution differed significantly between the four groups, with more favorable stages in 
patients with SD-CRC (p<0.001 ). Stage distribution was similar for patients with FIT interval CRC and 
for non-participants with CRC (p=0.39). There was a statistically significant difference between FIT 
interval cancers and SD-CRC (p=0.01 9). 
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All-cause mortality and 3-years survival 
All-cause mortality rates were significantly lower for patients with SD-CRC and those with FIT interval 
cancers compared to non-participants, and patients with colonoscopy interval CRC (p<0.001; Table 
4). 
Table 4. All-cause mortality of patients with screen-detected CRC, non-screen-detected CRC and the reference group. 
All-cause mortality 
Follow-up (months, IQR)* 
* follow ·up after the diagnosis of CRC 
Screen-
detected 
CRC 
SD-CRC 
(n= 116) 
13 (11) 
50 (25-76) 
Non-screen-detected CRC 
FIT interval Colonoscopy CRC in non-
cancer interval cancer participant 
p-va lue 
(n=27) (n=9) (n=109*) 
5 (1 9) 5 (56) 44 (40) <0.001 
40 (15-63) 19 (9-30) 
Reference 
group 
n=72612 
25221 (35) 
Survival in the reference group ofCRC cases was most similar to survival observed in non-participants. 
Median time after diagnosis for SD-CRC, FIT-interval cancers and for colonoscopy interval cancers 
was 46.1 months (IQR 18,1 -72,1 ). No follow-up time could be calculated for our reference group or 
for non-participants, since only year of diagnosis was provided and not the exact date of diagnosis. 
There was a significant difference in survival between SD-CRC, FIT interval cancers, and colonoscopy 
interval cancers with a worse outcome for colonoscopy interval cancers (p<0.001 ; Figure 3). 
100 
0 10 20 
Follow-up (months) 
30 
p<O.OOl 
40 
screen-detected 
carcinoma 
- FIT interval carcinoma 
post-colonoscopy 
interval carcinoma 
Figure 3. Cumulative survival of screen-detected carcinomas, FIT interval carcinomas and post-colonoscopy interval carcinoma. 
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Discussion 
The results of this study support the effectiveness of FIT-based screening program as SD-CRC were 
diagnosed in an earlier stage than non-SO-CRCs. Furthermore, FIT interval cancer proportion was 
low when using a low cut-off in FIT-based CRC screening with better survival than the population 
that was not offered screening. 
We are the first to describe interval cancers in a FIT-based screening program with long-term follow-
up. Our cohort consists of an average-risk population, comprising all age ranges commonly invited 
for CRC screening programs worldwide. This population was screen-naive when first approached, 
without the presence of any other CRC screening initiatives in the population. All data were 
prospectively collected and all invitees were linked to the Netherlands Cancer Registry by the Dutch 
Comprehensive Cancer Centre to identify all non-SO-CRC. Since 1989, the Netherlands Cancer 
Registry registers all patients diagnosed with cancer in the Netherlands and provides a unique and 
fully covered database. 
To fully appreciate our findings, some limitations also need to be addressed. Little information 
was available about non-participants developing CRC in our cohort because these data had to 
be delivered anonymously for privacy reasons. Their socioeconomic status could not be assessed. 
Previous studies have shown that especially socioeconomically deprived persons are less likely to 
take part in CRC screening though they presumably are at a higher risk of developing CRC due to 
poor general health 17•18• Also the date of diagnosis could not be related to the date of invitation. It is 
possible that a person was already diagnosed with CRC prior to being invited for screening. In such 
case, refraining from participation would be a justified decision. 
Although gFOBT screening has been shown to reduce mortality rates19, high proportions of gFOBT 
interval cancers have been reported, ranging from 48o/o to 55%20-23• Since FIT is more sensitive in 
detecting advanced neoplasia than gFOBT, one would expect lower interval rates for FIT. A previous 
Scottish FIT-based study, however, reported a FIT interval proportion of 51 o/o using a cut-off of 80 
11g Hb/g feces24• This FIT interval proportion was calculated as the number of FIT interval cancers 
divided by the sum of FIT interval cancer and SD-CRC. We found a much lower proportion of FIT 
interval cancers (19o/o), which could be explained by the substantially lower positivity cut-off (1 0 
11g Hb/ g feces) in this cohort. Zorzi et al. reported a comparable FIT interval cancer proportion of 
lSo/o using a cut-off of 20 11g Hb/g feces25• The Scottish study investigated the effect of different 
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cut-off levels of fecai-Hb on interval cancer proportions, and colonoscopy demand It reported an 
interval cancer proportion of 51 o/o at a cut-off of 80 ~g Hb/g feces versus a proportion of 38% using 
a cut-off of 10 ~g Hb/g feces with a significant increase in number of required colonoscopies for the 
latter cut-oft24• Hence, choosing a very low positivity cut-off leads to a higher number of SD-CRC 
and lower proportion of FIT interval cancer but at the cost of increased colonoscopy demand and 
increased numbers false positives24• 
Our results showed no evidence for gender differences in interval cancer rates, while previous 
studies have shown higher rates of interval cancers among women 22•25.27• As in other studies, women 
in our cohort were less likely to be diagnosed with CRC, but women were more often diagnosed 
with a post-colonoscopy interval cancer than men (44% versus 56%). Though actual numbers were 
small, and this difference did not reach significance. Our results are in line with a Spanish study, 
reporting SD-CRC and interval cancers during four rounds of FOBT screening using mainly gFOBT 
and a small portion FIT 23. Digby et al. also did not observe a significant difference in gender for FIT, 
but suggested a trend towards higher rates of FIT interval cancers in women24•26• 
Previous gFOBT-based studies have shown an increase in the detection of earlier stages of CRC in 
screening, resulting in an overall improvement in survival for individuals diagnosed with SD-CRC 
compared to non-SD-CRC10•19•20•28 • Our study showed that SD-CRC were most likely to be stage I, with a 
high survival rate, compared to non-SD-CRC, which confirms the findings of previous studies10•23•26•29• 
Next in our FIT-based program a higher percentage of stage I CRC were found than in previously 
reported gFOBT screening programs. This could be possibly be explained by the use of a relatively 
low cut-off for FIT. Comparable early stage distributions in FIT screening have been reported24•28• 
Regarding location of the cancers, most tumors were located distally, except for colonoscopy 
interval cancers, which were mainly located in the proximal colon. These findings are in line with 
previous studies23•30• FIT does not seem to be less sensitive for FIT interval cancers in our cohort. 
As SD-CRC are often asymptomatic and detected at an earlier stage, it could be expected that the 
outcome in these patients is better than patients with symptomatically diagnosed CRC (i.e. the 
reference group). This is known as the lead-time effect31• In contrast to previous literature which 
reported that prognosis of non-participants with CRC is actually poorer than that of patients with 
symptomatically diagnosed CRC, we observed that patient demographics, tumor location, tumor 
stage distribution, and survival rates of cancers arising were comparable between non-participants 
and the reference group11• Survival was significantly better in participants with FIT interval cancers 
than in non-participants with CRC. This is in contrast with findings of an English study that reported 
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similar outcomes for gFOBT interval cancers and a control group22• A possible explanation for this 
difference in outcome is the use of FIT (rather than gFOBT) and the use of a low cut-off. The better 
survival of FIT interval cancers compared to non-participants and the reference group, implicates that 
the theoretical risk of persons seeking delayed medical consultation in case of the development of 
abdominal symptoms due to (false) reassurance caused by a recent negative FIT result, fortunately, 
seems to have no immediate negative effect on all-cause mortality within our cohort. Nevertheless, 
these findings should be interpreted with caution since in theory FIT-participants could have been 
in better health than the reference group resulting in a selection bias. 
In our cohort, nine colonoscopy interval cancers were detected. As a proportion (0.32%), this 
is comparable to a recently published FIT-based study, reporting a rate of 0.31%29• In those nine 
persons, the performed colonoscopies were reported as having been complete with cecal 
intubation. In 6 cases sufficient bowel preparation was reported, in 3 cases this data was missing. 
Three patients received a colonoscopy surveillance advice but developed a CRC within this interval. 
One person received the advice of a 1 year surveillance interval, 1 person a 3 year interval and 1 
person a 6 years interval. Six patients were discharged from screening for 10 years as per protocol. As 
most colonoscopy interval cancers were detected in the proximal colon (78%), we should consider 
procedural factors, especially missed lesions (for instance due to inadequate bowel preparation). 
As both FIT interval cancers but also colonoscopy interval cancers within a FIT screening program 
are important for the quality and success of a screening program, both should be carefully 
monitored. Since the implementation of the national FIT-based CRC program in the Netherlands, a 
specialized clinical IT system has been developed to register, monitor and audit all quality indicator 
for colonoscopy according to the international quality guidelines 13• All endoscopists performing 
endoscopies for our CRC screening need to be accredited. All these measures have been made 
to further improve quality of bowel cancer screening in order to reduce the number of post 
colonoscopy interval cancers and complications. 
Five patients who did not want to undergo a colonoscopy after a positive FIT developed a CRC. 
Unfortunately, no information about their reason for refusal is available. To reduce these CRCs, 
additional strategies should be developed, to inform patients about the need for follow-up after 
a positive FIT. Modifiable determinants for non-adherence to endoscopy, such as embarrassment, 
lack of knowledge about CRC, fear of the procedure, or inconvenience should be discussed. Other 
strategies could be built on sending all non-respondents after a positive FIT result an additional 
information leaflet, or to offer them a consultation by phone. 
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In conclusion, our results show that survival in patients with FIT interval cancers in a population-
based CRC screening program is better than in clinical CRC patients outside a screening program. 
For non-participants with CRC survival is more comparable to that of the reference population. 
Among all CRCs, post-colonoscopy interval cancers had the worst outcome, which stresses the need 
for insuring best quality colonoscopy according to the most recent quality guidelines. Overall, our 
results support the effectiveness of FIT-screening programs. 
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Abstract 
Background and study aims The worldwide implementation of colorectal cancer (CRC) screening 
programs has led to an increased detection of early CRC. There is limited literature available on 
the prevalence of early CRCs in average CRC screening populations that can be curably resected 
by endoscopy (T1 ). We assessed the prevalence of patients with histological proven T1 colorectal 
carcinomas (pT1 CRC) in our screening cohort and how they were treated in current practice. 
Additionally, we assessed if histopathologic criteria for complete endoscopic resection were met 
according to the Dutch guidelines. 
Patients and methods A random sample of 1 7,614 persons from the general Dutch population, 
aged 50-74 years, were invited to participate in a FIT-based CRC screening program. Participants 
with a positive test were referred for colonoscopy. In accordance with the guidelines, T1 CRCs 
were considered amiable for endoscopic resection in case the tumour was good or moderately 
differentiated and there was no lymphovascular invasion present. Complete RO resection was 
achieved if all resection margins were ~ 1 mm free from cancer. 
Results CRC was detected in 86 subjects, of which 28 (33%) were diagnosed with pT1 CRC. Eighteen 
(64%) individuals with T1 CRC received endoscopic resection as initial treatment and ten (36%) were 
directly referred for surgery. In addition, nine patients underwent a surgical operation subsequent 
to endoscopic resection. Tumour morphology was significantly different between T1 CRCs initially 
treated by endoscopy (pedunculated) and those that were directly referred for a surgical operation 
(sessile), p=0.02. Of all 28 T1 CRCs, histopathology showed poor differentiation grade in one (4%) 
T1 CRC, lymphovascular invasion in two (7%). Endoscopic RO resection was achieved in 33% (6/1 8). 
Histopathologic criteria for curable endoscopic resection were met in 28% (5/1 8). 
Conclusions A substantial proportion of CRCs detected in a FIT-based CRC screening is a pT1 CRC 
and, according to the guidelines, amiable for endoscopic resection. In current practice, the majority 
of pT1 CRCs is eventually treated by surgical resection due to various reasons. The endoscopic 
approach to CRC should balance surgical morbidity against the potential benefits of endoscopic 
resection. Effort should be made to improve awareness of screening endoscopists to completely 
resect T1 CRCs. 
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Introduction 
The worldwide implementation of colorectal cancer (CRC) screening programs has led to an 
increased detection of CRC in early stages of the disease1•2• Early-stage CRCs (Tl) are observed 
more often in patients who participate in a CRC screening program than in symptomatic patients3·5• 
Although screening endoscopists are increasingly confronted with Tl colorectal carcinomas, the 
visual distinction at colonoscopy between these early CRCs and non-malignant adenomas remains 
challenging 6. 
A radical endoscopic resection is a curative treatment for patients with an early CRC that is limited 
to the upper third of the submucosa (Tl) and with no additional histopathological risk factors for 
lymph node metastasis7• In case unfavourable histopathologic features, such as poor differentiation 
grade of the tumour and/or lymphovascular invasion, are present in the tumour, additional surgery 
is still required8•9• However, information concerning these histopathological features is lacking at the 
time of the colonoscopy procedure. Therefore, intention to perform a radical endoscopic resection 
of the lesion is needed and could prevent patients from additional surgery. 
Endoscopic resections by endoscopic submucosal dissection (ESD) and endoscopic mucosal 
resection (EMR) have emerged as curative and minimal invasive alternatives to surgery in selected 
cases with Tl colorectal carcinomas. Minimization of invasive procedures is of crucial importance 
in screening programs, as screening involves healthy subjects. Though, safety of the endoscopic 
procedure is another important outcome parameter since endoscopic resections have been 
associated with risks of serious complications and recurrence 10• Therefore, the endoscopic approach 
to invasive Tl colorectal carcinomas must balance surgical morbidity against the potential benefits 
of endoscopic resection. International guidelines recommend to consider ESD for endoscopic 
removal ofTl carcinomas, particular for those larger than 20 mm11•12• ESD enables endoscopists to 
achieve en bloc resection regardless of the tumour size whereas EMR is only deemed suitable for 
en bloc resections of lesions ~20 mm. However, ESD is technically demanding and associated with 
higher complication rates than EMR13•14• 
There is limited literature available on the prevalence of Tl colorectal carcinomas in average CRC 
screening populations that can be adequately resected by endoscopy according to guidelines and 
how these lesions are treated in current practice. Our CRC screening program consists of a large 
cohort with data from four rounds of biennial faecal immunochemical test (FIT)-based screening. 
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First, we assessed the prevalence of patients with histological proven T1 colorectal carcinomas (pT1 
CRC) in our cohort. Secondly, we assessed the endoscopic aspects of these cancers and how they 
were treated. Thirdly, we estimated if patient characteristics or tumour aspects were associated with 
the initial choice of endoscopic or surgical treatment. Finally, we assessed if histopathologic criteria 
for complete endoscopic resection were met in these pT1 CRCs according to the guidelines. 
Methods 
Study design and population 
Data was available from four biennial rounds of faecal immunochemical test (FIT)-based CRC 
screening in a formerly screening-na·ive Dutch population. Details of the study have been 
published before15•16 . In total, 17,614 subjects (aged 50 to 74 years) were randomly invited once 
or more between November 2006 and October 2014. In each screening round invitees were asked 
to perform one- or two-sample FIT (OC -Sensor Micro, Eiken Chemical, Japan).[15,16] Participants 
were referred for colonoscopy in case of at least one positive test using a cut-off of ~ 50 ng/ml, 
which corresponds to ~1 O!Jg haemoglobin (Hb) per gram faeces. Exclusion criteria were a history 
of inflammatory bowel disease or CRC, an estimated life expectancy of less than five years, and if 
the individual underwent a colonoscopy, sigmoidoscopy or barium contrast enema in the last three 
years.[15] The original studies were approved by the Dutch Ministry of Health (PG/ZP 2.727.071, 
PG/ZP 2.823.158). All screenees gave written informed consent. For the purpose of the present 
study, all patients diagnosed with a pT1 CRC were included, based on the pathology reports of the 
resected surgical and endoscopic specimen. Interva l carcinomas were not taken into account. Data 
were retrieved from medical records, colonoscopy-, and pathology reports to assess tumour size, 
morphology, location, histopathologic features, and endoscopic resection techniques used. 
Treatment guidelines and definitions 
Dutch guidelines were followed for treatment recommendations. These guidelines are comparable 
to those of the American Society for Gastrointestinal Endoscopy (ASGE).[17,18] Definitions were 
based on the 2011 TNM (Tumour Node Metastasis) classification and Vienna classification.[19,20] 
T1 CRCs were defined as CRCs confined to the submucosa, without invasion of the muscularis 
propria or deeper wa ll.[21] CRC in situ, which comprises a lesion restricted to the epithelia l layer, 
was not considered as T1 CRC, but as non-invasive high-grade dysplasia (stage 0). 
In case an RO resection was performed in aT1 CRCwithfavourable histologicfeatures, thetumourwas 
considered curatively resected by endoscopy. Complete RO resection was achieved if all resection 
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margins were ;::::1 mm free from cancer17• Unfavourable histopathologicfeatures of malignant colonic 
polyps included, poorly differentiated histology and/or lymphovascular invasion. According to the 
guidelines additional surgery is warranted if unfavourable histopathologic features are present in 
the tumour and/or resection margins were not free of tumour. Morphology of the pT1 CRC was 
described according to the Paris classification: pedunculated, sessile, slightly elevated, flat, slightly 
depressed or excavated22• Location of the pT1 CRC was considered proximal or distal according to 
the location with respect to the splenic flexure. 
Statistical analysis 
Comparisons of continuous variables were performed using the Mann- Whitney U-test. Categorical 
variables with two or more categories were compared by using the x2 test. All p-values were two-
sided and considered significant if p<O.OS. 
Results 
In total, 9,327 eligible subjects participated at least once in four rounds of a one- or two-sample 
biennial screening. From the 2,280 participants that had a positive FIT in one of the four rounds, 
2,117 (93%) underwent colonoscopy. Overall, colorectal cancer was detected in 86 subjects, of 
which 28 (33%) patients were diagnosed with a pT1 CRC. 
Table 1./nitia/ treatment displayed per patient characteristics and endoscopic aspects ofT7 carcinomas. 
Initial endoscopic resection Initial surgical resection p-value 
(n=18) (n=10) 
Patient characteristics 
Sex, male (n, %) 14 (78) 6 (60) 
Age, > 60 years 12 (67) 8 (80) 0.45 
Endoscopic aspects 
Tumour locat ion proximal (n, %) 2 (11 ) 4 (40) 0.74 
Tumour s ize~ 20 mm (n,%) 3 (17) 5 (SO) 0.06 
Tumour morphology (n, %) 
Sessile 3 (17) 5 (SO) 
Pedunculated 10 (56) 0 
Flat 1 (6) 0 0.02 
Unknown 4 (22) 5 (SO) 
Total adenomas per patient > 2 (n, %) 7 (39) 4(40) 0.95 
Ill 
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sEndoscopic aspects at initial colonoscopy of pT7 colorectal carcinomas 
Polyp morphology was described as pedunculated in ten (36%) T1 CRCs, sessile in eight (29%), flat in 
one (4%) and in nine (32%) T1 CRCs no polyp morphology was reported. Mean size as measured by 
the endoscopists of all T1 CRCs was 16 mm (range 4-40 mm). Median number of adenomas in patients 
with a T1 CRC was two, ranging from one to 49 adenomas. This latter patient with 49 adenomas was 
diagnosed with familial adenomatous polyposis (FAP). Of all 28 pT1 CRCs, seventeen (61 %) were 
located in the sigmoid, four (14%) were located in the rectum, four (14%) in the ascending colon, 
two (7%) in the cecum, and one (4%) in the descending colon. 
Resection of pT7 colorectal carcinomas 
In total, nineteen (68%) of all 28 patients with a pT1 CRC had eventually undergone a surgical 
operation. Eighteen (64%) patients were initially treated by endoscopy and ten (36%) were directly 
referred for surgery (Figure 1). 
Tl carcinomas 
n=28 
I 
I 
Endoscopic resection 
n= 18 
Surgical resection 
n= 10 
I 
- EMR n=14 
- ESD n=2 
- not described n=2 
I 
Additional endoscopic 
biopsy 
n=2 
I 
Additional surgery 
n=9 
I 
-sigmoid resection n=S 
-rectum resection n= l 
-right-sided hemicolectomy n=2 
- rectosigmoid resection n= l 
Figure 1. Resection techniques used in pTl colorectal carcinomas. 
I 
-sigmoid resection n=4 
-rectum resection n=l 
- right-sided hemicolectomy n=3 
- lower anterior resecton n= l 
-subtotal colectom with 
ileorectal anastomosis n=l 
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Tumour morphology was significantly different between T1 CRCs initially treated by endoscopy 
and those that were directly referred for a surgical operation, p=0.02, Table 1. In T1 CRCs initially 
resected by endoscopy, polyp morphology was pedunculated in 56%, flat in 6%, sessile in 3%, and 
polyp morphology was not reported in 22%. In those referred for surgical resection, none were 
pedunculated or flat, 50% was sessile, and in 50% polyp morphology was not reported. Of the 
eighteen pT1 CRC for which an endoscopic resection was performed, 17% had a diameter~ 20 mm 
compared to 50% in those initially treated by surgery, p=0.06. The choice between an endoscopic 
or surgical resection was not significantly different for males or patients > 60 years compared to 
females and patients < 60 years of age (p=0.32 and 0.45; Table 1 ). 
In thirteen (46%) carcinomas of all patients with a pT1 CRC, a malignancy was correctly suspected by 
the endoscopist based on the endoscopic appearance of the lesion at initial screening colonoscopy. 
In the other fifteen (54%) patients the lesion was removed without any suspicion of a malignant 
polyp. Patients with lesions in which the malignancy was correctly identified as a T1 CRC at 
colonoscopy underwent significantly more surgical operations as initial treatment (69%) than those 
in which the lesion was not identified as being malignant (7%), p 0.001. 
Endoscopic resection techniques of pT1 colorectal carcinomas 
Endoscopic resections were performed by using various resection techniques including EMR 
and ESD, Figure 1. The endoscopic en bloc resection rate was 94% (17 /18). With regard to the 
endoscopic complication rate, one patient suffered from a colonic perforation subsequent to a 
primary endoscopic resection (ESD), for which a right-sided hemicolectomy was performed. Of all 
patients with a pT1 CRC that were directly referred for surgery, endoscopic biopsy was performed 
at screening colonoscopy to provide histological proof of malignancy in nine out of ten (90%). 
The other patient was diagnosed with FAP at screening colonoscopy and underwent subsequent 
surgery. The resected colon in this patient showed pT1 CRC. 
Histopathologic aspects of pT1 colorectal carcinomas 
Of aii28T1 CRCs, three (11 %) had unfavourable histopathologic characteristics: one (4%) was poorly 
differentiated and two (7%) showed lymphovascular invasion (Table 2). Endoscopic RO resection 
with resection margin> 1 mm free of cancer was achieved in six (33%) of eighteen pT1 CRCs resected 
by endoscopy. Of aiiT1 CRC resected by endoscopy, histopathologic criteria for a curable endoscopic 
resection (RO resection and favourable histopathologic features) were met in 28% (5/ 18). 
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Table 2. Histopathologic characteristics ofT7 carcinomas. 
Differentiation grade (n, %) 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Not described 
Lymphovascular invasion present (n, %) 
Endoscopic resection margins* 
Free >1mm 
Free :5 1 mm 
Not free or could not be assessed 
*Surgical resection not taken into account (n=18) 
Additional surgery 
T1 carcinomas 
(n =28) 
2 (7) 
17 (61) 
1 (4) 
8 (29) 
2 (7) 
6 (33) 
4 (15) 
8 (59) 
Of the eighteen patients with a T1 carcinoma that were initially treated with endoscopic resection, 
additional surgery was performed in nine (SO%) patients, Figure 1. Reasons for additional surgery in 
these patients were R1 resection or resection margin < 1 mm (n=3), histopathologicfeature missing 
(n=3), lymphovascular invasion (n=1 ), and colon perforation (n=1 ). In one patient the reason for 
additional surgery was unclear. 
Discussion 
In our FIT-based CRC screening cohort, one third of all patients with a screen-detected colorectal 
carcinoma had a pT1 CRC. Of these patients, 68% had eventually undergone surgery, either as initial 
treatment or as additional therapy to endoscopic resection. Regarding the endoscopic aspects 
of the pT1 CRCs, we found that all cancers with a pedunculated polyp morphology were initially 
resected by endoscopy, whereas sessile pT1 CRCs were significantly more treated by surgery. Also, 
there was a trend that larger polyps were treated more often by surgery than endoscopic resection. 
Unfavourable histopathologic features (lymphovascular invasion or poor differentiation) were 
found in only 11% of all pT1 CRCs, indicating that a substantial part of patients with these lesions 
could have been prevented from surgery according to the international guidelines. 
In accordance with these guidelines, the initial treatment of choice in practice was endoscopic 
resection in the majority of all patients with a pT1 CRC. Interestingly, surgery was significantly 
more often chosen as initial treatment in patients in which the lesion was correctly identified as 
malignant by the screening endoscopist than in patients in which the lesion was not suspected to 
Endoscopic resection of early colorectal cancer in FIT-screening 1291 
be malignant. Besides histopathological features, other important factors that determine whether a 
lesion can be adequately resected by endoscopy include tumour size, location, and spreading of the 
tumour, which have been associated with difficult endoscopic resections23. In line with literature, 
our results showed that all Tl CRCs with a pedunculated tumour morphology were initially treated 
by endoscopic resection whereas the majority of sessile malignancies were referred for surgical 
resection. This finding suggests that tumour morphology is an important factor in the decision 
making of endoscopists to perform an endoscopic resection or to refer to surgery. Also, there was 
a trend that larger and more proximal located Tl carcinomas were treated more often by primary 
surgery than endoscopic resection. 
In this study, endoscopic resections were performed by EMR in the majority ofTl CRCs. Preferable, 
resections for early-stage neoplasia are performed en bloc as en bloc resections allow full and 
accurate histological evaluation by pathologists and recurrence is less likely than for piecemeal 
resections24•27• Colorectal lesions smaller than 20 mm in diameter and pedunculated polyps 
can be treated effectively and safely by EMR28• ESD is recommended for larger-, flat- and sessile 
lesions11 •27• Although, we showed that en bloc resection rates were high, additional surgery was 
required in a substantial group of patients that were initially treated by endoscopic resection often 
due to incomplete resection margins. This finding underlines the importance of adequate use of 
endoscopic resection techniques. In case limited endoscopic resection techniques are available at 
screening site, referral to specialized hospitals can be considered for early neoplasia's that require 
more advanced resection techniques such as ESD. 
In order to accurately remove early CRC by endoscopy, it is mandatory that endoscopists distinguish 
malignant lesions from benign lesions. Several polyp classification systems have been published to 
identify high-risk polyps by predicting depth of invasion and risk of nodal involvement, such as the 
Kudo classification, the NICE classification and Paris classification22•29•30.ln this study, only half of the 
Tl CRCs were identified as lesions with malignant endoscopic features. This is in line with a recent 
publication, which showed that sensitivity for the diagnosis ofTl CRCs based on endoscopic images 
is poor6• Our finding indicates that effort should be made to increase the awareness of endoscopists 
to identify malignant polyps from benign polyps and carefully consider subsequent resection 
techniques. 
To the best of our knowledge, prevalence and current treatment ofTl CRCs that can be adequately 
treat ed by endoscopy have not previously been evaluated in a screening setting. Strong points 
2921 Chapter 14 
of our study are that the initial study was prospectively designed and that data were available 
from multiple hospitals (secondary, teaching and tertiary), resulting in a reliable reflection of a 
nationwide screening program. The fact that some of these hospitals may have had poor access 
to advanced endoscopic resection techniques, may have influenced the choice of treatment and 
resection techniques used. Thanks to these strengths, our findings provide insight into the current 
practice of identification and endoscopic removal ofTl CRCs in an average screening setting in the 
Netherlands. Our study has some limitations. The main limitation is the small number ofTl CRCs in 
this cohort and future research is needed to confirm our findings in larger screening populations. 
Nevertheless, our study provides a first impression on this subject. Another limitation is the wide 
time frame in which our CRC screening program was implemented. Since endoscopists awareness 
of the identification of malignant polyps and of choosing adequate resection techniques might 
have improved over the years, this could have affected our results. 
In conclusion, a substantial proportion of pTl CRCs detected in a FIT-based CRC screening is amiable 
for endoscopic resection according to the guidelines. In practice, the majority of pTl CRCs is treated 
by surgical resection, either as initial treatment or subsequent to an endoscopic resection. Adequate 
endoscopic resection as approach to invasive Tl CRC must balance surgical morbidity against the 
potential benefits of endoscopic resection. Effort should be made to improve awareness of screening 
endoscopists to identifyTl CRCs and make informed decisions on the resection method used. 
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Abstract 
Background Cecal intubation rate (CIR) and adenoma detection rate (ADR) have been found to 
be inversely associated with the occurrence of post-colonoscopy colorectal cancer. Depicting 
differences in CIR and ADR between hospitals could provide incentives for quality improvement. 
We aimed to compare quality parameters of routine colonoscopies between seven hospitals in the 
Netherlands to determine to what extent possible differences are attributable to procedural and 
institutional factors. 
Methods We prospectively included consecutive patients undergoing colonoscopy between 
November 2012 and January 2013 in two academic and five non-academic medical hospitals. 
Patients with inflammatory bowel disease or hereditary colorectal cancer syndromes were excluded. 
Main outcome measures were CIR and ADR. 
Results A total of 3,129 patients were included (46% male; mean age 59± 15 years). The majority of 
patients (86%) had a Boston Bowel Preparation Scale (BBPS) score ~6. Mean CIR was 95%, ranging 
from 89% to 99% between hospitals (p<0.001 ). After adjustment for casemix (age, gender, American 
Society of Anesthesiologists-score and indication for colonoscopy), factors associated with CIR 
were hospital and a BBPS ~6. Mean ADR was 32% and varied between hospitals, ranging from 25-
47% (p<0.001). Independent predictors for ADR were hospital, a BBPS ~6 and cecal intubation. By 
combining CIR and ADR per hospital we developed a colonoscopy quality indicator (CQI) that can 
be used by hospitals to stimulate quality improvement. 
Conclusion Differences in quality of colonoscopy between hospitals can be demonstrated using 
CIR and ADR. As both indicators are affected by institution and bowel preparation a comparison 
between hospitals based on the newly developed CQI could assist in further improving the quality 
of colonoscopy 
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Introduction 
Screening strategies employing colonoscopy for detection and removal of precursors of colorectal 
cancer (CRC) effectively reduce CRC-related mortalityl·2• Apart from participation grades, the efficacy 
of population-based CRC screening depends on the quality of colonoscopy. 
Colonoscopy quality is ultimately reflected by a reduction in the incidence of CRC following 
colonoscopy. However, measurement of post-colonoscopy CRC (PC-CRC) is cumbersome and 
does not allow direct feedback. Several procedural indicators have been suggested for monitoring 
quality3. Two recent studies have shown that the adenoma detection rate (ADR) of endoscopists 
was inversely associated with the risk of PC-CRC [4,5] and PC-CRC related death.[S] In another 
study, patients dying from CRC had a lower probability of having undergone a previous complete 
colonoscopy than matched controls6. In addition, a substantial proportion of colorectal tumors 
originates from the right sided colon,which underlines the importance of performing a complete 
colonoscopy, as measured by cecal intubation rate (CIR)1. 
ADR and CIR have been reported to vary between hospitals depending on casemix and institutional 
or procedural factors8-10• Casemix is determined by non-modifiable patient characteristics, such as 
age, gender, comorbidity and indication for colonoscopy. In order to provide a useful incentive for 
hospitals to improve quality of colonoscopy, a comparison of CIR and ADR between institutions 
should be able to detect differences that are independently affected by modifiable factors. In this 
study we compared the quality of routine colonoscopy between seven hospitals in the Netherlands 
to determine to what extent detected differences in CIR and ADR were indeed attributable to 
procedural and institutional factors. 
Methods 
Registration of colonoscopy data 
All colonoscopies performed between November 1st, 2012 and January 1Oth, 2013 in two academic 
medical centers and five large non-academic medical hospitals were prospectively registered. 
Patient characteristics, i.e. age, gender and American Society of Anesthesiologists (ASA) score were 
obtained from the electronic medical records. All endoscopists filled out data on the indication for 
colonoscopy, the type and dose of sedation used, quality of bowel preparation, cecal intubation, 
detection and removal of polyps, results from pathology reports and complications. 
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Definitions 
Endoscopists were categorized as gastroenterologists, fellows-in-training for gastroenterology or 
nurse endoscopists. Indications for colonoscopy were grouped into five categories: (1) anemia or 
abdominal symptoms; (2) overt or occult rectal blood loss; (3) screening or a positive family history 
for CRC; (4) surveillance after CRC or colorectal adenoma(s) and (5) other. The latter category 
consisted mostly of patients with liver metastases or other abnormalities found during imaging. 
Patients with inflammatory bowel disease or hereditary CRC or polyposis syndromes were excluded. 
Bowel preparation was scored according to the Boston Bowel Preparations Scale (BBPS). Adequate 
bowel preparation was defined as a BBPS ~6.[11] Sedation was provided using midazolam, propofol 
and/or opioid analgesics. Cecal landmarks were noted in the colonoscopy report; photographic 
documentation was not routinely obtained. The unadjusted CIR was defined as the proportion of 
colonoscopies in which the cecum was visualized, irrespective of reasons for not intubating the 
cecum. The adjusted CIR was calculated by excluding colonoscopies in which the endoscopist made 
the decision not to intubate the cecum because of severe colitis, colonic obstruction or therapeutic 
targets not necessitating cecal intubation.[12] Colonoscopies with poor bowel preparation were 
included in the adjusted cecal intubation rate, as preparation is considered to be part of the 
colonoscopy practice in hospitals. Complications were subdivided into bleeding (only taken into 
account if not stopped spontaneously or by an intervention during the colonoscopy), perforation 
and post-polypectomy syndrome. 
Factors comprised in the term casemix are patients' age, gender, ASA score and indication for 
colonoscopy. Correction for casemix was performed by taking these factors into account when 
analyzing the association of modifiable factors with the CIR and ADR. Modifiable factors were 
institution, i.e. the hospital where the colonoscopy was performed, and procedural factors, 
consisting of the type of endoscopist (gastroenterologists, fellows, nurse endoscopists), use of 
conscious sedation and BBPS score. 
Primary outcomes were unadjusted CIR, adjusted CIR and ADR, defined as the proportion of 
procedures in which one or more adenomas were found. Secondary outcomes were BBPS score, 
mean number of adenomas per procedure (MAP), mean number of adenomas per positive 
procedure (MAP+), and complications. 
We constructed a colonoscopy quality indicator (CQI) by plotting the adjusted CIR and the ADR per 
hospital. The sizes of the dots represent the number of colonoscopies performed in each hospital. 
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The position of each dot can be compared to other hospitals and to predetermined thresholds. For 
the adjusted CIR a minimum of95% is generally accepted3, but there is no unequivocal minimum for 
ADR during routine colonoscopies. Therefore, we chose to draw a line representing approximately 
the average ADR, creating a visual target of performing better than average. 
Statistical analysis 
Data are presented as percentages for categorical variables and means (including standard 
deviation) or medians (including ranges) for continuous variables, according to the nature of their 
distribution. Differences between groups were tested using the chi-squared test for categorical 
variables and the t-test for normally distributed continuous variables. We performed a logistic 
regression analysis to identify factors associated with adjusted CIR and ADR. Factors with a p-value 
<0. 10 in univariable analysis, were included in a multivariable model. A two-sided p-value of <0.05 
was considered statistically significant. Analyses were performed using SPSS 20.0 statistics software 
(IBM, Chicago, Ill.). 
Informed consent 
This study was exempted from patients' informed consent as determined by the Medical Ethical 
Committee of the UMC Utrecht in accordance with the Medical Research Involving Human Subjects 
Act. 
Results 
A total of 3,129 patients underwent colonoscopy during the study period. Mean age was 59 ± 1 5 
years and 46% were male (Table 1 ). In the majority of cases (63%) the indication for colonoscopy 
was anemia or abdominal symptoms. Ninety-one percent of patients had an ASA-score of 1 or 2. 
Conscious sedation was used in more than 90% of cases. Split dose bowel preparation was common 
practice in all 7 hospitals. Gastroenterologists performed most colonoscopies (60%), followed by 
gastroenterology fellows (24%). The number of colonoscopies per hospital ranged between 1 24 
and 793 (median 421 ). 
Eighty-six percent (n=2,697) of all procedures were performed in adequately prepared colons, with 
a median BBPS of 9 (interquartile range 6- 9) (Table 2). The unadjusted CIR was 95%. Reasons for not 
intubating the cecum were inadequate preparation (n=58, 36%), stenosis (n=35, 22%), technical 
difficulty (n=24, 1 5%), obstructing tumor (n=1 5, 9%), therapeutic goal for which cecal intubation 
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was not required (n= 11 , 7%), pain (n=9, 6%), diverticulosis (n=8, 5%) or severe inflammat ion (n=2, 
1 %). The adjusted CIR was 96%. 
Table 1. Baseline characteristics 
Age, mean ± SD (years) 
Male gender 
Indication 
Anemia I abdominal symptoms' 
Rectal (occult) blood loss 
Family history of CRC 
Surveillance after CRC I adenoma 
Other2 
ASA-score 
2 
3 
4 
Unknown 
Conscious sedation 
Yes 
No 
Unknown 
Endoscopist 
Gastroenterologist 
Gastroenterology fellow 
Nurse endoscopist 
Organization 
2 
3 
4 
5 
6 
7 
1. Includes changes in bowel habit. 
2. 1ncludes liver metastases, abnormalities found with other imaging modalities or diverticular disease 
Number of patients(%) 
(N= 3,129) 
59± 15 
1,423 (45.5) 
1,972 (63.0) 
226 (7.2) 
263 (8.4) 
626 (20.0) 
42 (1.3) 
1,784 (57.0) 
1,061 (33.9) 
160 (5.1) 
6 (0.2) 
118 (3.8) 
2,840 (90.8) 
158 (5.0) 
131 (4.2) 
1,870 (59.8) 
747 (23.9) 
512 (16.4) 
339 (10.8) 
245 (7.8) 
124 (4.0) 
639 (20.4) 
568 (18.2) 
421 (13.5) 
793 (25.3) 
One or more polyps were detected in 45% of all colonoscopies. The ADR was 32% with a mean 
number of 0.6 (± 1.2) adenomas per procedure for all procedures combined (MAP) and 1.9 (±1.5) for 
procedures in which at least one adenoma was found (MAP+). Complications were observed in 0.6% 
(n=19) of procedures, of which 47% (n=9) were bleedings. 
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A significant variability for CIR and ADR was found between hospitals (Table 3). Adequate bowel 
preparation varied between 79% and 98% (p<0.001 ). Unadjusted CIR ranged from 89% to 99% 
(p<0.001 ). Adjusted CIR was above 90% in all participating hospitals and was also significantly 
different between hospitals (p<0.001 ). ADR varied from 25% to 47% (P<0.001 ). CIR and ADR were 
combined in a colonoscopy quality indicator (CQI) to depict differences between hospitals, taking 
into account the number of performed procedures per hospital (Figure 1 ). 
AOR 
SO% 
40% 
30% 
• 
lmproveCIR Excellent 
e . • 
------------------------------------J--------~------
Improve CIR and ADR 
1 
t 
t 
• 
20% +-------.-------i--------, 
85% 90% 95% 100% 
Adjusted CIR 
Figure J. Quality indicators (adenoma detection rate (ADR) and cecal intubation rate (CIR)) per hospital. 
Complication rates were non-significantly different between hospitals (p=0.074). ADR or CIR 
were not higher in academic centers or centers with a higher volume. A comparison between the 
different types of endoscopists did not show differences in unadjusted or adjusted CIR (p=0.447 and 
p=0.501, respectively)(Table 3). Without correction for casemix, both nurse endoscopists (36%) and 
fellows (34%) had a higher ADR than gastroenterologists (30%, p=0.008). No association was found 
between the number of procedures per endoscopist and CIR or ADR. Complications occurred more 
frequently after colonoscopies performed by fellows (p=0.042). 
In univariable analysis, hospital, age, ASA-score, indication for colonoscopy and BBPS were identified 
as factors associated with adjusted CIR. Hospital, ASA-score, indication and BBPS remained 
significantly associated with the adjusted CIR in multivariable analysis (Table 4). In patients with 
an ASA score > 1, the cecum was less frequently intubated. If patients underwent colonoscopy for 
surveillance, the procedure was more often completed than in case of abdominal complaints or 
anemia. CIR was significantly higher in patients with adequate bowel preparation. 
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Table 2. Quality indicators for all hospitals. 
Indicators 
BBPS 2:6 
Yes 
No 
Unknown 
BBPS, median (interquartile range) 
CIR 
Yes 
No 
Adjusted CIR 
Yes 
No 
PDR 
ADR 
MAP 
MAP+ 
Complications 
Bleeding 
Post-polypectomy syndrome 
Perforation 
Other/unknown 
Results(%) 
(N=3,129) 
2,697 (86.2) 
310 (9.9) 
122 (3.9) 
9 (6-9) 
2,967 (94.8) 
162 (5.2) 
2,967 (95.7) 
134 (4.3) 
1,413 (45.2) 
996 (31.8) 
0.60 ± 1.22 
1.89 ± 1.48 
19 (0.6) 
9 (0.3) 
2 (0.1) 
1 (<0.1) 
7 (0.2) 
Hospital, type of endoscopist, gender, age, ASA-score, indication for colonoscopy, BBPS and 
unadjusted CIR were all associated with ADR in univariable analysis. In multivariable analysis, an 
association was shown for hospital, gender, age, indication, BBPS and unadjusted CIR (Table 5). 
Male gender and older age were associated with a higher ADR. One or more adenomas were more 
frequently found if the indication for colonoscopy was a positive family history, rectal blood loss or 
surveillance after previous adenoma(s) or CRC, in comparison to anemia or abdominal symptoms. 
Both adequate bowel preparation and cecal intubation increased the likelihood of detecting 
adenomas. After adjustment for casemix, there were no significant differences in ADR between 
gastroenterologists, fellows and nurse endoscopists. 
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Table 3 . Outcomes per hospital and type of endoscopist 
Hospital Number, n BBPS 2:6,% CIR, % Adj. CIR,% ADR, % Complications, % 
339 79.0 96.2 97.6 27.4 1.2 
2 245 87.0 93.1 95.0 33.5 1.6 
3 124 88.7 99.2 99.2 46.8 0.0 
4 639 97.3 97.5 97.8 31.3 0 .8 
5 568 95.8 98.1 98.1 24.8 0.2 
6 421 97.6 95.2 96.6 35.4 0.0 
7 793 80.2 89.4 90.5 34.4 0.6 
p<0.001 p <0.001 p<0.001 p <0.001 p=0.014 
Gastroenterologist 1870 90.1 95.3 95.5 29.8 0.5 
Fellow 747 85.7 94.7 95.7 34.0 1.2 
Nurseendoscopist 512 93.9 96.2 96.5 36.1 0.2 
p<0.001 p=0.447 p=0.629 p=O.OOB p=0.042 
Discussion 
In this prospective cohort of 3,129 routine colonoscopies in seven hospitals we demonstrated an 
overall CIR of 95% and an ADR of 32%, respectively. Our resu lts indicate a significant variability in 
both CIR and ADR between different hospitals. Both CIR and ADR were affected by hospital and 
bowel preparation, independent of case mix variation. We developed a colonoscopy quality indicator 
(CQI), which shows both CIR and ADR in a matrix that can be used for quality assessment and may 
assist in improving colonoscopy performance of hospitals and individual endoscopists. 
CIR and ADR in this study were higher than in previous studies, but the variability between hospitals 
was comparable. Mean CIR and ADR as reported in severa l studies including routine colonoscopies 
have been found to vary from 83 to 91 o/o and from 18 to 26%, respectivel yS· 13-18. De Jonge et al. 
reported an unadjusted CIR varying from 81 to 96% and an ADR varying from 13 to 32% in twelve 
Dutch academic and non-academic hospitals whereas Harris et al. found a CIR of 69 to 98% and an 
ADR of 8 to 27% in 21 experienced centers across Europe and Canada15-18. The variation ADR was 
even higher in the study by Radaelli et al, ranging from 6 to 46% in 116 Italian endoscopy centers 
participating in a nationwide registration study for routine colonoscopies 17• Different studies among 
screening populations have shown slightly higher CIRs and ADRs, but a comparable variability1°·19-21• 
The slightly better results in the current study may at least partly be explained by a specific focus on 
colonoscopy practice in the centers part icipating in this quality init iative. 
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Table 4 . Factors associated with adjusted cecal intubation rate 
Hospital 
2 
3 
4 
5 
6 
7 
Type of endoscopist 
Gastroenterologist 
Fellow 
Nurse-endoscopist 
Male gender 
Age, per 10 years increase 
ASA-score 
2 
3 
4 
Indication 
Anemia I abdominal sympt oms 
Rectal (occult) blood loss 
Family h istory of CRC 
Survei llance 
Sedation 
Adequate BBPS 
Unadjusted OR 
(95% CI) 
4.25 (2.03-8.93) 
1.98 (1.06-3.72) 
12.84 (1.77-93.21) 
4.65 (2.60-8.31) 
5.29 (2.78-1 0.05) 
2.99 (1.67-5.36) 
Reference 
Referen ce 
1.04 (0.69- 1 .58) 
1.29 (0.77-2.17) 
1.34 (0.94-1.91) 
0.78 (0.69-0.89) 
Reference 
0.45 (0.31-0.65) 
0 .25 (0. 1 4-0.46) 
0.09 (0.01-0.85) 
Reference 
1.70 (0.78-3.71) 
4.70 (1.48-14.93) 
1.85 (1.1 1-3.08 
0.74 (0.27-2.04) 
15.61 (1 0.56-23.08) 
Adjusted OR 
(95% CI) 
7.74 (2.68-22.31) 
1.17 (0.57-2.40) 
14.66 (1.78-120.66) 
1.75 (0.89-3.43) 
2.90 (1.33-6.35) 
1.99 (0.86-4.61) 
Reference 
0.92 (0.79-1.07) 
14.64 (9.25-23.16) 
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Table 5 . Factors associated with adenoma detection rate. 
Unadjusted OR Adjusted OR 
(95% CI) (95% CI) 
Hospital 
0.72 (0.54-0.95) 0.83 (0.58-1.19) 
2 0.96 (0.71-1.30) 0.95 (0.67-1.35) 
3 1.67 (1.14-2.45) 1.31 (0.83-2.07) 
4 0 .87 (0.70-1.08) 0.73 (0.56-0.93) 
5 0.63 (0.50-0.80) 0.55 (0.41-0.74) 
6 1.04 (0.81-1.34) 0.77 (0.56-1.04) 
7 Reference Reference 
Type of endoscopist 
Gastroenterologist Reference Reference 
Fellow 1.21 (1.01-1.46) 1.12 (0.89-1.42) 
Nurse-endoscopist 1.33 (1.09-1.64) 1.27 (0.98-1.63) 
Male gender 1.78 (1.53-2.07) 1.73 (1.47-2.05) 
Age, per 10 years increase 1.5 1 (1.43-1.61) 1.48 (1.38-1.59) 
ASA-score 
Reference Reference 
2 1.75 (1.49-2.06) 1.13 (0.93-1.37) 
3 2.01 (1.44-2.79) 1.37 (0.94-1.99) 
4 1.36 (0.25-7.44) 1.86 (0 .28-12.47) 
Indication 
Anemia I abdominal symptoms Reference Reference 
Rectal (occult) b lood loss 1.82 (1.37-2.41) 1.63 (1.16-2.29) 
Family h istory of CRC 1.14 (0.86-1.51) 1.42 (1.02-1.97) 
Surveillance 2.34 (1.98-2.88) 1.70 (1.38-2.09) 
Sedation 1.26 (0.88-1.80) 
Adequate BBPS 1.56 (1.19-2.05) 1.84 (1.33-2.55) 
Cecal intubation 1.81 (1.23-2.66) 1.99 (1.24-3.20) 
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The adjusted CIR in this study was found to be associated with ASA score and indication for 
colonoscopy as well as bowel preparation and hospital, which are both modifiable factors. Previous 
studies concluded that not only adequate bowel preparation is associated with CIR, but also the 
use of sedation 9•12•22•23• One other study found no association between sedation and CIR and only 
a non-significant (p=0.07) association between bowel preparation and CIR15• In our study, the use 
of sedatives was not related to adjusted CIR. The general Dutch practice is to perform colonoscopy 
under conscious sedation, unless the patient prefers not to do so. This may have resulted in 
confounding by indication. 
As expected, our study showed that more non-modifiable factors were associated with ADR than 
with CIR. Age, sex and indication for colonoscopy are known to affect the ADR and adjustment for 
these factors is required when measuring qualityl4•16•24•25 • Hospital, bowel preparation and cecal 
intubation were modifiable factors associated with ADR in multivariable analysis. Most previous 
cohort studies have reported an association between adequate bowel preparation and higher 
ADR9•10•15•20•26• It seems logical to assume that a higher CIR increases ADR, but not all previous studies 
have confirmed this 10•15•20• Sedation did not affect ADR and previous studies have shown only limited 
and largely conflicting evidence on this subject10•14•22•23• 
We developed the CQI, which is a tool that can provide incentives for hospitals to improve quality 
of colonoscopy. It is important to note that the CQI does not reflect absolute quality, as the results 
are not corrected for casemix. Therefore, it is not fair to consider one hospital to be better than 
the other, solely based on a different position in the CQI-matrix. Yet, the CQI may help hospitals or 
individual endoscopists to detect differences compared to other hospitals or endoscopists and look 
into reasons for these differences. If the variation appears to result from differences in procedural 
or institutional factors, as was shown for bowel preparation, hospitals or endoscopists can focus on 
this factor to improve quality. 
In this context, it is worth mentioning the seemingly outstanding performance of hospital 3 in a 
limited number of colonoscopies, represented by the small dot in the upper right corner of the 
CQI-matrix (Figure 1 ). Although multivariable analyses confirmed this performance to be at least 
partly independent of case mix, it appears that the high rates are importantly affected by differences 
in baseline characteristics of included patients (Supplementary Table 1 ). During the study period, 
significantly more colonoscopies were performed in patients with a positive fecal occult blood test 
as compared to the other hospitals. 
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Although it seems that there is no linear association between CIR and ADR in the CQI, it is important 
to emphasize that this conclusion cannot be drawn from the CQI, due to the intersection of the 
x- and y-axes at high percentages and the lack of correction for case mix. If the complete CQI would 
have been shown, i.e. with x- and y-axes ranging from 0 to 100%, one would have seen that all dots 
are in the upper right corner and that an estimation of co-linearity is not possible as all hospitals 
performed relatively well. The CIR was independently associated with the ADR in our multivariable 
analysis, but this cannot be directly interpreted from the CQI. It is possible to overcome this by 
constructing CQis for a specific indication and age group, for example in screening populations. 
The strength of this study is that our prospective registration resulted in reliable data on 
colonoscopies performed in a representative population of patients visiting academic and non-
academic hospitals. However, limitations of this study should be addressed as well. First, several 
population characteristics possibly affecting ADR and/or CIR were not or incompletely known in 
th is study. Patient's comorbidities, medication use and smoking status were not registered. ASA 
score as an indirect measure for these factors was registered in all patients. The indications for 
colonoscopy were consistently reported, but were not highly specific. Particularly, more than 60% 
of all patients were categorized in a combined group of anemia, abdominal symptoms or change 
in bowel habits, whereas one might expect this group to be heterogeneous with regard to risk 
of finding colorectal neoplasms. Second, some potentially important information on procedural 
factors was also not available. Endoscopists were aware of the recommendation that withdrawal 
with mucosal inspection should take at least six minutes, but withdrawal time was not recorded in 
this study3• The number of colonoscopies performed in each hospital per year and the experience 
of each endoscopist were not known, but no significant differences in CIR or ADR were found 
between different types of endoscopists. This is remarkable, as gastroenterologists are generally 
more experienced than fellows. 
In conclusion, we investigated the use of CIR and ADR as quality indicators for colonoscopy. The 
CQI is a simple combination of both indicators for comparison between hospitals. It can provide 
information to discuss differences, aiming to improve colonoscopy quality, as CIR and ADR can be 
positively affected by targeting modifiable factors, of which the most important is bowel preparation. 
Future studies are required to establish whether implementation of competitive feedback in such 
a comparative way will indeed improve quality of colonoscopy and what measures are best to be 
taken to improve bowel preparation. 
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General discussion and future perspectives 
Summary 
This thesis aimed to explore the current status of colorectal cancer screening and the role of fecal 
immunochemical testing (FIT). After discussing the current status of CRC screening in 
part I, the second part of thesis provided a discussion on different screening methods with a 
focus on screening by means of FIT. Next, the use of fecal hemoglobin concentration measured by 
quantitative FIT, was explored for personalized screening strategies. Hereafter, this thesis dealt with 
quality issues in colorectal cancer screening. In this final part, the findings of our research will be 
summarized and future perspectives will be discussed. 
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Colorectal cancer screening modalities with a focus on FIT (PART II) 
Various screening methods are available and can be broadly divided into two strategies; invasive, 
colonic imaging strategies such as colonoscopy, and non-invasive strategies such as fecal occult 
blood testing (FOBT)1• Fecal occult blood testing was originally most often done by means of guaiac 
FOBT (gFOBT), while at present many screening programs are changing to FIT2• We conducted 
a systematic review and meta-analysis on diagnostic test accuracy comparing FIT and gFOBT 
(Chapter 2). The results of this review showed a higher sensitivity for both advanced neoplasia as 
well as colorectal cancer with FIT-screening compared to gFOBT. Specificity for the two tests were 
comparable. 
With regard to endoscopic screening strategies, colonoscopy is considered the reference standard 
for diagnosing colorectal cancer (CRC). However, due to the invasiveness of the procedure, 
attendance rates in screening programs are generally low. Colonoscopy is recommended to 
be repeated every 10 years, whereas fecal occult blood testing is recommended to be repeated 
biennially or annuallyl. These different screening intervals make comparison between screening 
strategies arduous, especially taking into account that the true impact of FIT-screening is attained 
over multiple rounds4. Until now most studies have focused on comparing one-time endoscopic 
screening to only one-time FIT-screening instead of multiple rounds. For this reason, we compared 
colonoscopy, flexible sigmoidoscopy (FS) and FIT over four rounds of screening (Chapter 3). These 
results showed a superior performance for FIT among invitees, yielding two-times more advanced 
neoplasia (AN) than screening by FS or colonoscopy, with AN being found in 4.5% (95% Cl4.2-4.9) vs. 
2.3% (95% Cl 2.0-2.7) and 2.2% (95% Cl 1.8-2.6) respectively of all invitees. Moreover, FIT-screening 
had a three-times higher detection rate for CRC (0.6% vs. 0.2%; p<0.001 ). Lastly, numbers needed to 
scope to detect one scree nee with AN were lowest for FIT with 2, followed by FS with 3 and highest 
for colonoscopy with 11 . Nevertheless, it should be noted that the comparison of CRC detection 
rates between FIT and endoscopic screening is complex and results should be interpreted with 
caution. These results are firstly directly influenced by uptake of the screening test. Furthermore, 
colonoscopy allows detection and simultaneous removal of lesions in a first round, whereas FIT 
screening requires repeated screening at relatively short interva l to provide a similar preventive 
impact as colonoscopy in those who participate and are willing to undergo the screening-test. 
In 2014 a national CRC screening program was implemented in the Netherlands. Through a national 
tender it was decided to start screening with the FOB-Gold (Sentinel, Italy). Contradictory, most 
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previous research in the Netherlands was done using the OC-sensor (Eiken, Japan). To investigate 
how these two tests compare, we performed a randomized trial in the fourth round of our CRC 
screening cohort (Chapter 4). More non-analyzable tests were seen for the FOB-Gold, due to 
inappropriate use by the screenee. Furthermore, while both FITs had similar positive predictive 
values, the positivity rate of the OC -sensor was significantly higher (7.9% vs. 6.5%; p=0.002), leading 
to a higher colonoscopy demand and consequently a higher diagnostic yield, despite using the 
same cut-off for both FITs. Because FIT brands vary widely regarding sampling size and buffer, 
comparing brands has proven to be arduous. In 2011 the FIT for screening working group proposed 
to standardize FIT Hb concentrations into 1-1g Hb/g feces, instead of the previously used ng Hb/ 
ml buffer5• However, our results illustrated that even when using this standardized measurement, 
differences occur regarding positivity rate. This could be explained by the fact that FITs do not 
directly determine hemoglobin concentration in feces, but determine hemoglobin concentration 
in the kit's storage buffer. This depends on both the fecal hemoglobin concentration and the 
amount of fecal material put into the buffer. Although manufacturers assume that the volume of 
fecal material sampled is stable per device, sampling volumes can in practice vary substantially. 
Therefore, we proposed to compare FIT brands at the same positivity rate, rather than cut-off. 
Moreover, a comparison on positivity rate also directly reflects the necessary colonoscopy demand, 
which remains an important issue in CRC screening programs6•7• For FIT-screening to be successful, 
multiple screening rounds are required and with sufficient participation rates. We showed that over 
three rounds of screening positivity rates as well as positive predictive values decreased (Chapter 
5). The positivity rate was highest in the first round (8.4%) and decreased over the second (6.0%) and 
third (5.7%) screening rounds (p<0.001 ). Consequently, together with a lower PPV over the rounds, 
diagnostic yield decreased (round 1: 3.3%; round 2: 1.9%; and round 3: 1.3%; p<0.001 ). 
Hereafter, we focused solely on the participation rates over multiple FIT rounds and showed 
that participation remained stable over 4 screening rounds, and even increased slightly over the 
rounds (Chapter 6). Overall, 72% participated at least once in one of the four screening rounds, 
while around 28% never participated. This latter group mainly involved male subjects with a low 
socioeconomic status. Future research should evaluate new strategies to involve this deprived 
group in CRC screening, as male gender and low socioeconomic status are also considered to be risk 
factors for the development of CRC. At present, all subgroups receive the same screening invitation 
strategy, while it might be necessary that invitation strategies are different between subgroups to 
achieve even chances of optimal outcomes8• 
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In spite of high participation rates and a relatively high sensitivity for CRC of 75-85% depending on 
the cut-off used, the sensitivity of FIT for detection of advanced adenomas is lower and generally 
ranges below 50%9-11• Following, there is a need to increase FIT sensitivity, without losing specificity, 
as the latter is crucial in a screening setting. For this reason, we explored if the gut microbiome 
could be of clinical use in FIT screening (Chapter 7). We investigated four predefined bacteria 
associated with the development of CRC (Escherichia coli, Fusobacterium nucleatum, Bacteroides 
and Fecalibacterium prausnitzii) to evaluate if it was possible to measure bacteria in FIT by 
quantatitative PCR (qPCR) and to see if these microbiota remained stable over the course of days. 
Next, we compared the qPCR results to the most advanced finding at colonoscopy. Our data showed 
no additional benefit for each bacterium relative to the total amount of bacteria (i.e. 1 65). However, 
we did find that total bacterial load was significantly higher in FITs from patients with high-grade 
dysplasia or CRC. While these results did not aide in identifying specific bacteria to increase FIT 
diagnostic accuracy, the finding that the gut bacteria can be adequately measured in FIT-samples, 
paves the way for further research to determine the role of microbiota in FIT. Moreover, the concept 
remains interesting and deserves further exploration. 
Using FIT as a quantitative guide in colorectal cancer screening (PART Ill) 
FIT can be both qualitative, leading to either a positive or negative result, or quantitative resulting 
in the reporting of fecal Hb per 11g Hb per gram feces2• Despite the fact that quantitative FIT is most 
often used in screening settings, it is invariably used and reported as a qualitative test by using a 
pre-specified cut-off. In this third part of the thesis, fecal Hb (fHb) concentration as measured by 
quantitative FIT was evaluated to use in risk prediction models. 
Firstly we investigated fHb concentrations of FIT-negative screenees (i.e. fHb concentration <1 0 11g 
Hb/g feces). We showed that among negative-FIT sceenees, fHb can be of clinical aid in predicting 
who is most at risk of developing advanced neoplasia (Chapter 8). Participants with a fHb 
concentration of >8 11g Hb/g have an 8-fold higher risk of developing future AN, compared to those 
with a fHb concentration of 0 11g Hb/g. Moreover, consecutive FIT results provide even more insight 
into these risks, with two FITs of 811g Hb/ g leading up to a 1 4-fold risk increase of AN. We provided 
practical heat plots, to give an insight in these risks based on two previous negative-FIT resu lts. These 
results additionally underlined the fact that men have a two-fold higher risk of developing future 
AN than women. This risk difference between genders can be explained by the fact that men and 
women have different incidence rates of CRC and consequently have different risks of developing 
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AN12•13• Despite these well-known differences, both genders are screened invariably in the same 
manner12•14 • We provided an overview of these gender differences in FIT screening by analyzing 
screenees that performed a FIT before undergoing a screening-colonoscopy (Chapter 9). Using this 
data we worked out two scenario; gender-tailored strategies can either level sensitivity in men and 
women (i.e. lower cut-off in women) or level the amount of missed lesions (i.e. lower cut-off in men. 
Next, we looked at fHb concentrations of FIT-positive screenees in predicting who is at risk of a 
second look colonoscopy (Chapter 1 0). Moreover, we showed that there is a high rate of second 
look colonoscopies in a FIT-positive patient population and that it accounts for an additional 12% 
in required colonoscopy resources. Finally, we demonstrated that fHb concentrations could be used 
to alter screening intervals to optimize screening programs and related resources (Chapter 11 ). 
Combining the results from two FIT-based screening rounds, we illustrated that by lowering the cut-
off in round one, the second round could theoretically be extended, resulting in similar diagnostic 
yield and a lesser demand on screening program-related resources. 
Quality and endoscopy in colorectal cancer screening (PART IV) 
In part IV quality issues in CRC screening were discussed, including quality of patient information 
and quality of colonoscopy. Regarding quality of patient information, we showed that there is sti ll 
much to gain in providing complete and understandable information for those contemplating on 
CRC screening (Chapter 12). We developed a website accuracy score (WAS) to score website on 
quality and completeness of information on CRC screening together with validated internet quality 
instruments. Strikingly, there was a poor correlation between quality of websites and Google rank. 
These results suggest that persons will miss out on high quality websites and important information. 
More attention should be given to the aspects of web-based information, as the use of internet for 
health information is continuing to grow15• 
The main goal of a screening program is ultimately the reduction in the incidence and mortality of 
CRC, which is driven by the number of detected CRCs and missed lesions (i.e. interval carcinomas). In 
Chapter 13 we evaluated detection and miss rates of CRC over four rounds of FIT-based screening; 
CRC was detected in 3.9% of FIT-positive screenees, and 0.14% of FIT-negative screenees had an 
interval carcinoma within the FIT-screening interval. Additionally, 0.43% of those undergoing 
colonoscopy after a positive FIT,had a post-colonoscopy CRC. Interestingly, screen-detected CRC 
and FIT interval CRC were most often detected in the distal colon, while post-colonoscopy CRC were 
more often located in the proximal colon. This is in line with results from a gFOBT-based screening 
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program, and is potentially due to lower fHb concentrations from these lesions in feces6. Moreover, 
screen-detected CRCs had more favorable stages than non-screen-detected CRCs. Over the course 
of multiple screening rounds, the proportion of early CRC increases. Unfortunately, such lesions are 
frequently not adequately recognized at colonoscopy in FIT-positive screenees. This is an important 
issue, as recognition of these lesions, and a following adequate resection could potentially prevent 
unnecessary surgery. We showed that in our CRC-screening cohort, over half of the endoscopically 
resectable CRCs were not identified as such at initial colonoscopy (Chapter 14). More attention 
should be given to the diagnosis of early CRC and the available resection methods. 
Quality of a screening program is greatly dependent on the quality of colonoscopy, which is 
ultimately reflected by the number of post-colonoscopy CRC. However, measuring post-colonoscopy 
CRC is cumbersome and does not allow direct feedback. For this reason, several quality indicators 
have been suggested, most often used include adenoma detection rate (ADR) and cecal intubation 
rate (CIR)16•17. There is a growing body of evidence that ADR of endoscopists is inversely associated 
with the risk of post-colonoscopy cancers18•19 • For this reason, we looked at quality of colonoscopy 
between hospitals measured by the ADR and CIR, showing marked differences between centers 
(Chapter 15). We developed a colonoscopy quality indicator, to assist in further improving the 
quality of colonoscopy. Future studies should focus on these differences among hospitals to 
identify factors and implement strategies that can improve quality of colonoscopy. For example, 
in the national screening program in the Netherlands, endoscopists need to be certified to do 
screening colonoscopies. This certification is preceded by a training, which in part focuses on quality 
parameters. Such strategies could improve and uniform quality of colonoscopy among hospitals. 
Future perspectives 
Research on colorectal cancer screening has evolved greatly over the past decades. While 
improvements have been made regarding the quality and accuracy of screening strategies, the 
strategies itself have not changed much and still mainly consist either of colonoscopy screening 
or fecal occult blood test screening. The perfect screening test (e.g. with 100% sensitivity and 
specificity, that is non-invasive and done by all screenees) has unfortunately not been identified yet 
and it is unlikely that such a test will be available in the coming years. With the currently available 
screening methods, there is an ongoing debate on the most effective screening strategy. In the 
United States health care professionals tend to prefer colonoscopy. Yet, in Europe fecal occult blood 
t esting, most frequently using FIT, seems to be favorable2• This can partly be explained by the low 
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participation rates in Europe for colonoscopy as well as by the limited colonoscopy resources. 
Participation is a major issue in screening programs. A screening test can be highly sensitive, but 
is only effective when it gets done (and when it gets done right)20. Furthermore, colonoscopy 
screening puts a large demand on colonoscopy capacity. Though limited capacity is not an issue 
in the United States, limitations in health care resources is likely to become an issue like in other 
countries. Moreover, colonoscopy screening is costly, and it is an invasive procedure from a patient's 
perspective. Using colonoscopy as a first-line screening method leads to a high detection rate of non-
advanced adenomas at the cost of the occurrence of complications in otherwise healthy individuals. 
Ultimately, the numbers needed to scope to detect one person with advanced neoplasia or CRC are 
substantially lower for FIT compared to endoscopic screening. 
In the Netherlands, a national screening program started in January 2014 using FIT. Based on 
previous research, a screening interval of 2 years was chosen. At present, the roll-out of the screening 
program is ongoing, and all inhabitants between the ages 55 and 74 years are, or will be invited for 
CRC screening. With many different FIT brands being available, the FOB-Gold (Sentinel, Italy) was 
chosen in the Netherlands through a national tender. Choosing a brand for a national screening 
program is difficult, and often based on a balance between evidence based efficacy and costs. All 
FIT brands have different sampling devices and buffers. Though manufactures claim to measure 
similar concentrations of hemoglobin in feces, at the same threshold positivity rates between tests 
vary widely. These different sampling devices and buffers, makes comparing brands burdensome. 
Furthermore, screening tests are being developed and improved constantly, making results on 
positivity rates and detection rates in previously published studies often inapplicable to current 
situations. The FIT for screening WEO-working group has proposed to report FIT concentrations in 
IJg Hb/g feces, instead of the previously used ng Hb/ml buffer5• This in theory allows to standardize 
the reporting and comparison of results across programs. Nevertheless, current research has shown 
that even when using this standardized reporting unit, differences in positivity rates remain21• Policy 
makers should be cautious of these differences in performance and not rely on previous research 
solely. When implementing a screening program a pilot-phase, encompassing all screening ages, 
should be conducted prior to assess most optimal cut-off resulting in an acceptable number of 
colonoscopy referrals with an sufficient diagnostic yield. 
In the Netherlands, screening is done by a quantitative FIT. Both quantitative FITs as well as 
qualitative FITs are available for CRC-screening, though qualitative tests are infrequently used, and 
seem to be less sensitive than the quantitative tests. Quantitative tests can specifica lly measure 
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fecal Hb in IJg Hb per gram feces. Despite this quantitative nature of the test FITs are invariably used 
in a qualitative manner (i.e. using a pre-specified cut-off and reporting only a positive or negative 
result). By using FIT as a qualitative test, a great window of opportunity for personalized screening 
strategies is lost. Fecal Hb concentration can be used in various manners, including: 
using fecal Hb concentrations to predict an individuals risk of having advanced neoplasia, 
based on both risk factors as well as FIT-results. 
using fecal Hb concentrations of even very low values (i.e. under most currently used threshold) 
over multiple rounds to refer people for colonoscopy or to extend screening intervals. 
using different fecal Hb concentrations for men and women, thereby also incorporating 
different age categories. 
using fecal Hb concentrations to predict who is at risk of advanced neoplasia, and more 
specifically of large advanced adenomas. A pre-selection of these patients could, in theory, 
prevent the need for a second look colonoscopy. 
using fecal Hb concentrations after a colonoscopy to determine colonoscopy surveillance 
intervals. 
While some of the above-mentioned examples have been already explored in our cohort, other 
scenarios still require further determination, for example using MISCAN modeling. Also, the usability 
of such scenarios needs to be confirmed in other large screening settings. 
In the near future, the first results on long-term FIT screening and colonoscopy screening will be 
available. These results will show whether the expected decrease in CRC incidence, due to the 
removal of pre-cancerous adenomas, will really be overt on a population level. With respect to the 
most optimal screening method, until more effective, non-invasive and practical screening methods 
arrive, FIT remains the screening strategy of choice. However, there is still much to gain regarding 
the use offHb by quantitative FIT results in personalized-screening strategies. 
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lntroductie (Deell) 
Dikke darmkanker is een veelvoorkomende ziekte. In Nederland worden jaarlijks ongeveer 12.000 
men sen gediagnosticeerd met darmkanker1• Via een bevolkingsonderzoek kunnen mensen 
gescreend worden op darmkanker zodat de ziekte in een vroeg stadium wordt ontdekt of in een 
voorstadium van de ziekte. Wanneer dikke darmkanker in een vroeg stadium wordt vastgesteld is 
de kans op genezing groter2• Darmkanker begint als een poliep, dit is een verdikking in de darm. 
Veel poliepen worden nooit kwaadaardig, maar een klein deel groeit verder en ontwikkelt zich 
uiteindelijk tot darmkanker. Door het verwijderen van deze zogenoemde hoog-risico poliepen, 
het voorstadium van darmkanker, kan dikke darmkanker worden v66rkomen. Er zijn verschillende 
manier om te screenen op darmkanker. Dit proefschrift richt zich op ontwikkelingen op het gebied 
van dikke darmkankerscreening en de rol hierin van de fecale immunochemische test (FIT). In 
deell van dit proefschrift word een uitgebreid overzicht gegeven over de huidige status van dikke 
darmkankerscreening en de verschillende beschikbare screeningsmethoden. 
Darmkankerscreeningsmethoden met een focus op FIT (Deelll) 
Om te screenen naar darmkanker zijn verschillende methoden beschikbaar en deze kunnen 
grofweg in twee strategieen worden verdeeld; beeldvorming van de dikke darm (i.e. colon) met 
invasieve procedures zoals een kijkonderzoek van de darm (i.e. coloscopie), en niet-invasieve 
strategieen, zoals de fecale occult bloed test (FOBT)2. Deze laatste test, de FOBT, meet of er bloed 
aanwezig is in de ontlasting. Bloed in de ontlasting kan veroorzaakt worden door poliepen of kanker 
in de dikke darm, maar dit kan ook andere oorzaken hebben. lndien er bloed wordt gevonden in 
de ontlasting wordt de patient doorverwezen voor vervolgonderzoek. Voorheen werd voor het 
testen met de FOBT vaak de guaiac FOBT (gFOBT) gebruikt, echter, op dit moment wordt de gFOBT 
veelal vervangen door de FIP. Om deze twee testen te vergelijken hebben we een systematisch 
review en meta-analyse uitgevoerd waarin de testkarakteristieken en nauwkeurigheid van de FIT 
en gFOBT werden vergeleken (hoofdstuk 2). De resultaten van dit onderzoek toonden een hogere 
gevoeligheid voor zowel darmkanker als voor de hoog-risico poliepen bij het screenen met de FIT 
in vergelijking tot de gFOBT. 
Screenen voor darmkanker kan door mensen direct een coloscopie aan te bieden (primaire 
coloscopiescreening), door een deel van de dikke darm te onderzoeken met een kijkonderzoek 
(primaire sigmoidoscopiescreenign) of door eerst een FOBT aan te bieden. Een sigmoidoscopie 
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is eenzelfde onderzoek als de coloscopie, aileen wordt bij deze procedure niet de gehele darm 
bekeken, maar aileen de endeldarm en het rectum. lndien er afwijkingen worden gevonden bij 
de sigmoidoscopie wordt de patient verwezen voor een coloscopie. Voor FOBT-screening geld dat 
indien er bloed in de ontlasting wordt gevonden bij de FOBT, de patient doorverwezen wordt voor 
coloscopie. Coloscopie wordt beschouwd als de gouden standaard voor de diagnose van dikke 
darmkanker. lndien er geen afwijkingen worden gevonden bij coloscopie, is het advies om de 
coloscopie na 10 jaar te herhalen4. 1ndien er echter geen bloed wordt aangetoond bij een FOBT (i.e., 
gFOBT of FIT) dan wordt aanbevolen om de test jaarlijks of elke twee jaar te herhalen5. Tot op heden 
hebben de meeste wetenschappelijke onderzoeken zich gericht op het vergelijken van een ronde 
primair coloscopiescreening versus een ronde FIT-screening (1 0 versus 2jaar) en zijn er geen studies 
bekend die coloscopiescreening met meerdere rondes FIT vergelijken. Om deze reden hebben 
we coloscopiescreening, tlexibele sigmo"idoscopie (FS) screening en vier rondes FIT-screening 
met elkaar vergeleken (hoofdstuk 3). De resultaten van het vergelijkend onderzoek lieten een 
betere prestatie voor de FIT-screening zien, waarbij tweemaal meer hoog-risico poliepen werden 
gevonden bij FIT dan bij screening met FS of coloscopie. Hoog-risico poliepen werden gevonden 
in 4,5% (95% Cl4,2-4,9) vs. 2,3% (95% Cl2,0-2,7) en 2,2% (95% (11,8-2,6) respectievelijk onder aile 
genodigden. Bovendien werd bij FIT-screening driemaal vaker dikke darmkanker gevonden (0,6% 
tegenover 0,2%; p <0,001 ). Toch dient te worden opgemerkt dat deze resultaten met voorzichtigheid 
moeten worden ge"interpreteerd. Ten eerste worden deze resultaten sterk be"invloed door het aantal 
deelnemers aan de screeningstest. Ten tweede zou het zo kunnen zijn dat hoog-risico poliepen die 
verwijderd zijn bij coloscopie mogelijk in de toekomst dikke darmkanker hadden kunnen worden. 
Dit laatste gegeven maakt dat er mogelijk een onderschatting is van het aantal gevonden en 
voorkomen darmkankers bij coloscopiescreening in vergelijking met FIT-screening. 
In 2014 werd een landelijk bevolkingsonderzoek naar dikke darmkanker in Nederland gestart. Door 
middel van een nationale aanbesteding werd besloten om te screenen een FIT van het merk FOB-
Gold (Sentinel, Ita lie). Echter, de Nederlandse wetenschappelijke onderzoeken voorafgaand aan het 
landelijk bevolkingsonderzoek zijn gedaan met een ander merk, de OC-sensor (Eiken, Japan). Om 
te onderzoeken hoe deze twee tests zich tot elkaar verhouden, hebben we een gerandomiseerde 
trial uitgevoerd in de vierde ronde van het proefbevolkingsonderzoek (hoofdstuk 4). Dit 
proefbevolkingsonderzoek bestaat sinds 2006 en betreft een geselecteerde groep mensen die elke 
2 jaar voor darmkankerscreening met FIT zijn uitgenodigd. De resultaten in de vierde ronde lieten 
zien, dat be ide tests dezelfde positieve voorspellende waarde had den. Echter, er waren tevens meer 
positieve t esten bij de OC-sensor in vergelijking met de FOB-Gold (7,9% vs. 6.5%; p = 0,002). Dit 
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hogere aantal positieve testen leidde vervolgens tot een hoger verwijscijfer voor coloscopie en 
zodoende tot een hogere diagnostische opbrengst. Opvallend was dat het hog ere aantal positieve 
testen werd gevonden, ondanks dat voor beide testen eenzelfde afkapwaarde was gebruikt. Onze 
resultaten Iaten zelfs zien dat bij het gebruik van een gestandaardiseerde maat voor de afkapwaarde 
er verschillen optraden met betrekking tot het aantal positieve testen. Het aantal positieve testen 
is een belangrijk gegeven, omdat dit een directe weerspiegeling van het benodigde aantal 
coloscopieen is. Momenteel hebben veellanden wachttijden door de hoge aantallen coloscopieen 
die nodig zijn voor een bevolkingsonderzoek naar dikke darmkanker6·7• 
Bij het screenen naar dikke darmkanker middels FIT is een stabiele en hoge deelname over 
meerdere rondes belangrijk. We toonden aan dat de deelname aan screening stabiel was over ten 
minste drie screeningsrondes , maar dat het aantal positieve testen en de positief voorspellende 
waarde daalden {hoofdstuk 5). Het percentage positieve testen was het hoogst in de eerste ronde 
(8,4%) en nam af in de loop van de tweede (6,0%) en derde (5,7%) screening ronde (p <0,001 ). 
Logischerwijs nam ook de diagnostische opbrengst af over de ron des (ronde 1: 3,3%; ronde 2: 1 ,9%, 
en ronde 3: 1 ,3%; p <0,001 ). 
In het volgende hoofdstuk {hoofdstuk 6) werd de deelname over meerdere rondes uitgebreider 
beschreven, waarbij werd aangetoond dat deelname a an dikke darmkanker stabiel bleef gedurende 
vier screeningsrondes en dat de deelname zelfs Iicht toenam. Over aile vier de rondes, deed 72% ten 
minste een keer mee met screening, terwijl 28% van de uitgenodigde men sen in geen enkele ronde 
deelnam. Deze laatste groep bestond voornamelijk uit mannen met een lage sociaaleconomische 
status. In toekomstig onderzoek is er meer aandacht voor deze groep nodig omdat dit ook als 
een hoog-risico groep beschouwd wordt voor het ontwikkelen van darmkanker. Derhalve is 
vervolgonderzoek nodig om nieuwe strategieen te onderzoeken om deelname aan screening 
in deze groep te verhogen. Momenteel krijgt iedereen eenzelfde uitnodiging voor darmkanker 
screening, terwijl het mogelijk juist noodzakelijk is dat uitnodigingsstrategieen verschillen tussen 
subgroepen om zo gelijke kansen op optimale resultaten te bereiken8• 
Ondanks de hoge deelname aan FIT-screening en een relatief hoge gevoeligheid van de FIT voor 
dikke darmkanker van 75-85%, is de gevoeligheid van de FIT voor de detectie van hoog-risico 
poliepen veel lager. Om deze reden is het belangrijk om onderzoek te doen of de gevoeligheid 
van de FIT verbeterd kan worden. Hiervoor hebben we onderzocht of het combineren van de FIT 
met het meten van dikke darmbacterien (i.e. het microbioom) een verbetering in de diagnose van 
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darmkanker zou zijn (hoofdstuk 7). Voor dit onderzoek werden vier bacterien gemeten waarvan 
bekend is dat deze mogelijk een rol spelen in de ontwikkeling van darmkanker (Escherichia coli, 
Fusobacterium nucleatum, Bacteroides en Fecalibacterium prausnitzii). Onze resultaten toonden 
geen toegevoegde waarde van het combineren van de FIT en het microbioom wanneer we naar 
elke bacterie apart keken, maar we vonden wei dat het totale aantal bacterien hager was in de 
ontlasting van patienten met hoog-risico poliepen en dikke darmkanker. 
Het gebruik van FIT als een kwantitatieve gids binnen de darmkankerscreening (Deellll) 
Een FIT kan zowel kwalitatief zijn, wat leidt tot een positief of negatief resultaat, of kwantitatief 
waarbij de specifieke hoeveelheid bleed in de ontlasting kan worden gemeten3• Hoewel de 
kwantitatieve FIT vaakst wordt gebruik bij bevolkingsonderzoeken, worden de resultaten steevast 
op een kwalitatieve manier gerapporteerd. Dit houdt in dat de specifieke bloedwaarde niet wordt 
gerapporteerd, maar er aileen een positief of een negatief resultaat uit de test komt welke gebaseerd 
is op een vooraf ingestelde afkapwaarde. In dit derde deel van het proefschrift onderzoeken we of 
de specifieke bloedwaarde (i.e., fecaal bleed) in de ontlasting gebruikt kan worden om risico's te 
schatten en screeningstrategieen te verbeteren. 
Ten eerste hebben we de concentratie fecaal bleed van patienten onderzocht. Hierbij hebben we 
gekeken of de concentratie onder de afkapwaarde gebruikt kan worden om in te schatten wie 
het hoogste risico heeft op poliepen of darmkanker. We toonden aan het fecaal bleed van een FIT 
onder de afkapwaarde kan voorspellen wie in de komende jaren het meeste risico heeft op het 
ontwikkelen van hoog-risico poliepen en darmkanker (Hoofdstuk 8). Deelnemers met een fecale 
bloedconcentratie van > 8 119 Hb/g hadden een achtvoudig hager risico op het ontwikkelen van 
hoog-risico poliepen en darmkanker, in vergelijking met mensen met een fecaal bloedconcentratie 
van 0 119 Hb/g. Bovendien lieten onze resultaten zien dat opeenvolgende FIT resultaten nog meer 
inzicht in deze risico's geven en te gebruiken zijn om gepersonaliseerde strategieen op te baseren. 
Ook lieten de resultaten zien dat mannen een twee keer zo hoog risico hebben op het ontwikkelen 
van darmkanker als vrouwen. 
Ondanks be ken de verschillen tussen mannen en vrouwen, worden zij steevast gescreend op dezelfde 
manier9•10• In hoofdstuk 9 gaven we een overzicht van deze verschillen, in een screeningscohort 
waarbij aile deelnemers zowel een FIT hebben gedaan als een coloscopie hebben ondergaan. Met 
behulp van deze gegevens werkten we twee screeningsstrategieen uit: 1) een strategie waarbij de 
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sensitiviteit van de FIT gelijk is voor mannen en vrouwen kunnen beide niveaus gevoeligheid bij 
mannen en vrouwen (i.e., een lagere afkapwaarde bij vrouwen); 2) een strategie waarbij het aantal 
gemiste laesies gelijk is voor mannen en vrouwen (i.e., een lagere afkapwaarde bij mannen). Beide 
strategieen kunnen gebruikt worden, afhankelijk van het beoogde resultaat: een gelijke sensitiviteit 
versus een gelijk aantal gemiste leasies voor mannen en vrouwen. 
Vervolgens hebben we gekeken naar fecale bloedconcentraties van patienten met een concentratie 
boven de afkapwaarde. Deze resultaten lieten zien dat fecaal bloed gebruikt kan worden om te 
voorspellen wie een hoog risico heeft om een tweede coloscopie binnen 1 jaar moet ondergaan 
(hoofdstuk 10). Daarnaast bleek dat binnen deze patientenpopulatie er relatief vaak een tweede 
coloscopie moet plaatsvinden, en dat dit uiteindelijk tot 12% extra coloscopie capaciteit vergt 
binnen een screeningsprogramma. Tenslotte hebben we aangetoond dat fecale bloedconcentraties 
kunnen worden gebruikt screeningsintervallen op te baseren en om zo screeningprogramma's te 
optimaliseren (hoofdstuk 11 ). 
Kwaliteit en endoscopie binnen darmkankerscreening (DeeiiV) 
In deel IV werden kwaliteitszaken rondom darmkankerscreening besproken. Ten aanzien van 
de kwaliteit van patienteninformatie, hebben we Iaten zien dat er nog veel te winnen valt bij 
het verstrekken van volledige en begrijpelijke informatie voor degenen die overwegen deel te 
nemen aan dikke darmkankerscreening (hoofdstuk 12). We hebben een website nauwkeurigheid 
score (WAS) ontwikkeld en hiermee samen met gevalideerde scoresystemen medische websites 
beoordeeld op kwaliteit en volledigheid van informatie over darmkankerscreening. Opvallend was 
er een slechte overlap was tussen de kwaliteit van websites en hun plaats binnen Google. Deze 
resultaten suggereren dat mensen belangrijke en kwalitatief goede websites zullen missen, omdat 
deze websites pas onderaan de resultaten van Google staan. Er moet om deze reden meer aandacht 
worden besteed aan de kwaliteit en begrijpelijkheid van medische informatie op het internet, 
omdat gebruik van internet voor medische informatie in de toekomst zal blijven toenemen. 
Bij een bevolkingsonderzoek is het aantal gemiste darmkankers net zo belangrijk als het aantal 
gevonden darmkankers. Om deze reden hebben we het aantal gevonden en gemiste kankers binnen 
vier screeningsrondes met FIT vergeleken; in 3,9% van de FIT-positieve screenees werd darmkanker 
gevonden, en in 0,14% van de FIT-negatieve screenees werd een darmkanker gemist voordat de 
volgende FIT test gepland stond (hoofdstuk 13). In 0,43% van de patienten werd darmkanker 
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gediagnosticeerd binnen 10 jaar na de coloscopie. Dikke darmkankers die gevonden werden bij het 
screenen hadden een gunstiger stadium dan darmkankers die gediagnosticeerd werden buiten het 
screeningsprogramma. Over meerdere screeningsrondes neemt het aantal kankers dat in een vroeg 
stadium wordt ontdekt toe. Helaas worden deze laesies vaak onvoldoende herkend bij coloscopie. 
Dit is een belangrijke kwestie, omdat herkenning leidt tot adequate resectie van de kanker en zo een 
onnodige operatie kan voorkomen. We toonden aan dat in ons proefbevolkingsonderzoek cohort, 
meer dan de helft vroege darmkankers niet als zodanig werden ge"ldentificeerd bij eerste coloscopie 
(hoofdstuk 14). Daarom moet er in de toekomst meer aandacht komen voor het diagnosticeren en 
verwijderen van deze laesies. 
Kwaliteit van een screeningsprogramma is sterk afhankelijk van de kwaliteit van coloscopie. Om deze 
reden hebben we de kwaliteit van de coloscopie tussen ziekenhuizen gemeten. Deze resultaten 
lieten duidelijke verschillen tussen ziekenhuizen zien (hoofdstuk 1 5). Toekomstig onderzoek zou 
zich moeten richten op deze verschillen tussen ziekenhuizen om zo factoren te identificeren om de 
kwaliteit van coloscopien te verbeteren. 
FIT naar de toekomst 
Onderzoek naar darmkankerscreening heeft een enorme ontwikkeling doorgemaakt in de 
afgelopen decennia. Hoewel verbeteringen zijn aangebracht met betrekking tot de kwaliteit 
en de nauwkeurigheid van screening strategieen, zijn de strategieen zelf niet veel veranderd en 
bestaan deze nag steeds voornamelijk uit een coloscopiescreening of FOBT screening. De perfecte 
screeningstest (met 100% sensitiviteit en specificiteit, niet-invasieve en een test waaraan iedereen 
mee wil doen) bestaat helaas nog niet en het is onwaarschijnlijk dat een dergelijke test beschikbaar 
zal zijn in de komende jaren. 
In Nederland is er sinds januari 2014 een bevolkingsonderzoek naar darmkanker met FIT. Op basis 
van eerder onderzoek, werd een screeningsinterva l van 2 jaar gekozen. Momenteel is implementatie 
van het bevolkingsonderzoek nog bezig en worden gefaseerd aile inwoners in de leeftijd tussen 55 
en 74 jaar uitgenodigd voor het bevolkingsonderzoek. 
In de nabije toekomst zullen de eerste resultaten op de lange termijn FIT screening en 
coloscopiescreening beschikbaar komen. Deze resultaten zullen aantonen of de verwachte daling 
van dikke darmkankerincidentie zich ook daadwerkelijk zo zal ontwikkelen op populatie niveau. 
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Met betrekking tot de meest optimale screeningmethode blijft FIT de eerste keuze, zeker gezien 
de hoge deelnamegraad en praktische voordelen. Voor de toekomst valt er nog veel te winnen 
met betrekking tot het gebruik van patientkarakteristieken en fecale bloedconcentraties in 
gepersonaliseerde-screening strategieen. 
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Abbreviations 
AA advanced adenoma 
ADR adenoma detection rate 
AN advanced neoplasia 
ASA American society of anesthesiologists 
ASR age standardized ratio 
BBPS Boston bowel preparation score 
BCO Below the cut-off 
BMI body mass index 
Cl confidence interval 
CIR cecal intubation rate 
CQI colonoscopy quality indicator 
CRC colorectal cancer 
CTC computed tomography colonography 
DTA diagnostic test accuracy 
FIT fecal immunochemical test 
fHb fecal hemoglobin 
FOBT fecal occult blood test 
gFOBT guaiac fecal occult blood test 
FN false negatives 
FP false positives 
FS flexible sigmoidoscopy 
HGD high grade dysplasia 
HP hyperplastic polyp 
HR hazard ratio 
IQR inter quartile range 
MAP mean adenomas per procedure 
OR odds ratio 
PC post-colonoscopy 
PR Positivity rate 
SD standard deviation 
SP serrated polyp 
SSA sessile serrated adenoma 
TN 
TP 
TVA 
TA 
UICC 
true negatives 
true postives 
(tubulo) villous adenoma 
tubular adenoma 
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Rotterdam 
Cochrane Diagnostic Test Accuracy Review, authors' course Module 3, Cochrane Centre 
Birmingham, UK 
Introduction to data-analysis, Erasmus Summer Programme, Rotterdam 
Methods of public health research, Erasmus Summer Programme, Rotterdam 
Practice of Epidemiologic Analysis, Erasmus Summer Programme, Rotterdam 
Survival analysis course, Molecular medicine postgraduate school, Rotterdam 
Integrity in science for PhD researchers, Dept of EMdical Ethics an philosophy, Erasmus MC, 
Rotterdam 
Writing a Cochrane Diagnostic Test Accuracy Review, Julius UMC Utrecht 
Biomedical English writing and communication, Erasmus MC, Rotterdam 
Abdominal ultrasonography course, Dutch liver week 2012, Rotterdam 
lndesign workshop, Molecular medicine postgraduate school, Rotterdam 
Photoshop & Illustrator workshop, Molecular medicine postgraduate school, Rotterdam 
Oral presentations at international conferences 
Practice, indication and predictive factors of second look colonoscopy in a screening 
population. United European Gastroenterology Week, Vienna, Austria 
Guaiac-based faecal occult blood tests versus faecal immunochemical test for colorectal 
cancer screening in average-risk individuals. World Endoscopy Organization (WEO) 
Colorectal Cancer Screening Meeting, Barcelona, Spain 
Comparison of OC-sensor and FOB-Gold in population-based colorecta l cancer screening 
based on FIT. Digestive Disease Week, Washington D.C., United States of America 
Year Workload 
2013 
2013 
2013 
2013 
2013 
2013 
2013 
2013 
2014 
2014 
2014 
2012 
2015 
2015 
6 hours 
6 hours 
28 hours 
28 hours 
20 hours 
20 hours 
20 hours 
12 hours 
9 hours 
16 hours 
40 hours 
10 hours 
4 hours 
8 hours 
Year Workload 
2014 28 hours 
2015 32 hours 
2015 32 hours 
CRC screening in the Netherlands. Problems and solutions. IV symposium of molecular 
pathology "Advances in the management of breast and colo rectal cancer'; Madrid, Spain 
Comparison of colonoscopy, sigmoidoscopy and multiple rounds of FIT-based colorectal 
cancer screening: long-term follow-up. World Endoscopy Organization (WEO) Colorectal 
Cancer Screening Meeting, San Diego, United States of America & Digestive Disease Week, 
San Diego, United States of America Certificate of recognition 
Concentration of a Negative FIT Predicts Risk of Future Advanced Neoplasia: A Long-Term 
Follow-Up Study of Population-Based FIT Screenees. Digestive Disease Week, San Diego, 
United States of America Certificate of recognition 
Oral presentations at national conferences 
Practice, indication and predictive factors of second look colonoscopy in a screening 
population. Najaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Vel hoven, The 
Netherlands 
FIT-based colorecta l cancer screening: do we need to tailor screening for men and women? 
Voorjaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Velhoven, The 
Netherlands 
Comparison of OC-sensor and FOB-Gold in population-based colorecta l cancer screening 
based on FIT. Voorjaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Velhoven, 
The Netherlands 
Comparison of colonoscopy, sigmoidoscopy and multiple rounds of FIT-based colorectal 
cancer screening: long-term follow-up. Voorjaarscongres, Nederlandse Vereniging voor 
Gastro-enterologie, Vel hoven, The Netherlands 
Concentration of a Negative FIT Predicts Risk of Future Advanced Neoplasia: A Long-Term 
Follow-Up Study of Population-Based FIT Screenees. Voorjaarscongres, Nederlandse 
Vereniging voor Gastro-enterologie, Vel hoven, The Netherlands 
Poster presentations at (inter)national conferences 
Bowel preparation and hospital are important factors influencing quality of colonoscopy as 
measured by cecum intubation and adenoma detection. Digestive Disease Week, Chicago, 
United States of America 
Fecal hemoglobin level is an important factor in predicting the risk of a second look 
colonoscopy in a screening population. Digestive Disease Week, Chicago, United States of 
America 
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2016 32 
2016 40 
2016 32 
Year Workload 
2014 12 hours 
2015 12 hours 
2015 12 hours 
2016 12 hours 
2016 12 hours 
Year Workload 
2014 12 hours 
2014 12 hours 
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FIT-based colorectal cancer screening: do we need to tailor screening for men and women? 
Digest ive Disease Week, Washington D.C., United States of America Poster of excellence 
Guaiac-based faecal occult blood tests versus faecal immunochemical test for colorectal 
cancer screening in average-risk individuals. United European Gastroenterology Week, 
Barcelona, Spain 
Attended (inter)national conferences 
Najaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Velhoven, The Netherlands 
Digestive Disease Week, Chicago, United States of America 
Najaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Velhoven, The Netherlands 
United European Gastroenterology Week, Vienna, Austria 
Digestive Disease Week, Washington D.C., United States of America 
United European Gastroenterology Week, Barcelona, Spain 
Voorjaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Velhoven, The 
Netherlands 
Digestive Disease Week, San Diego, United States of America 
Voorjaarscongres, Nederlandse Vereniging voor Gastro-enterologie, Velhoven, The 
Netherlands 
United European Gastroenterology Week, Vienna, Austria 
Attended seminars 
3e Nationaal congres bevolkingsonderzoek darmkanker, Utrecht, the Netherlands 
28th Erasmus Liver day. Rotterdam, The Netherlands 
Wetenschapsmiddag Arts-assistenten verenig ing (AAV), Erasmus MC, Rotterdam 
World Endoscopy Organization (WEO) Colorectal Cancer Screening Meeting, Chicago, United 
States of America 
6e Lagerhuisdebat Hepatitis Band C, Utrecht, the Netheralnds 
World Endoscopy Organization (WEO) Colorectal Cancer Screening Meeting, Washington 
D.C., United States of America 
World Endoscopy Organization (WEO) Colorectal Cancer Screening Meeting, Barcelona, 
Spain 
11 e Jaarsymposium Gastro-enterologie, Amsterdam 
World Endoscopy Organization (WEO) Colorectal Cancer Screening Meeting, San Diego, 
United States of America 
2015 12 hours 
2015 12 hours 
Year Workload 
2013 12 hours 
2014 28 hours 
2014 12 hours 
2014 28 hours 
2015 28 hours 
2015 28 hours 
2015 12 hours 
2016 28 hours 
2016 12 hours 
2016 28 hours 
Year Workload 
2013 6 hours 
2013 6 hours 
2014 6 hours 
2014 8 hours 
2014 2 hours 
2015 8 hours 
2015 8 hours 
2016 6 hours 
2016 8 hours 
Awards 
United European gastroenterology week young investigator bursary 
United European gastroenterology week young investigator bursary 
United European gastroenterology week young investigator bursary 
Memberships 
Netherlands Association of Gastroenterology (NVGE) 
American Gastroenterologica l Assocation (AGA) 
Review activities 
Netherlands journal of medicine, BMC gastroenterology, Tria ls, Journal of Medical Screening 
Educational activities and lecturing 
Regioreferaat AAV, This is the end - het levenstestament (member of organizational 
committee and chair), Erasmus MC, Rotterdam 
Wetenschapsmiddag Arts-assistenten vereniging (AAV; member of organizational 
committee), Erasmus MC, Rotterdam 
Booklet practical guidelines; data management and quality for PhD-researchers 
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Year 
2014 
2015 
2016 
Year 
2013-present 
2013-2014 
Year Workload 
2015 28 hours 
2015 40 hours 
2016 12 hours 
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FOICKE & S(JICICE 
OOEN MEE AAN DE PILO"T 
wow! 
PEZE. MOST JE. 
OPST<.AREN AAN HET 
DARN\t<ANt<ER-
ONDERZOEK! 
QG.IT 
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Dankwoord 
Met deze laatste pagina's van dit boekje sluit ik een mooie peri ode af. Drie jaren waarin ik ontzettend 
veel geleerd heb, bijzondere en inspirerende mensen heb mogen ontmoeten en drie jaren waarop 
ik hoop verder te mogen bouwen. Want dit proefschrift vormt slechts een stap in een opleiding die 
nooit volledig zal zijn.lk had dit niet kunnen doen zonder de steun, het vertrouwen en de hulp van 
vele mensen en een aantal van hen wil ik graag in het bijzonder bedanken. 
Hooggeleerde prof. dr. Ernst J. Kuipers, beste Ernst, wat een geluk om onder jouw hoede te mogen 
promoveren. Als geen ander weet jij te inspireren en te motiveren. lk kijk terug op vele mooie 
overlegmomenten, waar ik altijd nog enthousiaster (hoewel ook vaak met wat meer werk) vandaan 
kwam. Bij deze overleggen voelde ik me vrij om de discussie met je aan te gaan en wist jij me vaak 
de ogen te openen bij lastige problemen waarvoor jij (ogenschijnlijk) eenvoudige oplossingen wist 
te vinden. Veel dank voor je steun en begeleiding van dit proefschrift en ik hoop in de toekomst nog 
veel metje van gedachte te mogen blijven wisselen. 
Lieve Manon (dr. Manon C. W. Spaander), na mijn eerste jaar promoveren werd jij mijn co-promotor, 
maar voor mijn gevoel was jij er al vanaf het begin. Gelukkig heb jij je door Ernst Iaten overtuigen 
om het CRC-team (i.e., het E-team) te begeleiden! Jouw kracht om van 'gewone' manuscripten, 
sterke stukken te maken heeft mij veel geleerd. En hoe jij de wet enschap (met de bijbehordende 
concurrentie) met de dagelijkse kliniek als dokter met geduld en vriendelijkheid kan combineren 
vind ik inspirerend. In de afgelopen jaren waren er naast gezellige en leerzame overlegmomenten, 
ook mooie avonden tijdens etentjes of barrels op congressen waar we ook over zaken buiten het 
ziekenhuis konden praten. Veel dank en ik zie er naar uit om over een paar jaar in het Erasmus MC 
ook metjou in de kliniek te mogen werken. 
Een belangrijk onderdeel van dit onderzoek vormde de CRC-stuurgroepvergaderingen waarbij 
verschillende instanties, specialisaties en bijbehorende persoonlijkheden elkaar aanvulden om 
zo het maximale eruit te halen. Beste Iris (dr. I. Lansdorp-Vogelaar), veel dank voor je scherpe 
inzichten, het prettige overleg en je talent om de methodologie binnen een manuscript altijd naar 
een hoger niveau te tillen. Dank dat j e plaats wilt nemen in de commissie. Best e Hanneke (dr. A.J. 
van Vuuren), veel dank voor je inzet in het laboratoriumonderzoek en je aanvullingen en inzichten 
tijdens stuurgroepvergaderingen. Beste Wolfert Spijker, Kristen lzelaar, Hans 't Mannetje en Jopie 
Krimpen, zonder jullie bestaat er geen proefbevolkingsonderzoek, heel veel dank voor jullie hulp 
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en ondersteuning. Beste Kirsten, jij bent pragmatisch en doortastend. Tijdens vergaderingen zag jij 
vaak de praktische oplossingen en wist jij als geen ander de hoofd- en bijzaken onder de aandacht 
te brengen, dit gold voor zowel de actuele problemen als het voorzien van toekomstige issues. 
Beste Hans, in momenten van chaos en paniek wist jij altijd de kalmte te bewaren en kon je precies 
die gegevens leveren waar ik naar op zoek was. Ook bij mijn vele hulpverzoeken over aantallen van 
testen, of vermiste deelnemers bleef jij altijd vriendelijk en heb je me heel vee I geholpen, dankjewel! 
Beste Agnes, veel dank voor je hulp met de patienten op de polikliniek en voor je hulp random de 
logistiek van het proefbevolkingsonderzoek in het ziekenhuis. Uiteraard wil ik ook de endoscopie-
verpleegkundigen, poli-assistenten, in het bijzonder Ronald, en endoscopisten, in het bijzonder 
Paul Didden, bedanken. 
Dank past ook aan aile deelnemers van het proefbevolkingsonderzoek. Zander jullie inzet waren er 
geen resultaten geweest, waarbij genoemd moet worden dat op ieder congres er met ontzag wordt 
gesproken over de ongelooflijk hoge deelnamegraad in de studie. 
I would also like to thank all (international) co-authors for the positive and fruitfull collaborations. 
Graag wil ik prof. dr. M.J. Bruno, prof dr. P.M. M. Bossuyt en prof dr. J.F. Lange hartelijk dan ken voor 
het beoordelen van mijn proefschrift en het plaastnemen in de kleine commissie. Prof. dr. Evelien 
Dekker, dank voor het zitting nemen in de promotiecommissie, ik bewonder jouw kracht en 
gedrevenheid en heb veel van je geleerd in de afgelopen jaren. Prof. dr. Stephan P. Halloran. I am 
hounoured that you are willing to take place in the PhD committee for my thesis defence. 
Beste prof dr. R.A. de Man, veel dank voor het in mij gestelde vertrouwen door mij op te leiden tot 
Maag-, Darm-, en Leverarts. 
Best dr. H. Boom, dr J. T. Brouwer en aile collega arts-assistenten en medisch specialisten van het 
Reinier de Graaf Gasthuis. Veel dank voor het warme welkom en het fijne opleidingsklimaat, ik kijk 
uit naar de komende drie jaar als arts-assistent in dit ziekenhuis. 
Lieve Manon, ook wei de Amsterdamse Esmee genoemd, of was ik nou juist de Rotterdamse Manon? 
Sa men gingen we dit onderzoek aan en hebben we over de jaren veel overleg gehad en bijzondere 
momenten meegemaakt. Jouw klinische blik en mijn voorliefde voor SPSS maakte ons een goede 
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combinatie. Gelukkig mogen we de komende tijd nog blijven samenwerken en blijven we ook in de 
toekomst MDL-collega's. lk heb nu al zin in de dag van jouw promotie. 
Er is mogelijk geen inspirerender omgeving dan het DAK. Lieve dak-duifjes & lab-ratjes, julllie 
hebben mijn promotietijd onvergetelijk gemaakt. Vele mooie momenten hebben we gedeeld, van 
zwetend zwoegen op het DAK tijdens zinderende zomers, tot borrels in de stad en de trips en 
feestjes tijdens vele congressen. Dankjulliewel! 
Lieve Eline, jij was degene die me wegwijs maakte in de CRC -screeningswereld en na onze trip naar 
Birmingham wist ik dat ik naast een hele leuke collega, er ook een vriendin bij had. Juist omdat we 
zo verschillend zijn heb ik heel vee I van je geleerd. Dankjewel voor je vriendschap en geduld. lk weet 
zeker dat jij binnekort zal schitteren tijdens jouw verdediging en dat je een fantastische huisarts zult 
worden. 
Lieve Els en Sil, ik voel me een geluksvolgel met jullie twee vandaag a an mijn zijde. Veel dank voor 
jullie steun, jullie eerlijkheid en aile gezelligheid. lk kijk uit naar onze toekomst als MDL-collega's, 
en weet zeker dat gedurende onze carriere (en wie weet zelfs daarna) we nog heel veel mooie 
momenten zullen delen, welke verder reiken dan aileen ons werk. Dankjulliewel dat jullie mijn 
paranifm willen zijn op deze dag. 
Lieve JB, dankjewel dat je mijn wereld verbreedt. Avec toi, on est vraiment mieux que d'etre en 
prison. 
Lieve broertjes, ik ben onzettend trots om jullie zus te mogen zijn. Lieve Thorn, dank voor je steun en 
humor, ik heb bewonderding voor je talent om mensen te Iaten groeien en leren, ik weet zeker dat 
jij een inspiratie zal zijn voor vele mensenlevens. Lieve Daan, dank voor je creatieve bijdrage a an de 
lay-out van dit boekje. lk bewonder hoe jij je eigen pad kiest, met jouw creativiteit en talent kom je 
er zeker! Lieve pap en mam, jullie liefde voor ons, maar vooral julie liefde voor elkaar is het mooiste 
cadeau dat jullie mij ooit konden geven. Lieve mam, jij houdt me met beide benen op de grond en 
laat me zien hoe veel moois het Ieven te bieden heeft. Lieve pap, het is bijzonder dat ik 30 jaar later 
aan de zelfde universiteit mijn proefschrift mag verdedigen en voel me trots dat ik hier vandaag als 
jouw dochter mag staan. Veel dank voor jullie onvoorwaardelijke steun en voor jullie bijdrage welke 
zich niet laat samenvatten in deze laatste zinnen. 
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